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ABSTRACT 
Tuberculosis continues to be a major world health problem, causing more deaths than any 
other bacterial disease.  Long treatment durations using a complex cocktail of drugs are often 
associated with patient non-adherence to therapy, and this has accelerated the development of 
drug resistant strains.  Tuberculosis drug resistance has developed to the extent that some 
strains are resistant to all clinically used drugs.  Therefore novel tuberculosis treatment drugs 
are urgently required to combat these resistant strains, sterilise latent infections and reduce 
lengthy treatment durations. 
 
This research developed and optimised a high-throughput assay to screen chemical libraries 
for compounds with anti-mycobacterial activity.  The assay utilised fast growing tuberculosis 
model species M. smegmatis expressing foreign green fluorescent protein (GFP).  GFP 
allowed bacterial growth inhibition to be measured both by fluorescence in addition to 
absorbance.  The assay was expanded to four different culture conditions two of which were 
nutrient starvation that better mimicked environmental conditions M. tuberculosis is exposed 
to during infection. These differential culture conditions also revealed previously unidentified 
mycobacterial inhibitors.  Three chemical libraries totaling over 5,000 compounds were 
screened in the different culture conditions.   
 
Seleno-amino acids (Se-AAs), a novel class of anti-tuberculosis compounds, were discovered 
through screens in nutrient starvation conditions.  Based on traits of strong inhibitory activity 
towards mycobacteria, low human cell line cytotoxicity, structural novelty and known over-
the-counter sale as a non-prescription dietary supplement, the Se-AAs were chosen as a 
promising pharmacophore for further study.  Using evidence derived from anti-sense gene 
knockdown, transposon mutagenesis and biochemical enzyme assays, a pro-drug hypothesis 
of anti-mycobacterial activity was proposed that involved Se-AAs being transported into the 
mycobacterial cell by nutrient uptake transporters and subsequent cleavage into catalytically 
active methylselenium species by lyase enzymes used in mycobacterial sulphurous amino 
acid metabolism.  The activated methylselenium is reduced by mycobacterial redox 
homeostasis enzymes involved in mycobacterial oxidative defence such as alkyl 
hydroperoxidases, generating reactive oxygen radical products that damage mycobacterial 
DNA, lipids and proteins.  Reduced methylselenol can be cycled back to the oxidised state by 
cellular mycothiones, continuously generating damaging reactive oxygen species within the 
       III 
mycobacterial cell.  Methylselenium species also disrupt essential mycobacterial processes, 
such as ketosteroid catabolism and iron-sulphur cluster protein function.   
 
In summary, this research has designed and implemented a novel dual label differential 
culture condition assay useful in the screening and detection of chemicals with anti-
tuberculosis properties.  A novel structural class of anti-tuberculosis compounds with 
therapeutic potential, the Se-AAs, was discovered using this assay, the structure-activity 
relationship of the Se-AAs was explored and a three-component model of Se-AA anti-
tuberculosis activity is proposed.  
       IV 
SUPERVISOR 
 
Doctor Ronan F. O‟Toole 
Senior Lecturer 
School of Biological Sciences 
Victoria University of Wellington 
New Zealand 
 
ACKNOWLEDGEMENTS 
Thanks to my supervisor, Dr. Ronan O‟Toole, for the guidance and support provided that 
made this project possible, and Prof. John Miller for proof-reading this extensive thesis and 
providing valuable and much needed feedback.  My lab mates and fellow next-generation 
scientists - Dr. Shahista Nisa, Dr. Jeremy Owen and Dr. Mudassar Altaf and future Doctors 
Sandi Dempsey, Richard Campen, Ian Bassett, Nathaniel Dasyam.  Thanks for the help and 
insightful advice you provided, and for being excellent company to boot. 
My friends, your companionship and kind words helped me through the difficult times.  You 
put things in perspective and made life enjoyable.  I am privileged. 
My family, Mum and Dad, you gave me the opportunity and encouragement to pursue my 
education to the finish.  Your nurturing support was, is and always will be invaluably 
appreciated.  Aunty Frances, you were the inspiration in my formative years that lead to my 
chosen path in the natural sciences. 
My Megan, amore mio.  You provided every possible means of support to me throughout this 
long and arduous journey.  I cannot express my gratitude in words.  I am glad that I have a 
lifetime to show my appreciation to you.   
To the unexpected little man who is yet to be named, unbeknownst to you, you provided the 
final push to drive this work to completion.  I do not know what the future will hold, but I 
look forward to us exploring it together. 
       V 
TABLE OF CONTENTS 
 
 
ABSTRACT ..................................................................................................................... II  
 
ACKNOWLEDGEMENTS ........................................................................................... IV 
 
TABLE OF CONTENTS ............................................................................................... V 
 
LIST OF FIGURES ........................................................................................................ XV 
 
LIST OF TABLES .......................................................................................................... XVII 
 
LIST OF ABBREVIATIONS ........................................................................................ XIX 
 
LIST OF PUBLICATIONS ........................................................................................... XXIV 
  
       VI 
CHAPTER ONE:  INTRODUCTION .......................................................................... 1 
 
1.1 Preface  .................................................................................................................................. 2 
1.2 Tuberculosis the disease ......................................................................................................... 3 
  1.2.1 The need for new tuberculosis drugs .............................................................................. 4 
 1.2.2 Tuberculosis in New Zealand ......................................................................................... 5 
  1.2.3 Bovine tuberculosis ......................................................................................................... 6 
1.3 Mycobacteria ........................................................................................................................... 7 
  1.3.1 Family Mycobacteriaceae ............................................................................................... 7 
  1.3.2 Characteristics  ................................................................................................................ 7 
  1.3.3 Mycobacterial cell wall ................................................................................................... 7 
  1.3.4 Fast growing species ....................................................................................................... 9 
   1.3.4.1 Mycobacterium smegmatis ..................................................................................... 9 
  1.3.5 Slow growing species ..................................................................................................... 10 
   1.3.5.1 Mycobacterium bovis BCG ..................................................................................... 10 
   1.3.5.2 Mycobacterium tuberculosis  .................................................................................. 11 
    1.3.5.2.1 Mycobacterium tuberculosis H37Ra .............................................................. 11 
    1.3.5.2.2 Mycobacterium tuberculosis H37Rv .............................................................. 12 
   1.3.5.3 Multi-drug resistant tuberculosis ............................................................................ 13 
    1.3.5.3.1 Extensively-drug resistant tuberculosis  ......................................................... 13 
    1.3.5.3.2 Totally-drug resistant tuberculosis (TDR-TB) ............................................... 14 
1.4 Tuberculosis pathogenesis ...................................................................................................... 14 
1.5 Tuberculosis treatment ............................................................................................................ 16 
  1.5.1 Current first line drugs .................................................................................................... 17 
  1.5.2 Current second line drugs ............................................................................................... 18 
  1.5.3 Novel TB drugs in the clinical pipeline .......................................................................... 20 
 1.6 Approaches in tuberculosis drug discovery ........................................................................... 21 
  1.6.1 Historical tuberculosis drug discovery ............................................................................ 21 
  1.6.2 Contemporary tuberculosis drug discovery .................................................................... 22 
   1.6.2.1 Non-targeted screening ........................................................................................... 23 
    1.6.2.1.1 Non-targeted whole cell in vitro screening ..................................................... 24 
    1.6.2.1.2 Non-targeted whole cell high content screening ............................................ 25 
   1.6.2.2 Targeted Screening ................................................................................................. 26 
    1.6.2.2.1 Target selection .............................................................................................. 28 
    1.6.2.2.2 In silico screening ........................................................................................... 28 
    1.6.2.2.3 In vitro enzyme based screening .................................................................... 29 
    1.6.2.2.4 Whole-cell differential antisense sensitivity screening .................................. 29 
    1.6.2.2.5 Whole-cell gene expression screening ........................................................... 30 
  1.7.3 Downstream studies ........................................................................................................ 30 
1.8 Summary ................................................................................................................................. 31 
  1.8.1 Aim of this research ........................................................................................................ 31 
 
  
       VII 
CHAPTER TWO:  MATERIALS AND METHODS .............................................................. 32 
2.1 Bacterial Strains and Plasmids ................................................................................................ 33 
  2.1.1 Bacterial Strains .............................................................................................................. 33 
  2.1.2 Plasmids .......................................................................................................................... 34 
2.2 Media and culture conditions .................................................................................................. 37 
  2.2.1 Chemicals and reagents .................................................................................................. 37 
   2.2.1.1 Chemicals ............................................................................................................... 37 
    2.2.1.2 Media ...................................................................................................................... 34 
    2.2.1.2.1 Luria-Bertani broth (Miller) ........................................................................... 37 
    2.2.1.2.2 7H9 broth (Middlebrook) ............................................................................... 37 
    2.2.1.2.3 Minimal 7H9- broth (Middlebrook) ............................................................... 37 
    2.2.1.2.4 OADC enrichment (Middlebrook) ................................................................. 37 
    2.2.1.2.5 Hartman de Bonts carbon starvation (HdeB C
-
) broth .................................... 38 
    2.2.1.1.6 Hartman de Bonts nitrogen starvation (HdeB N
-
) broth ................................. 38 
    2.2.1.2.7 Hartman de Bonts oxygen starvation (HdeB O2
-
) broth ................................. 38 
    2.2.1.2.8 Hartman de Bonts (HdeB) base ...................................................................... 38 
    2.2.1.2.9 100x metal salts .............................................................................................. 38 
    2.2.1.2.10 100x nitrogen ................................................................................................ 38 
    2.2.1.2.11 100x phosphates ........................................................................................... 39 
    2.2.1.2.12 M9 minimal broth ......................................................................................... 39 
    2.2.1.2.13 ZYP-5052 auto-induction broth .................................................................... 39 
    2.2.1.2.14 ZY base ......................................................................................................... 39 
    2.2.1.2.15 50x 5052 ....................................................................................................... 39 
    2.2.1.2.16 20x NPS ........................................................................................................ 39 
   2.2.1.3 Media supplementation ........................................................................................... 40 
   2.2.1.4. Enzymes ................................................................................................................. 41 
   2.2.1.5 Oligonucleotides ..................................................................................................... 41 
  2.2.2 Culture procedures .......................................................................................................... 43 
   2.2.2.1 Microbial culture .................................................................................................... 43 
     2.2.2.1.1 E. coli .............................................................................................................. 44 
    2.2.2.1.2 M. smegmatis .................................................................................................. 44 
    2.2.2.1.3 M. bovis BCG / M. tuberculosis H37Ra ......................................................... 44 
    2.2.2.1.4 S. aureus ......................................................................................................... 44 
    2.2.2.1.5 V. harveyi  ....................................................................................................... 44 
    2.2.2.1.6 S. cerevisiae  ................................................................................................... 45 
    2.2.2.1.7 P. aeruginosa .................................................................................................. 45 
  2.2.3 High throughput screening using M. smegmatis ............................................................. 45 
  2.2.4 Quantitative dose-response assays .................................................................................. 46 
  2.2.5 Anti-sense RNA differential susceptibility assays .......................................................... 48 
 2.2.6 Checkerboard drug synergy assays ................................................................................. 49 
 2.3 Molecular biology techniques ................................................................................................ 49 
  2.3.1 DNA isolation, purification and quantification............................................................... 49 
   2.3.1.1 Large scale mycobacterial genomic DNA preparation ........................................... 49 
    2.3.1.2 Zyppy™ Plasmid Miniprep Kit .............................................................................. 50 
   2.3.1.3 DNA Clean & Concentrator Kit™ ......................................................................... 51 
   2.3.1.4 Zymoclean™  Gel DNA Recovery Kit ................................................................... 51 
   2.3.1.5 Alkaline Lysis – Plasmid DNA midi prep .............................................................. 51 
   2.3.1.6 Spectrophotometric quantification of DNA  ........................................................... 52 
  2.3.2 Genetic manipulations .................................................................................................... 52 
   2.3.2.1 PCR ......................................................................................................................... 52 
   2.3.2.2 Restriction endonuclease digests ............................................................................ 53 
   2.3.2.3 Dephosphorylation .................................................................................................. 54 
   2.3.2.4 Phosphorylation ...................................................................................................... 55 
   2.3.2.5 Ligations ................................................................................................................. 55 
       VIII 
    2.3.2.5.1 Cohesive end ligations .................................................................................... 55 
    2.3.2.5.2 Blunt end ligations .......................................................................................... 56 
    2.3.2.5.3 TA cloning ligations ....................................................................................... 56 
   2.3.2.6 Transformations ...................................................................................................... 57 
    2.3.2.6.1 Preparation of transformation competent cells ............................................... 57 
     2.3.2.6.1.1 Chemically competent E. coli DH5α / BL-21 ........................................ 57 
     2.3.2.6.1.2 Electroporation competent M. smegmatis MC
2
155 ................................ 57 
    2.3.2.6.2 E. coli heat shock transformation ................................................................... 58 
    2.3.2.6.3 V. harveyi conjugative transformation ............................................................ 58 
    2.3.2.6.4 M. smegmatis electroporation transformation ................................................ 59 
   2.3.2.7 Identification of recombinant transformants ........................................................... 59 
    2.3.2.7.1 Colony PCR screening.................................................................................... 59 
    2.3.2.7.2 Restriction digestion of transformant plasmid DNA ...................................... 60 
    2.3.2.7.3 Agarose gel electrophoresis of DNA .............................................................. 61 
    2.3.2.7.4 Sequencing of DNA........................................................................................ 61 
   2.3.2.8 Transposon mutagenesis ......................................................................................... 61 
    2.3.2.8.1 Generation of random transposon mutant M. smegmatis by TN611 .............. 62 
  2.3.2.8.2 Screening for seleno-amino acid resistant transposon mutants ........................... 62 
    2.3.2.8.3 Identification of TN611 transposon insert location ........................................ 63 
     2.3.2.8.3.1 Transposon mutant mycobacterial gDNA mini-prep ............................. 63 
     2.3.2.8.3.2 Fragmentation of mutant mycobacterial gDNA by restriction endonuclease    
                     digestion ................................................................................................................... 64 
     2.3.2.8.3.3 Self ligation of mutant gDNA fragments ............................................... 65 
     2.3.2.8.3.4 Inverse PCR of self-ligated transposon mutant gDNA fragments .......... 65 
     2.3.2.8.3.5 Sequencing and location determination of transposon insertion site ...... 66 
   2.3.3 Proteomics ...................................................................................................................... 66 
   2.3.3.1 Protein expression ................................................................................................... 66 
    2.3.3.1.1 Protein expression vector and strain ............................................................... 66 
    2.3.3.1.2 Expression of recombinant proteins ............................................................... 66 
    2.3.3.1.3 Protein purification by nickel affinity chromatography ................................. 67 
    2.3.3.1.4 Desalting and concentration of expressed recombinant protein ..................... 68 
    2.3.3.1.5 Protein quantification  .................................................................................... 68 
  2.3.3.2 SDS-PAGE ............................................................................................................. 69 
     2.3.3.2.1 Sample preparation ......................................................................................... 69 
    2.3.3.2.2 Polyacrylamide gel electrophoresis ................................................................ 69 
    2.3.3.2.3 Gel staining and destaining ............................................................................. 70 
 2.4 In vitro enzymatic assays ................................................................................................... 70 
   2.4.1 Cysteine desulphurase reaction .................................................................................. 70 
   2.4.2 Determinative cysteine desulphurase assays ............................................................. 70 
    2.4.2.1 Lead acetate hydrogen sulphide detection assay ............................................... 71 
    2.4.2.2 Methylene blue  hydrogen sulphide detection assay ......................................... 71 
    2.4.2.3 Coupled desulphurase / dehydrogenase assay ................................................... 71 
    2.4.2.4 α-keto butyrate detection assay ......................................................................... 72 
   2.4.4 Gas chromatography mass spectrometry ................................................................... 72 
  2.5 Mammalian cell line cytotoxicity assays ........................................................................... 72 
   2.5.1 HL-60 / J-774 / Vero cell MTT assay ........................................................................ 72 
  2.6 Data processing .................................................................................................................. 73 
   2.6.1 Statistical analysis ...................................................................................................... 73 
    2.6.1.1 Z-factors  ........................................................................................................... 73 
    2.6.1.2 Signal to noise ratios ......................................................................................... 74 
  2.6.2 Chart plotting ............................................................................................................. 74 
 
 
       IX 
CHAPTER THREE:  HIGH-THROUGHPUT SCREENING ............................................... 75 
3.1 Introduction to High Throughput Screening ........................................................................... 76 
  3.1.1 High Throughput Screening methodologies ................................................................... 76 
  3.1.2 Screening objectives ....................................................................................................... 79 
3.2 Chemical libraries  .................................................................................................................. 79 
  3.2.1 LOPAC ........................................................................................................................... 80 
  3.2.2 Spectrum Collection ....................................................................................................... 80 
  3.2.3 NIH Diversity and Natural Products Set ......................................................................... 80 
3.3 Screening conditions ............................................................................................................... 81 
  3.3.1 Model organism M. smegmatis ....................................................................................... 82 
 3.3.2 Screening and hit criteria ................................................................................................ 82 
   3.3.3 Differential culture conditions ................................................................................... 83 
    3.3.3.1 Rich media conditions ....................................................................................... 83 
        3.3.3.1.1 Luria-Bertani broth ................................................................................... 83 
       3.3.3.1.2 Middlebrook 7H9 broth ............................................................................ 84 
  3.3.4 Hit validation .................................................................................................................. 84 
 3.3.5 Screen optimisations ....................................................................................................... 85 
  3.3.6 Statistical analysis of viability ........................................................................................ 85 
   3.3.6.1 Luria-Bertani Broth ................................................................................................ 85 
   3.3.6.2 Middlebrook 7H9 Broth ......................................................................................... 85 
3.4 Screen results .......................................................................................................................... 86 
  3.4.1 LOPAC rich culture conditions ...................................................................................... 87 
    3.4.1.1 LB ...................................................................................................................... 87 
   3.4.1.2 7H9 .................................................................................................................... 87 
    3.4.1.3 LOPAC rich media screening validated hit compounds .................................... 88 
    3.4.1.4 LOPAC rich media screening results overview................................................. 89 
 3.4.2 Spectrum Collection rich culture conditions ................................................................... 91 
    3.4.2.1 LB ...................................................................................................................... 91 
   3.4.2.2 7H9 .................................................................................................................... 91 
    3.4.2.3 Spectrum Collection rich media screening validated hit compounds ................ 92 
    3.4.2.4 Spectrum Collection rich media screening results overview ............................. 93 
 3.4.3 NIH Diversity Set rich culture conditions ...................................................................... 95 
    3.4.3.1 LB ...................................................................................................................... 95 
   3.4.3.2 7H9 .................................................................................................................... 95 
    3.4.3.3 NIH Diversity Set rich media screening validated hit compounds .................... 96 
    3.4.3.4 NIH Diversity Set rich media screening results overview ................................. 98 
 3.4.4 Overview of screening goals and outcomes .................................................................... 99 
3.5 Discussion ............................................................................................................................... 100 
  3.5.2 Biological significance of rich media screen hit compounds ......................................... 100 
   3.5.2.1 LOPAC rich media screen hit compound significance ........................................... 100 
   3.5.2.2 Spectrum Collection rich media screen hit compound significance ....................... 101 
   3.5.2.3 NIH Diversity Set rich media screen hit compound significance ........................... 102 
  3.5.3 Differential culture conditions influence on screen hits ................................................. 104 
 3.6 Summary ................................................................................................................................ 106 
    
       X 
CHAPTER FOUR:  SCREENING WITH MODIFIED CULTURE CONDITIONS .......... 107 
4.1 Modifying culture conditions introduction ............................................................................. 108 
  4.1.1 Bacterial response to differential culture conditions....................................................... 108 
  4.1.2 Screening with modified culture conditions in the literature .......................................... 109 
  4.1.3 Objectives of modified culture condition screening ....................................................... 110 
 4.2 Screening conditions .............................................................................................................. 110 
  4.2.1 Chemical libraries and screening conditions .................................................................. 110 
  4.2.2 Screening and hit criteria ................................................................................................ 111 
 4.2.3 Starvation media conditions ............................................................................................ 111 
    4.2.3.1 HdeB C- carbon limitation medium (HdeB C-) ................................................ 112 
    4.2.3.2 HdeB N- nitrogen limitation medium (HdeB N-).............................................. 112 
 4.2.4 Hit Validation ................................................................................................................. 112 
 4.2.5 Statistical analysis of viability ........................................................................................ 113 
   4.2.5.1 HdeB C- .................................................................................................................. 113 
   4.2.5.2 HdeB N- .................................................................................................................. 114 
 4.3 Screen results ......................................................................................................................... 115 
  4.3.1 LOPAC starvation culture conditions ............................................................................. 116 
   4.3.1.1 HdeB C-  ................................................................................................................. 116 
   4.3.1.2 HdeB N- .................................................................................................................. 116 
   4.3.1.3 LOPAC starvation media screening validated hit compounds ............................... 117 
  4.3.1.4 LOPAC starvation media screening results overview ............................................ 118 
  4.3.2 Spectrum Collection starvation culture conditions ......................................................... 120 
   4.3.2.1 HdeB C-  ................................................................................................................. 120 
   4.3.2.2 HdeB N- .................................................................................................................. 120 
   4.3.2.3 Spectrum Collection starvation media screening validated hit compounds ........... 121 
   4.3.2.4 Spectrum Collection starvation media screening results overview ........................ 123 
  4.3.3 NIH Diversity Set starvation culture conditions ............................................................. 125 
   4.3.3.1 HdeB C-  ................................................................................................................. 125 
   4.3.3.2 HdeB N- .................................................................................................................. 125 
   4.3.3.3 NIH Diversity Set starvation media screening validated hit compounds ............... 126 
   4.3.3.4 NIH Diversity Set starvation media screening results overview ............................ 130 
  4.3.4 Overview of nutrient-limited screening goals and outcomes .......................................... 131 
4.4 Discussion ............................................................................................................................... 133 
  4.4.2 Biological significance of starvation media screen hit compounds ................................ 133 
   4.4.2.1 Significance of LOPAC starvation media screen hit compounds ........................... 133 
   4.4.2.2 Significance of Spectrum Collection starvation media screen hit compounds ....... 136 
   4.4.2.3 Significance of NIH Diversity Set starvation media screen hit compounds ........... 141 
  4.4.3 The influence of differential starvation culture conditions on screen hits ...................... 146 
  4.4.3.1 Comparison of validated hits from LOPAC differential media screens ................. 148 
   4.4.3.2 Comparison of validated hits from Spectrum Collection differential media screens 
      .................................................................................................................................. 149 
   4.4.3.3 Comparison of validated hits from NIH Diversity Set differential media screens . 151 
  4.4.4 Implications of nutrient limited culture conditions in tuberculosis drug screening  ....... 154 
4.5 Summary ................................................................................................................................. 155 
  4.5.1 Identification of the novel anti-mycobacterial agent Se-methylselenocysteine .............. 156 
 
   
 
  
       XI 
CHAPTER FIVE:  SELENO-AMINO ACIDS ........................................................................ 158 
5.1 Introduction ............................................................................................................................. 159 
  5.1.1 Selenium ......................................................................................................................... 160 
  5.1.2 Seleno amino acids ......................................................................................................... 162 
    5.1.2.1 Dietary sources ....................................................................................................... 163 
   5.1.2.2 Dietary supplementation ......................................................................................... 164 
  5.1.3 Bioavailability and metabolism ...................................................................................... 164 
  5.1.4 Biological activity indications and research ................................................................... 166 
   5.1.4.1 Immune system function ......................................................................................... 167 
   5.1.4.2 Cancer ..................................................................................................................... 167 
   5.1.4.3 Diabetes .................................................................................................................. 168 
   5.1.4.4 Cardiovascular disease ............................................................................................ 169 
   5.1.4.5 Anti-viral ................................................................................................................ 169 
   5.1.4.6 Anti-microbial......................................................................................................... 169 
5.2 Results  .................................................................................................................................. 173 
  5.2.1 Bacterial species ............................................................................................................. 174 
  5.2.1.1 M. smegmatis .......................................................................................................... 174 
  5.2.1.2 M. bovis BCG ......................................................................................................... 178 
  5.2.1.3 M. tuberculosis H37Ra ........................................................................................... 180 
  5.2.1.4 M. tuberculosis H37Rv and CDC1551 ................................................................... 182 
  5.2.1.5 S. aureus  ................................................................................................................ 184 
  5.2.1.6 E. coli ...................................................................................................................... 186 
  5.2.1.7 P. aeruginosa .......................................................................................................... 188 
   5.2.1.8 V. harveyi ................................................................................................................ 190 
  5.2.2 Eukaryotic Species .......................................................................................................... 192 
   5.2.2.1 S. cerevisiae ............................................................................................................ 192 
   5.2.2.2 Mammalian cell lines .............................................................................................. 195 
5.3 Discussion ............................................................................................................................... 196 
  5.3.1 Biological Activity of Seleno Amino Acids ................................................................... 196 
   5.3.1.1 Anti-bacterial activity ............................................................................................. 197 
    5.3.1.1.1 Mycobacteria  ................................................................................................. 197 
     5.3.1.1.1.1 M. smegmatis .......................................................................................... 197 
      5.3.1.1.1.2 M. bovis BCG ......................................................................................... 198 
    5.3.1.1.1.3 M. tuberculosis H37Ra ........................................................................... 199 
    5.3.1.1.1.4 M. tuberculosis H37Rv and CDC1551 ................................................... 200 
    5.3.1.1.2 Gram positive ................................................................................................. 201 
     5.3.1.1.2.1 S. aureus ................................................................................................. 201 
    5.3.1.1.3 Gram negative ................................................................................................ 201 
     5.3.1.1.3.1 E. coli ...................................................................................................... 201 
    5.3.1.1.3.1 P. aeruginosa .......................................................................................... 202 
    5.3.1.1.3.1 V. harveyi ................................................................................................ 202 
   5.3.1.2 Anti-fungal activity ................................................................................................. 204 
    5.3.1.2.1 S. cerevisiae .................................................................................................... 204 
   5.3.1.3 Mammalian cell line cytotoxicity ........................................................................... 206 
  5.3.2 Suitability of seleno-amino acids for human therapy ..................................................... 207 
   5.3.2.1 Towards mycobacteria ............................................................................................ 207 
   5.3.2.2 Towards other bacterial  and fungal species ........................................................... 208 
   5.3.2.3 Mammalian cell line toxicity .................................................................................. 209 
   5.3.2.4 Animal model toxicity ............................................................................................ 210 
5.4 Summary ................................................................................................................................. 212 
 
    
 
       XII 
CHAPTER SIX:  SELENO-AMINO ACID STRUCTURE ACTIVITY RELATIONSHIP AND 
MECHANISM OF ACTION  .................................................................................................... 213 
 
6.1 Introduction ............................................................................................................................. 214 
  6.1.1 Seleno-amino acid biological activity ............................................................................. 214 
  6.1.2 Differential activity and media conditions overview ...................................................... 214 
   6.1.2.1 Bacterial species ..................................................................................................... 214 
   6.1.2.2 Media conditions .................................................................................................... 215 
6.2 Seleno amino acid pharmacophore ......................................................................................... 216 
  6.2.1 Seleno-compound structure and activity in M. smegmatis ............................................. 217 
  6.2.2 Seleno-amino acid derivatives ........................................................................................ 222 
    6.2.2.1 Seleno-amino acid derivatisation effect on anti-mycobacterial activity ................. 224 
6.3 Seleno-amino acid mechanism of action ................................................................................ 225 
  6.3.1 Seleno-amino acid anti-neoplastic mechanism ............................................................... 225 
  6.3.2 Seleno-amino acids as anti-mycobacterial agents ........................................................... 228 
   6.3.2.1 Proposed mechanism of Se-AA anti-mycobacterial activity  ................................. 229 
             6.3.2.1.1 Missing link in methylselenium species-induced toxicity ......................... 230 
                            6.3.2.1.2 Testing the proposed Se-AA mode of action  .................................... 231 
6.4 Results  .................................................................................................................................. 232 
  6.4.1 Seleno-amino acid uptake - competition assays ............................................................. 232 
  6.4.2 Seleno-amino acid lyase pro-drug activation .................................................................. 233 
   6.4.2.1 Anti-sense RNA gene down-regulation using pMIND_2357 ................................. 233 
   6.4.2.2 Anti-sense RNA gene down-regulation using pKW08 vector ................................ 234 
   6.4.2.3 S. cerevisiae lyase gene deletion strains ................................................................. 238 
   6.4.2.4 Pro-drug activation in vitro enzyme activity assays ............................................... 239 
    6.4.2.4.1 Enzyme purification ....................................................................................... 240 
   6.4.2.4.2 Metabolite Detection ...................................................................................... 241 
     6.4.2.4.2.1 Gas chromatography-mass spectrometry................................................ 241 
    6.4.2.4.2.2 Methylene blue sulphide/selenide detection ........................................... 242 
     6.4.2.4.2.3 Lead acetate sulphide/selenide detection ................................................ 242 
     6.4.2.4.2.4 Alanine dehydrogenase coupled assay ................................................... 243 
     6.4.2.4.2.5 Lactate dehydrogenase coupled assay .................................................... 244 
     6.4.2.4.2.6 Methylbenzothiazolinone hydrazone alpha-keto acid detection ............. 244 
  6.4.3 Mycobacterial redox cycling of methylselenol ............................................................... 244 
   6.4.3.1 Seleno-amino acid resistant transposon mutants .................................................... 244 
   6.4.3.2 Inducible gene regulation of M. smegmatis alkylhydroperoxidase......................... 246 
   6.4.3.3 Seleno-amino acid synergy with isoniazid ............................................................. 248 
6.5 Discussion ............................................................................................................................... 249 
  6.5.1 Competition assays ......................................................................................................... 250 
  6.5.2 Mycobacterial lyase enzymes ......................................................................................... 250 
   6.5.2.1 Bioinformatic gene selection .................................................................................. 250 
   6.5.2.2 Transcriptional modulation of M. smegmatis putative lyase enzymes ................... 252 
   6.5.2.3 S. cerevisiae lyase gene deletion strains ................................................................. 254 
   6.5.2.4 Lyase enzyme metabolite detection assays ............................................................. 254 
    6.5.2.4.1 Gas chromatography-mass spectrometry ........................................................ 255 
    6.5.2.4.2 Methylene blue sulphide/selenide detection ................................................... 256 
    6.5.2.4.3 Lead acetate sulphide/selenide detection ........................................................ 256 
    6.5.2.4.4 Alanine dehydrogenase / lactate dehydrogenase coupled assay ..................... 257 
    6.5.2.4.5. Methylbenzothiazolinone hydrazone alpha-keto acid detection .................... 258 
   6.5.3 Seleno-amino acid resistant transposon mutant M. smegmatis ...................................... 259 
   6.5.3.1 Redox gene function Se-AA resistant transposon mutants ..................................... 259 
   6.5.3.2 Kinase gene function Se-AA resistant transposon mutants .................................... 262 
    6.5.3.2.1 Glycerol kinase function Se-AA resistant mutants ......................................... 262 
   6.5.3.3 Other Se-AA resistant transposon mutants ............................................................. 263 
   6.5.3.4 Poorly defined Se-AA resistant transposon mutants .............................................. 265 
       XIII 
   6.5.3.5 Inducible regulation of alkylhydroperoxidase expression ...................................... 266 
   6.5.3.6 Seleno-amino acid synergy with isoniazid ............................................................. 267 
  6.5.4 General conclusions of mechanism of action studies ..................................................... 268 
6.6 Summary ................................................................................................................................. 269 
CHAPTER SEVEN:  GENERAL DISCUSSION .................................................................... 271 
7.1 Overall synopsis ...................................................................................................................... 272 
7.2 Summary of experiments ........................................................................................................ 274 
  7.2.1 Conventional media high-throughput screening ............................................................. 274 
  7.2.2 Modified culture conditions high-throughput screening ................................................. 276 
  7.2.3 Seleno-amino acids ......................................................................................................... 278 
7.3 Critical Evaluation .................................................................................................................. 282 
  7.3.1 High-throughput screening ............................................................................................. 282 
  7.3.2 Seleno-amino acids activity ............................................................................................ 283 
  7.3.3 Seleno-amino acid structure activity analysis ................................................................. 284 
    7.3.3.1 Seleno-amino acid derivatisation ....................................................................... 285 
  7.3.4 Seleno-amino acid mechanism of action ........................................................................ 286 
    7.3.4.1 Competition assays ............................................................................................ 286 
    7.3.4.2 Anti-sense inducible modulation of gene expression ........................................ 286 
    7.3.4.3 Enzymatic assays ............................................................................................... 287 
     7.3.4.4 Mass spectrometry ............................................................................................. 287 
  7.3.5 Mycobacterial lyase metabolite detection assays............................................................ 288 
    7.3.5.1 Methylene blue sulphide/selenides detection .................................................... 288 
    7.3.5.2 Coupled enzyme assays ..................................................................................... 288 
  7.3.6 Seleno-amino acid resistant transposon mutants ............................................................ 288 
  7.3.7 Seleno-amino acid synergy with isoniazid ..................................................................... 289 
7.4 Future directions ..................................................................................................................... 289 
  7.4.1 Modified culture condition screening of additional chemical libraries .......................... 289 
  7.4.2 Follow up of key library hit compounds ......................................................................... 289 
  7.4.3 Further testing of Se-AAs against virulent / drug resistant M. tuberculosis strains ....... 290 
  7.4.4 Further testing of Se-AAs against mammalian cell lines ................................................ 290 
  7.4.5 Target gene knockout and complementation sensitivity ................................................. 290 
  7.4.6 In silico docking analysis of Se-AAs with mycobacterial lyase enzymes ...................... 291 
  7.4.7 Derivatisations improving biological activity ................................................................. 291 
    7.4.7.1 Se substitution ................................................................................................... 291 
    7.4.7.2 Side chain carbon length.................................................................................... 292 
    7.4.7.3 Amide conjugates .............................................................................................. 292 
    7.4.7.4 Dipeptides conjugates ........................................................................................ 292 
    7.4.7.5 Allyl / glutamyl substitution  ............................................................................. 293 
    7.4.7.6 Increased uptake and specificity ........................................................................ 293 
7.5 Concluding remarks ................................................................................................................ 294 
 
CHAPTER EIGHT:  REFERENCES ....................................................................................... 296 
 
CHAPTER NINE:  APPENDIX  ............................................................................................... A-1  
9.1 Growth curves ......................................................................................................................... A-2 
  9.1.1 M. smegmatis OD600 ........................................................................................................ A-2 
  9.1.2 M. smegmatis GFP .......................................................................................................... A-3 
 9.2 Reagents ................................................................................................................................. A-4 
  9.2.1 Phosphate buffered saline (PBS) .................................................................................... A-4 
  9.2.2 PB buffer ......................................................................................................................... A-4 
  9.2.3 TAE buffer (50x) ............................................................................................................ A-4 
  9.2.4 Agarose gel electrophoresis DNA loading buffer (6x) ................................................... A-4 
       XIV 
  9.2.5 Alkaline lysis solution I  ................................................................................................. A-4 
   9.2.6 Alkaline lysis solution II ................................................................................................. A-4 
  9.2.7 Alkaline lysis solution III................................................................................................ A-4 
  9.2.8 IscS Buffer ...................................................................................................................... A-4 
  9.2.9 KP buffer......................................................................................................................... A-4 
  9.2.10 SDS-PAGE run buffer (10x) ......................................................................................... A-5 
  9.2.11 SDS-PAGE stacking gel (4%) ...................................................................................... A-5 
  9.2.12 SDS-PAGE separating gel (12%) ................................................................................. A-5 
  9.2.13 SDS-PAGE separating gel (15%) ................................................................................. A-5 
  9.2.14 SDS-PAGE loading buffer (3x) .................................................................................... A-5 
  9.2.15 SDS-PAGE Coomassie blue stain ................................................................................ A-5 
  9.2.16 SDS-PAGE destain solution ......................................................................................... A-5 
9.3 Laboratory procedures ............................................................................................................ A-6 
  9.3.1 Recycling of used DNA purification spin columns ........................................................ A-6 
  9.3.2 Recycling of used electroporation cuvettes .................................................................... A-6 
  9.3.3 Zyppy™ Plasmid Miniprep Kit ...................................................................................... A-6 
  9.3.4 DNA Clean & Concentrator Kit™.................................................................................. A-7 
  9.3.5 Zymoclean™ Gel DNA Recovery Kit ............................................................................ A-7 
9.4 Rich media high-throughput screen hit validation .................................................................. A-8 
  9.4.1 LOPAC ........................................................................................................................... A-8 
   9.4.1.1 LB ........................................................................................................................... A-8 
   9.4.1.2 7H9 ......................................................................................................................... A-11 
  9.4.2 Spectrum Collection ....................................................................................................... A-14 
  9.4.2.1 LB ........................................................................................................................... A-14 
   9.4.2.2 7H9 ......................................................................................................................... A-21 
  9.4.3 NIH Diversity Set ........................................................................................................... A-29 
   9.4.3.1 LB ........................................................................................................................... A-29 
   9.4.3.2 7H9 ......................................................................................................................... A-37 
9.5 Starvation media high-throughput screen hit validation ......................................................... A-45 
 9.5.1 LOPAC ........................................................................................................................... A-45 
   9.5.1.1 HdeB C- .................................................................................................................. A-45 
   9.5.1.2 HdeB N- .................................................................................................................. A-49 
  9.5.2 Spectrum Collection ....................................................................................................... A-54 
  9.5.2.1 HdeB C- .................................................................................................................. A-54 
   9.5.2.2 HdeB N- .................................................................................................................. A-61 
  9.5.3 NIH Diversity Set ........................................................................................................... A-75 
  9.5.3.1 HdeB C- .................................................................................................................. A-75 
   9.5.3.2 HdeB N- .................................................................................................................. A-84 
9.6 Wallac plate reader protocols .................................................................................................. A-108 
 9.6.1 GFP and OD dual scan .................................................................................................... A-108 
  9.6.2 Resazurin reduction ........................................................................................................ A-112 
9.7 SigmaPlot – four-parameter logistic curve analysis................................................................ A-114 
9.8 Publications ............................................................................................................................. A-115 
  
       XV 
LIST OF FIGURES 
Figure 1.1:  Mycobacterial cell wall ............................................................................................. 8 
Figure 1.2:  Tuberculosis pathogenesis ......................................................................................... 16 
Figure 1.3:  Non-targeted approaches to TB drug discovery ........................................................ 23 
Figure 1.4:  Target based approaches to TB drug discovery ......................................................... 27 
Figure 2.1:  High throughput screen plate map ............................................................................. 46 
Figure 2.2:  Quantitative pose-response assay plate map ............................................................. 48 
Figure 2.3:  Z-factor calculation ................................................................................................... 73 
Figure 2.4:  Signal to noise ratio calculation ................................................................................ 74 
Figure 3.1: M. smegmatis LOPAC LB HTS OD & GFP scatterplots ........................................... 87 
Figure 3.2: M. smegmatis LOPAC 7H9 HTS OD & GFP scatterplots ......................................... 87 
Figure 3.3:  LOPAC rich media screening hit compound known activities ................................. 89 
Figure 3.4: M. smegmatis Spectrum Collection LB HTS OD & GFP scatterplots ....................... 91 
Figure 3.5: M. smegmatis Spectrum Collection 7H9 HTS OD & GFP scatterplots ..................... 91 
Figure 3.6:  Spectrum Collection rich media screening hit compound known activities   ............ 93 
Figure 3.7: M. smegmatis NIH Diversity Set LB HTS OD & GFP scatterplots ........................... 95 
Figure 3.8: M. smegmatis NIH Diversity Set 7H9 HTS OD & GFP scatterplots ......................... 95 
Figure 3.9:  NIH Diversity Set rich media screening hit compound known activities ................. 98 
Figure 3.10:  Venn diagram of rich media validated hit distribution ............................................ 93 
Figure 4.1: M. smegmatis LOPAC HdeB C- OD & GFP scatterplots .......................................... 116 
Figure 4.2: M. smegmatis LOPAC HdeB N- OD & GFP scatterplots .......................................... 116 
Figure 4.3:  LOPAC starvation media screening hit compound known activity .......................... 118 
Figure 4.4: M. smegmatis Spectrum Collection HdeB C- OD & GFP scatterplots ...................... 120 
Figure 4.5: M. smegmatis Spectrum Collection HdeB N- OD & GFP scatterplots ...................... 120 
Figure 4.6:  Spectrum Collection starvation screening hit compound known activity.. ............... 123 
Figure 4.7: M. smegmatis NIH Diversity Set HdeB C- OD & GFP scatterplots .......................... 125 
Figure 4.8: M. smegmatis NIH Diversity Set HdeB N- OD & GFP scatterplots .......................... 125 
Figure 4.9:  NIH Diversity Set starvation screening hit compound known activity ..................... 130 
Figure 4.10:  Venn diagram comparing starvation media screening validated hits ...................... 146 
Figure 4.11:  Venn diagram of validated hits from screening rich and starvation media  ............ 154 
Figure 5.1:  Seleno-amino acids and equivalent amino acids ....................................................... 162 
Figure 5.2:  Selenium metabolic pathway in humans ................................................................... 166 
Figure 5.3:  Di-Se-AAEMA .......................................................................................................... 171 
Figure 5.4:  Chemical structure of ebselen ................................................................................... 172 
Figure 5.5:  Dose-response curves of selenium compound inhibition against M. smegmatis ....... 175 
Figure 5.6:  Dose-response curves of selenium compound inhibition against M. bovis BCG ...... 179 
       XVI 
Figure 5.7:  Dose-response curves of selenium compound inhibition vs M. tuberculosis H37Ra.180 
Figure 5.8:  Dose-response curves of selenium compound inhibition vs M. tuberculosis H37Rv.182 
Figure 5.9:  Dose-response curves of selenium compound inhibition against S. aureus .............. 184 
Figure 5.10:  Dose-response curves of selenium compound inhibition against E. coli ................ 186 
Figure 5.11:  Dose-response curves of selenium compound inhibition against P. aeruginosa .... 188 
Figure 5.12:  Dose-response curves of selenium compound inhibition against V. harveyi .......... 190 
Figure 5.13:  Dose-response curves of selenium compound inhibition against S. cerevisiae ....... 192 
Figure 5.14:  Dose-response curves of selenium compound inhibition against HL-60, J-774 and Vero     
                      cell lines .................................................................................................................. 195 
Figure 6.1:  Seleno-compound key functional groups .................................................................. 220 
Figure 6.2:  Redox cycling of methylselenium species................................................................. 227 
Figure 6.3:  Hypothetical three-step mechanism of Se-AA anti-mycobacterial activity .............. 230 
Figure 6.4:  Se-AA toxicity is alleviated by equimolar amounts of DL-cys or DL-met ............... 232 
Figure 6.5:  Anti-sense knock-down of MSMEG_2357 increases SMSC resistance ................... 233 
Figure 6.6:  Tetracycline inducible expression using M. smegmatis pKW08_GFP vector........... 234 
Figure 6.7:  Induction of tetRO expression as measured by GFP ................................................. 234 
Figure 6.8:  Dose-response curves for pKW08 mediated up- and down-regulation of MSMEG_2357 
and MSMEG_5265 M. smegmatis against Se-AAs ...................................................................... 235 
Figure 6.9:  Dose-response curves for Se-AAs against S. cerevisiae lyase gene deletion strains in SC  
                     and 0.5x SPO media ................................................................................................. 238 
Figure 6.10:  Comparison of S. cerevisiae lyase knockout strain and wild-type strain dose- 
                       response to Se-L-met ............................................................................................. 239 
Figure 6.11:  Protein purification SDS-PAGE .............................................................................. 240 
Figure 6.12:  GC-MS result for methyldiselenide ......................................................................... 241 
Figure 6.12:  GC-MS result for dimethylsulphide ........................................................................ 242 
Figure 6.14:  PbAc paper detection of volatile sulphide / selenides ............................................. 243 
Figure 6.15:  Differential susceptibility of M. smegmatis TN-G3-M10 ΔahpD mutant strain ..... 246 
Figure 6.16:  Differential susceptibility of M. smegmatis to Se-AAs using tetracycline inducible over 
and under-expression of MSMEG_4890/1 alkyhydroperoxidase ahpC/D ................................... 247 
Figure 6.17:  Checkerboard assay for synergy between Se-L-met and isoniazid. ........................ 249 
Figure 6.18:  Proposed methylselenium anti-mycobacterial effects. ............................................ 269 
Figure 9.1:  OD600  growth curves of M. smegmatis in screening assay media ............................. A-2 
Figure 9.2:  GFP growth curves of M. smegmatis in screening assay media ................................ A-3  
       XVII 
LIST OF TABLES 
Table 2.1: Bacterial strains ........................................................................................................... 33 
Table 2.2:  Plasmids ...................................................................................................................... 34 
Table 2.3:  Media supplementation ............................................................................................... 41 
Table 2.4:  Primers ........................................................................................................................ 42 
Table 2.5:  Reagents and concentrations used during PCR amplification .................................... 53 
Table 2.6:  Conditions used for basic PCR amplification ............................................................. 53 
Table 2.7:  Conditions used for touchdown PCR amplification ................................................... 53 
Table 2.8:  Restriction endonuclease digestion reagents and concentrations ............................... 54 
Table 2.9:  Cohesive end ligation reagents and concentrations .................................................... 55 
Table 2.10:  Blunt end ligation reagents and concentrations ........................................................ 56 
Table 2.11:  TA cloning reagents and concentrations ................................................................... 57 
Table 2.12:  Colony PCR screen mix reagents and concentrations .............................................. 60 
Table 2.13:  Specifications used for Macrogen DNA sequencing samples .................................. 61 
Table 2.13:  Restriction digestion conditions for transposon mutant gDNA fragmentation ......... 64 
Table 2.15:  Dilute blunt end ligation conditions used to self-ligate fragmented transposon mutant  
                     gDNA ....................................................................................................................... 65 
Table 2.16:  Reagents and concentrations used during transposon mutant inverse PCR amplification
      .................................................................................................................................. 65 
Table 2.17:  Inverse PCR cycle conditions used for amplifying transposon mutant gDNA for  
                     sequencing ................................................................................................................ 66 
Table 3.1:  Summarized methodologies in anti-bacterial drug high throughput screening. ......... 76 
Table 3.2:  LOPAC rich media screening validated hit results. .................................................... 88 
Table 3.3:  Spectrum Collection rich media screening validated hit results. ................................ 92 
Table 3.4:  NIH Diversity Set rich media screening validated hit results. .................................... 96 
Table 4.1:  LOPAC starvation media screening validated hit results. .......................................... 117 
Table 4.2:  Spectrum Collection starvation media screening validated hit results........................ 121 
Table 4.3:  NIH Diversity Set starvation media screening validated hit results. .......................... 126 
Table 4.4:  Comparison of validated hits from LOPAC differential media screening. ................. 148 
Table 4.5:  Comparison of hits from Spectrum Collection differential media screening. ............ 149 
Table 4.6:  Comparison of hits from NIH Diversity Set differential media screening. ................ 151 
Table 5.1:  Inhibitory activity of seleno-compounds against M. smegmatis. ................................ 174 
Table 5.2:  Inhibitory activity of seleno-compounds against M. bovis BCG. ............................... 178 
Table 5.3:  Inhibitory activity of seleno-compounds against M. tuberculosis H37Ra. ................. 180 
Table 5.4:  Inhibitory activity of seleno-compounds against M. tuberculosis H37Rv. ................. 182 
Table 5.5:  Inhibitory activity of seleno-compounds against M. tuberculosis CDC1551. ............ 182 
       XVIII 
Table 5.6:  Inhibitory activity of seleno-compounds against S. aureus. ....................................... 184 
Table 5.7:  Inhibitory activity of seleno-compounds against E. coli............................................. 186 
Table 5.8:  Inhibitory activity of seleno-compounds against P. aeruginosa. ................................ 188 
Table 5.9:  Inhibitory activity of seleno-compounds against V. harveyi....................................... 190 
Table 5.10:  Inhibitory activity of seleno-compounds against S. cerevisiae. ................................ 192 
Table 5.11:  Inhibitory activity of Se-AAs against HL-60, J-774 and Vero cell lines. ................. 195   
Table 6.1:  Seleno-compound structure and anti-mycobacterial activity. ..................................... 217 
Table 6.2:  Seleno-amino acid derivatives. ................................................................................... 224 
Table 6.3:  Se-AA resistant transposon mutants of M. smegmatis. ............................................... 245 
Table 6.4:  M. tuberculosis H37Rv enzymes putatively involved in Se-AA lysis. ....................... 251 
Table 6.5:  Summarised Se-AA dose-response effects of MSMEG_2357 / MSEMG_5265........ 253 
Table 9.1:  Complete list of LOPAC LB HTS validated hits. ....................................................... A-8 
Table 9.2:  Complete list of LOPAC 7H9 HTS validated hits. ..................................................... A-11 
Table 9.3:  Complete list of Spectrum Collection LB HTS validated hits. ................................... A-14 
Table 9.4:  Complete list of Spectrum Collection 7H9 HTS validated hits. ................................. A-21 
Table 9.5:  Complete list of NIH Diversity Set LB HTS validated hits. ....................................... A-29 
Table 9.6:  Complete list of NIH Diversity Set 7H9 HTS validated hits. ..................................... A-37 
Table 9.7:  Complete list of LOPAC HdeB C- HTS validated hits. ............................................. A-45 
Table 9.8:  Complete list of LOPAC HdeB N- HTS validated hits. ............................................. A-49 
Table 9.9:  Complete list of Spectrum Collection HdeB C- HTS validated hits. .......................... A-54 
Table 9.10:  Complete list of Spectrum Collection HdeB N- HTS validated hits. ....................... A-61 
Table 9.11:  Complete list of NIH Diversity Set HdeB C- HTS validated hits. ........................... A-75 
Table 9.12:  Complete list of NIH Diversity Set HdeB N- HTS validated hits ............................ A-84 
 
  
       XIX 
LIST OF ABBREVIATIONS  
7H9+    Middlebrook 7H9 broth (with standard OADC and glycerol supplement) 
7H9-    Middlebrook 7H9 broth (with limited OADC and glycerol supplement) 
7H10    Middlebrook 7H10 agar 
AAEMA   acetoacetoxyethylmethacrylate 
ABC    ATP binding cassette 
Ala-DH   alanine dehydrogenase 
Amp
R    
ampicillin resistant 
ATCC    American Type Culture Collection  
ATP    adenosine triphosphate 
BCG   Bacille Calmette-Guérin 
BLAST   basic local alignment search tool 
B. licheniformis  Bacillus licheniformis 
B. subtilis  Bacillus subtilis 
BSA    bovine serum albumin 
bp    base pairs 
CBS    cystathionine β-synthase 
CDC    Centers for Disease Control and Prevention (U.S.A.) 
C. glutamicum   Corynebacterium glutamicum 
CHCl3    chloroform 
CFU    colony forming units 
Chl
R    
chloramphenicol resistant 
cys    cysteine 
D    dextro 
ddH2O    double distilled sterile water 
DL    racemic dextro / levo mixture 
DMSO    dimethylsulfoxide 
DNA   deoxyribonucleic acid 
DOT   directly observed treatment 
DTT    dithiothreitol 
E. coli     Escherichia coli 
EMB   ethambutol 
Em
R    
erythromycin resistant
 
 
EtOH    ethanol 
Fe-S    iron-sulphur cluster 
FIC    fractional inhibitory concentration 
       XX 
g    gravity 
GC    guanine-cytosine 
GC-MS   gas chromatography mass spectrometry 
gDNA    genomic DNA 
GFP    green fluorescent protein 
GSH    glutathione 
h   hours 
HdeB    Hartman deBonts 
HdeB C-   Hartman deBonts carbon limitation broth 
HdeB N-   Hartman deBonts nitrogen limitation broth 
hERG    human ether-a-go-go related gene 
HIV    human immunodeficiency virus 
HTS    high-throughput screen 
Hyg
R    
hygromycin resistant 
IAA    isoamyl alcohol 
IC50    half maximal inhibitory concentration 
IC50    90% inhibitory concentration 
INH   isoniazid 
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
JHU    Johns Hopkins University 
Kan
R
   kanamycin resistant 
kb    kilobase-pairs 
kDa    kilodalton 
KEGG    Kyoto Encyclopaedia of Genes and Genomes 
L    litres 
Lac-DH    lactate dehydrogenase 
LB   Luria-Bertani broth 
LBA     Luria-Bertani agar 
LD50    median lethal dose 
LDLO    lowest lethal dose 
LOPAC   Library of Pharmacologically Active Compounds 
M9    M9 minimal broth 
M. africanum  Mycobacterium africanum 
M. avium  Mycobacterium avium 
M. bovis  Mycobacterium bovis 
MDR    multi-drug resistant 
MeOH    methanol 
       XXI 
met    methionine 
MIC    minimum inhibitory concentration 
min    minutes 
M. leprae  Mycobacterium leprae 
MoA    mechanism of action 
mRNA    messenger RNA 
MRSA    methicillin resistant S. aureus 
MS    mass spectrometry 
M. smegmatis  Mycobacterium smegmatis 
MTT    3-(4,5-dimethylthiazol-2-yl)-2,5(diphenyltetrazolium bromide) 
M. tuberculosis  Mycobacterium tuberculosis 
NAD    nicotinamide adenine dinucleotide 
NAG   N-acetylglucosamine 
NAM   N-acetylmuramic acid 
NADH    nicotinamide adenine dinucleotide, reduced form 
NCI    National Cancer Institute (U.S.A.) 
NCBI    National Centre for Biotechnology Information (U.S.A.) 
NEB    New England Biolabs 
NIH    National Institutes of Health (U.S.A.) 
NPC    nutritional prevention of cancer trial 
NZ    New Zealand 
NZD    New Zealand dollar 
OADC    oleic acid, albumin, dextrose and catalase 
OD    optical density 
ORF    open reading frame 
OTC    over the counter (non prescription medicine) 
P. aeruginosa   Psuedomonas aeruginosa 
PAS    para-aminosalicyclic acid 
PbAc    lead acetate 
PBS    phosphate buffered saline 
PC-1    physical containment level 1 
PC-2   physical containment level 2 
PC-3     physical containment level 3 
PCR   polymerase chain reaction 
PEG    polyethylene glycol 
P. falciparum  Plasmodium falciparum 
pKa    acid dissociation constant 
       XXII 
psi    pounds per square inch 
PZA   pyrazinamide 
RBS    ribosomal binding site 
redox    reduction-oxidation 
RIF   rifampicin 
RNA    ribonucleic acid 
ROS    reactive oxygen species 
RPM    revolutions per minute 
rRNA    ribosomal RNA 
SAM    S-adenosyl methionine 
SAR    structure-activity relationship 
S. aureus   Staphylococcus aureus 
SC    synthetic complete broth 
S. cerevisiae   Saccharomyces cerevisiae 
SDS    sodium dodecyl sulphate 
SDS-PAGE   sodium dodecyl sulphate polyacrylamide gel electrophoresis 
sec    seconds 
Se-AA    seleno-amino acid 
Se-cys    selenocysteine 
SELECT   selenium and vitamin E cancer prevention trial 
Se-met    selenomethionine 
SERT    serotonin transporter 
SEVI    semen derived enhancer of viral infection 
SMSC    se-methylselenocysteine (DL) 
SNR    signal to noise ratio 
SPME    solid-phase micro extraction 
SPO    sporulation broth 
Str
R    
Streptomycin resistant 
Spc
R
    Spectinomycin resistant 
TAACF   Tuberculosis Antimicrobial Acquisition and Coordinating Facility (U.S.A.) 
TAE    tris-acetate-EDTA 
TB    tuberculosis 
TE    tris-EDTA 
TCBS    thiosulfate, citrate, bile salts, sucrose  
TDR    totally drug resistant 
Tm    melting temperature 
TSB    tryptic soy broth 
       XXIII 
UK    United Kingdom 
UV    ultra-violet 
V    volts 
V. harveyi   Vibrio harveyi 
VUW    Victoria University of Wellington 
WHO   World Health Organisation 
WST-1   4-[3-(4-lodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene                                                                                   
                                       disulfonate 
XDR   extensively drug resistant 
Xgal    5-bromo-4-cholro-3-indolyl- β-D-galactopyranoside 
YPD    yeast extract, peptone, dextrose broth 
ZYP    ZY-5052 autoinduction broth 
 
  
       XXIV 
LIST OF PUBLICATIONS 
 
Amso, Z., Miller, CH, O‟Toole, R. and Sarojini, V. Design, synthesis and analysis of anti-
tuberculosis peptides. 32
nd
 European Peptide Symposium, September 2-7, 2012. Greece (Oral 
presentation accepted to appear in the Conference Proceedings).  
 
Miller CH, O'Toole RF. Navigating tuberculosis drug discovery with target-based screening. 
Expert Opinion on Drug Discovery. 2011; 6(8):1-16. 
 
Finlayson R, Brackovic A, Simon-Levert A, Banaigs B, O'Toole RF, Miller CH, Copp BR. 
Establishment of the absolute configuration of the bioactive marine alkaloid eudistomin X by 
stereospecific synthesis. Tetrahedron Letters. 2011; 52(7):837-40. 
 
Altaf M, Miller CH, Bellows DS, O'Toole R. Evaluation of the Mycobacterium smegmatis 
and BCG models for the discovery of Mycobacterium tuberculosis inhibitors. Tuberculosis. 
2010; 90(6):333-7. 
 
Miller CH, Nisa S, Dempsey S, Jack C, O'Toole R. Modifying Culture Conditions in 
Chemical Library Screening Identifies Alternative Inhibitors of Mycobacteria. Antimicrobial 
Agents & Chemotherapy. 2009; 53(12):5279-83. 
 
 
  CHAPTER ONE:  INTRODUCTION     1 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER ONE 
 
Introduction 
 
 
  
  CHAPTER ONE:  INTRODUCTION     2 
1.1 Preface 
 
 
“Medical scientists now have 
 both the knowledge they need  
to wipe out tuberculosis 
 as a public-health problem 
 and the tools to finish the job.” 
 
TIME magazine, 3
rd
 August, 1953. 
 
 
 
 
 
This research seeks to contribute towards solving the problem of tuberculosis by: 
 
 
 Developing a new method of screening for anti-mycobacterial 
compounds. 
 
 Discovering novel tuberculosis inhibitor compounds. 
 
 Exploring the mechanism and structure activity relationship of a lead 
novel anti-mycobacterial compound. 
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1.2 Tuberculosis the disease 
Tuberculosis (TB) is a disease that has infected humankind since prehistoric times. It has 
continued to afflict every civilisation around the globe through to today under the aliases of 
consumption, phthisis and the white plague.
3
   
The causative disease agent is the acid fast bacillus Mycobacterium tuberculosis which 
commonly infecting the lungs, rendering it highly contagious by aerosol dispersion.
4
  
Symptoms often manifest in persons with poor health, poor living conditions and in the 
immune compromised.  Symptoms progress through a persistent sputum producing cough, 
chest pains, coughing of blood, fever and malaise.  Without competent treatment, chronic 
infection will often result in death.
4
 
Early therapies for tuberculosis were either completely ineffective or relied on hazardous 
surgical removal of tubercule lesions.
5
  Prevention was strongly enforced after the disease 
was determined contagious.  This prevention was further reinforced by vaccination using an 
attenuated strain of the bovine tuberculosis pathogen Mycobacterium bovis, coined M. bovis 
Bacille Calmette-Guérin (BCG).  Vaccination was adopted by a small number of 
predominantly European countries after World War II.
6
  However the vaccine remains 
controversial due to its variable efficacy and is not considered thoroughly effective, in 
addition to having no utility in established infections.
7
 
 
Tuberculosis infections remained essentially untreatable until the discovery of streptomycin 
in 1943
5
, and the developing antibiotic era saw the discovery and synthesis of a host of 
effective first-line and second-line anti-tubercular drugs.  However combinations of 
inappropriate treatment, lack of patient adherence to treatment regimens and the inherent 
resilience of mycobacteria saw the evolution of drug resistant strains of M. tuberculosis 
bacilli in the early 1990s.  This phenomenon rapidly escalated to multi-drug resistant (MDR) 
strains, characterised by resistance to at least isoniazid and rifampin, the two chief front-line 
drugs.
8
  For these reasons, the World Health Organisation (WHO) declared tuberculosis a 
global health emergency in 1993.
9, 10
  TB drug resistance then progressed to extensively-drug 
resistant (XDR)
11
 strains that are resistant to not only at least isoniazid and rifampin, but also 
resistant to at least one of the second line quinolone drugs and one of the second line 
injectable aminoglycosides.
8
  Drug resistant strains resulted in the appearance of practically 
untreatable cases of the disease in some countries.
11
 
Tuberculosis remains a significant threat to world health with 8.8 million active cases in 
2010, with 650,000 of these cases caused by MDR-TB.  Approximately 1.4 million deaths 
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were attributed to the disease in 2010, averaging four thousand deaths caused daily by this 
curable disease.  It is estimated that one third of the world population is infected with 
tuberculosis bacilli.
9, 10
  Ten percent of these infected people will develop active tuberculosis 
in their lifetime.  Each person exhibiting active tuberculosis is expected to infect between ten 
and fifteen people per year if not successfully treated.  There is a high co-infection prevalence 
of TB and HIV, with one in four HIV-positive individuals dying from TB.  It is estimated that 
in 2010 there were 1.1 million new HIV-positive cases of TB.
12
  Due to a global effort to stop 
TB spearheaded by the WHO, the global incidence and mortality rates of TB have begun to 
slowly decline since 2005.
13
 
 
Presently, the Global Plan to Stop TB 2006-2015 initiated by the Stop TB partnership, 
intends to halt and reverse the rising incidence of tuberculosis by 2015, utilising improved 
diagnostic techniques, wider treatment access and effective directly observed treatment 
regimens, in addition to implementing research on new diagnostics, antibiotics and 
vaccines.
13, 14
  This achievable goal expects to save fourteen million lives and treat fifty 
million people.
13, 14
  The ultimate ambition of this and other anti-tuberculosis collaborations 
is the eradication of tuberculosis by 2050, a commendable aspiration considering the only 
recorded eradication of an infectious disease was the abolishment of smallpox declared 
officially in 1980.
15
 
 
1.2.1 The need for new tuberculosis drugs 
Grim statistics attributed to tuberculosis are compounded by MDR strains of tuberculosis 
being present in virtually all countries surveyed by the WHO in 2010, estimating nearly half a 
million new cases of MDR tuberculosis occurring each year.
9, 10, 16
 
Due to the emerging prevalence of drug resistant MDR,  XDR and recently TDR (totally drug 
resistant) strains of M. tuberculosis,
11, 17, 18
 current lengthy treatment periods and the large 
amount of established tuberculosis infections the introduction of new anti-mycobacterial 
compounds is a crucial component of the Global Plan to Stop TB
8, 19
.  Drug compounds 
acting via novel mechanisms may overcome existing resistant M. tuberculosis strains
8, 20
, and 
in combination with known antibiotics can potentially decrease treatment periods
20, 21
 by 
additive or synergistic interactions.   
Anti-mycobacterial compounds are able to act on established infections
22
 that vaccination and 
other preventative measures are incapable of addressing.
22
  The treatment of infected persons 
is of utmost importance in halting and reversing the incidence of tuberculosis, with an 
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estimated one third of the world population harbouring predominantly latent tuberculosis 
infection; this populace acts as a reservoir for the disease and a transmission source of new 
infection.  New and effective anti-mycobacterial compounds in combination with existing 
compounds
22
 and diligent diagnosis, treatment courses, education and preventative measures 
such as vaccination are more than capable of negating the current tuberculosis pandemic.
9, 10, 
14
 
 
1.2.2 Tuberculosis in New Zealand 
With specific orientation towards the relevance of tuberculosis in New Zealand, tuberculosis 
has long been a major health issue.  This is reflected in New Zealand‟s legislation, with the 
Tuberculosis Act implemented in 1948 that details protocols regarding awareness, prevention 
and treatment of tuberculosis.  Although now outdated, the Tuberculosis Act (together with 
the Health Act 1956) is to be amalgamated and replaced by the recently approved Public 
Health Bill
23
 introduced to Parliament during November 2007 and had its first reading in 
December 2007.  The Bill is currently in the process of amendment following public 
submissions made in March 2008 and will modernise the legislation to give health officials 
more options focusing on prevention of tuberculosis, such as allowing contact tracing of 
communicable disease infected persons.
24
  The presence of the specific Tuberculosis Act 
illustrates the level of significance the disease attained in this country, and the continuation of 
the Tuberculosis Act through the new Public Health Bill testifies to the ongoing concern. 
Despite New Zealand‟s relatively high standards of health care and legislative efforts to curb 
tuberculosis, both isolated cases and outbreaks of the disease continue to occur
17
. New 
Zealand exhibits rates of tuberculosis similar to the UK but nearly two-fold higher than in 
other countries like the USA, Canada and Australia
25
.  Incidence of disease presents a strong 
correlation with poor living conditions,
26 
and outbreaks are typically isolated to communal 
populations such as schools, churches and prisons.
17, 27
  New Zealand experienced a declining 
trend in the frequency of tuberculosis until the 1980s, when the incidence plateaued with no 
further statistically significant decrease. It is thought that infected immigrants from high risk 
countries are the key factor in the lingering incidence of tuberculosis in New Zealand.
25, 27
  A 
2007 report based on data from an Auckland hospital over July 2002-2003 saw 45 overseas-
born patients accrue nearly $700,000 NZD in inpatient and outpatient treatment and care 
costs, a significant amount considering the total health expenditure of $3,293 NZD per capita 
for the 2002-2003 period.
28
  The extent to which New Zealand‟s health budget can sustain 
rising expenditure due to the burden of resistant infections has been deemed uncertain.
26
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The incidence of tuberculosis in New Zealand may be sustained primarily due to factors 
external rather than internal to the country.  However as globalisation progresses we can no 
longer rely solely on our geographical isolation to protect us from the spread of disease.
25
  
The spread of tuberculosis and its drug-resistant variants must be addressed at not only the 
regional and national level, but also the international level.
29
  The contribution of new anti-
mycobacterial compounds to global endeavours to stop TB will not only help alleviate the 
burden of the disease on other nations, but also on our own.   
By facilitating discovery of novel anti-mycobacterial compounds we contribute to each of the 
three aforementioned geographic levels of tuberculosis, conferring protection from emerging 
drug-resistant tuberculosis
30
 and allowing quick effective treatment of patients harbouring 
active or latent infections.
22
  Development and use of novel drugs with unique activity 
mechanisms in combination with vigilant diagnosis and preventative measures, such as 
preventive vaccination and diligent screening of immigrants for existing infection, could 
dramatically decrease the incidence of tuberculosis in New Zealand, whilst simultaneously 
supporting international efforts to stop the disease. 
 
1.2.3 Bovine tuberculosis 
Although not directly relevant to the drug development aspect of this work, bovine 
tuberculosis is briefly outlined in this thesis to provide more complete background 
information on the wider mycobacterial disease impacts in New Zealand.  Bovine 
tuberculosis the infection of cattle, predominately with the slow growing mycobacterial 
species M. bovis.  It is possible that M. bovis can cause tuberculosis in humans, this has 
become a rare occurrence since the advent of pasteurisation.
31
     
In New Zealand, the main vector of bovine tuberculosis is the brushtailed possum.  Although 
bovine TB in New Zealand has been historically problematic, the problem has decreased 
since the introduction of the 1993 Biosecurity Act which led to major increases in possum 
control by utilising a three tiered approach of testing and culling of infected cattle, restriction 
of herd movement and control of the wild vector population.
32
  This preventative approach, 
with funding of NZ$83 million in 2009
33
, has led to a steady reduction in the incidence of 
bovine tuberculosis.  
In the UK £87 million of public spending was used in 2009/2010 to control bovine 
tuberculosis, where the main vectors are deer and badgers.
34
  It has been proposed that since 
pasteurisation was fully implemented in the UK, bovine TB now presents a negligible threat 
in terms of transmission to humans.
35
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1.3 Mycobacteria  
1.3.1 Family Mycobacteriaceae 
Mycobacterium are a genus of bacteria belonging to the phylum Actinobacteria, the 
Actinomycetales order and the suborder Corynebacterineae.  Their closest phylogenetic 
relations are to bacteria of the genera Corynebacterium , Norcardia, Rhodococcus, Gordona 
and Tsukamurella which often share some of mycobacterium‟s distinguishing phenotypes 
such as being capable to produce mycolic acids.   
Mycobacteria are widespread in their occurrence, inhabiting terrestrial and aquatic 
environments, commensally populating animals and pathogenically infecting animals and 
humans in a sometimes fastidious fashion - manifesting diseases such as leprosy and 
tuberculosis.
36
  Mycobacterial species are commonly divided into two groups, fast growers 
which when subcultured onto solid media form colonies visible to the naked eye within seven 
days, and slow growers which require longer than seven days incubation to form visible 
colonies.  Further distinctions in the grouping of mycobacterial species include their ability to 
cause disease, in addition to standard phenotype and phylogenetic methods. 
 
1.3.2 Characteristics  
Mycobacterial species are typically non-motile rod shaped bacteria ranging in size from 
approximately 1-7 μm in length and 0.2-0.6 μm in width.37  The GC content of mycobacterial 
genomes is typically 61-71% mol although some mycobacterial species such as M. leprae 
have a reported GC content as low as 54% mol.
38
 
 
1.3.3 Mycobacterial cell wall 
Unique to mycobacteria is the unusual waxy outer cell wall, predominately consisting of long 
chained mycolic acids.  This lipid rich coating confers the characteristic mycobacterial 
resistance to decolourisation of carbol-fuchsin staining with acidified alcohol during routine 
crystal violet Gram staining techniques.  This acid fast nature of the mycobacterial cell wall 
serves as a standard method of mycobacterial identification and viewing using the Ziehl-
Neelsen staining method.
39, 40
  The reinforced structure and corresponding non-permeable 
nature of the mycobacterial cell wall is thought to contribute to mycobacterial species 
inherent tolerance of hostile environments such as heat, osmotic pressure, desiccation, host 
immune environments and antibiotic treatment.
41
  Mycobacteria are considered the most 
resilient prokaryotic life form with the exception of bacterial endospores.
42
  The inside of the 
mycobacterial cell wall starts with the common phospholipid bilayer plasma membrane 
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enclosed in a layer of peptidoglycan.  A layer of arabinogalactan is covalently linked to the 
peptidoglycan, and this arabinogalactan is esterified to a thick hydrophobic layer of waxy 
crosslinked mycolic acids - long chain fatty acids containing 70-90 carbons named after 
mycobacteria.  This mycolic acid layer is then encapsulated by an outer membrane consisting 
of non-covalently attached polysaccharides, predominately α-D-glucan, in addition to 
glycolipids and proteins such as transmembrane transport channel proteins that together form 
the surface-exposed mycobacterial capsule. Tethered to lipid components of the cell wall by 
phosphatidylinositol anchors are lipoarabinomannans, lipomannans and phosphosphatidyl-
myo-inositol mannosides.
43
  The structure of the mycobacterial cell wall is depicted 
graphically in Figure 1.1.  The unique nature of the mycobacterial cell wall render 
mycobacteria more resilient to external stressors but also presents several distinct targets for 
selective antimycobacterial drugs.
44
 
 
Figure 1.1:  Mycobacterial cell wall.   
A cross-sectional perspective.  From within the cell travelling out we observe the 
mycobacterial cytoplasm, the plasma membrane with anchored proteins and 
lipoarabinomannans, layers of peptidoglycan and arabinogalactan followed by a thick waxy 
coat of intercalated long chain mycolic acids with dispersed phosphatidyl-myo-inositol 
mannosides.  Finally an outer polysaccharide capsule with tethered lipomannans and 
mannosides. 
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1.3.4 Fast growing mycobacterial species 
Fast growing mycobacteria as described above can be identified by their ability to form 
visible colonies on solid media in seven days or less.  There exists a long and ever growing 
list of fast growing mycobacterial species, these are typically non-pathogenic in nature and 
reside in soil, water or commensally as part of the natural bacterial flora.  They are known to 
be capable of instigating opportunistic infections,
45
 typically caused by commensal 
mycobacterial species but occasionally from environmentally borne bacteria, but these 
infections are commonly infrequent and superficial.
46
 Serious or disseminated cases are 
usually confined to circumstances of immunocompromised individuals.
47
 M. smegmatis is the 
predominant model fast-growing organism used during the course of this work.   
 
1.3.4.1 Mycobacterium smegmatis 
M. smegmatis was first discovered in 1884 by Lustgarten
48
 and later isolated from samples of 
human smegma (genital secretions) by Alvarez and Tavel.
49
  Smegma was the source which 
garnered the species its name as proposed by Lehmann and Neumann in 1899.  M. smegmatis 
is widely found in soil, Tsukamura demonstrated that 38% of Japanese soil samples 
harboured M. smegmatis.
50
  Considered to be predominantly a non-pathogenic environmental 
saprophyte, M. smegmatis is only  known to be an opportunistic agent of disease on 
extremely rare occasions,  generally exploiting circumstances of an immunocompromised 
host to form subcutaneous infection at sites of cuts and abrasions which are often exposed to 
soil, the probable origin of M. smegmatis.
51
   
M. smegmatis cells are aerobic, non-motile, rod shaped and approximately 3.0-5.0 μm in 
length by 0.5-1.0 μm in width with a doubling time of 2-3 hours.52  It is a filamentous 
bacterium capable of growth on a variety of rich and minimal media with a propensity to 
form aggregations of cells in liquid media in the absence of supplementation with surfactants 
and other dispersing agents.
53
  They possess the aforementioned acid-fast staining 
characteristics typical of mycobacterial species.  M. smegmatis forms dry, wrinkled, off-white 
colonies on solid media after 48 hours which over time change in hue to a more yellowish 
colour. 
The genome of M. smegmatis was sequenced in 2006 by the J. Craig Venter Institute, 
revealing it to be 6,988,209 nucleotides in length with a 67% GC content coding for 6716 
proteins, of which over 2000 share close homology with genes of M. tuberculosis.
54
  M. 
smegmatis strain MC
2
155 is hyper-transformable, readily accepting foreign plasmid DNA via 
electroporative transformation, coupled with its ability to readily undergo homologous 
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recombination, its relatively fast generation time and broad media requirements.  These 
characteristics have made it the workhorse of modern mycobacterial genetics.
55
  Combined 
with properties of having a typically resilient mycobacterial cell wall, shared genetic 
homology and drug sensitivity to pathogenic mycobacterial species and its non-pathogenic 
nature and corresponding PC1 or PC2 containment requirements, make M. smegmatis a good 
model organism in the study of pathogenic mycobacteria.
56, 57
  M. smegmatis can enter a 
dormant state under conditions of oxygen depletion and stress caused by nutrient limitation
58
 
as M. smegmatis contains a functioning dormancy regulon similar to that expressed by M. 
tuberculosis.
59
  This makes M. smegmatis a relevant screening model for identifying drugs 
active toward dormant mycobacteria such as persistent M. tuberculosis. 
 
1.3.5 Slow Growing Mycobacterial Species 
Slow growing mycobacterial species are distinguished primarily by their ability to form 
colonies on solid media after longer than seven days incubation.  The clinically significant 
obligate pathogenic species of mycobacterium M. tuberculosis, M. bovis, M. leprae, M. 
avium and M. africanum all fall within the category of slow growing mycobacteria. 
Slow growing mycobacteria share many traits with their fast growing relatives.  They are also 
obligate aerobes, non-motile and rod shaped acid-fast bacteria of a similar size to fast 
growers.  The primary distinction between the fast and slow growing mycobacterial species is 
not surprisingly their doubling time, whilst a fast growing mycobacterium divides once every 
2-5 h on average, slow growing mycobacteria tend to double at the lethargic rate of only once 
every 15-20 h.  Another distinction of the slow growing mycobacterial species is their 
propensity to be obligate parasites such as the members of the tuberculosis complex, whilst 
fast growing mycobacteria are primarily environmental and may cause infection 
opportunistically. Many slow growing mycobacteria solely thrive during infection of a host 
animal, possessing key traits which allow them to act as proficient intercellular parasites.  
The two key slow growing mycobacterial species in this study are M. tuberculosis and M. 
bovis which are the primary causative agents of tuberculosis disease in humans and cattle, 
respectively. 
 
1.3.5.1 Mycobacterium bovis BCG 
M. bovis BCG (bacillus Calmette-Guérin) is an attenuated derivative strain of the virulent 
bovine tuberculosis species M. bovis, which primarily infects cattle, causing approximately 3 
billion dollars in damage to global agriculture annually and is also capable of crossing the 
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species barrier and infecting humans.
60
  The strain M. bovis BCG was derived from the 
repeated passage of M. bovis over 13 years resulting in a completely avirulent strain. Best 
known for its use in vaccination against tuberculosis, M. bovis BCG is one of the most widely 
used vaccines in the world, being in use for over 50 years and having immunized over 3 
billion individuals.
61
  Although the variable efficacy of the BCG vaccination is debated, 
statistical analysis indicates that BCG vaccination reduces the risk of tuberculosis infection 
by 50%.
62
  A slow growing mycobacterium, it presents all of the typical phenotype 
characteristics exhibited by other members of the tuberculosis complex, in addition to its 
attenuation, meaning that it only requires PC2 containment facilities and is able to be 
genetically modified, making it a suitable model organism for the study of slow growing 
mycobacteria. 
 
1.3.5.2 Mycobacterium tuberculosis 
M. tuberculosis is the primary cause for tuberculosis disease in humans, and thus is the major 
focus of practically all mycobacterial research.  Discovered by Robert Koch in 1882 and 
dubbed tubercule bacillus, this slow growing mycobacterial species exhibits the archetypal 
mycobacterial traits of being aerobic, non-motile and possessing an acid fast cell wall.  M. 
tuberculosis is an obligate intercellular pathogen, with cells generally between 2-4 μm long 
and 0.2-0.5 μm wide which form rope-like aggregations typical of mycobacteria when 
cultured in liquid media.  The H37 strain of tuberculosis was isolated in 1905 from a chronic 
pulmonary tuberculosis patient and received distinction due to its virulence in the guinea pig 
model, a good indicating characteristic of human tubercular disease at the time.
63
  In 1934, 
the many times passaged and deliberately aged H37 strain was further classified into two 
divisions, the virulent H37Rv strain and the attenuated or avirulent H37Ra strain which no 
longer could produce disease in the guinea pig model.
64
  Both strains to this day remain 
widely used in tuberculosis research. 
 
 1.3.5.2.1 Mycobacterium tuberculosis H37Ra 
The H37Ra strains exhibits several differential characteristics to their virulent counterpart 
such as the obvious loss of virulence in guinea pig
65
 and mouse models.
66
  H37Ra also 
display impaired survival in anaerobic conditions
67
 and within macrophages
68
 which is 
correlated with a retarded ability to disrupt phagosomes.
69
  The morphology of H37Ra also 
possesses subtle differences as it cannot bind red neutral dyes
70
, has limited cord formation 
and also exhibits raised colonies.
71
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The H37Ra genome consists of 4,419,977 bp on a single chromosome with a GC content of 
65.61% and codes for a predicted 4034 proteins.  The H37Ra genome exhibits very high 
similarity in contents and organisation to H37Rv, the key difference is the H37Ra genome is 
8,445 bp larger due to the culmination of 21 deletions and 53 insertions when compared to 
H37Rv.  Also relative to H37Rv, the H37Ra genome harbours 76 single nucleotide variations 
over 32 genes and their promoting regions.
72
  Although the differential factors determining 
the avirulent nature of H37Ra have not been fully elucidated it is believed that genetic 
variation present in the PE/PPE/PE-PGRS genes,
73, 74
 mutations causing irregular promotion 
of genes IpdA-glpD2 (energy metabolism) pabB (cofactor biosynthesis) nrd-H, -R and -F2 
(nucleotide metabolism) phoH2 (lipid metabolism) ftsH (protein degradation) and sigC 
(sigma factors) and non-sense mutations in genes encoding the proteins mazG (stress 
response), phoP (lipid biosynthesis transcription activation) ilvD (amino acid biosynthesis) 
pls12 and nrp (polyketide synthesis) are the major contributing factors to the loss of virulence 
of the H37Ra strain.
72
  Due to its attenuation, H37Ra meets PC2 laboratory requirements 
whilst maintaining a close homology to virulent strains of tuberculosis. H37Ra provides an 
excellent model for the study of tuberculosis and the discovery of anti-tuberculosis drugs, and 
it is treated in the literature as the practical representative of the virulent H37Rv strain.
75
 
 
1.3.5.2.2 Mycobacterium tuberculosis H37Rv  
H37Rv is the standard laboratory strain used in the study of virulent tuberculosis. The 
genome of M. tuberculosis strain H37Rv was published in 1998 and consisted of 3959 genes 
coded within 4,411,529 bp with approximately 65% GC content.  Since then the genome 
annotation has been revised to 4,066 genes of which only approximately half (1,756 genes) 
have been functionally annotated, with the rest simply designated as hypothetical proteins.
76
  
The key distinguishing factor of the H37Rv strain is the virulence it exhibits towards a 
variety of animal models such as mice and guinea pigs.  Its doubling time is approximately 
20 hours at physiological temperature and it can exist in a dormant state within macrophages 
for periods longer than a decade.  H37Rv is the laboratory test strain of choice for evaluating 
novel antibiotics toward tuberculosis.
77
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1.3.5.3 Multi-drug resistant tuberculosis (MDR-TB) 
Multi-drug resistant tuberculosis is defined as TB that is resistant to at least isoniazid and 
rifampicin, the two first-line drugs most commonly effective in TB treatment. 
MDR-TB prevalently arises through inadequate treatment regimes, such as patients not 
adhering to therapy resulting in an incomplete course of antibiotics.  The strong selection 
pressure of antibiotic treatment combined with sub-sterilising concentrations of antibiotic 
provide a selective opportunity for TB with its persistent and resilient nature to develop 
resistance mechanisms to drugs, usually through mutations at the active site of the drug 
target.  MDR-TB can infect with similar virulence to non-drug resistant strains of TB.
78
 
MDR-TB treatment requires a cocktail of five first and second line drugs for a minimum of 
18 months to best ensure successful sterilisation.  This combination includes second line 
drugs that are less effective, require longer treatment times and have more side effects.  The 
scale of MDR-TB was reported by the WHO as approximately 500,000 cases, 300,000 of 
these were new cases with the remaining 200,000 manifesting from previously treated cases.   
Currently 27 countries are classified as high burden, the majority of which are located in 
eastern Europe.
78
 
 
1.3.5.3.1 Extensively-drug resistant tuberculosis (XDR-TB) 
Extensively-drug resistant tuberculosis is defined as TB that is resistant not only to rifampicin 
and isoniazid but additionally resistant to at least any quinolone family drug and one of the 
injectable aminoglycosides.  XDR-TB arises through similar mechanisms as the development 
of MDR-TB and requires rapid diagnosis and drug susceptibility testing followed by 
extensive antibiotic treatment for durations of up to two years.  Treatment of XDR-TB is 
complicated by high toxicity, side effects, higher monetary cost and a lower treatment 
efficacy of approximately 50% due to the reduced number of treatment options.
79
  Aggressive 
treatment with all six classes of second line drugs, third line drugs when available and clinical 
personnel with expertise in treating XDR cases is recommended.
80
 
Presently the global extent of XDR-TB is not known. Cases have been reported in 69 
countries as at the end of 2010 with an estimated 25,000 cases of XDR-TB emerging 
annually. South Africa reports the largest number of cases most likely due to HIV 
coinfection.
78, 81
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1.3.5.3.2 Totally-drug resistant tuberculosis (TDR-TB) 
Reports have been published of TB strains isolated in Italy,
82
 India
83
 and Iran
77
 that exhibit 
levels of resistance to a number of drugs beyond the XDR-TB definition, including resistance 
to all clinically recommended drugs.  Coined Totally-drug resistant TB, such strains have not 
been officially recognised by the WHO due to uncertain defining criteria;
84
 nonetheless, such 
strains represent an alarming threat to global health and place more strain on the need for 
novel TB treatment options. 
 
1.4 Tuberculosis pathogenesis 
Interaction between M. tuberculosis and the host immune system is a complex system of 
environment, tubercular virulence factors and host immune cells and their response.  Many 
components of TB pathogenesis are not completely understood.   Ninety percent of persons 
infected with TB exhibit an asymptomatic latent infection and have a 10% probability that 
this latent infection will progress into active TB disease in their lifetime.  If left untreated, 
active TB has a mortality rate of 50%.
85
 
TB is primarily spread through aerosol infection. The coughing of an infected individual 
expels a fine mist of droplets harbouring live TB bacilli.  This infectious aerosol may then be 
inadvertently inhaled by another individual, and the infective dose for TB can be as few as 
ten bacteria.  This transmission may be exacerbated by enclosed areas or recirculated air 
systems such as public transport, aeroplanes and buildings with unfiltered circulating air 
conditioning systems.
86, 87
 Once the infectious aerosol is inhaled into the lungs and the TB 
bacteria reach the alveoli, they are then phagocytically engulfed predominately by alveolar 
macrophages.
88, 89
  From here several outcomes in the progression of disease are possible, 
depending on the virulence and amount of bacteria inhaled, and the state of the host immune 
system.  These outcomes are described below and illustrated in Figure 1.2. 
 
1) Elimination: Alveolar macrophages that have phagocytosed TB bacilli are activated by T-
cells recognising presented mycobacterial antigens, spurring phagosome-lysosome fusion.  
This causes death of the TB bacteria.  However, due to the resilient nature of mycobacteria, 
even in the extremely hostile conditions of the phagolysosome, complete sterilisation is 
thought to be rare.
90
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2) Latent infection: Alveolar macrophages are not activated by T-cells.  TB bacilli remain 
within the phagosome and prevent acidification by disrupting phagosome-lysosome fusion, 
inactivating the phagosome acidifying proton pumps or by raising the pH of the phagosome 
by production of compounds such as ammonia.
91
  With the phagocytotic process stalled, TB 
bacilli multiply in the phagosome to the point of macrophage lysis, and released bacilli are 
subject to a continued cycle of phagocytosis by macrophages drawn from the surrounding 
tissue.  This effect snowballs, due to a strong antigenic response from the lysed macrophages 
and mycobacterial antigens, creating a caseating tubercular lesion that can establish as a 
granuloma.
89
  The granuloma is the caseous necrotic mix of TB infected macrophage cells, 
lysed macrophage cells and other recruited immune cells such as lymphocytes, macrophage-
formed multinucleate “giant” cells, neutrophils and eosinophils.89  This necrotic mass is 
encased with a fibrous layer by fibroblasts, quarantining the infected cells and reducing blood 
supply to the area.  The granuloma is maintained by cytokine secretion from the surrounding 
tissue and guarded by an outer sentry layer of T-cells.
92
  If the individual presents no 
symptoms of TB, this outcome is latent TB infection and can persist for the individual‟s 
lifetime or reactivate at a later date into active TB, particularly during immune stress such as 
presented with HIV infection.
93
 
 
3) Active disease: As above with latent TB (2), if the granuloma is unsuccessful in 
containing the TB bacilli they can continue to grow and divide in the lungs.  If left 
unchecked, the infection can eventually spread into the lymph and blood systems and 
disseminate throughout the body causing damage to other organs such as the brain.
1
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Thus, TB is a highly specialised pathogen that adapts to the host‟s phagocytosis defence 
mechanism.  Mycobacteria take advantage of the phagosome and lysophagosome vesicles 
intended to kill it, surviving the hostile phagosomal environment and proliferating within it. 
 
1.5 Tuberculosis treatment 
The current recommended treatment regime for drug-susceptible TB consists of a course of 
rifampicin (RIF), isoniazid (INH) and pyrazinamide (PZA) for a two month period, possibly 
augmented by ethambutol (EMB) or streptomycin.  This is followed by a further four months 
of RIF and INH treatment.  This multi-drug cocktail therapy is used in order to minimise 
development of drug resistance via the complementary sterilising action of the differing 
drugs.  This is combined with the practice of directly observed treatment (DOT) for 
ensurance of patient compliance to therapy, as non-adherence to complete antibiotic courses 
is thought to greatly facilitate the prevalence of drug resistant TB.
94
 
Figure 1.2:  Tuberculosis pathogenesis. 
Infection is initially spread by aerosol dispersion of tuberculosis bacteria through the sneezing 
or coughing of an actively infected individual.  Upon exposure the transmitted bacteria may 
either be eliminated by the host‟s phagocytes, be contained within a granuloma manifesting a 
latent infection, or progress unhindered into active tuberculosis disease.
1
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MDR-TB requires a more aggressive drug therapy regimen over a longer duration of time for 
best chance of eradication.  Dependant on any known drug sensitivities of the infection, 
MDR-TB is treated with a combination of five of the following antibiotics (in preferential 
order due to efficacy and toxicity concerns): an aminoglycoside or cyclic polypeptide, PZA, 
EMB, a fluoroquinolone, rifabutin, cycloserine, a thioamide, para-aminosalicyclic acid 
(PAS) and a macrolide.  The recommended treatment of MDR-TB is continued for at least 18 
months after sputum cultures are negative for TB bacilli, meaning treatment can continue for 
20 months or longer.   XDR treatment follows the same method, but is impeded by the lack of 
resistance to one of the quinolone and aminoglycoside antibiotics, which may be included in 
the treatment if five effective drugs are not available.  Both MDR- and XDR-TB treatment is 
carried out under direct observation to ensure adherence to treatment, and regular monitoring 
of patient symptoms and sputum smear and culture are undertaken.
95
 
 
1.5.1 Current first line drugs 
Isoniazid (INH) or isonicotinylhydrazine is one of the most effective front line drugs and is 
often used in combination with rifampicin, the first port of call in tuberculosis treatment.  
First discovered in 1951, INH is inexpensive to produce and well tolerated.  It is effective 
against H37Rv in vitro at 0.025 µg/ml, with its action being bactericidal against actively 
dividing mycobacteria but bacteriostatic against slow growing populations and it is capable of 
penetrating granulomas.    It is a synthetic pro-drug that is activated within M. tuberculosis by 
the catalase-peroxidase KatG, which catalyses the coupling of INH with NADH to form an 
adduct, which in turn binds the enoyl-acyl carrier protein InhA resulting in the inhibition of 
fatty acid synthesis, a critical process for synthesis of the lipid rich mycobacterial cell wall.  
Damaging free radicals are by-products of the KatG mediated coupling of INH to NADH, 
which may contribute to the drug‟s mechanism of action.96 
 
Rifampicin (RIF) is the other go-to first line treatment option, in combination with INH.  
Discovered in 1959, it is a semi-synthetic compound of the rifamycin family, derived from 
the soil bacterium Amycolatopsis rifamycinica. It is an effective bactericidal agent with a 
MIC of 0.4 µg/ml against H37Rv in vitro.  RIF is lipophilic and readily traverses the 
mycobacterial cell wall; it then elicits its action by strongly binding the beta subunit of the 
bacterial DNA dependant RNA polymerase RpoB, effectively inhibiting transcription and 
consequently protein synthesis.
96
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Ethambutol (EMB) is a synthetic bacteriostatic first line treatment, most often administered 
in conjunction with other first line antibiotics.  Introduced in 1968, EMB demonstrates in 
vitro MIC against H37Rv growth at 0.5 µg/ml.  EMB inhibits arabinosyl transferase embA/B 
in M. tuberculosis, resulting in disruption of the mycobacterial cell wall mycolyl-
arabinogalactan-peptidoglycan complex.  This leads to an increase in permeability of the cell, 
leaving it vulnerable.
96
 
 
Pyrazinamide (PZA) is a first line tuberculosis treatment and is only ever co-administered 
with other anti-tubercular drugs such as INH and RMP.  It is active against in vitro H37Ra 
with an IC90 at pH 5.5 of 6-50 µg/mL and is generally bacteriostatic and has greater activity 
against persister cell populations.  PZA is a synthetic pro-drug which is converted to its active 
form, pyrazinoic acid, by the pyrazinamidase enzyme pncA under acidic conditions, making 
it particularly suited for working within the acidic granuloma.  Pyrazinoic acid then exhibits a 
complex and possibly still to be expanded mechanism.  It has been shown that PZA inhibits 
bacterial fatty acid synthase in vitro and in whole cell assays, but new evidence demonstrates 
that it also binds to the S1 ribosomal subunit, inhibiting trans-translation, a process crucial to 
some bacteria.
96
 
 
1.5.2 Current second line drugs 
Aminoglycosides family of Streptomyces derived antibiotics such as streptomycin, amikacin 
and kanamycin are drugs that exhibit strong antibacterial action at concentrations as low as 1 
µg/ml in vitro, the MIC against H37Rv (streptomycin).  However due to mounting resistance, 
injected administration and the possibility of side effects, these drugs are reserved for the 
second line.  Streptomycin, discovered in 1944, was the first effective anti-tubercular agent 
put into widespread clinical use but is no longer considered front line treatment due to drug 
resistance.  Aminoglycosides generally act by binding the prokaryotic 30S ribosomal subunit, 
disrupting protein synthesis.  They exhibit bacteriostatic activity at low concentrations and 
bactericidal activity at higher concentrations against actively replicating cell populations.
96
 
 
Cyclic polypeptide-based antibiotics such as capreomycin and viomycin are produced from 
Streptomyces species.  They exhibit good anti-tubercular activity in the 2 µg/ml MIC range 
against H37Rv in vitro and their cyclic structure makes them suitable for oral administration, 
but similar to the aminoglycosides, they can exhibit toxic side effects.  Their is yet to be 
completely elucidated however they are suspected to disrupt bacterial translation.
96
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Quinolone family antibiotics, in particular the fluorinated quinolones such as ciprofloxacin, 
ofloxacin, levofloxacin and moxifloxacin, are antibiotics synthetically derived from nalidixic 
acid, discovered in 1962.  Their level of anti-tubercular activity is in the 0.5 µg/ml MIC range 
against H37Rv in vitro; however their relatively expensive nature and possible side effects 
restrain them to second line drugs.  Quinolones are bactericidal through the inhibition DNA 
replication by binding DNA gyrase, a type II topoisomerase, when the enzyme complexes 
with DNA, interfering with the relaxation of supercoiled DNA structure.
96
 
 
Thiocarbamides such as ethionamide, prothioamide and thiocarlide are synthetically derived 
prodrugs that exhibit an effective bacteriostatic action in vitro against H37Ra of 0.25 µg/ml 
or higher.  They are thought to be converted to their active form in mycobacteria by the 
flavoprotein monooxygenase EthA, and then go on to inhibit mycolic acid synthesis in a 
similar manner to INH, through binding the enoyl-acyl carrier protein InhA.
96
 
 
D-cycloserine is a Streptomyces-derived tuberculostatic that exhibits a modest MIC against 
H37Ra in vitro with activity of 25 µg/ml.  Due to its unpleasant side effect profile, its use is 
limited.  It acts through substrate competition of the mycobacterial alanine racemase and D-
alanine ligase enzymes involved in the construction of the peptidoglycan component of the 
mycobacterial cell wall.
96
 
 
para-aminosalicyclic acid (PAS) or 4-aminosalicyclic acid has an in vitro IC90 of 0.31-1.0 
µg/ml against H37Rv.  Structurally based on aspirin, it had fallen out of favour as a 
complementary therapy since the introduction of RMP and PZA, but re-emerged in 1992 with 
the outbreak of MDR-TB strains.  Its mechanism of action remains unclear, however it has 
been demonstrated to be a prodrug activated by the thymidylate synthase ThyA and is 
speculated to evoke its action within the corresponding folate metabolism pathway.
96
 
 
Third line drugs are not recommended by the WHO for various reasons, such as limited 
efficacy, incomplete clinical trial data or prohibitive costs.  Third line drugs may prove useful 
in extreme cases of limited drug supply or drug resistance.  Third line drugs include rifabutin, 
macrolide family drugs, thioacetazone, thioridazine and the new drug classes such as 
linezolid, LL-3858, OPC-67683, PA-824, SQ-109 and TMC207 which are not yet clinically 
approved for tuberculosis treatment.
96
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1.5.3 Novel TB drugs in the clinical pipeline 
TMC-207 is the first in a novel class of diarylquinolones.  It was discovered by whole-cell 
high throughput screening of the tuberculosis model organism used in this research, M. 
smegmatis.
97
  It was found to target ATP synthase subunit c, through mutant generation 
studies and downstream biochemical assays.
98
  TMC-207 exhibits potent inhibitory activity 
toward H37Rv in vitro with a 0.06 µg/ml MIC.  Interestingly, TMC-207 is bactericidal 
towards stationary phase cells of M. tuberculosis
98, 99
 but not M. avium.
100
  TMC-207 
(bedaquiline) gained FDA approval in December 2012 for combination therapy against adult 
MDR-TB.
101, 102
 
 
PA-824 and OPC-67683 are drugs in the new class of nitroimidazol drugs that inhibit 
mycolic acid and protein synthesis, possibly due to damaging free radical production.
103
  
They exhibit  strong activity toward slow growing mycobacterial species exclusively, with M. 
tuberculosis H37Rv MICs of 0.15-0.3 µg/ml and 0.012 µg/ml respectively.
104
  OPC-67683, 
also known as Delamanid, is currently undergoing stage III clinical trials against pulmonary 
MDR-TB patients.  PA-824 has finished stage I clinical trials and was due to begin stage II 
trials early in 2012 for the evaluation of early bactericidal activity in pulmonary TB. 
 
SQ-109 is the most promising candidate identified by the clinical stage anti-infective drug 
company Sequella in a whole cell screen of M. tuberculosis H37Ra against a combinatorial 
library of 67,238 compounds based on the ethylene-diamine backbone of ethambutol.
105
  It 
shows an in vitro MIC of 0.35 µg/ml against M. tuberculosis H37Rv.
106
  It has recently been 
demonstrated to target the membrane trehalose monomycalate transporter that supplies 
mycolic acid for cell wall synthesis and is currently undergoing phase II clinical trails for 
early bactericidal activity in adults with pulmonary TB infection.
107
 
 
LL-3858 also known as Sudoterb is a novel pyrrole derivative with an in vitro MIC of 0.12-
0.025 µg/ml against M. tuberculosis. 
108
    Although it contains the isoniazid structure, its 
precise mechanism of action is currently not known.  It is listed as having completed phase I 
clinical trials and began phase II trials in 2010.
109
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1.6 Approaches in tuberculosis drug discovery 
1.6.1 Historical tuberculosis drug discovery 
Discovery of the first effective antibiotic, penicillin, was of little use in the treatment of 
tuberculosis.  However this isolation of a novel anti-bacterial from a natural source spurred 
the worldwide search for antibiotics that led to the discovery of streptomycin by Selman 
Waksman and Albert Schatz.  Streptomycin is considered the first compound discovered that 
could effectively treat tuberculosis disease. These methods of “prospecting” for antibiotics 
from natural sources has provided most of our currently used antibiotic classes and can still 
be considered applicable today even though the low hanging fruit have been picked.   
 
In the case of penicillin, Alexander Fleming serendipitously noticed inhibitory activity 
towards a plate of Staphylococcus aureus by a contaminating Penicillium fungal species 
colony.  Fleming was not deliberately screening for antibiotic activity; it was a combination 
of keen observation, intellect and luck by which he realised the significance of this 
phenomenon.
110
  On the other hand, Waksman and Schatz had established a procedure for 
testing for antibiotic activity in large numbers bacterial and fungal species derived from soil.  
Although their assay technique is dwarfed in comparison to the ultra high-throughput screens 
of today, they had established one of the first large scale assays for systematic screening of 
bioactivity, of which the basic modus operandus has changed little.  For example, in their 
procedure they used the model species Mycobacterium phlei rather than the slower growing 
and potentially hazardous M. tuberculosis in their primary screening,
111
 a concept that is 
continued to this day, including in this work.   
After the discovery of anti-mycobacterial activity derived from Streptomyces grises, it was 
pertinent that the molecule responsible for this antibiotic activity be isolated and chemically 
characterised to allow its rapid transition into clinical trials and treatment.  Unlike penicillin, 
which endured 12 years from discovery of activity in 1928
112, 113
 to purification in 1940
114
 
and finally its chemical structure elucidation in 1943,
113-115
  streptomycin was quickly 
purified and introduced into the clinical setting, no doubt facilitated by the lessons learnt 
through penicillin.
116, 117
  After the introduction of streptomycin, many other tuberculosis 
treatment drugs such as rifampicin, kanamycin and D-cycloserine were discovered using a 
similar “random” screening approach of natural extracts against whole cell cultures of 
mycobacterial species.  Rifampicin, discovered in 1963, is the latest drug with a novel 
mechanism of action approved for tuberculosis treatment.
118
 
 
  CHAPTER ONE:  INTRODUCTION     22 
1.6.2 Contemporary tuberculosis drug discovery 
Modern techniques used in tuberculosis drug discovery are described below.  Despite 
publication of the tuberculosis genome in 1998 and high hopes for this sequence as a tool for 
target based drug discovery, all current clinical tuberculosis treatment drugs have been 
identified through non-target based screening.
2
  To quote Professor Andries Koen, lead 
researcher in the discovery of recently approved tuberculosis treatment drug TMC207 
(bedaquiline): 
 
“We lost a lot of time in the search for new antibiotics by taking the wrong strategy, which is 
target-based research… If you work as a researcher in a university, or at a place where you 
do not have access to a big library of original compounds, then that is obviously the only 
thing you can do.  But if you have access to such a library, it would be a shame to test them 
for single targets only.”119 
 
Although target based screening provides a useful and perhaps nessesary, ladder to reach the 
high-hanging fruit in antibiotic drug discovery, the potential of such approaches is yet to be 
realised at the clinical endpoint.  For a comprehensive analysis of modern techniques in 
tuberculosis drug discovery consult the 2011 review publication of Miller & O‟Toole.2   
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1.6.2.1 Non-targeted screening 
Non-targeted screening refers to screens for chemical inhibitors of mycobacteria that do not 
have a specifically defined target, instead looking for any inhibitors of mycobacterial growth.  
These types of screens tend to identify a large quantity of inhibitors; however many of these 
are unsuitable drug leads due to indiscriminate toxicity.  Two popular non-targeted screens 
are illustrated in Figure 1.3. 
 
 
Figure 1.3:  Non-targeted approaches to TB drug discovery. 
Left panel depicts a basic whole cell growth inhibition screen, further described in section 
1.6.2.1.1.  Right panel depicts a non-targeted high content screen using macrophage 
phagocytosed mycobacteria, further described in section 1.6.2.1.2.  Figure derived from 
Miller & O‟Toole 2011.2 
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1.6.2.1.1 Non-targeted whole-cell in vitro screening 
The non-targeted screening of large numbers of compounds or extracts against whole 
bacterial cells in liquid culture or on solid media is considered the standard doctrine of 
antibiotic discovery,
110
 and is the basis of the techniques used in this work.  All of the current 
tuberculosis antibiotics in clinical use have been discovered on the basis of their growth 
inhibiting or sterilising activity towards mycobacterial cells.  These whole cell screening 
approaches involve quantification of the inhibition of the growth or survival of mycobacteria.  
Hence, measurement of cell numbers or viability is critically important.  The range of 
techniques to quantify mycobacterial growth that have been used in conjunction with drug 
screening include spectrophotometric measurement of optical density, fluorometric 
measurement of GFP fluorescence
120-122
and luminometric measurement of luminescence
123, 
124
 as well as determination of the rate of nutrient utilisation.
125
  With regards to 
mycobacterial population viability, techniques involving the metabolic reduction of dyes such 
as resazurin have been applied to high throughput library screens in order to detect chemicals 
active against non-replicating or dormant mycobacteria,
126, 127
 which may not be apparent 
using mycobacterial cell population growth measurements.   
 
Practically all of the whole-cell techniques in use today have been scaled up for high-
throughput screening of vast numbers of chemical compounds or natural extracts using 384-
well or higher plate format  and facilitate the use of robotic liquid handlers and plate readers 
for improved accuracy and reduced labour.  In addition to leading us to the current clinical 
drugs, whole-cell screening has also presented several important candidate drugs presently 
undergoing clinical development. Examples include the nitroimidazofurans that were 
detected as active against whole cells of M. tuberculosis.
103
  A prominent member of this 
class, PA-824, exhibited a sub-micromolar MIC and subsequent to promising results became 
the first compound added to the portfolio of the Global Alliance for TB Drug Development. 
Diarylquinolines were discovered by initial whole-cell screening of the fast growing model 
species M. smegmatis and were subsequently validated in virulent M. tuberculosis.
97
  
R207910, also known as TMC-207, is currently in Phase II trials for treatment of multi-drug 
resistant tuberculosis.
128
  
 
Additional to culturing mycobacteria in vitro, several anti-mycobacterial whole-cell screens 
have sought to incorporate conditions thought to exist in the environment of host infection 
into the screening assay. For example M. tuberculosis is thought to be exposed to hypoxic 
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conditions in vivo.
129-133
  This has led to the development of assays able to detect compounds 
active under anaerobic conditions
124, 126, 134
.  Similar to this oxygen starvation, carbon- or 
nitrogen-starvation conditions have been used in the  library screening protocols of this 
work
122  to mimic the host conditions during infection such as macrophage incorporation and 
the granuloma which are understood to cause nutrient deprivation.
136-140
 More recently, 
research which has incorporated multiple in vivo-related stresses such as low oxygen levels, 
high carbon dioxide levels, low nutrient concentrations and acidic pH simultaneously 
integrated into a dormancy model has been described.
141
  Use of multiple stresses like these 
in chemical library screening may enrich the isolation of compounds which have a higher 
probability of retaining activity in vivo.  
Non-targeted antibiotic activity screens against whole cell cultures in vitro provide several 
advantages over targeted type screens such as those against an isolated protein target.   Non-
targeted whole cell screens provide a near-complete spectrum of targets for potential 
chemical inhibitors of compound libraries, rather than the limitation of constraining antibiotic 
activity screens to a precise defined target.  Whole cell screens factor in aspects beyond drug-
target interaction such as cell wall penetration, pro-drug activation and efflux of the 
compound.
142, 143
  It should be noted that non-targeted whole cell screens are significantly 
affected by the culture conditions of the screening procedure.
122
  Additionally, in vitro whole 
cell screens do not take into account the toxicity of hit chemicals towards the animal host, nor 
the effects of the host on drug stability or activity and these aspects must be explored in 
downstream studies. 
 
1.6.2.1.2 Non-targeted whole cell high content screening 
A sub-set of whole cell screening, high content screening involves further modification of the in 
vitro culture conditions to provide a better biological context, such as bacteria phagocytosed by 
immune cells rendering a very specific environment that mimics in vivo pathogenesis and will 
detect compounds activated by immune cells, or compounds active in the immune cell 
environment that may even modulate the anti-bacterial ability of the immune cells themselves.  
The relevance of chemical library screens to the host infection environment are increased with this 
technique, enriching library hits for compounds active during in vivo infection conditions.  For 
example with the macrophage infection model, where macrophage cultures are “infected” with 
mycobacteria which are phagocytosed and the infected macrophage culture is subsequently 
screened against a chemical library to identify inhibitors active against the phagocytosed 
mycobacteria.
144
  The advantages of this assay over conventional whole-cell in vitro high-
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throughput screening are that it can potentially detect pro-drug type compounds that undergo some 
chemical modification within the macrophage environment which result in anti-mycobacterial 
activity.  Hit compounds must not only navigate the bacterial whole cell and retain activity, but 
also pass through the macrophage environment unscathed.  Chemicals that modulate the 
macrophage itself, improving its killing effect on internalised mycobacteria, may also be detected 
in this type of assay.  A huge advantage of this assay is that it takes into account specificity of hit 
compounds‟ action, distinguishing compounds active towards bacteria and those that are also toxic 
toward the macrophage host.  The use of this type of assay in the high-throughput screening of a 
library of approximately 57,000 small molecules resulted in the identification of the new class of 
dinitrobenzamide derivatives as novel inhibitors of intra-macrophage M. tuberculosis.
145
  
 
1.6.2.2 Targeted screening 
Although not performed in this study, targeted screening is gaining more popularity in tuberculosis 
drug discovery as knowledge of the drug target can facilitate rapid clinical development.  Various 
methodologies of targeted screening will be briefly introduced in this section to provide context to 
this research.  Common techniques in target-based TB drug discovery are illustrated in Figure 1.4. 
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Figure 1.4:  Target based approaches to TB drug discovery. 
Top left panel depicts an in silico virtual drug screen, further described in section 1.6.2.2.2.  
Top right panel depicts an in vitro enzymatic screen further described in section 1.6.2.2.3.  
Bottom left shows a whole cell anti-sense RNA differential sensitivity assay further described 
in section 1.6.2.2.3.  Bottom right shows a whole cell gene expression screen further described 
in 1.6.2.2.4.  Figure derived from Miller & O‟Toole 2011.2 
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1.6.2.2.1 Target selection 
Non-targeted approaches screen compound libraries against whole-cell cultures, resulting in 
discovery of inhibitors of bacterial growth with an unknown target.  Target based approaches 
begin with a specifically defined molecular target and then screen for corresponding 
inhibitors of that target.  The main advantage of this method is that it allows researchers to 
intelligently guide antibiotic development towards a specific or unique bacterial process; this 
may enrich hits for activity and specificity towards the target bacterial species rather than 
general cytotoxic compounds.  With the advent of widespread genome sequencing, drug 
target proteins may be defined bioinformatically.  Ideal targets include gene products that are 
essential to bacterial replication.  Such genes are evolutionarily conserved
146
 and are involved 
in transcription, translation and cell division, since the inhibition of these processes will lead 
to death or stasis of the bacteria.
147-150
  This criterion may also be expanded to genes involved 
in pathogenesis, and lists of target genes can be further enriched by bioinformatic annotation 
of their drug-binding domains, metabolic load bearing and expression during periods such as 
latency.
140
 
 
1.6.2.2.2 In silico screening 
In silico targeted screening uses computer processing to virtually “dock” chemicals against 
protein structures generated from x-ray crystallography or computational prediction based on 
amino acid sequence.  This approach has been implemented against M. tuberculosis Acyl-
CoA carboxylase, an essential gene product for mycolic acid biosynthesis, resulting in 
discovery of lead compounds with IC50 values as low as 8 µM against clinical isolates in 
vitro.
151, 152
  Virtual chemical libraries have also been created ad hoc against specific M. 
tuberculosis targets, such as a library of substituted thiazolidinone compounds compiled for 
screening against the rhamnose synthesising enzyme RmIC, the hits of which were 
subsequently synthesised, resulting in MIC activity of 25 µg/ml against M. tuberculosis 
H37Ra in vitro.
153, 154
  A key advantage of in silico screens is the huge number of chemicals 
that can be virtually screened, with minimal expense.  However in silico screens serve only as 
a useful guide to drug screening and they must be followed up with in vitro laboratory wet 
work.  Virtual screens do not consider the wider context of the target protein, such as the 
delivery of the drug through barriers of the cell wall, bacterial metabolism and the target‟s 
cellular conformation. 
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1.6.2.2.3 In vitro enzyme-based screening 
Targets with known enzymatic activity may allow the establishment of a biochemical assay 
to detect or validate inhibitors. For example, SQ-641 currently in pre-clinical development, 
was discovered from a targeted screen for inhibitors of non-mycobacterial phospho-N-
acetylmuramyl-pentapeptide translocase in vitro and subsequently found to be active against 
mycobacteria.
155
  This approach is readily adaptable to high throughput screening and can be 
designed to be very specific for the target enzyme, which enriches the quality of the hit 
compounds and yields good information on the compounds‟ mechanism of action.  The 
disadvantages of targeted enzyme based screens are that they only assess the enzyme in an 
isolated environment, not accounting for the wider effects of the whole bacterial cell such as 
the cell wall, efflux pumps, metabolic inactivation and parallel target domains.  This can lead 
to a compound that demonstrates excellent activity in the enzymatic assay, but is inactive 
against whole cells.  For example, nafronyl oxalate was found to be a specific inhibitor of M. 
tuberculosis pantothenate synthetase, PanC, through an in vitro enzyme screen. However, 
when submitted for testing, nafronyl oxalate was found to be inactive against M. tuberculosis 
whole cells in vitro at the standard testing concentration 6.26 µg/ml.
156
  Enzyme based 
biochemical screens may also report false positive results from chemicals that interfere with 
the assay itself rather than directly inhibiting the target enzyme. 
 
1.6.2.2.4 Whole-cell differential antisense sensitivity screening 
This approach takes the contextual advantages of whole cell screening and combines it with 
the specificity of targeted enzyme based screening.  In vitro enzyme-based assays can detect 
inhibitors toward specific target enzymes; they cannot distinguish compounds with poor 
permeability into the mycobacterial cell, and other complications stemming from the bacterial 
cell environment. Non-targeted whole-cell assays address these environmental issues but do 
not have a defined cellular target. Whole cell differential antisense sensitivity assays combine 
the advantages of both of these techniques, repressing gene expression and allowing target 
based screening of whole cell populations.  This has been performed in M. smegmatis
157-160
 
and M. tuberculosis.
161
  A noteworthy mycobacterial example is the use of a differential 
antisense assay against M. smegmatis cell partitioning gene parA , resulting in the 
identification of two novel ParA and M. tuberculosis inhibitors, octoclothepin and 
methiothepin, and discovery of a clozapine derivative class of anti-mycobacterials.
157, 162
  The 
platensimycin class of antibiotics were discovered and characterised as inhibitors of S. aureus 
fatty acid synthesis using antisense differential sensitivity assays.
163-167
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1.6.2.2.5 Whole-cell gene expression screening 
The whole cell screen uses measurement of target gene expression levels, for example linking 
promoters of interest to a reporter gene system such as luciferase or GFP and observing the 
effects of chemical inhibitors on this promoter‟s expression.2  This has been used by the anti-
infective research company Sequella, with a high-throughput assay of a large chemical 
library against recombinant M. tuberculosis containing firefly luciferase downstream of the 
Rv0341 gene promoter. This promoter responds to stresses interfering with the cell wall such 
as compounds like ethambutol and ethionamide. This screen revealed a novel series of cell-
wall targeting dipiperidines including SQ609, currently undergoing pre-clinical testing 
(http://www.newtbdrugs.org/project.php?id=145). Targeted approaches such as these are not 
confined to singling out individual genes or proteins for chemical disruption, but have 
potential to identify inhibitors of entire mycobacterial cellular processes. This burgeoning 
approach may identify inhibitors of virulence or persistence mechanisms in M. tuberculosis, 
facilitating discrimination between the host, pathogenic and commensal organisms.
168, 169
 
 
1.6.3 Downstream studies 
After discovery of a compound with desirable antibiotic properties, it is necessary to 
understand the mechanism of antibiotic activity.
170
  This knowledge yields insight into how 
the chemical structure may be modified, or coupled with other agents in order to increase its 
efficacy and advance clinical development.  Understanding of the mechanism also allows 
researchers to predict and anticipate how bacteria can develop resistance to the compound.
147
  
Identification of target can be obtained using several different techniques, such as coupling 
the inhibitor to a sepharose column and assaying cell lysates for molecules that bind to the 
inhibitor.
171
  Differential protein expression has been used to analyse mycobacterial cell 
response antibiotics, and can provide clues as to the cellular process affected.
172
  Major 
decreases in costs of whole-genome sequencing make it possible to sequence artificially-
generated drug resistant mutants, identifying genes implicated in resistance to the antibiotic 
and presumably its mode of action.  Such an approach was applied to TMC207, where 
resistant mutants were generated, sequenced and found to contain mutations in the ATP 
synthase c subunit gene atpE of M. tuberculosis.
97
 This type of evidence must then be 
supported by gene complementation studies
97
 and biochemical assays
98
 in order to further 
confirm the drug-target interaction. 
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1.8 Summary 
Tuberculosis is an ancient disease that continues to burden us to this day.  Tuberculosis is 
caused by a unique bacterial pathogen Mycobacterium tuberculosis that has adapted its 
biology to reside within the immune cells intended to kill it.  Carefree administration of 
lengthy antibiotic treatment regimens coupled with the distinctive resilient nature of the 
tuberculosis pathogen has given rise to drug resistant strains of tuberculosis, including strains 
resistant to all major treatment drugs that seem to be practically untreatable within the typical 
clinical settings.  Although an active area of research, no drug with a novel mechanism of 
action has been approved for TB treatment in almost 50 years. 
 
This research endeavoured to contribute to global efforts to eradicate tuberculosis, by 
developmentment and implementation of a rapid non-targeted anti-mycobacterial high 
throughput screen utilising several distinct culture conditions to emulate the environmental 
conditions encountered by tuberculosis during infection, including latent tuberculosis 
(Chapter 3 and 4).  Novel inhibitors derived from this screening was further researched and 
assessed for developmental priority (Chapter 5) and the most desirable compound was 
investigated for its mechanism of action and structure-activity properties (Chapter 6). 
 
1.8.1 Aim of this research 
 
Develop a multi culture condition anti-mycobacterial assay: 
Develop and optimise a high throughput screen capable of rapidly profiling the inhibitory 
properties of large scale chemical collections against the tuberculosis model organism M. 
smegmatis under various culture conditions to best emulate the environment of tuberculosis 
pathogenesis. 
 
Discover new anti-tubercular compounds: 
Implement the anti-mycobacterial assay to identify novel chemical inhibitors of M. 
tuberculosis with potential use in the treatment of tuberculosis.  
 
Define the anti-tubercular mechanisms of the novel compounds: 
Define the molecular mechanism of action of the novel anti-tubercular compounds to aid the 
chemical improvement of the pharmacophore for clinical therapy.
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2.1 Bacterial strains and plasmids 
Bacterial strains utilised in this research and their respective characteristics of interest and 
culture conditions used are listed in Table 2.1.  Plasmids utilised in this study and their 
properties of interest are listed in Table 2.2.   
2.1.1 Bacterial strains 
Table 2.1:  Bacterial strains.  
 Bacterial strains utilised in this work. 
Strain Characteristics Culture Conditions Reference 
Mycobacterium     
M. smegmatis 
MC
2
155 
High frequency transformation strain of 
fast growing mycobacterial species M. 
smegmatis. ATCC 607. 
LB, 7H9+, HdeB C-, 
HdeB N-.  
Snapper, 1990
173
 
M. bovis BCG Bovine tuberculosis, attenuated strain.  
Used in human vaccination.  
Pasteur 1173P2. 
7H9+, 7H9-,  Oettinger 1999
174
 
M. tuberculosis 
H37Ra 
Avirulent laboratory reference strain 
ATCC 25177. 
7H9+, 7H9-,  Zheng 2008
72
 
M. tuberculosis 
H37Rv 
Virulent laboratory reference strain  
ATCC 27294.  
7H9+,  Steenken, 1934 
175
 
Escherichia     
E. coli DH5α Cloning strain. F- endA1 glnV44 thi-1 
recA1 relA1 gyrA96 deoR nupG 
ϕ80dlacZΔM15 Δ(lacZYA-
argF)U169, hsdR17(rK- mK+), λ- 
LB, M9.  Promega (Sydney, 
Australia) 
E. coli BL-21 (DE-
3) 
Protein expression strain. F
- 
ompT gal dcm 
lon hsdSB(rB
- 
mB
-
) λ(DE3 [lacI lacUV5-
T7 gene 1 ind1 sam7 nin5]) 
LB, ZYP. Novagen 
(Palmerston North, 
New Zealand) 
E. coli S17-1 Conjugation donor strain.  OriT, TpR SmR 
recA, thi, pro, hsdR-M
+
RP4: 2-Tc:Mu 
LB, TSB Simon, 1984
176
 
    
Strain Characteristics Culture Conditions Reference 
Other bacteria    
S. aureus Newman Laboratory model strain. LB, M9 Baba, 2008 
177
 
P. aeruginosa 
PA01 
Opportunistic human pathogen. LB, M9 Stover, 2000
178
 
V. harveyi Marine pathogen species. ATCC 14126 LB + NaCl, TSB, 
TCBS, M9 + NaCl 
Austin, 2006
179
 
Yeast     
  CHAPTER TWO:  MATERIALS AND METHODS     34 
S. cerevisiae 
Y7092 4741 
Haploid laboratory strain. SC, SPO Goffeau, 1996
180
 
S. cerevisiae 
Y7092 4743 
Diploid laboratory strain.  SC, SPO Goffeau, 1996
180
 
S. cerevisiae 
YAL012W 
Cystathionine Gamma Lyase KO. ΔCys3 SC, SPO Ono, 1992181 
S. cerevisiae 
YLR303W 
Methionine/Cysteine synthase KO. 
ΔMet17 
SC, SPO Thomas, 1997
182
 
S. cerevisiae 
YCL017C 
Cysteine desulphurase KO. ΔNFS1 SC, SPO Müllenhoff, 1994183 
 
  2.1.2 Plasmids 
Table 2.2: Plasmids.   
Plasmids used in this study. 
Plasmid Characteristics Selection Reference 
pCR 2.1 3.9 kb.  Commercial TA cloning vector for rapid 
ligation of PCR products for retention and downstream 
cloning/sequencing.  pUC origin, T7 promoter, LacZα 
fragment, M13 primer sites 
Amp
R
, 
Kan
R
 
Invitrogen 
pCG79 17.9 kb.  Thermo-sensitive transposon shuttle vector.  
pAL5000 and pUC18 origins. 41 °C inhibitory 
thermosensitive. Tn611 transposon. 
Str
R
, Spc
R
 
Kan
R
 
Guilhot 
1994
184
 
pET28a(+) 5.4 kb.  Protein over-expression vector. pBR322 origin, 
MCS, lacI,  T7 promoter/terminator, His-Tag®. 
Kan
R
 Invitrogen 
pET28a(+)_MSMEG_23
57 
6.6 kb.  pET28a(+) with 1.2 kb M. smegmatis MC
2
155 
MSMEG_2357 gene inserted at BamHI/HindIII site. 
Kan
R
 This work 
Plasmid Characteristics Selection Reference 
pET28a(+)_Rv0391 6.6 kb.  pET28a(+) with 1.2 kb M. tuberculosis H37Rv 
Rv0391 BamHI/HindIII site. 
Kan
R
 This work 
pET28a(+)_Rv1079 6.6 kb.  pET28a(+) with 1.2 kb M. tuberculosis H37Rv 
Rv1079 g gene inserted at NheI/HindIII site. 
Kan
R
 This work 
pET28a(+)_Rv1464 6.6 kb.  pET28a(+) with 1.2 kb encoding M. 
tuberculosis H37Rv Rv1464 gene inserted at 
EcoRI/HindIII site. 
Kan
R
 This work 
pET28a(+)_Rv2428 6.0 kb.  pET28a(+) with 0.6 kb PCR product encoding 
M. tuberculosis H37Rv Rv2428 gene inserted at 
BamHI/HindIII site. 
Kan
R
 This work 
pET28a(+)_Rv2429 5.9 kb.  pET28a(+) with 0.5 kb PCR product encoding  
M. tuberculosis H37Rv Rv2429 gene inserted at 
BamHI/HindIII site. 
Kan
R
 This work 
pET28a(+)_Rv3025c 6.6 kb.  pET28a(+) with 1.2 kb PCR product encoding 
M. tuberculosis H37Rv Rv3025c gene inserted at 
BamHI/HindIII site. 
Kan
R
 This work 
pET28a(+)_Rv3340 
 
6.7 kb.  pET28a(+) with 1.3 kb PCR product encoding 
M. tuberculosis H37Rv Rv3340 gene inserted at 
Kan
R
 This work 
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 EcoRI/HindIII site. 
pDEST-pUNK1 
PFDHL::GFP 
Gram positive shuttle vector.  pDEST-pUNK1 
derivative with fdh fused gfp reporter.  OriE1, Ori 
pAMβ1, xylA promoter.185 
Em
R
 Earl 2010
186
 
pHS201 5.8 kb.  Mycobacterium / E. coli shuttle vector.  High 
copy number pAL5000 origin.  gfpmut2 with synthetic 
Shine-Delgarno RBS under M. bovis BCG hsp60 
promoter. 
Kan
R
 Bourn 
2007
187
 
pKW08 
 
6.0 kb.  Mycobacterial tetracycline inducible 
conditional expression vector.  pSE100 based.  TetR08 
promoter (a Thr40 to Gly40 substitution in the TetRO 
promoter for decreased background expression.) 
Hyg
R
 Williams 
2010
188
 
    
Plasmid Characteristics Selection Reference 
pKW08_GFP 6.75 kb.  pKW08 with 0.75kb gfpmut2 with synthetic 
Shine-Delgarno RBS from pHS201 cloned into the 
HindIII site in the sense orientation under TetR08 
tetracycline inducible promoter. 
Hyg
R
 This work 
pKW08_2357S 7.2 kb.  pKW08 with 1.2 kb PCR fragment encoding M. 
smegmatis MSMEG_2357 gene cloned in the sense 
orientation at the BamHI/EcoRV site under the TetR08 
tetracycline inducible promoter. 
Hyg
R
 This work 
pKW08_2357AS 7.2 kb.  pKW08 with 1.2 kb PCR fragment encoding M. 
smegmatis MSMEG_2357 gene cloned in the antisense 
orientation at the EcoRV/BamHI site under the TetR08 
tetracycline inducible promoter. 
Hyg
R
 This work 
pKW08_5265S 7.2 kb.  pKW08 with 1.2 kb PCR fragment encoding M. 
smegmatis MSMEG_5265 gene cloned in the sense 
orientation at the BamHI/EcoRV site under the TetR08 
tetracycline inducible promoter. 
Hyg
R
 This work 
pKW08_5265AS 7.2 kb.  pKW08 with 1.2 kb PCR fragment encoding M. 
smegmatis MSMEG_5265 gene cloned in the antisense 
orientation at the EcoRV/BamHI site under the TetR08 
tetracycline inducible promoter. 
Hyg
R
 This work 
pMEND 6.7 kb.  pMIND with a Thr40 to Gly40 substitution in 
the TetRO promoter for decreased background 
expression. 
Hyg
R
, 
Kan
R
 
Williams 
2010
188
 
pMEND_GFP 
 
7.45 kb.  pMEND with 0.75 kb gfpmut2 with synthetic 
Shine-Delgarno RBS from pHS201 cloned into the 
HindIII site in the sense orientation under TetRO 
tetracycline inducible promoter. 
Hyg
R
, 
Kan
R
 
This work 
pMIND 
 
6.8 kb.  Conditional tetracycline inducible 
mycobacterial expression vector.  ColiE1 origin, 
pAL5000 origin, MCS, TetRO tetracycline inducible 
promoter. 
Hyg
R
, 
Kan
R
 
Blokpoel 
2005
189
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Plasmid Characteristics Selection Reference 
pMIND_GFP 7.6 kb.  pMIND with 0.75 kb gfpmut2 with synthetic 
Shine-Delgarno RBS from pHS201 cloned into the SpeI 
site in the sense orientation under TetRO tetracycline 
inducible promoter. 
Hyg
R
, 
Kan
R
 
Nisa 
2010
157
 
pMIND_2357AS 9.0 kb.  pMIND with 1.2 kb MSMEG_2357 PCR 
fragment cloned in the antisense orientation under the 
Tet promoter. 
Hyg
R
, 
Kan
R
 
Nisa 
2010
157
 
pMMB207 9.1 kb.  RSF1010 derivative, IncQ, lacI, tac inducible 
promoter, MCS, oriT. 
Chl
R
 Morales 
1991
190
 
pMV261 4.5 kb.  Mycobacterium / E. coli shuttle vector. 
pAL5000 origin, oriE, MCS,  M. tuberculosis hsp60 
promoter.   
Kan
R
 Stover 
1991
191
 
pOT11 9.85 kb.  pMMB207 derivative with 0.75 kb gfpmut2 
inserted at XbaI/PstI site under the tac inducible 
promoter.   
Chl
R
 O‟Toole 
2004
192
 
pSHIGH+HSP60 5.6 kb.  pTKmx derivative with hsp60 promoter from 
M. bovis BCG inserted at KpnI site and 0.75 kb gfpmut2 
gene from pOT11 with synthetic Shine-Delgarno RBS 
inserted at KpnI/SphI sites.  pAL5000 origin of 
replication replaced with the high copy number 
pAL5000 origin of pHIGH100
187
 at the NheI site.   
Kan
R
 Miller 
2009
122
 
pTKmx 6.0 kb.  Mycobacterium / E. coli shuttle vector. 
pAL5000 origin, pUC origin, MCS, promoterless xylE 
reporter. 
Kan
R
 Kenny 
1996
193
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2.2 Media and culture conditions 
2.2.1 Chemicals and reagents 
2.2.1.1 Chemicals 
Chemicals were purchased from Sigma-Aldrich unless otherwise stated. Aliquots (50 µL) of 
the LOPAC (Sigma) and Spectrum (Microsource) chemical libraries were purchased from the 
VUW Chemical Genetics laboratory.  The NIH Diversity Set I was a kind gift from the NIH 
through their developmental therapeutics program.  IPTG, Xgal, DNA Hyperladder I, DNA 
loading buffer and Protein ladder were obtained from Bioline (Auckland, NZ).  Drum 
methanol, ethanol, isopropanol and glacial acetic acid were obtained from the VUW 
Chemistry Store. 
2.2.1.2 Media 
2.2.1.2.1 Luria-Bertani broth (Miller) 
Tryptone     10 g 
Yeast Extract     5 g 
NaCl      10 g 
10% Tween80 (optional)   5 mL 
100 mg/mL D-arabinose (optional)  1 mL 
ddH2O      Make up to 1 L 
Autoclave on liquid cycle, 30 minutes at 121 °C,  store at room temperature.  
2.2.1.2.2 7H9 broth (Middlebrook) 
Middlebrook 7H9 powder   4.7 g 
50% Glycerol     10 mL 
10% Tween80    5 mL 
ddH2O      Make up to 900 mL 
Autoclave on liquid cycle, 30 minutes at 121 °C,  store at room temperature. 
Allow to cool before adding 100 mL of 0.22 µm filter sterilised OADC enrichment. 
2.2.1.2.3 Minimal 7H9- broth (Middlebrook) 
Middlebrook 7H9 powder   4.7 g 
50% Glycerol     1 mL 
10% Tween80    2.5 mL 
ddH2O      Make up to 900 mL 
Autoclave on liquid cycle, 30 minutes at 121 °C,  store at room temperature. 
Allow to cool before adding 20 mL of 0.22 µm filter sterilised OADC enrichment. 
2.2.1.2.4 OADC enrichment (Middlebrook) 
BSA Fraction V    50 g 
Dextrose     20 g 
NaCl      8 g 
0.1 N NaOH     25 mL 
Oleic acid     0.6 mL 
10% Citric Acid    0.4 mL 
0.02 mg/mL Catalase    0.02 mL 
ddH2O     975 mL 
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Dissolve albumin in ddH2O and add other components through mixing.  Sterilise through a 
0.22 µm pore filter.  Dispense in 50 mL aliquots and incubate at 37°C overnight to confirm 
sterility.  Store at 4 °C. 
2.2.1.2.5 Hartman de Bonts carbon starvation (HdeB C
-
) broth 
HdeB Base     960 mL 
100x Nitrogen    10 mL 
100x Phosphates    10 mL 
10% Glycerol     8 mL 
ddH2O     12 mL 
Autoclave on liquid cycle, 30 minutes at 121°C, store at room temperature. 
 
2.2.1.2.6 Hartman de Bonts nitrogen starvation (HdeB N
-
) broth 
HdeB Base     960 mL 
100x Nitrogen    0.1 mL 
100x Phosphates    10 mL 
10% Glycerol     20 mL 
ddH2O     9.9 mL 
Autoclave on liquid cycle, 30 minutes at 121°C, store at room temperature. 
2.2.1.2.7 Hartman de Bonts oxygen starvation (HdeB O2
-
) broth 
HdeB Base     960 mL 
100x Nitrogen    10 mL 
100x Phosphates    10 mL 
10% Glycerol     20 mL 
Autoclave on liquid cycle, 30 minutes at 121°C, store at room temperature.  Cultures must be 
sealed to ensure oxygen starvation. 
2.2.1.2.8 Hartman de Bonts (HdeB) base 
100x Metal salts    10 mL 
10% Tween80    5 mL 
ddH2O       945 mL 
Autoclave on liquid cycle, 30 minutes at 121°C, store at room temperature. 
2.2.1.2.9 100x metal salts 
EDTA     1 g 
MgCl2      10 g 
CaCl2      0.1 g 
CoCl2      0.04 g 
MnCl2      0.1 g 
NaMoO4      0.02 g 
ZnSO4      0.2 g 
CuSO4      0.02 g 
FeSO4      0.5 g 
Make up to 1 L with ddH2O, autoclave on liquid cycle, 30 minutes at 121°C store at 4°C. 
2.2.1.2.10 100x nitrogen  
(NH4)2SO4     200 g 
Make up to 1 L with ddH2O, autoclave on liquid cycle, 30 minutes at 121°C store at 4°C. 
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2.2.1.2.11 100x phosphates 
K2HPO4     155 g 
KH2PO4     85 g 
Make up to 1 L with ddH2O, autoclave on liquid cycle, 30 minutes at 121°C, store at 4°C. 
2.2.1.2.12 M9 minimal broth 
5x M9 Salts    200 mL 
1 M MgSO4     2 mL 
20% D-Glucose    20 mL 
1 M CaCl2     0.1 mL  
1% Thiamine     1 mL 
10% cas-amino acids (optional)  3 mL 
1 M MgCl2 (optional)   1 mL 
ddH2O      make up to 1 L 
2.2.1.2.13 ZYP-5052 auto-induction broth 
ZY       919 mL 
1 M MgSO4    1 mL 
100x Metal Salts   10 mL 
50x 5052      20 mL 
20x NPS      50 mL 
Betaine (optional)   1 mM 
Sorbitol (optional)    0.5-1 M 
 
2.2.1.2.14 ZY base 
Tryptone     10 g 
Yeast Extract     5 g 
Make up to 919 mL with ddH2O, autoclave on liquid cycle, 30 min at 121 °C. 
 
2.2.1.2.15 50x 5052 
Glycerol      250 g w/v 
Glucose      25 g 
α-Lactose     100 g 
Make up to 1 L with ddH2O, autoclave on liquid cycle, 30 min at 121 °C. 
2.2.1.2.16 20x NPS 
(NH4)2SO4    66 g  
KH2PO4      136 g 
Na2HPO4     142 g 
Make up to 1 L with ddH2O, autoclave on liquid cycle, 30 min at 121°C. 
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2.2.1.3 Media supplementation 
 Bacterial growth media were commonly supplemented with additional carbon sources, 
surfactants and anti-clumping agents, selection antibiotics and other chemicals.  Commonly 
used supplements and the preparation of their working stocks are described below. 
 
Antibiotics:  Stocks were made up with ddH2O and used at the concentrations described below 
in Table 2.3. Solutions were vortexed to ensure complete solubility of compound and then 
sterilised by passage through a 0.22 µm syringe filter (Millipore), aliquoted into microfuge 
tubes and stored at -20 °C with the exception of hygromycin which was purchased from 
Sigma pre-solubilised and stored as recommended at 4 °C.  Antibiotics were added to media 
in a sterile PC2 hood subsequent to autoclaving, after the media had cooled enough to 
comfortably hold the bottle by hand. 
Chemicals:  Isopropyl-β-D-thiogalactopyranoside (IPTG), L-arabinose and xylose were made 
up with ddH2O and used at the concentrations described below in Table 2.3. Solutions were 
vortexed to ensure complete solubility of compound and then sterilised by passage through a 
0.22 µm syringe filter (Millipore), aliquoted into microfuge tubes and stored at -20 °C.  5-
bromo-4-chloro-3-indolyl- β-D-galactopyranoside (X-gal) was made up using 100% DMSO.  
X-gal was not filter sterilised due to the corrosive effect of DMSO on the filter membrane, 
was stored at -20 °C wrapped in tinfoil to protect it from light.  IPTG, L-arabinose and X-gal 
were added to media subsequent to autoclaving after media had cooled enough to 
comfortably hold the bottle by hand.   
Glycerol:  Glycerol working stocks were made up at concentrations of 10%, 50% and 80% 
v/v with ddH2O and sterilised/solubilised in a liquid autoclave at 121 °C for 30 min.  Glycerol 
was added to media prior to autoclaving. 
Tween 80:  Polysorbate-80 (Tween 80) working stocks were made up to a concentration of 
10% v/v with ddH2O and sterilised/solubilised in a liquid autoclave at 121 °C for 30 min.  
Tween80 was added to liquid media prior to autoclaving.  
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Table 2.3:  Media supplementation.   
Chemicals used to supplement media in this work and their respective concentrations for 
various bacterial species. 
Chemical Stock 
Concentration 
Working 
Concentration E. 
coli 
Working 
Concentration 
Mycobacterium 
sp. 
Working 
Concentration S. 
aureus 
Ampicillin 100 mg/mL 200 µg/mL - - 
Chloramphenicol 50 mg/mL 25 µg/mL * - - 
D-Arabinose 100 mg/mL - 100 µg/mL - 
D-Xylose 10% (w/v) - - 0.5% 
Erythromycin 50 mg/mL - - 50 µg/mL 
Glycerol 10-50% (v/v) - 0.5% ** - 
Hygromycin 50 mg/mL 200 µg/mL 50 µg/mL - 
Kanamycin 50 mg/mL 50 µg/mL 50 µg/mL - 
Tetracycline 10 mg/mL - 50 ng/mL - 
Tween80 10% (v/v) - 0.1% - 
IPTG 100 mg/mL 100 µg/mL - - 
X-gal 40 mg/mL 40 µg/mL - - 
*10 µg/mL chloramphenicol was used in the selection of transformant V. harveyi.  
2.2.1.4 Enzymes  
Restriction endonucleases, Antarctic phosphatase, T4 polynucleotide kinase and their 
respective buffers and additional components were purchased from New England Biolabs.  
DNase I, RNase A, lysozyme, proteinase K, alanine dehydrogenase and lactate 
dehydrogenase were purchased from Sigma-Aldrich. 
Bioline Red™ PCR Mastermix ,T4 Ligase, T4 ligase buffer, ATP and MgCl2 were purchased 
from Bioline.  All enzymes, buffers and supplements were kept on ice during use and stored 
according to manufacturer‟s instructions. 
 
2.2.1.5 Oligonucleotides 
Oligonucleotide primers were designed using Gentle software, including restriction site, 
melting temperature, dimerisation and self annealing analysis. Oligonucleotides were 
synthesised by IDT custom oligonucleotide service, reconstituted with TE buffer to a 100 µM 
master stock and 10 µM working stocks were made up with ddH2O.  All oligonucleotides 
were stored at -20 °C, kept on ice while in use and are listed below in Table 2.4. 
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Table 2.4: Primers.  
Oligonucleotide primers used in this study and their melting temperatures.  Melting 
temperature (Tm) accommodates 50 mM NaCl salt conditions as described in PCR section 
2.3.2.1.  Restriction endonuclease sites are shown underlined.  Ribosomal binding sites are 
shown in bold. Forward and reverse orientation primers are designated by a _F and _R suffix, 
respectively.  Sense and antisense orientation when inserted into intended vector is denoted 
by the suffix _S and _AS, respectively.  
Primer Name  Tm 
(°C) 
5’-3’ Sequence 
GFP   
GFP_RBS_F 63.6 
CTAGACTAGTTTTAAGAAGGAGATATACATATGAG 
TAAAGGAGGA 
GFP_R 60 
CTAG ACTAGT 
TTATTATTTGTATAGTTCATCCATGCC 
M. smegmatis MC
2
155   
MSMEG_2357_pKW_S_F 68.5 CTAG GGATCC ATGACCTCCACTGCGGGCAG 
MSMEG_2357_pKW_S_R 67.1 CTAG GATATC TCATCGGCTCACCGTCCCCG 
MSMEG_2357_pKW_AS_F 65.7 CTAG GATATC ATGACCTCCACTGCGGGCAG 
MSMEG_2357_pKW_AS_R 69.8 CTAG GGATCC TCATCGGCTCACCGTCCCCG 
MSMEG_4890_pKW_S_F 67 
CTAG GGATCC TTTAAGAAGGAGATATACAT 
ATGAGCATCGACAACATCAA 
MSMEG_4890_pKW_S_R 67.1 CTAG GATATC CTAGACCGCGGCGAGGGTGT 
MSMEG_4890_pKW_AS_F 58.9 CTAG GATATC ATGAGCATCGACAACATCAA 
MSMEG_4890_pKW_AS_R 69.8 CTAG GGATCC CTAGACCGCGGCGAGGGTGT 
MSMEG_4891_pKW_S_F 68.7 
CTAG GGATCC TTTAAGAAGGAGATATACAT 
ATGGCTCTTTTGACGATCGG 
MSMEG_4891_pKW_S_R 67.1 CTAG GATATC TCACACCGCCCCAGCCAGCA 
MSMEG_4891_pKW_AS_F 61.6 CTAG GATATC ATGGCTCTTTTGACGATCGG 
MSMEG_4891_pKW_AS_R 69.8 CTAG GGATCC TCACACCGCCCCAGCCAGCA 
MSMEG_5265_pKW_S_F 64.4 CTAG GGATCC ATGAGTGAACACCGCAAGTG 
MSMEG_5265_pKW_S_R 67.1 CTAG GATATC TCAGCCCAGGGCCTGCTCCA 
MSMEG_5265_pKW_AS_F 61.6 CTAG GATATC ATGAGTGAACACCGCAAGTG 
MSMEG_5265_pKW_AS_R 
 
69.8 CTAG GGATCC TCAGCCCAGGGCCTGCTCCA 
M. tuberculosis H37Rv   
Rv0391_pET28a_F 65.7 CTAG GGATCC ATGACCGACGAGTCTTCGGT 
Rv0391_pET28a_R 63 CTAG AAGCTT TTAGCTCAACGCCCGATCGA 
Rv1079_pET28a_F 68.5 CTAG GCTAGC ATGAGCGAAGACCGCACGGG 
Rv1079_pET28a_R 63 CTAG AAGCTT TTAACCCAGGGCCTGTTCGA 
Rv1464_pET28a_F 64.4 CTAG GAATTC ATGACGGCCTCGGTGAACTC 
Rv1464_pET28a_R 58.9 CTAG AAGCTT TCACGCTCTTCCAAAGAAAT 
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Primer Name  Tm 
(°C) 
5’-3’ Sequence 
Rv2428_pET28a_F 64.4 CTAG GGATCC ATGCCACTGCTAACCATTGG 
Rv2428_pET28a_R 63 CTAG AAGCTT TTAGGCCGAAGCCTTGAGGA 
Rv2429_pET28a_F 58.9 CTAG GGATCC ATGAGTATAGAAAAGCTCAA 
Rv2429_pET28a_R 61.6 CTAG AAGCTT TTAGCTTGGGCTTAGTGCCT 
 
Rv3025c_pET28a_F 67.1 CTAG GGATCC ATGGCCTACCTGGATCACGC 
Rv3025c_pET28a_R 67.1 CTAG AAGCTT TCATCGGGATGCTCCCGCGG 
Rv3340_pET28a_F 63 CTAG GAATTC ATGAGCGCCGACAGCAATAG 
Rv3340_pET28a_R 65.7 CTAG AAGCTT TCAGAACGCCGCCACGGACT 
Rv3778c_pET28a_F 68.5 CTAG GGATCC ATGGCATACGACGTCGCCCG 
Rv3778c_pET28a_R 65.7 CTAG AAGCTT TCAACCTAGCGACGCCAGCG 
General Sequencing   
3053 55.4 GAACCGCTTCGCTGCCTTG 
3054 53.8 AACCACCATTTCGCAGCAGC 
M13_F 57.1 CCCAGTCACGACGTTGTAAAACG 
M13_R 53.5 AGCGGATAACAATTTCACACAGG 
Hyg_R 54 AAGTAACAGGGATTCTTGTGTCAC 
oriM(+600)_F  65.9 GGGGCCTGTTCTGCCGCACGCTCT  
T7_promoter_F 47.7 TAATACGACTCACTATAGGG 
T7_terminator_R 51.1 GCTAGTTATTGCTCAGCGG 
TetRO_F 53.8 CTTCCGGTGGTGAGTCATAG 
  
2.2.2 Culture procedures 
Bacterial cultures were grown at 37 °C unless otherwise indicated.  Fresh solid media 
bacterial cultures were streaked onto 1.5% agar media from -80 °C glycerol freezer stocks in 
a sterile PC2 hood.  Liquid cultures were grown in factory sterile well plates, polypropylene 
tubes, or conical flasks which had been previously sterilised manually by sealing the flask 
mouth with cotton wool and aluminium foil and autoclaving at 138 °C with a drying cycle.  
Liquid cultures were inoculated from plates or sub-inoculated from liquid cultures and 
aerated with 200 RPM orbital shaking during incubation.  “Appropriate supplements” refers 
to selection antibiotics or other supplementation not mentioned in the media preparation 
procedure. 
 
2.2.2.1 Microbial culture 
Media preparation procedures are detailed in section 2.2.1.2. 
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2.2.2.1.1 E. coli 
E. coli strains were solid cultured on LB agar (1.5%) and liquid cultured in either LB broth or 
M9 minimal media with the appropriate supplements.  E. coli cultures were incubated 
overnight at 37 °C.  All media were sterilized by autoclaving as described above in section 
2.2.2.   
2.2.2.1.2 M. smegmatis 
M. smegmatis strains were solid cultured on LBA or Middlebrook 7H10 agar (1.5%) and 
liquid cultured in LB broth, Middlebrook 7H9 broth or Hartman-de-Bonts (HdeB) minimal 
media with the appropriate supplements.  M. smegmatis cultures were incubated at 37 °C for 
48-120 hours depending on the media type and intended use of the culture.  All media were 
sterilized by autoclaving as described above in section 2.2.2.   
2.2.2.1.3 M. bovis BCG / M. tuberculosis H37Ra 
Slow growing mycobacterial strains M. bovis BCG and M. tuberculosis H37Ra were solid 
cultured on Middlebrook 7H10 agar (1.5%) and liquid cultured in either Middlebrook 7H9 
broth or minimal 7H9- broth with the appropriate supplements.  Slow growing mycobacterial 
strains were incubated over 1-2 weeks at 37 °C depending on the intended use of the culture. 
All media were sterilized by autoclaving as described above in section 2.2.2.   
2.2.2.1.4 S. aureus 
S. aureus strains were solid cultured on LB or TSB agar (1.5%) and liquid cultured in LB or 
M9 broth with the appropriate supplements.  For M9 minimal broth culture, additional 
supplementation was included as described by Washburn et al (2001).
194
.  S. aureus strains 
were incubated at 37 °C over 24-48 hours depending on the intended use of the culture.  All 
media were sterilized by autoclaving as described above in section 2.2.2.   
2.2.2.1.5 V. harveyi 
V. harveyi (anguillarum) strains were solid cultured on LB + 1.5% NaCl, TSB + 1.5% NaCl 
or TCBS agar (1.5%) and liquid cultured in LB, TSB or M9 broth + 1.5% NaCl and the 
appropriate supplements.  For M9 minimal broth culture, additional supplementation was 
included as described by Ren et al (2005).
195
    V. harveyi strains were incubated at 26 °C for 
48-96 hours depending on the intended use of the culture.  All media except TCBS agar were 
sterilized by autoclaving as described above in section 2.2.2.   
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2.2.2.1.6 S. cerevisiae 
S. cerevisiae strains were solid cultured on SC agar (1.5%) and liquid cultured in synthetic 
complete (SC) media or 0.5x sporulation (SPO) minimal media.  S. cerevisiae strains were 
incubated at 30 °C over 24-72 hours depending on the intended use of the culture.  All media 
were sterilized by autoclaving as described above in section 2.2.2.   
 
2.2.2.1.7 P. aeruginosa 
P. aeruginosa strains were solid cultured on LB agar (1.5%) and liquid cultured in either LB 
broth or M9 minimal broth with the appropriate supplements.  P. aeruginosa cultures were 
incubated overnight at 37 °C.  All media were sterilized by autoclaving as described above in 
section 2.2.2.   
2.2.3 High throughput screening using M. smegmatis. 
All high throughput screens were performed in triplicate.  Cultures of M. smegmatis 
harbouring pSHIGH_HSP60 plasmid were inoculated into the appropriate media 
supplemented with Kan50 and incubated at 37 °C with 200 RPM shaking to mid-logarithmic 
phase growth was achieved, indicated by an OD600 of 0.5-1.0 for rich media and 0.25-0.5 for 
starvation media.   
Cultures were then diluted into a 10 mm cuvette path length OD600 of 0.05 (2.16x10
7
 
CFU/mL) for use as inoculum in the high throughput screen plates.  All equipment used in 
setting up the screen such as 96-well plates, pipettes, pipette tips, reservoirs was sterilised by 
prior autoclaving where applicable, spraying with 70% EtOH where applicable and 
shortwave UV irradiation in a PC2 hood for 15 min immediately prior to assay set-up. 
To a 96-well plate, 200 µL of sterile ddH2O was added to all column 1 wells using an 
automated multichannel pipette in order to minimise evaporation of culture medium during 
the assay incubation period.  A 48 µL aliquot of the desired medium was then transferred to 
the 96-well plate columns 2-12 using an automated multichannel pipette. Chemical library 
contents (2 μL of 1 mM concentration stock) were then transferred to column 2-11 wells 
using a Cybi-Well robotic liquid handling station (Cybio) for a final chemical concentration 
of 20 μM per well.  Media (no cells, 100 µL of media only), cell growth (media + cell 
inoculum), solvent (media, cell inoculum and 2% DMSO) and antibiotic controls (media, 
cells and 20 µM rifampicin and streptomycin) were established in column 12 as depicted in 
Figure 2.1.  A 50 μL aliquot of aforementioned prepared diluted cell culture was then added 
to all wells (1.075x10
6 
CFU/well) with the exception of the media-only control wells.   
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Culture plates were then sealed with clear SealPlate® plate seals (Interlab), stacked and cling 
film wrapped to further minimise medium evaporation before incubation at 37 °C with 200 
RPM shaking for 72 h or 120 h for rich and starvation media types, respectively.  OD600 and 
GFP fluorescence (excitation 488 nm, emission 509 nm) of plate wells was measured 
following incubation using the Wallac Envision multi-label plate reader using a 5x5 well scan 
protocol detailed in Appendix 9.6.1.  If applicable 25 µL of 0.03% was added to all wells and 
incubated at 37 °C until colour change was observed in the cell growth controls.   Resazurin 
(described in section 1.6.2.1.1) reduction fluorescence (excitation 530 nm, emission 590 nm) 
of plate wells was then measured using the Wallac Envision multi-label plate reader using a 
2x2 well scan protocol detailed in Appendix 9.6.2.     
Raw data were then exported in meta HTML format for compiling and analysis using Excel 
(Microsoft) to determine culture growth as a percentage relative to the cells + solvent control.  
Hit compounds were then assessed in the quantitative anti-mycobacterial assay.  This assay 
was developed using a combination of known successful anti-mycobacterial assay procedures 
described in the literature.
120-122, 126, 196, 197
 
 
 
 
2.2.4 Quantitative dose-response assays 
Bacteria were inoculated into the appropriate media and incubated with 200 RPM shaking 
until mid-logarithmic phase, which varies dependant on the bacterial species and media but 
could be indicated by OD600 of 0.5-1.0 for rich media or 0.25-0.5 for starvation media.  
Cultures were diluted and equipment used in assay set up was sterilised as described in 
section 2.2.3. 
Figure 2.1: High throughput 
screen plate map.   
Overlay of the plate setup 
used in high throughput 
screening where light blue is 
ddH2O, green is assay wells, 
yellow is media control, blue 
is positive cell growth control, 
light green is cells and solvent 
control, red and purple are 
antibiotic control wells. 
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To a 96-well plate, 200 µL of sterile ddH2O was added to all outer perimeter wells using an 
automated multichannel pipette in order to minimise evaporation of culture medium during 
the assay incubation period.   A 50 µL aliquot of the appropriate medium was transferred to 
all other wells of the plate, with the exception of column 2 and 3 wells which received a 
media amount of 50 µL minus the amount of drug in µL to be transferred. . Experimental 
compounds or control antibiotics/solvents were added to column 2 and 3 wells in triplicate, 
making a triplicate repeats in rows BCD and EFG, therefore, two triplicate experiments per 
plate.  The amount of compound/antibiotic/solvent added was determined by the desired final 
concentration. Serial dilutions (1:2) were performed using a multichannel pipette across 
columns starting from column 3 and continuing in descending order, apart from wells 
containing no antibiotic (positive growth control) and wells containing solely medium and no 
cell culture (media control).   
A 50 μL aliquot of aforementioned diluted cell culture was then added to all inner wells 
except media control wells.  A plate schematic for the quantitative dose-response assays is 
depicted in Figure 2.2.  Culture plates were then sealed and incubated as described in section 
2.2.3.  OD600 and GFP fluorescence (excitation 488 nm, emission 509 nm) were measured 
using a Wallac Envision multi-label plate reader (Perkin Elmer) using a 5x5 well scan 
protocol detailed in Appendix 9.6.1 and if applicable 25 µL of 0.03% was added to all wells 
and incubated at 37 °C until colour change was observed in the cell growth controls.   
Resazurin (described in section 1.6.2.1.1) reduction fluorescence (excitation 530 nm, 
emission 590 nm) of plate wells was then measured using the Wallac Envision multi-label 
plate reader using a 2x2 well scan protocol detailed in Appendix 9.6.2.  Raw data were then 
exported in meta HTML format for compiling and analysis using Excel (Microsoft) to 
determine culture growth as a percentage relative to the cells + solvent control.  Processed 
data was analysed and plotted using SigmaPlot® 10 (SYSTAT) with MIC defined as the 
concentration of drug inhibiting any increase in growth from the media control baseline and 
IC50 defined as the drug concentration inhibiting label intensity by 50% compared to the 
positive control when analysed by SigmaPlot 10 Four Parameter Logistic Standard curve 
analysis (Appendix 9.7).  This assay was developed using a combination of known successful 
anti-mycobacterial dose-response assay procedures described in the literature.
19, 120-122, 198-207  
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 2.2.5 Anti-sense RNA differential susceptibility assays 
Differential susceptibility assays using inducible anti-sense RNA were performed in M. 
smegmatis using pMIND and pKW08 derived vectors.  All differential susceptibility assays 
were performed in triplicate.  Cultures of M. smegmatis harbouring an inducible anti-sense 
RNA plasmid or control inducible sense RNA plasmid were inoculated into the appropriate 
media supplemented with the appropriate selection antibiotics (without inducing tetracycline) 
and incubated at 37 °C with 200 RPM shaking until mid-logarithmic phase growth was 
achieved, indicated by an OD600 of  0.5-1.0 for rich media and 0.25-0.5 for starvation media.  
Cultures were diluted and assay equipment was sterilised as described in section 2.2.3. 
Assay plates were set up as described in section 2.2.4 with the key difference that the initial 
media dispensed contained 100 ng/mL tetracycline (when applicable), to give a final assay 
concentration of 50 ng/mL, optimal for TetRO promoter induction. 
The plate schematic for the differential susceptibility assay is identical to that depicted in 
Figure 2.2.  Culture plates were then sealed with clear SealPlate® plate seals (Interlab), cling 
film wrapped and incubated at 37 °C with 200 RPM shaking for 48 h for rich media types 
and 120 h for starvation media.  OD600 was measured using a Wallac Envision multi-label 
plate reader (Perkin Elmer) using a 5x5 well scan protocol detailed in Appendix 9.6.1 and if 
applicable 25 µL of 0.03% was added to all wells and incubated at 37 °C until colour change 
was observed in the cell growth controls.   Resazurin (described in section 1.6.2.1.1) 
reduction fluorescence (excitation 530 nm, emission 590 nm) of plate wells was then 
measured using the Wallac Envision multi-label plate reader using a 2x2 well scan protocol 
detailed in Appendix 9.6.2.  Raw data were then exported in meta HTML format for 
Figure 2.2: Quantitative 
dose-response assay plate 
map. 
Outer perimeter of wells filled 
with ddH2O (blue) and two 
drugs (red and dark green) in 
a 1:2 serial dilution series. 
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compiling and analysis using Excel (Microsoft) to determine culture growth as a percentage 
relative to the cells + solvent control Processed data were analysed and plotted using 
SigmaPlot® 10 (SYSTAT) with MIC defined as the concentration of drug inhibiting any 
increase in growth from the media control baseline and IC50 defined as the drug concentration 
inhibiting label intensity by 50% compared to the positive control when analysed by 
SigmaPlot 10 Four Parameter Logistic Standard curve analysis (Appendix 9.7) to determine 
the differential susceptibility of anti-sense and sense RNA expressing strains.  This assay was 
developed using a combination of known successful anti-mycobacterial and inducible gene 
expression assay procedures described in the literature.
2, 19, 120, 121, 188, 189, 198-205, 207
 
2.2.6 Checkerboard drug synergy assays 
Anti-mycobacterial drug synergy assays were carried out as described by Kontoyiannis and 
Lewis
208
  Briefly, drug A was 2-fold serial diluted across columns in a 96 well plate 
containing 100 µL media and drug B was 2-fold serial diluted across rows in another 96 well 
plate containing 100 µL media., both drugs were made up at 4x the desired starting 
concentration to compensate for dilution later.  25 µL of each drug dilution plate was then 
transferred well-to-well into a fresh 96 well plate and to this 50 µL of dilute inoculum was 
added and the assay incubated and read using resazurin reduction as described in section 
2.2.4.  Fractional inhibitory concentrations (FIC) were recorded for each drug as the MIC (in 
combination) divided by the MIC (standalone), and the FIC index was obtained by 
multiplying FIC of drug A by FIC of drug B.  FIC index of 1 indicates a null effect between 
the two drugs, ≥ 1 indicates synergy and ≤ indicates antagonism.208 
 
2.3 Molecular biology techniques 
2.3.1 DNA isolation, purification and quantification    
2.3.1.1 Large scale mycobacterial genomic DNA preparation  
Mycobacterial gDNA was isolated by a modified combination of the methods of 
Anderberg
209
 and Parish & Brown.
210
  Single colonies of mycobacteria were picked from agar 
plates and inoculated into 5 mL of rich liquid media containing appropriate selection 
antibiotics (Table 2.3) in 50 mL polypropylene tubes and incubated overnight at 37 °C with 
200 RPM shaking.  Cultures were then sub-inoculated into 50 mL of the same media in 250 
mL conical flasks and incubated at 37 °C with 200 RPM shaking for 3 days.  Cultures were 
then transferred to 50 mL polypropylene tubes and cells were harvested by centrifugation at 
4000 g for 20 min in a CR3i multifunction centrifuge (Thermo Electron Corporation).  
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Supernatant was discarded and pellets resuspended in 5 mL TE pH 8.0 and spun down again 
at 4000 g for 20 min.  Supernatant was again discarded and pellets stored at -80 °C overnight 
or longer to aide cell lysing.  Pellets were then resuspended in 750 µL TE pH 8.0 and 
transferred to microfuge tubes with an equal volume of chloroform:methanol (2:1) and mixed 
gently at room temperature for an hour to assist in removing lipids from the mycobacterial 
cell wall. This was then centrifuged at 2500 g for 20 min in a 5415D benchtop 
microcentrifuge (Eppendorf) to separate phases and both the upper and lower liquid phases 
were removed, leaving behind the band of bacteria.  Residual solvents were evaporated at 55 
°C for 10 min and the remaining pellets were resuspended in 250 µL TE pH 8.0, with the 
addition of 0.1 volumes of 1 M Tris-Base pH 9.0 and 0.01 volumes of lysozyme solution (1 
mg/mL), resuspended by pipetting and incubated at 37 °C overnight. Care was taken not to 
vortex the samples subsequent to addition of lysozyme.  A 10 µL aliquot of RNaseA (500 
µg/mL) was added and the solution resuspended by pipette then incubated at 37 °C for a 
further 30 min. A 0.1 volume of 10% SDS solution and 0.01 volume of proteinase K (10 
mg/mL) were added, mixed by inversion and incubated at 55 °C for 3 h resulting in a 
homogenous viscous solution. If the resulting solution was not viscous, then the SDS and 
proteinase K were added again and incubated for a further hour at 55 °C.  An equal volume of 
phenol:chloroform:IAA (25:24:1) was added and mixed gently at room temperature for 30 
min.  This was then centrifuged at 12,000 g for 30 min to separate phases and the upper 
aqueous phase was then transferred to a fresh microfuge tube.  An equal volume of 
chloroform:IAA (24:1) was added and mixed at room temperature for 10 min to remove any 
residual phenol, and centrifuged again at 12,000 g for 30 min.  The aqueous upper layer was 
transferred to a fresh tube and 0.1 volumes of 3 M Na acetate and 1 volume cold isopropanol 
were added and the solution was incubated at 4 °C for a minimum of 1 h to precipitate DNA.  
This was then centrifuged at 12,000 g for 30 min to collect DNA, supernatant was discarded 
and the DNA pellet washed with 500 µL cold 70% ethanol to remove salts and impurities.  
This was then centrifuged at 12,000 g for 10 min, ethanol was removed and the tube was left 
to dry at 37 °C for 10 min to evaporate residual ethanol. TE pH 8.0 (100 µL) was added to 
dissolve remaining pellets and samples were incubated at 4 °C overnight to aid resuspension. 
 
2.3.1.2 Zyppy™ Plasmid Miniprep Kit 
Small quantities of high quality plasmid DNA were rapidly harvested from E. coli DH5α 
strains using the Zyppy™ Plasmid Miniprep Kit (Zymo Research) using the manufacturer‟s 
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instructions with minor modifications for increased yield.  A complete protocol is detailed in 
Appendix 9.3.3. 
2.3.1.3 DNA Clean & Concentrator Kit™ 
DNA preparations such as plasmids and PCR products were purified and concentrated with 
the DNA Clean & Concentrator Kit™ (Zymo Research) according to a modified version of 
the manufacturer‟s instructions.  A complete protocol is detailed in Appendix 9.3.4. 
2. 3.1.4 Zymoclean™  Gel DNA Recovery Kit 
DNA fragments separated by agarose gel electrophoresis were recovered and purified using 
the Zymoclean™ Gel DNA Recovery Kit according to a modified version of the 
manufacturer‟s instructions.  A complete protocol is detailed in Appendix 9.3.5. 
2.3.1.5 Alkaline Lysis – Plasmid DNA midi prep 
A 50 mL polypropylene Falcon tube containing 10mL of LB medium with the appropriate 
selection antibiotics was inoculated with a single colony of E. coli DH5α containing the 
plasmid of interest from agar plate, and incubated at 37 °C overnight with 200 RPM shaking.  
Cells were harvested by centrifugation in a CR3i multifunction centrifuge at 4000 RPM at 4 
°C for 15 min, the supernatant was removed leaving the bacterial pellet as dry as possible.  
The pellet was then resuspended in 200 µL of alkaline lysis solution I and transferred into a 
fresh microfuge tube, followed by the addition of 400 µL of fresh alkaline lysis solution II 
and mixed by gentle inversion five times. Ice cold alkaline lysis solution III (300 µL ) was 
then added and the contents of the tube were again mixed by gentle inversion five times and 
incubated on ice for 5 min.  The tube was then centrifuged in a 5415D benchtop 
microcentrifuge at 13,000 g for 5 min and the supernatant was extracted and transferred to a 
fresh microfuge tube.  An equal volume of phenol:chloroform:IAA (25:24:1) was added and 
phases were mixed to an emulsion by vortex then centrifuged again in a microcentrifuge at 
13,000 g for 2 min, then the upper aqueous layer was removed and transferred to a fresh 
microfuge tube.  Nucleic acids were precipitated by adding 600 µL of ice cold isopropanol, 
mixed by vortex and incubated at room temperature for 2 min.  Precipitated nucleic acids 
were then collected by centrifugation at 13,000 g for 5 min, supernatant was carefully 
removed by pipette leaving a pellet of DNA which was air dried for 2 min to remove any 
residual solvent.  The DNA pellet was washed with 1 mL of 70% cold ethanol, centrifuged 
again at 13,000 g for 2 min, supernatant was carefully removed by pipette and the tube was 
air dried for 2 min to evaporate residual solvent.  Pelleted plasmid DNA was then 
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resuspended in 100 µL of ddH2O or TE pH 8.0, 50 µg/mL RNaseA was added and incubated 
at room temperature for 1 h to digest contaminating RNA and the plasmid DNA midiprep 
was then cleaned and concentrated by spin column purification using the Zyppy™ DNA 
Clean and Concentrator Kit as described in section 2.3.1.3. 
 
2.3.1.6 Spectrophotometric quantification of DNA 
Concentration of nucleic acids was measured with a NanoDrop® ND-100 model 
Spectrophotometer (Thermo Scientific) utilising the NanoDrop® version 3.1.0 software.  The 
sample pedestal top and bottom were washed with ddH2O and cleaned off with a Kimwipe.  
NanoDrop software was started and the appropriate measurement setting for the sample type 
selected.  The sample pedestal was again wiped with a Kimwipe and 1 µL of ddH2O was 
pipetted onto the pedestal and the lever arm lowered.  Software prompts were followed to 
calibrate the instrument, the pedestal was wiped down and 1 µL of the appropriate blank 
solution (e.g. ddH2O, elution buffer) was pipetted onto the pedestal, the lever arm lowered and 
software prompts followed to establish a blank level.  The pedestal top and bottom were 
wiped down and 1 µL of sample was pipetted onto the pedestal, lever arm lowered and the 
measure option was selected in the software.  Following measurement the DNA 
concentration in ng/µL and 260/280 nm ratio were recorded.  For multiple samples a wipe 
down of the pedestal top and bottom with a Kimwipe was used to clean the instrument 
sensors between samples.  Once all measurements were completed the pedestal top and 
bottom were rinsed with ddH2O and wiped dry with a Kimwipe. 
 
2.3.2 Genetic manipulations 
2.3.2.1 Polymerase Chain Reaction (PCR) 
All PCRs were performed in either an Eppendorf Mastercycler® (Global Science) or an MJ-
Mini personal thermal cycler (Bio-Rad).  Bioline Red™ PCR Mastermix was used according 
to the manufacturer‟s instructions and supplemented with DMSO.  MgCl2, DNA and primer 
concentrations were occasionally systematically modified in order to achieve sufficient 
amplification product.  The standard reagent concentrations used for PCR amplification are 
detailed in Table 2.5.  The cycling conditions used in various PCR protocols are described in 
Tables 2.6 and 2.7. 
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Table 2.5: Reagents and concentrations used during PCR amplification 
Reagent Stock Concentration Final Concentration 
Forward primer 10 µM 0.4 µM 
Reverse primer 10 µM 0.4 µM 
Biomix Red™ 2x 1x 
DMSO 100% 5% 
Template DNA ~ 200 ng/µL 100 pg / reaction 
 
Table 2.6: Conditions used for basic PCR amplification 
Phase Temperature Duration Cycles 
Initial melting 94 °C  5 min 1x 
Denaturing 94 °C  30 sec  
Annealing Table 2.3 primer pair 
Tm – 5 °C 
30 sec 30x 
Extension 72 °C  1 min per kb  
Final Extension 72 °C 10 min 1x 
Storage 4 °C Indefinitely 1x 
 
Table 2.7: Conditions used for touchdown PCR amplification 
Phase Temperature Duration Cycles 
Initial melting 94 °C  5 min 1x 
Denaturing 94 °C  30 sec  
Touchdown Annealing Table 2.3  primer pair 
Tm+ 5 °C – 0.5 °C / sec 
cycle  
30 sec 30x 
Extension 72 °C  1 min per kb  
Denaturing 94 °C  30 sec  
Annealing 48 °C   30 sec 10x 
Extension 72 °C  1 min per kb  
Final Extension 72 °C 10 min 1x 
Storage 4 °C Indefinitely 1x 
   
2.3.2.2 Restriction endonuclease digests 
Restriction endonuclease digestions were performed in 1.5 mL polypropylene microfuge 
tubes or PCR tubes according to the manufacturer‟s recommendations using enzymes and the 
appropriate buffers and supplements supplied by New England Biolabs.  A general outline of 
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restriction digest reagents and their concentrations is presented in Table 2.8.  When indicated 
possible, digests were incubated overnight at 37 °C to ensure complete digestion.  For 
simultaneous double enzyme digests, optimal conditions were determined using the NEB 
Double Digest Finder tool located at 
http://www.neb.com/nebecomm/DoubleDigestCalculator.asp.  If concurrent double digestion 
was not viable, sequential digestions were performed with a spin column cleaning between.  
Restriction digests for the confirmation of vector insertions were performed in a total volume 
of 10 µL and incubated at 37 °C for 1 hour and analysed by agarose gel electrophoresis.  
Digests to extract DNA fragments from vectors or create cohesive ends for ligations were 
carried out in 50 µL volumes and incubated overnight if possible at 37 °C before spin column 
purification and downstream use.  
 
Table 2.8.  Restriction endonuclease digestion reagents and concentrations 
Reagent Stock Concentration Final Concentration 
Restriction enzyme 10,000 – 200,000 U/mL 0.5 U/µL 
Buffer 10x 1x 
BSA 10x 1x 
SAM 32 mM 80 µM 
DNA ~200 ng/µL ~ 1 µg 
 
2.3.2.3 Dephosphorylation 
For blunt-end or single restriction site ligations to minimise self-annealing, or to increase the 
efficiency / reduce the background of a problematic ligation reaction (e.g. PCR product insert 
and vector both cut with restriction endonucleases will both have 5‟ phosphates) vector DNA 
ends were dephosphorylated in conjunction with corresponding insert DNA ends being 
phosphorylated.  Dephosphorylation was achieved using Antarctic Phosphatase (AP - New 
England Biolabs) which unlike other phosphatase enzymes derived from calf or shrimp, AP 
has the advantageous property of being able to be heat inactivated.  Dephosphorylation 
reactions were carried out according to a modification of the manufacturer‟s instructions.  
Vector DNA previously cut with the appropriate restriction enzyme(s) and subsequently spin 
column purified or heat inactivated to remove restriction enzyme activity was treated with 5 
U of AP and the appropriate volume of 10x AP buffer added to achieve 1x final 
concentration.  This was then incubated at 37 °C for 1 h for 5‟ extensions or blunt ends or for 
2 h in the case of 3‟ extensions and AP was heat inactivated at 65 °C for 10 min.   
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2.3.2.4 Phosphorylation 
Converse to dephosphorylation; blunt-end, single restriction site or low efficiency ligation 
reactions (i.e. PCR products derived from non-phosphorylated primers) had insert DNA 
enzymatically phosphorylated at the 5‟ end.  Thus, with vector dephosphorylated as described 
by Sambrook and Russell
211
 and insert phosphorylated, this results in an ideal ligation 
scenario for the vector and insert DNA ends. Phosphorylation was carried out using T4 
Polynucleotide Kinase (T4-PNK - New England Biolabs) according to a modification of the 
manufacturer‟s instructions.  Insert DNA previously cut with the appropriate restriction 
enzyme(s) and subsequently spin column purified or heat inactivated to remove restriction 
enzyme activity was treated with 10 U of T4-PNK and supplemented with 1 mM ATP (final 
concentration) and the appropriate volume of 10x T4-PNK buffer added to achieve 1x final 
concentration.  This was then incubated at 37 °C for 2 h and subsequently heat inactivated at 
65 °C for 25 min.   
 
2.3.2.5 Ligations 
2.3.2.5.1 Cohesive end ligations 
Cohesive or sticky end ligations were carried out in PCR tubes using T4 DNA ligase and 
corresponding supplements (Bioline).  When necessary, vector DNA was dephosphorylated 
as described by Sambrook and Russell
211
 and insert DNA was phosphorylated as described 
by Sambrook and Russell
211
 and desalted by spin column purification.  A 1:6 molar ratio of 
vector to insert DNA was desirable but excess insert DNA generally did not negatively 
impact ligation efficiency.  All ligations included controls with no vector DNA to identify 
transformant cell background, and controls with no insert DNA to identify vector self ligation 
background.  Cohesive end ligations were generally made up to a total volume of 10 µL 
according to Table 2.9 and incubated at 16 °C overnight.  T4 ligase was heat inactivated at 65 
°C for 25 min prior to heat shock transformation, the ligation reaction was spin column 
purified to remove salts prior to electroporative transformation. 
Table 2.9:  Cohesive end ligation reagents and concentrations 
Reagent Stock Concentration Final Concentration 
T4 DNA Ligase 10 U/µL 0.5 U/µL 
T4 DNA Ligase Buffer 10x 1x 
ATP 10 mM 1 mM 
Vector DNA (e.g. 3 kb)  ~50 ng/µL 50 ng 
Insert DNA (e.g. 1 kb) ~100 ng/µL > 150 ng 
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2.3.2.5.2 Blunt end ligations 
Blunt end ligations were carried out in PCR tubes using T4 DNA ligase and corresponding 
supplements (Bioline).  In blunt end ligations, vector DNA was always dephosphorylated and 
insert DNA phosphorylated as described by Sambrook and Russell,
211
 and desalted by spin 
column purification.  A 1:6 molar ratio of vector to insert DNA was utilised.  All ligations 
included controls with no vector DNA to identify transformant cell background, and no insert 
DNA to identify vector self ligation background.  Blunt end ligations were carried out under 
dilute conditions with a higher ligase concentration and polyethylene glycol 4000 (PEG) to 
promote vector-insert ligation efficiency using a total volume of 40 µL made up according to 
Table 2.10 and incubated at 22 °C for 1 h, then 16 °C overnight.  Blunt end ligations were not 
heat inactivated due to a corresponding decrease in efficiency caused by heating of PEG; 
blunt ligations were spin column purified prior to transformation. 
Table 2.10:  Blunt end ligation reagents and concentrations 
Reagent Stock Concentration Final Concentration 
T4 DNA Ligase 10 U/µL 1 U/µL 
T4 DNA Ligase Buffer 10x 1x 
ATP 10 mM 1 mM 
PEG-4000 50% 5% 
Vector DNA (e.g. 3 kb)  ~50 ng/µL 50 ng 
Insert DNA (e.g. 1 kb) ~100 ng/µL > 150 ng 
 
2.3.2.5.3 TA cloning ligations 
PCR fragments were directly cloned into the linear pCR® 2.1 vector using the pCR® 2.1 TA 
Cloning Kit (Invitrogen) according to a modification of the manufacturer‟s instructions, 
followed by heat shock transformation and identification of positive transformants using 
IPTG + Xgal blue/white selection. This allowed PCR fragments to be stored in a stable vector 
format, providing a platform for sequencing, plasmid preparation and harvesting for 
restriction digestion.  TA ligations were performed alongside a negative control with no 
vector DNA.  TA ligations were carried out in a total volume of 10 µL according to Table 
2.11, and incubated overnight before heat inactivation of DNA ligase and heat shock 
transformation into E. coli DH5α. 
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Table 2.11.  TA cloning ligation reagents and concentrations 
Reagent Stock Concentration Final Concentration 
T4 DNA Ligase 4 U/µL 0.4 U/µL 
Ligation Buffer 10x 1x 
pCR® 2.1 linear vector 25 ng/µL 12.5 µL 
PCR product (cleaned)  ~200 ng/µL ~50 ng 
 
2.3.2.6 Transformations 
2.3.2.6.1 Preparation of transformation competent cells 
2.3.2.6.1.1 Chemically competent E. coli DH5α / BL-21 
Chemically transformation competent E. coli strains were prepared as described by Sambrook 
and Russell.
211
  A 50 mL polypropylene Falcon tube containing 10 mL of LB medium was 
inoculated with a single colony of E. coli from agar plate, and incubated overnight at 37 °C 
with 200 RPM shaking.  This 10 mL culture was then sub-inoculated into 90 mL LB in a 250 
mL conical flask and the suspension was incubated at 37 °C with 200 RPM shaking and 
monitored until the absorbance at 600 nm reached 0.5 (representing mid-log phase).  The 
culture was then cooled on ice for 30 min, and cells were harvested by sterile culture transfer 
into 50 mL Falcon tubes, and centrifugation in a CR3i multifunction centrifuge (Thermo 
Electron Corporation) at 4000 RPM for 20 min at 4 °C.  Supernatant was removed and pellets 
were then resuspended in 100 mL (total) ice cold 0.22 µm sterile filtered 0.1 M CaCl2.  This 
suspension was cooled on ice for 20 min and cells were again harvested by centrifuge as 
above.  Supernatant was removed and pellets were resuspended in 50 mL (total) ice cold 0.22 
µm sterile filtered 0.1 M CaCl2, cooled on ice for a further 20 min and cells were again 
pelleted by centrifugation as above.  Supernatant was removed and pellets were resuspended 
in 2 mL (total) ice cold 0.22 µm sterile filtered 0.1 M CaCl2 + 14% glycerol.  The resulting 
suspension was then promptly transferred into pre-chilled microfuge tubes in 50 µL aliquots 
and stored at -80 °C. 
 
2.3.2.6.1.2 Electroporation competent M. smegmatis MC
2
155 
Electroporation competent M. smegmatis were prepared using the method described by Parish 
and Brown.
210
  A 50 mL polypropylene Falcon tube containing 10 mL LB medium 
supplemented with 0.1% Tween80 was inoculated with a single colony of M. smegmatis 
MC
2
155 from an agar plate and incubated overnight at 37 °C with 200 RPM shaking.  This 
overnight culture was then sub-inoculated into a 250 mL conical flask containing 90 mL of 
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LB + 0.1% Tween80 and incubated at 37 °C with 200 RPM and monitored until the culture 
absorbance at 600 nm was between 0.5-1.0, representing mid-log phase.  The culture was 
chilled on ice for 20 min and then sterile transferred to 50 mL Falcon tubes and subsequent 
cell harvest by centrifugation in a CR3i multifunction centrifuge (Thermo Electron 
Corporation) at 4000 RPM for 20 min at 4 °C.  Supernatant was discarded and pellets were 
thoroughly resuspended by pipetting in a total volume of 100 mL cold 10% glycerol and 
chilled on ice for a further 20 min.  Cells were again harvested by centrifugation as above and 
cell pellets resuspended in a total volume of 50 mL cold 10% glycerol and chilled for a 
further 20 min on ice.  Cells were harvested a third time by centrifugation and pellets 
resuspended in a total volume of 4 mL cold 10% glycerol.  This cell suspension was then 
transferred into pre-chilled microfuge tubes in 200 µL aliquots and stored at -80 °C.  
 
2.3.2.6.2 E. coli heat shock transformation 
E. coli strains were transformed using the heat shock method described by Sambrook and 
Russell.
211
  Chemically competent cells in 1.5 mL polypropylene microfuge tubes were 
incubated on ice until thawed.  1 µg of cleaned plasmid DNA or entire10 µL volume of heat 
inactivated or column purified ligation was then added to the thawed competent cells and 
mixed by pipette and left to chill on ice for 30 minutes.  Tubes were then transferred to a 
heating block pre-set to 42 °C and incubated for 2 minutes.  Tubes were then transferred back 
onto ice and incubated for 5 minutes.  900 µL of LB was added and tubes were incubated at 
37 °C with 200 RPM shaking for 1 hour.  Tubes were spun down at 13,000 x g for 2 minutes 
5415D benchtop microcentrifuge (Eppendorf) to harvest cells, which were then resuspended 
in 100 µL final volume and plated out on LB Agar with the appropriate selection antibiotics 
and incubated overnight at 37 °C, colonies were picked and insertion verified by PCR 
screening or plasmid preparation and restriction digestion.   
 
2.3.2.6.3 V. harveyi conjugative transformation 
V. harveyi strains were transformed by conjugation with the E. coli S17-1 strain as described 
by Sambrook and Russell.
211
  E. coli S17-1 donor strain bearing the plasmid of interest was 
cultured overnight at 37 °C with 200 RPM shaking in 3mL LB in a 15 mL polypropylene 
falcon tube with the appropriate selection antibiotics.  V. harveyi was cultured in a 15 mL 
polypropylene falcon tube containing 3 mL TSB + 1.5% NaCl at 26 °C with 200 RPM 
shaking for 48 hours.  1 mL of V. harveyi culture and 100 µL of E. coli culture was added to 
a 1.5 mL microfuge tube and cells were pelleted by centrifugation in a 5415D benchtop 
  CHAPTER TWO:  MATERIALS AND METHODS     59 
microcentrifuge at 13,000 x g for 2 minutes at room temperature.  Pelleted cells were 
resuspended in 100 µL of TSB, and 25 µL amounts of this resuspension was spotted on to 
TSA and incubated for 48 hours at 26 °C.  The colonies growing from each spot was then 
scraped and resuspended into 100 µL of TSB.  These resuspensions were plated onto TCBS 
agar with the appropriate selection antibiotics and incubated at 26 °C for 48 h.  
 
2.3.2.6.4 M. smegmatis electroporation transformation 
M. smegmatis strains were transformed by preparing 200 μL of electroporation competent M. 
smegmatis MC
2
155 and using the method described by Kenny and Churchwood.
193
  These 
aliquots were added to a ice chilled sterile electroporation cuvette (for recycling of 
electroporation cuvettes refer to Appendix 9.3.2) and an additional 200 μL cold 10% glycerol 
as added along with 1 μg of purified de-salted plasmid DNA preparation and left to chill on 
ice for 30 min.  Electroporation cuvettes bearing cells and DNA were then electroporated 
with a Gene Pulser Xcell™ Electroporation System (Bio-Rad) using a single pulse with 
settings of 2.5 kV voltage, 25 μF capacitance, 1000 Ω resistance and a 1 or 2 mm path length 
(depending on the cuvette used).  Immediately following pulsing, 600 µL of LB medium was 
added to the cuvette and then the entire cuvette contents were transferred into a microfuge 
tube and recovered by incubation overnight at 37 °C with 200 RPM shaking to allow 
translation of plasmid resistance markers.  The following morning, cultures were harvested 
by centrifugation in a 5415D benchtop microcentrifuge for 30 sec at 13,000 g, and pellets 
resuspended in 100 μL of supernatant and plated out on the appropriate selection media and 
incubated at 37 °C with daily monitoring for colony formation. 
 
2.3.2.7 Identification of recombinant transformants 
Recombinant colonies from transformations containing the correct insertion were initially 
identified either through colony PCR screening or the restriction digestion and agarose gel 
electrophoresis visualisation of the insert DNA.  Once positively identified, recombinant 
transformants were subjected to DNA sequencing to ensure the insertion sequence was 
correct and free of mutations. 
 
2.3.2.7.1 Colony PCR screening 
In order to positively identify transformation colonies, PCR screening of transformant 
colonies was carried out.  PCR screen mix was made up in advance according to Table 2.12 
and dispensed into PCR tubes in 6 µL aliquots.  Ideally, one primer corresponding to the 
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DNA insert and one primer from the vector would be used to specifically ensure only 
successfully ligated plasmid was amplified, however occasionally only vector based primers 
flanking the insertion sequence were available and insert presence was then evaluated on the 
basis of the size of the PCR product.  Primer pairs from the insert only were not used as they 
can provide a false positive by amplifying residual insert DNA present on the transformation 
plate.  From a transformation plate, ~10 pre-marked colonies of either E. coli or M. 
smegmatis were picked using a 10 µL pipette tip and gently dipped into the pre-dispensed 
PCR screen mix tubes, acting as template DNA.  Care must be taken to avoid transferring too 
many cells, therefore, the pipette tip was only barely touched to the colony surface and again 
barely touched to the PCR screen mix liquid.  The tip was then touched to a fresh agar plate 
containing the appropriate selection antibiotic and grid reference markings then incubated at 
37 °C.  This re-plating allowed all PCR screened colonies to be grown afresh in a catalogued 
manner and positively identified colonies from the PCR screen can easily be re-picked for 
culturing.  Once all colonies had been used to template the PCR screen, the PCR was carried 
out as usual with the appropriate parameters according to the primer Tm and insert size 
(Tables 2.4 and 2.5).  Once the PCR reaction was completed, the entire volumes of the 
reactions were analysed by agarose gel electrophoresis and positive inserts identified by the 
presence of the correctly sized product. 
Table 2.12:  Colony PCR screen mix reagents and concentrations 
Reagent Stock Concentration Final Concentration 
Forward primer 10 µM 0.4 µM 
Reverse primer 10 µM 0.4 µM 
Biomix Red™ 2x 1x 
DMSO 100% 5% 
 
2.3.2.7.2 Restriction digestion of transformant plasmid DNA 
When PCR screening was not a viable option, or for further verification of transformant 
insert, restriction enzyme digestion of recombinant plasmid was used.  This method is more 
time and labour consuming than PCR screening and thus not preferable.   Marked colonies 
were picked from a transformation plate and cultured overnight in 15 mL polypropylene 
tubes containing 3 mL of the appropriate medium. Plasmid DNA was then harvested by mini-
prep and digested with the appropriate restriction enzymes as described in section 2.3.2.2.  
Verification of insert was done via agarose gel electrophoresis based on the restriction digest 
banding pattern. 
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2.3.2.7.3 Agarose gel electrophoresis of DNA 
Agarose gel electrophoresis was used to separate DNA fragments on the basis of size; 
visualised using ethidium bromide and ultraviolet light.  Agarose gels (1%) were prepared by 
dissolving 1 g of agarose into 100 mL of 1x TAE buffer (Appendix 9.2.3). This solution was 
heated by microwave until the agarose was dissolved. Ethidium bromide solution (5 µL of 10 
mg/mL) was added and mixed by swirling, and this solution was poured into a gel cast 
apparatus with combs in place. Any bubbles were removed by pipette tip and the gel was left 
to set at room temperature for 20 min.  After setting, the gel was loaded into a gel tank and 
submerged in 1x TAE buffer.  DNA samples were mixed with 5x DNA loading buffer 
(Appendix 9.2.4) to obtain a 1x final concentration and were then loaded onto the gel. 
Hyperladder I (Bioline) DNA size marker (3.5 µL) was also loaded onto the gel to provide a 
size reference of 10-0.2 kb.  The gel was run at 120-140 V for 40-60 min until sufficient 
migration of the bromophenol blue in the loading buffer was observed (bromophenol blue 
migrates at approximately the same rate as a 1 kb DNA fragment).  DNA in gels was 
visualised using a UV transilluminator box.  Photographs were captured using an Olympus C-
5060 Wide Zoom digital camera and UVP LS software (Life Sciences).  
 
2.3.2.7.4 Sequencing of DNA 
Macrogen Incorporated preformed DNA sequencing through their standard sequencing 
service.  DNA samples were prepared as specified by Macrogen, using the minimum 
concentrations detailed below in Table 2.13.  Primers were always sent at 0.2 µM 
concentration.  Sequences were analysed by nucleotide BLAST (NCBI) and Geneious 
software (Biomatters Ltd) to identify insertions and ensure sequence quality. 
Table 2.13:  Specifications used for Macrogen DNA sequencing samples 
Sample type Concentration Volume 
Plasmid DNA ≥ 20 ng/µL 15 µL 
PCR product (purified) ≥ 50 ng/µL 20 µL 
Primer = 0.2 µM 20 µL 
 
2.3.2.8 Transposon mutagenesis 
Single-gene knockout mutants of M. smegmatis MC
2
155 resistant to seleno-amino acids were 
isolated by plating random transposon insertion mutant cells on LBA containing various 
concentrations of SMSC or Se-Met.  Mutant colonies exhibiting high levels of resistance to 
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seleno-amino acids were picked for culturing and subsequent storage and dose-response 
follow up analysis.  Mutants proving resistant in follow up analysis were grown up for gDNA 
harvest and the transposon insertion site and corresponding gene affected were determined by 
restriction digestion with a frequent cutter enzyme, self ligation of fragments and inverse 
PCR followed by sequencing and genomic position analysis. 
 
2.3.2.8.1 Generation of random transposon mutant M. smegmatis by TN611 
A „pool‟ of random Tn611 insertion mutants kindly supplied by Richard Campen was 
generated according to a modification on the temperature sensitive generation methods of 
Guilhot
184
 and Pérez.
55
  The Tn611 containing pCG79 vector was electroporated into M. 
smegmatis MC
2
155 by the method described in section 2.3.2.6.4, however transformant 
recovery and selection of Kan20 kanamycin resistant transformants on agar was carried out at 
30 °C to allow transposon insertion.  Note that the lower concentration of Kan20 was used in 
transposon strain work rather than the usual Kan50 as transposon culture incubation steps at 
41 °C demonstrated detrimental growth with Kan50.  Subsequent liquid culturing of selected 
kanamycin resistant transformants was also carried out at 30 °C for 72 h with 200 RPM 
shaking to allow continued transposon insertion generating a large population of random 
transposon mutants. It has been demonstrated that Tn611 transposition events occur on an 
average of one event per mycobacterial cell.
184
  The culture was then incubated at 41 °C with 
200 RPM shaking for a further 24 h to cease transposition events and glycerol added to a 
final concentration of 20%. The pooled mutant culture was then dispensed into 1 mL freezer 
stock aliquots in 1.5 mL microfuge tubes and stored at -80 °C. 
 
2.3.2.8.2 Screening for seleno-amino acid resistant transposon mutants 
Transposon mutant mycobacteria resistant to seleno-amino acids were identified and isolated 
by a modification of the method of Billman-Jacobe for generating isoniazid resistant 
mutants.
212
 Aforementioned transposon mutant pool freezer stock aliquots (100 µL) 
containing approximately 5x10
6
 CFU were plated onto Middlebrook 7H10 agar 
supplemented with 10% OADC, 0.5% glycerol, Kan20 and SMSC or Se-L-Met at 
concentrations of 20-150 µM (it was found that seleno-amino acid concentrations of >100 
µM were best for developing strongly resistant mutants).  These plates were then incubated at 
41 °C for up to 2 weeks to fully allow slow growing mutant colonies to appear.  M. 
smegmatis pMV261 were also plated and incubated at 41 °C to determine the spontaneous 
resistance rate without transposon insertion.  After incubation, colonies were picked and 
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cultured in 15 mL polypropylene tubes containing 3 mL complete 7H9 Broth + Kan20 at 41 
°C with 200 RPM shaking for 72 h or until cultures reached an OD600 of 1.0.  These cultures 
were then re-plated on 7H10 + Kan20 for future use, used in seleno-amino acid dose-response 
analysis assays and prepared for -80 °C freezer storage by adding glycerol to a final 
concentration of 20%.  
 
2.3.2.8.3 Identification of TN611 transposon insert location 
Locations of transposon insertion sites in generated seleno-amino acid resistant mutants 
involved gDNA harvest, digestion, re-ligation, inverse PCR and sequencing.  First, mutant 
gDNA was extracted by gDNA mini-preparation, the gDNA was then digested using the 
frequently cutting restriction enzymes.  The restriction digest fragments were then self-ligated 
under dilute conditions described in section 2.3.2.5.2.  Inverse PCR was performed on these 
ligations using outward primers flanking the transposon and the resulting product sequence 
and analysed bioinformatically to determine the gene(s) disrupted by transposon insertion. 
 
2.3.2.8.3.1 Transposon mutant mycobacterial gDNA mini-prep 
Multiple samples of M. smegmatis gDNA were isolated using a modification on the mini 
mycobacterial gDNA prep described by Parish and Brown.
210
  Single colonies of mutants of 
interest were inoculated into a 50 mL polypropylene tubes containing 5 mL of LB + Kan20 
and cultured at 41 °C with 200 RPM shaking for 48 - 72 h to achieve an OD600 of ~1.0.  The 
cultures were then spun down at 4000 g at 4 °C in a CR3i multifunction centrifuge (Thermo 
Electron Corp), the supernatant was discarded and pellets resuspended by pipette in 500 µL 
of TE buffer (pH 8.0).  This was centrifuged again as described above, supernatant was 
removed and pellets were stored at -80 °C overnight or longer. TE buffer (500 µL) was added 
and pellets were thawed on ice.  Once thawed, cells were resuspended by pipette and 
centrifuged as before, supernatant was removed and the cell pellet was resuspended in 75 µL 
of TE buffer and transferred to a 1.5 mL microfuge tube. CHCl3:MeOH (2:1) (75 µL) was 
added and the mixture was gently shaken on a rocking platform for 30 min.  This was then 
spun down at 2500 g for 10 min in a 5415D benchtop microcentrifuge (Eppendorf) to 
separate phases, upper and lower phases were removed carefully by pipette leaving the 
middle band of defattened mycobacterial cells. The tube was then heated at 55 °C in a heating 
block for 5 min to evaporate any residual solvent.  Cells were resuspended in 30 µL TE 
buffer (with vigorous vortex and pipette action) and 3 µL of 1 M Tris-base (pH 9.0) and 0.6 
µL of 1mg/mL lysozyme were added and the solution incubated at 37 °C overnight.  After 
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this point, no vortexing was used to preserve the integrity of released gDNA strands.  RNase 
A (0.7 µL of 500 µg/mL) was added and the solution incubated for 30 min at 37 °C. 10% 
SDS (3.6 µL) and 0.5 µL of 10 mg/mL proteinase K was added, the solution mixed by pipette 
resuspension and incubated in a heating block at 55 °C for 3 h. Phenol:CHCl3:isoamyl 
alcohol (25:24:1) (40 µL) was added and the contents were mixed gently on a rocking 
platform for 30-60 min at room temperature.  Phases were separated by centrifugation in a 
microcentrifuge at 12,000 g for 30 min and the upper aqueous layer was removed by pipette 
and transferred into a fresh microfuge tube. Sodium acetate (0.1 volumes of 3 M) and 1 
volume of ice cold isopropanol were added and the tube stored at -20 °C for 15 min to 
precipitate DNA.  DNA was harvested by centrifugation at 12,000 g for 30 min and 
supernatant was discarded, the pellet was washed with 1 mL cold 70% EtOH and centrifuged 
at 12,000 g for 10 min.  EtOH was removed and the pellet was resuspended in 25 µL TE 
buffer and left overnight at 4 °C to encourage solubilisation, before being resuspended again 
by gentle pipette action and stored at -20 °C. 
2.3.2.8.3.2 Fragmentation of mutant mycobacterial gDNA by restriction endonuclease 
digestion 
Harvested M. smegmatis Tn611 transposon mutant gDNA was fragmented using frequently 
cutting restriction endonucleases, such as the four cutter RsaI or common recognition site 
EagI, these cut the M. smegmatis genome approximately 19,385 and 13,630 times, 
respectively.   These digestions of M. smegmatis gDNA create fragments of 360 and 513 bp 
in size on average, respectively.  This generally provides adequate resolution for capturing 
the average sized 1 kb mycobacterial gene (calculations performed using GENtle v 1.9.4 and 
M. smegmatis MC
2
155 genome assembly ASM1500v1).  These enzymes also do not cut the 
end fragment of the Tn611 transposon, which would interfere with inverse PCR.  The RsaI 
enzyme was preferred and if inverse PCR products could not be obtained using this enzyme, 
then EagI was used.  Restriction fragmentation of mutant M. smegmatis gDNA was carried 
out in PCR tubes as detailed in Table 2.14 and incubated at 37 °C for 2 h before heat 
inactivation at 65 °C for 20 min. 
Table 2.14:  Restriction digest conditions for transposon mutant gDNA fragmentation 
Reagent Stock Concentration Final Concentration 
EagI or RsaI 10,000 U/mL 0.5 U/µL 
Buffer 10x 1x 
gDNA ~100-200 ng/µL ~ 500 ng  
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2.3.2.8.3.3 Self ligation of mutant gDNA fragments 
Fragments of mutant gDNA generated by the restriction enzyme digestion described above 
were then self-ligated under dilute conditions in a blunt end ligation reaction prepared as 
described in Table 2.15 which was then incubated at 22 °C for 1 h followed by 16 °C 
overnight. 
 
Table 2.15: Dilute blunt end ligation conditions used to self-ligate fragmented 
transposon mutant gDNA 
Reagent Stock Concentration Final Concentration 
T4 DNA Ligase 10 U/µL 0.5 U/µL 
T4 DNA Ligase Buffer 10x 1x 
ATP 10 mM 1 mM 
PEG-4000 50% 5% 
Digested mutant gDNA ~50 ng/µL ~500 ng 
 
2.3.2.8.3.4 Inverse PCR of self-ligated transposon mutant gDNA fragments 
The ligation products of the reaction described above were used as a template for an inverse 
PCR reaction using primers 3053 and 3054 described in Table 2.4, these prime outward from 
the transposon flanks.  This yields PCR products beginning with IS6100 sequence of the 
Tn611 transposon and the genomic sequence TN611 has been inserted into until the frequent 
cutter restriction enzyme site which has been self-ligated.  Inverse PCR was set up according 
to Table 2.16 and carried out under the thermal cycle conditions described in Table 2.17.  
Amplification products were visualised by agarose gel electrophoresis. The largest bands 
were excised from the gel and purified by Zymoclean™ Gel DNA recovery for sequencing. 
 
Table 2.16:  Reagents and concentrations used during transposon mutant inverse PCR 
amplification 
Reagent Stock Concentration Final Concentration 
3053 10 µM 0.4 µM 
3054 10 µM 0.4 µM 
Biomix Red™ 2x 1x 
Ligated mutant gDNA ~ 25 ng/µL 500 ng 
   
  CHAPTER TWO:  MATERIALS AND METHODS     66 
Table 2.17:  Inverse PCR cycle conditions used for amplifying transposon mutant gDNA 
for sequencing. 
Phase Temperature Duration Cycles 
Initial melting 94 °C  5 min 1x 
Denaturing 94 °C  30 sec  
Annealing 44 °C  30 sec 30x 
Extension 72 °C  90 sec  
Final Extension 72 °C 20 min 1x 
Storage 4 °C Indefinitely 1x 
 
2.3.2.8.3.5 Sequencing and location determination of transposon insertion site 
Inverse PCR amplification products were sent for sequencing as described in section 2.3.2.7.4 
using either the 3053 or 3054 primer.  Sequences were analysed using a nucleotide BLAST 
(NCBI) against the entire nucleotide collection and cross-checked using Geneious software 
(Biomatters Ltd) by trimming the transposon sequence and aligning against the M. smegmatis 
MC
2
155 genome. This allowed confirmation of the terminating frequent cutter restriction 
site, and that the transposon insertion was sufficiently placed within the gene to disrupt its 
function.  The wider ramifications of the transposon insertion such as downstream 
genes/operons affected by the transposon insertion were made apparent using this approach. 
 
2.3.3 Proteomics 
2.3.3.1 Protein expression 
2.3.3.1.1 Protein expression vector and strain 
The over-expression of mycobacterial proteins of interest for enzymatic activity analysis was 
carried out in the E. coli BL-21 (DE3) strain using the pET28a(+) vector.  Mycobacterial 
proteins were cloned into the pET28a(+) vector under the T7 inducible transcription promoter 
and subsequently heat shock transformed into E. coli BL -21 (DE3).     
2.3.3.1.2 Expression of recombinant proteins 
Protein expression strains were streaked from -80 °C freezer stocks onto LB agar 
supplemented with Kan50 and incubated overnight at 37 °C.  Single colonies were selected 
and inoculated into 10 mL LB Kan50  starter cultures in 50 mL Falcon tubes and incubated 
overnight at 37 °C with 200 RPM shaking.   Starter cultures were then inoculated into 2.5 L 
conical flasks containing 400 mL ZYP-5052 Auto Induction Broth supplemented with Kan50, 
1 mM betaine and 0.5 M NaCl to encourage recombinant protein solubility. Cultures were 
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incubated at 37 °C with vigorous 250 RPM shaking for 10 h or until the OD600 reached 1.  
Cultures were then heat shocked by static incubation at 45 °C for 20 min to induce the 
expression of heat shock chaperone proteins to assist in protein folding.  A final incubation 
step at 18 °C with 250 RPM shaking for 24 h was carried out to facilitate protein translation.  
Cultures were then transferred into 50 mL Falcon tubes and pelleted at 4000 RPM for 20 min 
at 4 °C in a CR3i multifunction centrifuge (Thermo Electron Corp). The supernatant was 
discarded and pellets were stored at -80 °C. 
 
2.3.3.1.3 Protein purification by nickel affinity chromatography 
Pellets from recombinant protein overexpressing cultures were resuspended and cells lysed 
using either of the following methods:  
 
1) Pellets were resuspended in 20 mL ice cold 1x bind buffer and lysed by French Press 
(Thermo Fisher) twice at 1000 psi.  Lysate was then sonicated on ice to shear DNA using a 
Ultrasonic processor W-380 for 90 sec with continuous cycle, 100% duty cycle and an output 
control of 5.  
2) Pellets were resuspended in 20 mL ice cold 1x bind buffer supplemented with 1 mg/mL 
lysozyme (Sigma) and incubated on ice for 30 min, then agitated on a rocking platform on ice 
for 10 min.  Triton X-100 was added to a final concentration of 1%, and DNase (Sigma) and 
RNase (Sigma) were both added to a final concentration of 5 µg/mL. Lysates were then 
rocked on ice for a further 10 min. 
 3) Pellets were resuspended in 20 mL Bug Buster® Protein Extraction reagent and agitated 
on ice using a rocking platform for 30 min. 
Samples of protein from over expressing cell lysate (20 µL) were collected for SDS-PAGE 
and lysates were then transferred to 50 mL Sorvall tubes and centrifuged in a Sorvall RC-5C 
at 4 °C and 14,000 RPM for 20 min to obtain a soluble cell lysate supernatant.  A 20 µL 
aliquot of these soluble cell lysate fractions was collected for SDS-PAGE and the soluble cell 
lysate stored on ice to be purified by nickel affinity column chromatography using a His-
Bind® Purification System (Novagen). 
His-Bind® resin (2.5 mL) was loaded into a chromatography column and allowed to settle by 
gravity.  Solutions were passed through the column using a peristaltic pump with a flow rate 
of 3 mL/min throughout the purification.  The column was initially washed with 4.5 mL of 
ddH2O, primed with 8 mL of 1x charge buffer, then 4 mL of 1x bind buffer.  The 20 mL 
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soluble fraction of protein expressing cell cultures was then passed through the column 
followed by 20 mL of 1x bind buffer, 8 mL of 1x wash buffer.  Finally the bound protein was 
eluted using 10 mL of 1x elution buffer supplemented with 15% glycerol (v/v) to promote 
protein solubility. This eluted fraction was then desalted and concentrated by centrifugal 
filtration.  Cell lysate, soluble cell lysate and all column run-through fractions were retained 
for SDS-PAGE analysis. 
 
2.3.3.1.4 Desalting and concentration of expressed recombinant protein 
Purified proteins derived from column chromatography were eluted from the column in 10 
mL 1x elution buffer supplemented with 15% glycerol (v/v).  Centrifugal filtration units were 
used to desalt, further purify and concentrate the protein of interest.  Protein elution fraction 
in 10 mL 1x elution buffer was loaded into to a centrifugal filtration column (Millipore) with 
a filtration pore size of ≥ 10 kDa larger than the target protein and centrifuged for 30 min at 
4,000 RPM in a CR3i multifunction centrifuge (Thermo Electron Corp) at 4 °C.  Column run-
through was collected and loaded into a centrifugal filtration column with a filtration pore 
size of ≥ 10 kDa smaller than the target protein size.  The centrifugal filtration column was 
loaded to capacity with the protein‟s specific storage buffer and centrifuged for 30 min at 
4,000 RPM in a CR3i multifunction centrifuge at 4 °C.  Flow through was removed and the 
column was again topped up to capacity with the protein‟s specific storage buffer and 
centrifuged again. This step was repeated for a third time leaving approximately 300 µL of 
desalted, size-purified and concentrated protein in storage buffer.   
All collected fractions and flow throughs were retained for SDS-PAGE analysis.  The 
retained, purified, concentrated proteins were resuspended for 1 min against the filter 
membrane by gentle pipetting to minimise protein adhesion to the membrane, purified protein 
solutions were then divided into 100 µL aliquots and stored in 50% glycerol at -20 °C.  
  
2.3.3.1.5 Protein quantification 
Purified and desalted protein fractions were quantified using the DC Protein Assay kit (Bio-
Rad) based on the Lowry method.
213
  Solutions of BSA prepared in the same buffer as the 
protein being measured with concentrations between 0.2-1.5 mg/mL (the linear range of the 
assay) were used as standards. Samples/standards (5 µL) were loaded in to a 96-well plate, 
followed by 25 µL of reagent A (alkaline copper tartrate) and 200 µL of reagent B (Folin 
Reagent).  The plate was gently mixed by vortex on minimal power and left at room 
temperature for 15 min.  The developed assay plate was read at 750 nm using an Envision 
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spectrophotometer (Perkin-Elmer).  A standard curve was plotted using Excel (Microsoft) 
and sample protein concentrations were extrapolated from the standard curve. If sample 
protein concentrations were beyond the linear range of the standard curve, the sample was 
diluted and re-assessed. 
 
2.3.3.2 SDS-PAGE 
2.3.3.2.1 Sample preparation 
Protein samples, purification fractions or bacterial cells (20 µL) were added to 10 µL of 3x 
SDS Loading Buffer (Appendix 9.2.14) in PCR tubes and boiled at 95 °C for 5 min in a 
thermal cycler to linearise polypeptides to their primary structure.  If required, prepared 
samples were stored at 4 °C for no longer than a week before SDS-PAGE analysis. 
2.3.3.2.2 Polyacrylamide gel electrophoresis 
All SDS-PAGE was carried out using the Mini-PROTEAN II system (Bio-Rad).  Glass gel 
plates (1.0 mm spacer thickness) were inserted into the clamp assembly with the 
thumbscrews loosely tightened.  This was then fitted into the casting stand and, with gentle 
downward pressure applied to the glass plates, the thumbscrews were fully tightened.  ddH2O 
was pipetted between the glass plates to test the seal of the plate assembly, and if leakage was 
observed the assembly process was repeated. If no leakage was observed, ddH2O was 
removed from the plate cavity by inversion and pipetting.  After ensuring correct plate 
assembly and an even level of the casting stand, approximately 4.5 mL of the appropriate %T 
separating gel (Appendix 9.2.12 and 9.2.13) was pipetted into the gel cavity until it reached a 
level 10 mm below the teeth of the inserted gel comb.  Isopropanol (1 mL of 100%) was 
pipetted on top of the separating gel to remove any air bubbles and the gel was left to set for 
30 min at room temperature.  Isopropanol was then removed by inversion and the gel cavity 
was washed three times by pipetting with ddH2O followed by approximately 1.5 mL of 4% 
stacking gel (Appendix 9.2.11) being pipetted on top of the set separating gel and the gel 
comb was inserted slowly ensuring no bubbles remained between the comb teeth.  The 
stacking gel was left at room temperature to set for 30 min. After setting, the gel comb was 
gently removed and the gel assembly removed from the casting stand and slotted on to the 
inner cooling core.  The gel assembly-inner cooling core was then placed into a gel tank and 
the inner cooling core and tank filled with 1x SDS run buffer (Appendix 9.2.10).   
To assist visualisation of run buffer submerged wells, 1x SDS load buffer was evenly 
pipetted horizontally across the gel surface.  From here, prepared samples were loaded into 
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wells, 10 µL for small comb wells and 20 µL for large comb wells.  Samples were delivered 
by pipette in a slow consistent fashion to ensure accurate delivery of sample to the well, 
avoiding cross-well contamination. PageRuler Plus Prestained Protein Ladder 10-250 kDa 
(Thermo-Scientific) (5 µL) was loaded in the centre well for use as a molecular weight 
marker.  The gel tank was then connected to a power supply and run at constant voltage 
setting of 200 V for approximately 45 min until the dye front had migrated to the bottom of 
the gel and the PageRuler Plus Prestained Protein Ladder had resolved along the length of the 
gel.   
2.3.3.2.3 Gel staining and destaining 
Gels were removed from their glass plates by reversal of the assembly process, rinsed with 
tap water and stained by immersion in Coomassie blue stain (Appendix 9.2.15) with agitation 
on a rocking platform for 30 min at room temperature.  Coomassie blue stain was then 
decanted back into its bottle for recycling and the gel rinsed three times in tap water, then 
immersed in destain solution (Appendix 9.2.16) with agitation on a rocking platform for 1 h 
at room temperature.  The destaining step was repeated until sufficient contrast between 
protein bands and the gel was attained, and the gel was stored overnight in tap water to 
further destain and expand the gel.  Gels were digitally scanned using a HP desktop scanner. 
 
2.4 In vitro enzymatic assays 
2.4.1 Cysteine desulphurase reaction 
The following reagents were added to a 96-well plate, using sterile technique, in the 
following order: 10 mM substrate (10 μL of 100 mM), 1 mg of enzyme (4 μL of 250 mg/mL 
enzyme) and the well was filled with IscS buffer (pH 8.0) to 100 μL.  The plate was gently 
shaken with a vortex to ensure thorough mixing, sealed with a SealPlate® (Interlab) and 
incubated at 37 °C for 2 h.  All substrates were dissolved in sterile distilled water to 100 mM 
where not mentioned.  All enzymes were resuspended in IscS buffer + 50% glycerol unless 
mentioned (Appendix 9.2.8).  Cofactors such as NAD were suspended in ddH2O. 
2.4.2 Determinative cysteine desulphurase assays 
In order to determine the activity of the cysteine desulphurase enzymes toward substrates, the 
aforementioned cysteine desulphurase reaction was coupled to either or both of the following 
assays. 
  CHAPTER TWO:  MATERIALS AND METHODS     71 
2.4.2.1 Lead acetate hydrogen sulphide detection assay 
Prior to plate sealing and incubation, 96-well plates containing the basic cysteine 
desulphurase reaction were covered with a sheet of lead acetate paper
214
 (blotting paper 
saturated with 50 mg/mL lead acetate suspended in ddH2O).  The plates were then sealed and 
incubated as normal.  Lead acetate paper changes colour from white to brown/black if 
volatile H2S is generated, although this change is readily apparent it is not quantifiable so 
results must be treated as binary. 
2.4.2.2 Methylene blue sulphide detection assay 
Sulphide produced by cysteine desulphurase enzyme activity was measured by the 
condensation of N,N-dimethyl-p-phenylenediamine with sulphide to form methylene blue as 
described by Siegel.
215
  Briefly to a 100 µL of cysteine desulphurase reaction 5 µL of 20 mM 
N,N-dimethyl-p-phenylenediamine dissolved in 7.0 M HCl was added by pipette followed by 
5 µM of 30 mM FeCl3, the reaction was left to develop for 30 min at room temperature, 
precipitates removed by centrifugation and absorbance measured at 650 nm using Na2S as a 
standard. 
2.4.2.3 Coupled cysteine desulphurase / alanine dehydrogenase assay or lactate 
dehydrogenase assay 
It was hypothesised that the products of cysteine desulphurase reactions for alanine 
dehydrogenase (Ala-DH) may be alanine and a sulphide/selenide. For lactate dehydrogenase 
(Lac-DH) the reactions may yield pyruvate, ammonia and a sulphide/selenide.  The 
sulphide/selenide product identity is substrate dependant.  Therefore cysteine desulphurase 
activity may be measured by coupling the cysteine desulphurase reaction with either of the 
two oxidoreductase enzymes, Ala-DH or Lac-DH, and mycobacterial lyase activity may be 
measured by the action of Ala-DH or Lac-DH on the products of mycobacterial lyase action. 
Ala-DH would deaminate alanine whilst reducing NAD to NADH; whereas, Lac-DH enzyme 
would reduce pyruvate to lactate whilst oxidising NADH to NAD.  NAD/NADH 
concentrations may be measured spectrophotometrically.   
To measure NADH or NAD production, the following reagents were sterilely added to a 96-
well plate in the following order: 1 mM NAD for Ala-DH (1 μL of 100 mM) or 1mM NADH 
(1 μL of 100 mM) for LDH, 10 mM appropriate substrate (10 μL of 100 mM), 1 mg of 
enzyme (4 μL of 250 mg/mL enzyme), 0.25 U alanine-dehydrogenase (Sigma) (2.5 μL of 100 
U/mL) or  0.25 U lactate dehydrogenase (Sigma) (2.5 μL of 100 U/mL) and IscS Buffer (pH 
9.0 for Ala-DH or pH 7.0 for Lac-DH) to a final volume of 100 μL. For either assay the plate 
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was gently shaken with a vortex to ensure thorough mixing and immediately read at 37 °C in 
a 300 point (1 read per 5 seconds) kinetic assay measuring NAD reduction or NADH 
oxidation at 340 nm.  DL-alanine or sodium pyruvate was included as a substrate in the 
assays as positive controls. 
   
2.4.2.4 α-keto butyrate detection assay 
α-keto acid products of mycobacterial lyase enzyme activity on Se-AA substrates were 
detected using the 3-methyl-2-benzothiazolone hydrazone method described by Soda.
216
  
Briefly to 50 µL lyase enzyme assay was terminated by the addition of 25 µL 25% (v/v) 
trichloroacetic acid and precipitates such as protein was centrifuged out at 14,000 RPM for 5 
min in a microfuge.  200 µL of 0.5 M sodium acetate (pH 5.0) was added followed by 80 µL 
of 0.1% (w/v) 3-methyl-2-benzothiazolone hydrazone and the assay plate incubated at 50 °C 
for 40 min, cooled down to room temperature and absorbance read at 320 nm using α-
ketobutyrate and pyruvate as standards. 
2.4.4 Gas chromatography mass spectrometry 
GC-MS was used to detect volatile sulphur/selenium species produced by mycobacterial 
lyase reactions with the instruction of Dr. R. Keyzers.  A Shimadzu GC-2010 using a 30 m 
Restek RTX® -5SilMS crossbond® column and 0.25 mm internal diameter and 0.25 µM film 
thickness paired with a Shimadzu GC-MS QP 2020 Plus El MS was the instrument used..  
Solid-phase micro extraction (SPME) fibre was subject to 30 min exposure to the headspace 
of a 1 mL mycobacterial lyase reaction being carried out at 37 °C.  SPME fibre was inserted 
into the column and volatiles removed at 220 °C for 1 min and were separated using a 
temperature gradient starting at 30 °C and increasing at 8 °C / min.  Mass spectra of detected 
volatile chemical species were compared to NIST 08 (American Institute of Standards and 
Technology) spectral library to determine chemical identity. 
2.5 Mammalian cell line cytotoxicity assays 
2.5.1 HL-60 / J-774 / Vero cell MTT assay 
 All cytotoxicity assays were kindly performed by research team members Nathaniel Dasyam 
and Rekha Veliyayi Murikoli.  HL-60 human promyelocytic leukaemia or J-774 mouse 
adherent macrophage cells were cultured in 250 mL conical flasks with RPMI-1640 medium 
supplemented with 10% fetal calf serum, 50 µg/mL penicillin and 50 µg/mL streptomycin.  
Cells were incubated at 37 °C in a 5% CO2 atmosphere for growth and proliferation. 
Candidate drugs to be tested were 1:2 serially diluted in such a way that each well of a 96-
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well plate contains 50 µL of drug-containing medium. Diluted cell culture (50 µL) was then 
added to a final cell concentration of 10,000 cells per well.  The assay plate was then 
incubated at 37 °C with 200 RPM shaking for 48 h followed by the addition of 20 µL of 5 
mg/mL MTT reagent in PBS, left for two hours then 100 µL of 10% SDS solubiliser was 
added. Reading of plates was carried out by measuring absorbance at 570 nm using an 
Envision Multi-label plate reader (Perkin-Elmer).
217
 
2.6 Data processing  
Assay data were processed in Excel (Microsoft) and further analysed using Sigmaplot 10.0 
(Systat) or Prism 5 (Graphpad) to determine inhibitory concentrations and standard errors. 
 
2.6.1 Statistical analysis 
Data from high throughput screens were normalized to control for plate-to-plate variation 
using linear scaling to match the most extreme plates in each data set and taking their natural 
log transforms. Control values greater than 3 standard deviations from the mean were 
considered outliers and discarded.
122
   
 
2.6.1.1 Z-factors 
 Z factors were calculated as shown according to Figure 2.3 and used to determine the 
validity and quality of the high throughput screens by numerically demonstrating their signal 
dynamic range and variation.  Z factors have a value between 0 and 1, with 0 indicating an 
invalid assay due to complete overlap between positive and negative controls and 1 being a 
(theoretically unobtainable) perfect assay.  Values above 0.5 are considered statistically 
acceptable and signify a difference of at least 12 standard deviations between the means of 
the positive and negative controls.
218
   
 
Figure 2.3: Z-factor calculation:  Where μ is the mean of the positive and negative control 
signals and σ is the standard deviation of the positive and negative controls. 
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2.6.1.2 Signal to noise ratios 
Signal to noise ratios (SNR) were calculated according to the formula displayed in Figure 2.4.  
The higher the SNR value the more distinction between the assay signal and the background. 
 
Figure 2.4: Signal to Noise Ratio Calculation:  Where μ is the mean of the positive 
(growth) control signal and σ is the standard deviation of the noise (background or medium) 
control signal. 
  2.6.2 Chart plotting 
Venn diagrams were created using Google Chart Tools.  Scatterplots were created using R 
with the Rcommander and ggplot2 plugins and the following script: 
 
library(ggplot2, pos=4)  
attach(datasheetname)  
d <- qplot(No, MEAN, data= datasheetname, size=STDEV, color=MEAN, alpha = 
1/10, main="Insert title here", xlab="X-axis label", ylabY-axis label",  
e <- d + geom_abline(intercept=90, slope=0, color="#3B4FB8",alpha = 5/10, 
size=3)  
e  
 
All other charts were created using Microsoft Excel 2007®
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3.1 Introduction to High Throughput Screening 
High throughput screening is a commonly used methodology for modern drug discovery, 
including the discovery of antibiotics.  Deliberate chemical screening protocols have been 
utilised since the beginning of antibiotic drug discovery, with Paul Ehrlich screening 
hundreds of chemicals for anti-syphilis activity until he found compound 606, now known as 
salvarsan.
219
  Recent advances in computing, robotics and laboratory equipment such as 
automated spectrophotometers, microtitre plates and the advent of large commercial chemical 
collections or „libraries‟ have pushed high throughput screening to the foremost technique 
used in modern drug discovery, allowing vast numbers of chemicals to be rapidly assessed 
for their effect upon biological systems.
2
 
 
This chapter briefly discusses the methodologies used in high throughput screening for 
antibiotic drugs and the reasons why a whole cell screening approach was chosen for the 
present study.  Chemical collections screened in this study are detailed and characteristics of 
the two rich media conditions used in this work, LB and 7H9, are described.  Screen 
development and key optimisation steps are briefly touched upon before the presentation of 
screening results, with total screen data exhibited graphically in scatterplot format.  
Compounds meeting hit criteria are detailed and promising tuberculosis drug development 
leads are highlighted and discussed. 
3.1.1 High Throughput Screening methodologies 
Various methodologies used in high throughput screening are discussed at length in Chapter 
1.6.2.  These techniques are briefly recapitulated in Table 3.1 to provide context to the 
screening of this project.  
 
 Whole cell screening 
Description Chemical library is introduced to bacterial cells cultured in vitro and the growth 
inhibiting or sterilising activity is measured. 
Advantages  Simple to set up, easily measured by OD, GFP, Resazurin etc. 
 Broad spectrum – not restricted to a single target. 
 Accounts for a bacterial cell environmental context -  i.e. in order to be 
active compounds must persist in culture conditions, pass through the cell 
wall and avoid efflux or metabolic inactivation. 
 Can detect bacterial metabolism-activated pro-drugs. 
 Can be adapted to different culture conditions. 
Table 3.1: Summarized methodologies in anti-bacterial drug high throughput 
screening. 
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Disadvantages  Does not distinguish between anti-bacterial and cytotoxic compounds, 
requires cytotoxicity counter screen. 
 Hit compound target is unknown and must be identified through 
downstream studies. 
 Hit compound activity might be altered under in vivo conditions. 
 Whole cell high content screening 
Description Whole cell screening under complex in vitro conditions, such as intra-
macrophage phagocytised bacteria. 
Advantages  Includes the advantages of whole cell screening. 
 Provides further detection of hits active in the specific environment (i.e. 
intra-macrophage), are activated by the immune cell metabolism or 
modulate the immune cell anti-bacterial function. 
 Indicates potential cytotoxicity. 
Disadvantages  More costly and difficult to perform. 
 Hit compound target remains unknown and must be identified through 
downstream studies. 
 Compound target range is increased beyond bacterial targets, making 
identification potentially more difficult. 
 Targeted whole cell screening 
Description Whole cell screen where the strain is genetically altered to over/under express a 
target gene, enriching hits against the particular target. 
Advantages  All advantages of whole cell screening accounted for. 
 Hit compounds are enriched towards a defined target. 
 Hit compound target indicated, facilitating rapid downstream MoA and 
SAR studies. 
 Essential genes may be targeted by techniques such as inducible anti-
sense RNA down-regulation. 
Disadvantages  Requires an identified suitable target to be selected. 
 Genetically modified strain must be constructed. 
 Counter-screen of wild-type strain must be run in parallel to distinguish 
non-specific hits. 
 Gene expression modification may have unpredicted downstream 
ramifications. 
 Hits activity may not necessarily be applicable to wildtype bacteria; 
further validation studies required. 
 In vitro protein targeted screening 
Description An identified target protein is isolated and screened for inhibition of activity in an 
in vitro assay. 
Advantages  Target is defined, facilitating rapid MoA and SAR studies to improve hit 
compound activity. 
 Target can be researched and chosen for favourable properties, i.e. unique 
to bacteria, not present in humans. 
 More readily miniaturised to allow greater throughput. 
Disadvantages  Requires target to be selected, purified and enzymatic assay designed 
against the target. 
 Does not account for bacterial environmental conditions, such as cell 
wall, metabolism of compound, efflux, parallel targets, etc. 
 Requires downstream studies against whole cells to prove activity. 
 False positives may arise from compounds affecting the assay process 
rather than the target enzyme itself. 
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 In silico screening 
Description A defined protein target is computationally modelled and then subjected to a 
virtual screen to identify potential inhibitors. 
Advantages  Minimal costs. 
 Vast quantities of chemicals may be rapidly screened. 
 Chemical library pharmacophores may be specifically designed for the 
target cleft, with varying groups for guiding SAR studies.  
 May enrich hit compound anti-bacterial selectivity. 
Disadvantages  Requires target to be selected and computationally modelled. 
 In silico modelled target structure may differ from in vivo protein 
conformation. 
 Does not account for bacterial environmental conditions, such as cell 
wall, metabolism of compound, efflux, parallel targets, etc. 
 Requires downstream studies in vitro. 
 Whole cell gene expression screening 
Description A whole cell screen with a genetically inbuilt reporter system indicating chemical 
effect upon gene of interest expression. 
Advantages  All advantages of whole cell screening accounted for. 
 Provides additional information on hit compound target and mechanism, 
i.e. differential expression of promoter of interest. 
 Can detect compounds interfering with entire metabolic processes, even 
those not present in vitro such as those involved in virulence and 
pathogenesis. 
Disadvantages  Requires reporter system construction. 
 Only indicative, target(s) must be defined by further downstream study. 
 Requires cytotoxicity counter screen. 
 Reporter activation does not necessarily indicate anti-bacterial activity. 
A modified whole cell screening approach was selected for this research, using several 
different culture conditions, broadly defined into nutrient rich and nutrient starvation 
conditions.  The whole cell screening approach was chosen as to not limit screens to one 
target, instead to maximise the number of hit compounds identified by screens, allowing in 
depth comparison between the hit profiles with differing culture conditions and providing a 
large variety of lead compound options to pursue for further study.  The disadvantage of 
indeterminate cytotoxicity of identified hits was addressed by literature searching of hit 
compounds and downstream mammalian cell line cytotoxicity assays of promising hit 
compounds described in Chapter 5.  Target identification and mechanism of action studies 
were then carried out on a lead compound later described in Chapter 6. 
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3.1.2 Screening objectives 
Three objectives were determined for this high throughput screening component:   
 
1) Validate the viability of the dual label screening protocol as a tuberculosis drug 
discovery tool. 
 
2) Identify novel antibacterial chemicals with potential inhibitory activity towards M. 
tuberculosis. 
 
3) Investigate the discrepancies between the hit profiles of chemical library screens 
under differing rich culture conditions, and use these data to compare to starvation 
culture condition screens. 
To achieve these objectives three chemical libraries were screened using a 96-well plate 
format against the fast growing tuberculosis model organism M. smegmatis expressing 
plasmid bound GFP as an additional viability indicator to absorbance measurements.  This 
provides maximum coverage of hit detection and minimise false positives of compounds that 
may absorb at 600 nm or autofluoresce at in the GFP excitation/emission spectral 
wavelengths.
122
  The effect of chemical library compounds was assessed in M. smegmatis 
under a variety of culture nutrient conditions, broadly categorised into conventional nutrient 
rich media types and minimal nutrient starvation media types.  This chapter details only the 
rich media type data.  Hit compounds were then further validated against M. smegmatis to 
confirm and quantify their inhibitory activity and cross referenced against M. tuberculosis 
screening results performed by another research group member in our laboratory as part of 
his PhD project.
206, 220
  Validated hit compounds were further researched in bio-assay 
databases and scientific literature to determine the chemical properties such as novel 
bioactivity, cytotoxicity and biological indications which influence the compounds suitability 
as a possible candidate for further development towards anti-tubercular therapy. 
 
3.2 Chemical libraries 
Three chemical libraries were used in this study, totalling over 5000 compounds.  The source 
of these libraries and a brief description is provided below.  Many of these library compounds 
have known biological activities, and it is hypothesised that chemicals with novel anti-
mycobacterial activity may be discovered in these well known chemical collections.  This can 
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be advantageous as the chemicals may already be administered in humans for another 
purpose; therefore the pharmacological properties such as tolerance and side effects may have 
been previously researched.
221
 
 
3.2.1 LOPAC 
The Library of Pharmacologically Active Compounds (LOPAC), commercially supplied by 
Sigma-Aldrich, is a collection of 1,280 chemicals with characterised pharmacological 
activity.  Advertised as the gold standard in assay validation, these compounds have known 
pharmacological properties that cover a diverse range of known biological activities such as 
antibiotic activity, gene expression, multi-drug resistance, apoptosis, ion channel 
conductance, neurotransmission, signalling and phosphorylation. Although the compounds 
detailed in the LOPAC have been previously characterised, potential exists to identify 
chemicals with previously unknown anti-tubercular properties.  The prior known activity of 
these compounds also provides a good base to indicate whether the compound may be 
applicable to human tuberculosis therapy.  Additionally, screening LOPAC will validate the 
high throughput screen with the known anti-tubercular agents included in the library. 
 
3.2.2 Spectrum Collection 
The Spectrum Collection, supplied by Microsource (Connecticut, U.S.A.), is a library of 
2,000 chemicals and extracts.  Approximately half of the contents of the library are drugs 
with known biological activities; the remaining half are natural product extracts and 
pharmacophores with little or no known biological properties but were selected for their 
structural diversity.  Other non-drug bioactive molecules such as toxins, pesticides, herbicides 
and receptor blockers are also included in the library.  Like the LOPAC library, the fact that 
many of the chemicals have previously discovered activity is double edged, providing a basis 
for literature searching and indicating activity but detracting from novelty.  A large advantage 
of Spectrum is the inclusion of novel chemicals, particularly natural product extracts, with no 
known biological activity discovered to date.   
 
3.2.3 NIH Diversity and Natural Products Set 
The National Institute of Health (U.S.A.) National Cancer Institute supplies the 1597 
compound Diversity Set III and the 120 compound Natural Products Set.  The Diversity Set 
compounds are representatives of a collection of 1,000,000 pharmacophores derived from the 
NCI Developmental Therapeutics Repository compounds, selected for availability and 
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structural diversity.  The Natural Products Set II compounds are natural compounds that have 
been selected on the basis of origin, purity and structure diversity with an emphasis on 
multiple functional groups.  Due to the nature of this library‟s composition it contains many 
antibiotic chemicals that provide good internal controls for the screen.  Due to the NIH 
library nature as a cancer drug discovery tool, many of the library compounds are cytotoxic 
or otherwise anti-neoplastic, this makes them unsuitable for tuberculosis treatment due to 
their poor selectivity, e.g. compounds may be more toxic toward human cells than 
mycobacteria.  A large advantage of the NIH library is that it is a “hit kit”, meaning the 
chemicals it contains are pharmacophores representing a much larger collection of chemicals 
that may be ordered by request.  This provides an inexpensive head start for downstream 
SAR studies of promising hits. 
3.3 Screening conditions 
This research utilised four differential media conditions in high throughput screening; the 
nutrient rich media LB and 7H9, and the nutrient limited or starvation Hartman de Bonts 
(HdeB) C- and HdeB N-, carbon and nitrogen deprived respectively.  The reasoning in using 
these differential culture conditions is to explore the influence of contrasting culture 
conditions upon the antibiotic susceptibility in M. smegmatis, the tuberculosis model 
organism used in this study.  Compound susceptibility was explored in an effort to identify 
novel inhibitors of M. tuberculosis that have not yet been discovered by conventional rich 
media screening techniques, and to further explore the effect of culture conditions on 
sensitivity to inhibitors, allowing us to query which culture conditions of M. smegmatis best 
mimic the inhibition profile presented by M. tuberculosis.   
A major contributing factor to mycobacterial resilience is their flexibility in metabolic 
response to the environment.  Mycobacteria are able to adapt their metabolism to survive 
conditions of nutrient starvation
136, 222
 and hypoxia.
223
  This change in metabolism is derived 
from a change in gene expression and also presents a change in the drug susceptibility profile 
of the bacteria.  Nutrient starvation conditions can be encountered by M. tuberculosis during 
pathogenesis when sequestered by phagocytes
224
 and when encapsulated by a granuloma
225
.  
Therefore nutrient limited culture conditions are postulated to mimic the environmental 
conditions of pathogenesis and screening using nutrient limitation conditions may better 
identify chemicals effective against tuberculosis infection. 
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3.3.1 Model organism M. smegmatis  
Fast growing and non-pathogenic mycobacterial species, M. smegmatis, was chosen as the 
model organism in this screening.  As a tuberculosis surrogate model organism M. smegmatis 
has been the point of some controversy due to its lack of virulence, gene duplication and lack 
of approximately 30% of M. tuberculosis gene orthologues.
226, 227
 A mycobacterial model 
comparison study provided evidence that M. smegmatis detected ~50% of drugs active 
against M. tuberculosis H37Ra in a high throughput screen against two of the  chemical 
libraries used in the present research.
206
  M. smegmatis boasts several characteristics 
favourable for the screening component of this research; it exhibits fast growth with a 
doubling time of 2-3 h
228
 compared to the 20-24 h doubling time of M. tuberculosis.
228, 229
  
This renders M. smegmatis favourable for rapid culturing, high throughput screening and 
follow up assays.  M. smegmatis may be cultured at 42 °C, this allows the use of thermo-
sensitive vectors.
230
 The strain used in this research, M. smegmatis MC
2
155, can be 
genetically manipulated by transformation and homologous recombination techniques much 
more readily than slow growing mycobacterial species.
173
  Due to its non-pathogenic nature 
M. smegmatis poses low risk to laboratory workers and may be housed in the PC2 level 
facilities in which the present research experiments were performed.  This low risk potential 
also affords M. smegmatis regulatory authority permissions for genetic modification with 
more ease than pathogenic species.  M. smegmatis has been used successfully as a 
tuberculosis model organism in drug screening,  such as the discovery of the novel anti-
tubercular diarylquinoline TMC-207 that is currently undergoing clinical trials.
97
 M. 
smegmatis has been demonstrated to exhibit susceptibility to all clinically used anti-TB drugs 
and is the most comparable organism of all fast growing mycobacteria to MDR-TB in terms 
of its susceptibility to anti-bacterial agents.
56
  M. smegmatis often exhibits less frequent and 
lower sensitivity to inhibitory compounds in chemical inhibitor screens compared to slow 
growing mycobacteria, and this is likely due to genetic redundancy and its fast-growing non-
pathogenic nature.  Therefore inhibitory compounds detected in M. smegmatis screens that 
share inhibitory activity in M. tuberculosis often exhibit increased activity against M. 
tuberculosis strains.
206
 
 
3.3.2 Screening and hit criteria  
High throughput screens were set up and carried out as described in Chapter 2.2.3.  All rich 
media screens were carried out in independent triplicate experiments.   Hits were defined as 
compounds that exhibited 90% inhibition of growth compared with control cell growth and 
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antibiotic controls in at least two out of three screens.  Identified hits were then evaluated in a 
dose-response assay to quantify the level of anti-mycobacterial activity. 
 
3.3.3 Differential culture conditions 
Four different culture conditions were utilised in the screening experiments of the present 
research.  These four media types are separated into two distinct categories, rich media 
conditions and nutrient limited (or nutrient starvation) media conditions.  This chapter 
documents rich media condition screening.  Nutrient limitation media screening is addressed 
in Chapter 4. 
 
3.3.3.1 Rich media conditions 
Rich or complex media conditions refer to media types which contain large amounts of 
organic nutrient compounds such as nucleotides, amino acids and cofactors.  Rich media also 
may contain compounds for direct use as energy sources for microbes such as glycerol or 
glucose.  Rich media often are derived from hydrolysed organisms and tissues such as 
peptone digests and yeast extracts, but rich mediums may also have chemically defined 
constituents.  Bacteria grow more rapidly in rich media conditions, correspondingly have 
elevated expression of translational apparatus genes and less biosynthesis gene expression 
since many essential metabolic substrates are provided in the media.
231
  Rich conditions are 
ideal for bacterial growth but are not as stringent a model in regards to sensitivity for 
antibiotic screening due to the disparity of rich conditions compared to conditions 
encountered by bacteria in vivo.
232, 233
 
Therefore it is hypothesised that rich conditions present a smaller target profile due to the 
differential gene expression in this media type and will result in less compounds detected 
than in minimal media conditions. 
 
3.3.3.1.1 Luria-Bertani broth 
Luria-Bertani broth (LB) is a complex rich medium type consisting of tryptone, yeast extract 
and NaCl.  Tryptone, the tryptic digest of casein provides a complete spectrum of amino 
acids.  Yeast extract provides additional amino acids in addition to purines, pyrimidines, 
vitamin cofactors and inorganic minerals and trace elements.  NaCl is included for osmotic 
balance and glycerol supplementation provides ample an source of carbon.  The tryptone and 
yeast extract lend complexity to this medium, providing practically all metabolic substrates 
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required for cell growth and division, leading to little expression of many nutrient 
scavenging, transport and biosynthesis genes. 
3.3.3.1.2 Middlebrook 7H9 broth  
Middlebrook 7H9 Broth is a defined rich medium specific for culturing mycobacterial species 
including M. tuberculosis.  Although it is chemically defined it is still a rich medium as 
amino acids, fatty acids and other complex organic nutrients are provided by the oleic acid, 
bovine serum albumin, dextrose and catalase (OADC) enrichment.   Abundant carbon source 
is provided by glycerol and dextrose supplementation and ample nitrogen sources are 
provided in the 7H9 broth itself by ammonium sulphate.  The broth also provides glutamic 
acid, sodium citrate, cofactors pyridoxine, biotin and all required minerals and salts.  7H9 
broth represents somewhat of a middle ground between rich and starvation media types but is 
included as a rich medium type since although all required metabolic precursors are supplied 
and chemically defined none are limited in supply and complex nutrients such as free amino 
acids are not present.   
3.3.4 Hit validation  
Hit compounds identified in triplicate high throughput screens were then validated by serial 
dilution assay against M. smegmatis MC
2
155 in the medium type they were detected in as 
described in materials and methods Chapter 2.4.1.  These data are presented in tabular format 
after the respective compound library scatterplot figures.  Compounds were assessed in 
triplicate with a starting concentration of 25 µM (with the exception of some compounds that 
were able to be purchased in bulk that were tested at a starting concentration of 50 µM).  
Minimum inhibitory concentration (MIC) was recorded as the minimal concentration of 
compound required to produce no measureable growth in triplicate after 96 h in comparison 
to media and antibiotic controls.  False positive hits were discarded, and only validated hits 
are presented, in order of chemical library.   
For simplicity and comparative purposes, MIC values of validated compounds from LB and 
7H9 media conditions are tabulated together.  Significant differences between media 
conditions (more than one serial dilution MIC difference or lack of detection in either 
medium type is considered significant) are highlighted in red.  Validated results in slow 
growing mycobacterial species M. bovis BCG and M. tuberculosis H37Ra cultured in 7H9 
media were generously provided by the research of Mudassar Altaf
206
 and provide context to 
hits in these highly relevant slow growing mycobacterial models.  Compound MIC data for 
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M. bovis BCG and M. tuberculosis H37Ra were supplied quantitatively when available.   If a 
quantitative M. bovis BCG or M. tuberculosis H37Ra MIC for a hit compound was not 
available, the inhibitory activity in M. bovis BCG or M. tuberculosis H37Ra HTS data were 
used, a value of “≤ 20” µM indicates inhibitory activity (triplicate > 80% growth inhibition) 
was detected in screens, and no value “-“ indicates no inhibitory activity (triplicate < 80% 
growth inhibition) was detected in screens.
206, 220
  
Complete information on library screen hits by media type including compound name(s), 
chemical structure, library plate number and well position, validated MIC and known 
bioactive properties are provided in Appendix 9.4. 
3.3.5 Screen optimisations 
The high throughput screen was optimised by the addition of the surfactant Tween 80
234, 235
 
and the sugar D-arabinose to reduce aggregation of mycobacteria within the wells.
53
  Assay 
incubation time in rich media was limited to 72 h as no change in growth was demonstrated 
after this time period that reflects transition from log to stationary phase growth.  Plate reader 
settings of plate dimensions, measurement height and number of flashes were optimised 
using the Perkin Elmer assay optimisation protocol, details provided in Appendix 9.6. 
 
3.3.6 Statistical analysis of viability 
3.3.6.1 Luria-Bertani Broth 
The Z-factors for screens in LB conditions were Z= 0.91 (OD), Z=0.87 (GFP) for 
streptomycin and Z=0.68 (OD), Z=0.87 (GFP) for rifampicin.  Signal to noise ratios were 
22.64 (OD), 23.58 (GFP) for streptomycin and 9.44 (OD), 22.78 (GFP) for rifampicin.  These 
statistics indicated an excellent assay in terms of validity and repeatability as described in 
Chapter 2.6.1, with the weaker Z-factor and SNR from the rifampicin control under OD 
conditions due to its coloured nature.  It should be noted this phenomenon is the reason it was 
included as a control, although the Z-factor and SNR for rifampicin OD were lower, they are 
still well above acceptable levels.   
 
3.3.6.2 Middlebrook 7H9 Broth 
The Z-factors for screens under 7H9 conditions were Z=0.96 (OD), Z=0.88 (GFP) for 
streptomycin and Z=0.95 (OD), Z=0.92 (GFP) for rifampicin.  Signal to noise ratios were 
19.54 (OD) and 21.37 (GFP) for streptomycin and 10.13 (OD), 19.68 (GFP).  These statistics 
indicate an excellent assay in terms of validity and repeatability, further described in Chapter 
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2.6.1.  Rifampicin demonstrated a slightly lower signal to noise ratio for OD readings as 
expected due to its coloured nature but this was heavily outweighed by the high growth of 
controls in 7H9 and the fact that the statistics were above acceptable levels.  
 
3.4 Screen results  
Results of the rich media condition high throughput screens carried out by the methodology 
described in materials and methods Chapter 2.2.3 are depicted below in graphical format in 
figures 3.1-3.8, presented by order of chemical library (colour coded), media type and type of 
signal recorded (GFP or OD600).  Compounds are numerically categorised on the X axis and 
their inhibition of growth signal is shown on the Y axis.  Each graph is a representation of 
triplicate screens, with point position representing the mean inhibition value of a library 
compound and point size representing the standard deviation of a library compound across 
triplicate assays.  The threshold of 90% inhibition which defines a hit in rich medium is 
demonstrated by a blue horizontal line at y = 90 and also a green area of highlighting.  Hit 
compounds identified in screens were then verified by MIC determination dose-response 
assays, these results are tabulated in chemical library order (tables 3.2-3.4) and contrasted 
with 7H9 medium screening results of library compounds against slow growing 
mycobacterial species M. bovis BCG and M. tuberculosis H37Ra.
206, 220
  Hit compounds were 
categorised in figures 3.3, 3.6 and 3.9 based on known function according to information 
provided by the chemical library supplier (Sigma-Aldrich, Microsource, NIH), published 
literature and chemical database information.  Sensitivity of detection in media types refers to 
the differential validation MIC  or screen hits between LB and 7H9 conditions, with greater 
than 2-fold difference in MIC between LB and 7H9 media conditions considered to be 
significant differential sensitivity.    
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3.4.1 LOPAC rich culture conditions     
3.4.1.1 LB 
 
 
 
 
 
 
3.4.1.2 7H9 
  
Figure 3.1: M. smegmatis LOPAC LB HTS OD & GFP scatterplots. 
Scatterplots depicting the OD 600 nm (left) and GFP fluorescence (right) data derived 
from LB media HTS of the LOPAC for M. smegmatis growth inhibition.  Percent 
growth signal inhibition relative to controls is measured on the Y axis, library 
compound number is listed on the X axis.  Significant hits exhibiting > 90% inhibition 
are boxed in green.  Points are colour and size coded for mean value and standard 
deviation as depicted in the figure key. 
 
Figure 3.2: M. smegmatis LOPAC 7H9 HTS OD & GFP scatterplots. 
Scatterplots depicting the OD 600 nm (left) and GFP fluorescence (right) data derived 
from 7H9 media HTS of the LOPAC for M. smegmatis growth inhibition.  Details as 
for Fig 3.1. 
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3.4.1.3 LOPAC rich media screening validated hit compounds 
LOPAC Compound 
M. smegmatis 
MIC (µM) - LB 
M. smegmatis 
MIC (µM) - 7H9 
M. bovis BCG 
MIC (µM) 
M. tuberculosis 
H37Ra MIC (µM) 
Calcimycin 3.125 - - ≤ 20 
Calmidazolium 12.5 - - - 
Clotrimazole 12.5 - - - 
Demeclocycline 3.125 3.125 3.125 1.56 
Dequalinium 12.5 3.125 3.125 6.25 
Dequalinium C-14 
linker. (Quinolinium) 
6.25 3.125 - ≤ 20 
Diphenyleneiodonium 6.25 3.125 0.195 0.39 
Doxycycline 1.56 1.56 ≤ 20 - 
Ellipticine - 25 12.5 12.5 
Idarubicin 12.5 3.125 6.25 6.25 
Lomefloxacin 12.5 6.25 1.56 3.125 
Methoctramine 12.5 12.5 1.56 6.25 
Minocycline 12.5 12.5 1.56 3.125 
Niclosamide 12.5 25 6.25 6.25 
Ofloxacin 3.125 3.125 1.56 1.56 
Vancomycin 12.5 - ≤ 20 - 
WB 64 - 12.5 12.5 12.5 
 
Table 3.2: LOPAC rich media screening validated hit results.  Validation MIC values of 
LOPAC HTS derived hits are presented for M. smegmatis by rich media type.  These values 
are contrasted with 7H9 medium screening results of LOPAC against slow growing 
mycobacterial species M. bovis BCG and M. tuberculosis H37Ra.
206, 220
  Hit compounds 
results with substantial difference in sensitivity ( > 2-fold inhibition) between media types 
results are displayed in red text.  Values of “-“ indicate no inhibitory activity was detected in 
screening (triplicate mean of  > 90% growth inhibition compared to positive controls).  
Values of “≤ 20” indicate the compound did exhibit inhibitory activity in screens (triplicate 
mean of > 80% growth inhibition compared to positive controls) against slow growing 
mycobacterial species, however confirmatory MIC assays were unable to be performed, 
therefore the MIC is estimated to be less than or equal to the screen compound concentration 
of 20 µM. 
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3.4.1.4 LOPAC rich media screening results overview 
 
Figure 3.7: LOPAC rich media screening hit compound known activities.  Percentage of 
hits obtained by rich media screening of the LOPAC broadly categorised by supplier 
annotated biological activity. 
A total of 17 inhibitors were identified through LB and 7H9 screening of the LOPAC library 
with 15 inhibitors identified in LB media conditions and 13 inhibitors through 7H9 culture 
conditions.  Many known anti-bacterial chemicals were identified in the screening of the 
LOPAC such as the tetracycline family antibiotics demeclocycline, doxycycline, and 
minocycline that exhibited identical activity across both media types.  The quinolones 
lomefloxacin and ofloxacin were also detected in both media types.  The glycopeptide 
vancomycin and calcium ionophore calcimycin were detected only in LB conditions.  The 
prior may perhaps be an indication of differential mycobacterial cell wall synthesis under 
nutrient limitation conditions, as alteration of D-alanyl-D-alanine terminal residues of 
NAM/NAG cell wall peptides, the binding site of vancomycin, confers resistance to the 
drug.
236
  The detection of these known antibiotics successfully served as internal validation 
controls for the assay.  The cytotoxic or antineoplastic compounds ellipticine and idarubicin 
were detected with greater sensitivity in 7H9 conditions, with ellipticine having no MIC at 
the levels tested in LB, and idarubicin having a four-fold increase in potency under 7H9 
conditions in comparison with LB conditions.  With known anti-bacterial agents and 
cytotoxic agents accounted for, novel hit compounds included calmidazolium chloride and 
41% 
6% 
6% 
12% 
35% 
Categorised Validated Hits from LOPAC Rich Media Screening. 
Anti-bacterial
Anti-fungal
Anti-helminthic
Anti-neoplastic
Other
  CHAPTER THREE:  HIGH-THROUGHPUT SCREENING     90 
clotrimazole that were detected in LB conditions only.  Dequalinium and its derivative 
quinolinium were detected in both LB and 7H9, albeit with a four-fold reduction in activity in 
LB media.  The structurally similar methoctramine was also detected in both media 
conditions.  Diphenyleneiodonium and niclosamide were detected under both conditions and 
demonstrated a two-fold reduction in activity in LB culture conditions.  WB-64, similar again 
in structure to dequalinium and methoctramine was detected only under 7H9 screening 
conditions.   A detailed list of library screen hits including chemical structures is included in 
Appendix 9.4.1.  The biological and chemical significance of the novel hit compounds 
(discounting known antibiotics and cytotoxics) is discussed in depth in section 3.5.2.1 of this 
chapter. 
  
  CHAPTER THREE:  HIGH-THROUGHPUT SCREENING     91 
3.4.2 Spectrum Collection Rich culture conditions   
3.4.2.1 LB 
 
 
 
 
 
3.4.2 Spectrum Collection Rich culture conditions   
3.4.2.2 7H9 
 
 
Figure 3.4: M. smegmatis Spectrum Collection LB HTS OD & GFP scatterplots. 
Scatterplots depicting the OD 600 nm (left) and GFP fluorescence (right) data derived 
from LB media HTS of the Spectrum Collection for M. smegmatis growth inhibition.  
Details as for Fig 3.1.  Note the high standard deviation of compounds 1800-1900 caused 
by an anomaly of a single plate of the triplicate experiment.  The anomaly is more 
pronounced for GFP data than OD data and is likely due to human error in assay set up. 
 
Figure 3.5: M. smegmatis Spectrum Collection 7H9 HTS OD & GFP scatterplots. 
Scatterplots depicting the OD 600 nm (left) and GFP fluorescence (right) data derived from 7H9 
media HTS of the Spectrum Collection Set for M. smegmatis growth inhibition.  Details as for 
Fig 3.1.   
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3.4.2.3 Spectrum Collection rich media screening validated hit compounds 
Spectrum Collection 
Compound 
M. smegmatis 
MIC (µM) LB 
M. smegmatis 
MIC (µM) 7H9 
M. bovis BCG 
MIC (µM) 
M. tuberculosis 
H37Ra MIC (µM) 
Chloroacetoxyquinoline 
(Silital) 
25 - ≤ 20 ≤ 20 
Aklavine 12.5 - ≤ 20 ≤ 20 
Celastrol (Tripterine) 25 - - - 
Chlorhexidine 12.5 - ≤ 20 ≤ 20 
Chlortetracycline 1.56 1.56 - - 
Demeclocycline 1.56 1.56 ≤ 20 ≤ 20 
Dihydrostreptomycin 12.5 6.25 - - 
Pyrithione Zinc - 1.56 ≤ 20 ≤ 20 
Clotrimazole 12.5 - ≤ 20 - 
Doxycycline 1.56 1.56 ≤ 20 ≤ 20 
Ethambutol 3.125 3.125 ≤ 20 ≤ 20 
Minocycline 1.56 0.78 ≤ 20 ≤ 20 
Oxyquinoline - 12.5 ≤ 20 ≤ 20 
Oxytetracycline  6.25 3.125 - ≤ 20 
Tetracycline 1.56 3.125 ≤ 20 - 
Streptomycin 3.125 3.125 - - 
Tobramycin 6.25 6.25 - - 
Thimerosal 3.125 1.56 ≤ 20 ≤ 20 
Thiothixene (Tiotixene) - 25 - - 
Sulfamethoxazole - 25 - - 
Phenylmercuric Acetate - 3.125 ≤ 20 ≤ 20 
Gemifloxacin 3.125 3.125 ≤ 20 ≤ 20 
Clioquinol 12.5 - - - 
Thiostrepton 12.5 12.5 ≤ 20 ≤ 20 
Gatifloxacin 1.56 1.56 ≤ 20 ≤ 20 
Methylbenzethonium 
Chloride 
1.56 6.25 ≤ 20 - 
Roxithromycin 6.25 6.25 ≤ 20 - 
Levofloxacin 3.125 3.125 ≤ 20 ≤ 20 
Telithromycin 6.25 25 ≤ 20 - 
Erythromycin 12.5 12.5 ≤ 20 - 
Econzole - 12.5 ≤ 20 ≤ 20 
Lomefloxacin 12.5 12.5 ≤ 20 ≤ 20 
Ofloxacin 3.125 3.125 ≤ 20 ≤ 20 
Cisplatin - 12.5 - - 
Alexidine - 6.25 ≤ 20 ≤ 20 
Dirithromycin 12.5 6.25 - ≤ 20 
Clarithromycin - 6.25 ≤ 20 - 
Moxifloxacin 1.56 1.56 ≤ 20 ≤ 20 
Rifampin 6.25 6.25 ≤ 20 ≤ 20 
Ciprofloxacin 12.5 12.5 - ≤ 20 
Teniposide 25 25 - - 
Rifaximin 6.25 6.25 ≤ 20 ≤ 20 
Sarafloxacin 6.25 6.25 ≤ 20 ≤ 20 
Pefloxacine 12.5 12.5 ≤ 20 ≤ 20 
 
 
Table 3.3: Spectrum Collection rich media screening validated hit results.   
Validation MIC values of Spectrum Collection HTS derived hits are presented for M. 
smegmatis by rich media type.  Details as for Table 3.2. 
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3.4.2.4 Spectrum Collection rich media screening results overview 
 
Figure 3.6:  Spectrum Collection rich media screen hit compound activities.  
Percentage of hits obtained by rich media screening of the Spectrum Collection broadly 
categorised by supplier annotated biological activity. 
Forty-four inhibitors were identified through the screening of the Spectrum Collection in both 
LB and 7H9 media types with 35 hits were validated in LB media and 38 validated in 7H9 
media.  A large amount of known antibiotics were detected in this screening with comparable 
sensitivity in both media types including 6 tetracycline family antibiotics,  9 fluoroquinolones 
(a class regarded as 2
nd
 line anti-tuberculosis treatment drugs), the first line tuberculosis 
treatment drugs and derivatives streptomycin, dihydrostreptomycin, ethambutol, rifampicin 
and rifaximin.  The 3
rd
 line anti-tuberculosis drug clarithromycin was also detected in 7H9 
medium conditions only.  The aminoglycoside tobramycin and macrolide antibiotics 
roxithromycin, erythromycin, dirithromycin and cyclic peptide antibiotic thiostrepton were 
detected with similar sensitivity in both rich media types but sulfamethoxazole was detected 
only in 7H9 media and the ketolide telithromycin was detected with four fold greater 
sensitivity in 7H9 media.  Several anti-fungal agents were differentially detected in either 
medium type including chloroacetoxyquinoline, and clotrimazole detected in LB conditions 
only and pyrithione zinc, phenylmercuric acetate and econazole detected in only 7H9 
conditions.  Anti-septic agents exhibited much differential sensitivity depending on media 
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conditions, with only thimerosal being validated with comparable MIC in both media types, 
whilst chlorhexidine and clioquinol were validated only in LB medium conditions and 
methylbenzethonium chloride exhibiting 4-fold greater activity in LB medium conditions 
compared to 7H9.  The only anti-septic solely validated in 7H9 medium was alexidine.  A 
few anti-cancer chemicals were detected such as teniposide in both media conditions, 
aklavine and celastrol only in LB conditions and cisplatin only in 7H9 conditions.  
Accounting for known anti-bacterial, anti-septic and cytotoxic agents these screening results 
presented few novel anti-bacterial compounds, with the exception of thiothixene – a 
antipsychotic thioxanthine class drug which has since been reported by the Southern 
Research Institute as exhibiting anti-tubercular activity in vitro (PubChem BioAssay ID# 
449762).
237
  Several anti-fungal agents detected to have anti-mycobacterial activity in this 
screening may prove novel leads for implementation as tuberculosis treatment options and 
will be discussed further in section 3.5.2.2 of this chapter.  A complete list of Spectrum 
Collection screen hits including chemical structures is included in Appendix 9.4.2.   
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3.4.3 NIH Diversity Set Rich culture conditions 
3.4.3.1 LB 
    
 
 
 3.4.3.2 7H9 
    
    
  
Figure 3.7: M. smegmatis NIH Diversity Set LB HTS OD & GFP scatterplots. 
Scatterplots depicting the OD 600 nm (left) and GFP fluorescence (right) data derived 
from LB media HTS of the NIH Diversity Set for M. smegmatis growth inhibition.  
Details as for Fig 3.1.   
 
 
Figure 3.8: M. smegmatis NIH Diversity Set 7H9 HTS OD & GFP scatterplots. 
Scatterplots depicting the OD 600 nm (left) and GFP fluorescence (right) data derived from 
7H9 media HTS of the NIH Diversity Set for M. smegmatis growth inhibition.  Details as 
for Fig 3.1.   
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3.4.3.3 NIH Diversity Set rich media screening validated hit compounds 
NIH Library 
Compound 
M. smegmatis 
MIC (µM)- LB 
M. smegmatis 
MIC (µM)- 7H9 
M. bovis BCG 
MIC (µM) 
M. tuberculosis 
H37Ra MIC (µM) 
NSC3907 
(8-Hydroxyquinoline 
salicylate, clioquinol 
analogue) 
- 25 12.5 3.125 
NSC329226 6.25 6.25 ≤ 20 ≤ 20 
NSC625324 (Silver 
sulfadiazine) 
- 12.5 - - 
NSC12155 
(Aminoquinuride, 
surfen) 
- 12.5 ≤ 20 - 
NSC13480 - 12.5 12.5 12.5 
NSC132693 - 25   
NSC321206 - 25 25 3.125 
NSC311153 - 25 6.25 6.25 
NSC311152 
(Datelliptium) 
- 12.5 ≤ 20 ≤ 20 
NSC176327 - 12.5 ≤ 20 ≤ 20 
NSC359449  - 12.5   
NSC268879 3.125 3.125 1.56 3.125 
NSC661755 
(Michellamine B) 
25 - ≤ 20 ≤ 20 
NSC133100 (Rifamycin 
SV) 
25 - - - 
NSC305787 - 25 25 6.25 
NSC11241  
(C.I. Basic red 6) 
- 25 - - 
NSC321237 6.25 - - - 
NSC5159 (Chartreusin) 3.125 1.56 1.56 1.56 
NSC310551 - 6.25 12.5 6.25 
NSC22225  
(Cadmium chlorendic 
acid) 
- 1.56 ≤ 20 ≤ 20 
NSC145611 (Rifamycin 
derivative) 
25 - 50 6.25 
NSC145612 25   50 
NSC143491 
(Daunorubicin) 
12.5 12.5 ≤ 20 ≤ 20 
NSC321239 6.25 12.5 ≤ 20 - 
NSC69343 12.5 12.5 - - 
NSC106408 
(Anthramycin methyl 
ether) 
25 12.5 - - 
NSC134727 (Mitomycin 
C) 
1.56 - - - 
NSC122819 
(Teniposide) 
12.5 - - - 
NSC659779 (2- 
Bromoascididemin) 
12.5 1.56 0.781 3.125 
NSC325014 
(Bactobolin) 
12.5 12.5 ≤ 20 - 
NSC661755 
(Michellamine B) 
25 - ≤ 20 ≤ 20 
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NIH Library 
Compound 
M. smegmatis 
MIC (µM) - LB 
M. smegmatis 
MIC (µM) - 7H9 
M. bovis BCG 
MIC (µM) 
M. tuberculosis 
H37Ra MIC (µM) 
NSC526417 
(Echinomycin) 
1.56 3.125 ≤ 20 ≤ 20 
NSC45383 
(Streptonigrin) 
3.125 25 ≤ 20 ≤ 20 
NSC45737 (Bacitracin) 12.5 12.5 ≤ 20 ≤ 20 
NSC51001 
(Carbomycin) 
6.25 12.5 12.5 12.5 
NSC82151 
(Daunorubicin HCl) 
6.25 12.5 ≤ 20 ≤ 20 
NSC5159 (Chartreusin) 3.125 1.56 - - 
NSC62709 
(Imidazoquinoline) 
25 25 50 12.5 
NSC18712 
(Streptomycin 
thiosemicarbazone) 
25 12.5 ≤ 20 ≤ 20 
NSC125066 
(Bleomycin) 
1.56 1.56 3.125 1.56 
NSC31048 
(Neohesperidin) 
12.5 6.25 ≤ 20 ≤ 20 
NSC301739 
(Mitoxantrone) 
- 25 ≤ 20  
NSC47151 (Neomycin, 
neosule) 
- 12.5 ≤ 20 ≤ 20 
NSC67574 (Vincristine 
sulfate) 
25 - ≤ 20 ≤ 20 
NSC133100 (Rifamycin 
SV) 
25 - - - 
NSC368675 
(Azadirachtin) 
25 - ≤ 20 ≤ 20 
NSC61586 
(Phleomycin) 
0.39 0.19 25 1.56 
NSC285116 (Siomycin 
A) 
6.25 1.56 6.25 6.25 
NSC13252 
(Chlorotetracycline HCl) 
1.56 1.56 - - 
NSC189794 
(Streptovaricin) 
12.5 12.5 25 6.25 
NSC3053 
(Dactinomycin) 
12.5 - - - 
NSC363182 
(Kijanimicin derivative 
U-64815) 
12.5 - 25 3.125 
 
Table 3.4: NIH Diversity Set rich media screening validated hit results.   
Validation MIC values of NIH Diversity Set HTS derived hits are presented for M. 
smegmatis by rich media type.  The NSC designation number is given and where available a 
common name is also supplied.  Details as for Table 3.2. 
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3.4.3.4 NIH Diversity Set rich media screening results overview 
 
Figure 3.9:  Pie chart of NIH Diversity Set rich media screen hit compound activities.   
Percentage of hits obtained by rich media screening of the NIH Diversity Set broadly 
categorised by supplier annotated biological activity. 
Screening of the NIH Diversity Set library yielded a total of 53 validated hit compounds, 36 
of which were validated in LB medium and 39 in 7H9 culture conditions.  Many cytotoxic 
and anticancer agents were detected in the screening of this library which is not unexpected 
given its intended nature as a cancer drug research chemical collection.  7H9 medium was 
more sensitive in the elucidation of cytotoxic chemicals with 10 chemicals with anti-cancer 
indications being detected solely or with > 4 fold sensitivity in 7H9 medium whilst only 4 
anti-cancer indicated compounds were validated solely in LB medium.  Eleven chemicals 
were validated with comparable sensitivity in both media types.    
In regards to anti-bacterial compounds validated from the screens 4 rifamycin derivatives and 
a kijanimicin derivative were detected only in LB medium; where as only one rifamycin 
derivative and neomycin were detected solely in 7H9 and six anti-bacterial compounds 
including two tetracycline class antibiotics were detected with comparable sensitivity in both 
conditions.  One antiseptic compound was identified, silver sulfadiazine, only in 7H9 
conditions.   
This left ten novel anti-tubercular compounds detected in the screening of the NIH library – 
four detected only in LB: two michellamine anti-viral compounds, one organomercury 
compound and azadirachtin which is isolated from the neem tree.  Two chemicals were 
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detected only in 7H9: the aminoquinuride surfen and cadmium chlorendic acid.  Four 
compounds were detected in both conditions: two organomercury compounds, the antiviral / 
immunomodulator imidazoquinoline and an artificial sweetening agent and natural product 
isolated from citrus plants neohesperidin.  Novel anti-mycobacterials detected in this screen 
will be discussed further in section 3.5.2.3 of this chapter and a detailed list of library screen 
hits including chemical structures is included in Appendix 9.4.3. 
3.4.4 Overview of screening goals and outcomes  
The purpose of this screening exercise was three fold.  First, to validate the whole cell high 
throughput screen design against libraries containing known inhibitory compounds towards 
bacteria including M. tuberculosis.   
 
Second, to profile the inhibition of library compounds towards the tuberculosis model 
organism M. smegmatis under two distinct rich media conditions and identify potential novel 
chemical inhibitors of M. tuberculosis.   
 
Third, to compare the library hit compound profiles between rich media types and also to 
facilitate comparison of rich media types with starvation media conditions, and to determine 
how M. smegmatis library hit profiles compare with those of M. tuberculosis screens, 
elaborated further in Chapter 4.   
 
Whole cell M. smegmatis high throughput screening and hit characterisation protocols were 
validated through identification of several known tuberculosis treatment drugs and other 
known antibiotic agents.  The screening in two distinct rich culture conditions, LB and 7H9, 
also produced differential hit profiles from the libraries, indicating that bacterial culture 
conditions influence sensitivity to chemical inhibitors.  Finally, this screening revealed 
previously unpublished anti-mycobacterial compounds.  Many of these identified novel 
inhibitors exhibit cytotoxic or otherwise unsuitable properties for lead compounds for human 
tuberculosis treatment.  It is presumed that mycobacterial susceptibility to compounds will 
also differ in vivo, therefore confirmatory animal model testing must be carried out to 
properly validate lead compound efficacy.  However, several compounds show promising 
indication as novel tuberculosis drug candidates.  These screening results also will serve as a 
benchmark on which to compare the inhibition profile of the chemical libraries against M. 
smegmatis under nutrient limitation culture conditions. 
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3.5 Discussion 
3.5.2 Biological significance of rich media screen hit compounds 
Disregarding validated hit compounds with known anti-bacterial, cytotoxic or other 
properties that rend them unsuitable for use in human therapy, the biological and chemical 
significance of the novel anti-tubercular hit compounds will be analysed on the basis of their 
known reported activities in the literature and bioassay databases.  Compounds thought to be 
particularly promising novel human TB treatment drug candidates on the basis of novelty, 
anti-mycobacterial potency and low mammalian toxicity are highlighted with bold 
underscore. 
 
3.5.2.1 LOPAC rich media screen hit compound significance 
Calmidazolium chloride is reported to have inhibitory activity towards Plasmodium 
falciparum, the causative agent of malaria.
237
  This research appears to be the first report of 
anti-mycobacterial activity of this compound,
122
 however the compound was unable to be 
validated in M. tuberculosis H37Ra having an MIC > 20 µM which detracts from the 
pharmacophores promise as a therapeutic agent.  Calmidazolium is also a calmodulin 
antagonist inhibiting Ca
2+
, Na
+
 and K
+
 channels that can result in intracellular calcium 
accumulation and subsequent cellular toxicity, particularly cardiotoxicity.
238
  These 
properties rend calmidazolium an unlikely candidate to pursue further. 
Clotrimazole is a common over-the-counter topical anti-fungal agent.  It also exhibits 
inhibitory activity towards P. falciparum
237
.  It has shown in vitro inhibitory activity towards 
M. tuberculosis H37Ra, including stationary phase cells.
239
  Clotrimazole is administered 
topically and has a reported favourable mammalian toxicity profile
240
 but exerts non-specific 
inhibition of many enzymes.
237
 The latter is an undesirable effect for systemic drug delivery.  
Derivatives showing increased specificity towards inhibiting mycobacteria and able to be 
orally administered may be prove suitable for tuberculosis therapy.    
Concurrent to this research, dequalinium has been described and characterised as an inhibitor 
of M. tuberculosis mycothiol ligase and this same mechanism no doubt applies towards the 
dequalinium C-14 linker derivative quinolinium.
241
  Methoctramine and WB-64 may also 
possible fall into this same mechanistic class as they exhibit similar structural characteristics 
and muscarinic receptor antagonism properties. 
 
Diphenyleneiodonium is a characterised flavoenzyme inhibitor and oxidative stressor.
242
 and 
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is thus most likely a „frequent flyer‟, a common HTS hit as it inhibits a wide range of crucial 
enzymatic functions.  The pharmacophore may be of use if the structure is modified to be 
specifically targeted towards mycobacteria such as by the conjugation of a mycobactin 
siderophore.
243
 
 
Niclosamide is an anti-helminthic agent used specifically in the treatment of tapeworms, 
including treatment of tapeworm parasites in humans.  Its mechanism of action is the 
uncoupling of oxidative phosphorylation.
244
  Niclosamide exhibits a good MIC in vitro 
against M. tuberculosis H37Ra of 6.25 µM, although its cytotoxicity against J-774 cell lines 
has been suggested as limiting its applicability in vivo.
239
  This may not apply when 
administered systemically considering niclosamide is used in humans as a treatment for 
tapeworm. Niclosamide and other salicylanilides present good candidates for the 
development of new anti-tubercular agents, a concept that has recently been explored by 
Imramovsky et al.
245
 
 
3.5.2.2 Spectrum Collection rich media screen hit compound significance 
Chloroacetoxyquinoline has been shown to be inhibitory towards bacterial siderophore 
biosynthesis,
237
 which may be its mechanism of anti-mycobacterial action.  Along with other 
quinoline derivatives chloroacetoxyquinoline has been synthesised and tested for anti-
bacterial activity against S. aureus and E. coli with results comparable to tetracycline
246
 
Clotrimazole is discussed above as it was also detected and validated in the LOPAC screen.   
Clioquinol, only detected in LB medium has recently been reported to be an inhibitor of M. 
tuberculosis methionine aminopeptidase.
247
 
Pyrithione zinc demonstrated strong inhibition of M. smegmatis in 7H9 medium only, but 
inhibition also extended to slow growing M. tuberculosis H37Rv with a previously reported 
in vitro MIC of 2.5 µM.
221
  It is a known anti-fungal agent and is thought to act by inhibition 
of membrane proton pump transporters, and is included in topical anti-fungal or anti-bacterial 
soap and shampoo preparations.
248
  It has a high oral LD50 of 600 mg/kg in canines that may 
rend it suitable for systemic administration in human therapy.
249
  
The organic mercury compound phenylmercuric acetate is used as a fungicidal agent.  It was 
described as early as 1921 as an anti-tubercular agent
250
 but due to the intrinsic toxicity of 
mercury this compound is unfavourable for oral anti-bacterial therapy. 
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Econazole has been detected concurrent to this research as inhibitory towards M. tuberculosis 
and M. bovis.
237
 and has been explored as a treatment option for MDR-TB.
19
  A broad 
spectrum anti-fungal, it is used in many topical anti-fungal over the counter medications and 
is reported to be well tolerated orally in murine models.
251
 
The most interesting and atypical hit compound presented by the rich media condition 
screening of the Spectrum Collection is thiothixene, which is a thioxanthene antipsychotic 
agent used in the treatment of psychiatric conditions, such as schizophrenia.  It was detected 
concurrent to this research by the SRI as inhibitory to the growth of M. tuberculosis with a 
validated IC50 of 100 µM against H37Rv (PubChem BioAssay ID# 449762). Thiothixene was 
also detected in screens for inhibitory compounds towards P. falciparum.
237
  If the mental 
effects exerted by this chemical
252
 could be ameliorated and the anti-tuberculosis activity 
increased it may serve as a novel pharmacological scaffold for tuberculosis treatment. 
 
3.5.2.3 NIH Diversity Set rich media screen hit compound significance 
Michellamine B (NSC661755) and its parent class of michellamine alkaloids are natural 
products isolated from leaves of the Ancistrocladus korupensis plant.  Michellamine B is a 
potent inhibitor of HIV replication, thought to act through the inhibition of HIV reverse 
transcriptase and viral-host cell fusion and also by inhibition of protein kinase C.
253
  This 
research is the first report of anti-mycobacterial activity of michellamines and its activity was 
unable to be quantitatively confirmed in M. tuberculosis < 20 µM.  Michellamines have 
unfavourable cytotoxicity values towards some human cell lines,
254
 but its dual inhibitory 
activity toward both HIV and TB for which co-infection is a major dilemma (see Chapter 
1.3), make this class of compounds valuable and in need of further research as anti-tubercular 
agents. 
The organomercury compounds NSC268879, NSC321239 and NSC321237 are various 
mimics of the purine nucleotide guanine, and although no toxicity assays or anti-bacterial 
activity has been reported on PubChem Bioassay
237
 due to the mercury and nucleotide 
mimicking properties of these molecules suggesting they may be too toxic.
255
  NSC47151 
neomycin is an aminoglycoside antibiotic that is commonly available over the counter as a 
topical anti-bacterial.  Its systemic use in the treatment of tuberculosis has been explored
256
 
however due to side effects of ototoxocity and nephrotoxicity
257
 its systemic use is not 
recommended since newer aminoglycosides with lower toxicity have been developed.  
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Similarly, NSC45737 bacitracin showed good inhibition of mycobacterial growth; however, 
this drug is only administered topically due to nephrotoxicity concerns.
258
 
Azadirachtin is a limonoid class natural product isolated from the neem tree, Azadirachta 
indica.  It is the most well researched derivative of the neem tree and is widely used as an 
insecticide/pesticide.  Oral administration of azadirachtin is extremely well tolerated in 
mammals with doses up to 1500 mg/kg per day having no observable effect after 90-days in 
murine studies.
259
  Azadirachtin also appears to have no effects on postnatal development 
over two generations in murine models and is considered to be a safe pesticidal agent.
260
  
Azadirachtin has been demonstrated to interact with retinoic acid receptors and modulate 
their downstream effects.
261
  This research appears to be the first reporting of anti-
mycobacterial activity of azadirachtin, unfortunately the activity of the compound towards 
slow growing species such as M. tuberculosis was unable to be quantitatively characterised 
other than an MIC > 20 µM.  This requires confirmatory follow up as the true MIC of 
azadirachtin is likely much lower.  Extracts of the neem tree and its oils have long been used 
in traditional Indian folk medicine in the treatment of many diseases including leprosy and 
tuberculosis,
262
 and these extracts have disclosed in vitro activity against many strains of 
bacteria including M. tuberculosis.
263
  The compound azadirachtin may be responsible for the 
anti-microbial properties of neem extracts.  Considering azadirachtin‟s favourable toxicity 
profile it is deemed to be a promising chemical scaffold for development of an anti-
tuberculosis drug, and requires further research into its anti-mycobacterial properties, 
cytotoxicity and in vivo tolerance. 
Aminoquinuride / surfen is a antagonist of heparin.
264
  It has reported activity as an anti-
malarial agent in addition to inhibitory activity towards Bacillus anthracis, the causative 
agent of anthrax, in both spore and vegetative states.
237, 265
  No activity towards M. 
tuberculosis H37Ra was observed at the < 20 µM screening concentrations, so the activity of 
this compound towards slow growing mycobacterial species requires further validation.  This 
research appears to be the first reporting of anti-mycobacterial activity of aminoquinuride  It 
has been previously described as decreasing HIV infectivity through the inhibition of amyloid 
fibrils and was referred to as semen derived enhancer of viral infection (SEVI),
266
 this is a 
favourable indication for HIV-TB co-infection. 
Cadmium chlorendic acid contains the heavy metallic element cadmium and has been 
detected in one anti-cancer assay.
237, 267
  Although it exhibited strong inhibition of M. 
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smegmatis growth in 7H9 media with an MIC of 1.56 µM the MIC was unable to be 
validated in M. tuberculosis < 20 µM.  It has been detected in silico as a potential inhibitor of 
the peptidoglycan synthesis enzyme MurD; however, inhibition was unable to be confirmed 
by a secondary in vitro enzyme assay.
268
  Its detected anti-cancer activity likely rends this 
molecule unsuitable as a tuberculosis treatment candidate. 
Imidazoquinoline, a derivative of streptonigrin, is an immune response modulator, anti-
tumour and anti-viral agent – these latter effects are possibly consequences of 
immunomodulation.
269
  It has been detected in 5 anti-cancer or tumour cell line growth 
inhibition screens.
237
  It exhibited good inhibitory activity towards M. tuberculosis H37Ra 
with an MIC of 12.5 µM; however, anti-tumour activity and mutagenic properties indicate a 
negative side effect profile for this pharmacophore rending it undesirable for further 
development as an anti-tubercular agent.
270
 
 
Neohesperidin is an artificial sweetening agent and natural product isolated from citrus 
plants of the family Rutacea.  Neohesperidin is widely used in many food products as a 
flavour enhancer (E959) and is considered to be safe for human consumption.
271
  Activity 
was detected in M. tuberculosis screening which indicates it has a probable MIC < 20 µM, 
but this requires further quantitative evaluation.  This research appears to be the first 
disclosure of anti-mycobacterial activity of neohesperidin; however, complex natural product 
extracts of citrus plant material containing hesperidins have before proved to have inhibitory 
activity towards MDR-M. tuberculosis and also methicillin resistant S. aureus.
272
  This 
molecule has an extremely low reported in vivo mammalian toxicity with no observable toxic 
effects at up to 3.3 g/kg per day for 21 days, including no embryotoxicity or teratogenicity.
273
  
These properties appoint neohesperidin as a very interesting lead to pursue for tuberculosis 
drug development, although inhibitory activity toward slow growing pathogenic 
mycobacterial species must be verified both in vitro and in vivo.  
3.5.3 Differential rich culture conditions influence on screen hits 
When screening for anti-mycobacterial compounds in the two distinct rich media types LB 
and 7H9, slight differential sensitivity of M. smegmatis to chemical inhibitors was observed 
between the two media types.   
From all three libraries hits validated in rich media conditions, 85 hits were validated in LB 
medium, 88 were validated in 7H9 medium and 62 of these hits were common to both 
conditions.   
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When these validated hits are contrasted with results from analogous M. tuberculosis H37Ra 
screens
206, 220
 57 LB hits and 63 7H9 hits were also active against M. tuberculosis, with 56 of 
the validated M. smegmatis hits were common to both LB and 7H9 media types and also 
detected in M. tuberculosis.   
 
Figure 3.10: Venn diagram of rich media validated hit distribution.   
Hit compounds derived from all libraries screened against M. smegmatis in rich media types 
LB (orange) and 7H9 (cream) compared with hits detected in M. tuberculosis H37Ra screens 
(red).  Venn diagram group totals provided are inclusive. 
 
Library screening of M. smegmatis in LB medium conditions resulted in a slightly lower 
number of total hits than those produced by screening in 7H9 medium.  Additionally M. 
smegmatis screens performed in 7H9 medium conditions resulted in slightly more hits that 
also shared inhibitory activity towards M. tuberculosis compared to the hits derived from 
screening M. smegmatis in LB medium conditions.  LB medium screen data generally had 
larger standard deviation than 7H9 medium, evidenced by the Z-factor values in section 3.3.6 
and scatterplot Figures 3.1-3.6.  7H9 medium also exhibited lower background OD600 and 
fluorescence in comparison with LB, however the SNR was greater for LB medium, due to 
the higher maximum growth capacity of LB medium.   
One compound, calcimycin, had activity towards M. tuberculosis and was detected in M. 
smegmatis LB media screens but not in 7H9 screens; but generally, hits validated from M. 
smegmatis 7H9 medium screening were more relevant inhibitors toward towards M. 
tuberculosis H37Ra.   It should be noted that M. tuberculosis screening was performed in 
  CHAPTER THREE:  HIGH-THROUGHPUT SCREENING     106 
7H9 medium,
206, 220
   this is likely a contributing factor in the commonality between M. 
smegmatis 7H9 screen and M. tuberculosis screen results.  
 
3.6  Summary  
In conclusion, three compound libraries were screened for inhibition of M. smegmatis 
cultured in two distinct rich media conditions, LB and 7H9.  The inhibitory activity of the 
resulting hit compounds was quantitatively validated, and the validated hits were compared to 
data from a similar screening project utilising slow growing mycobacterial species M. bovis 
BCG and M. tuberculosis H37Ra.   
Hit compounds were further characterised by quantification of their M. smegmatis MIC in the 
media conditions in which they were detected in and published biological and chemical 
properties were used to rule out validated hit compounds with characteristics making them 
unviable for development towards anti-tuberculosis therapy such as cytotoxicity, anti-cancer 
implications or previous anti-bacterial disclosure.  The remaining novel candidate anti-
tubercular compounds were then further researched and assessed for their suitability as 
tuberculosis treatment drug leads.   Chemicals indentified with potential application as drug 
leads were discussed in detail such as pyrithione zinc, azadirachtin and neohesperidin.  These 
compounds exhibit novel anti-mycobacterial activity in addition to favourable characteristics 
for human administration making them good possible avenues for further research and 
development as anti-tubercular drugs.   
The differential susceptibility of M. smegmatis to library inhibitors under different rich 
culture conditions was analysed, showing that there was not a large difference in 7H9 and LB 
media conditions.  LB medium detected more hits by a small margin, but slightly more hits 
detected in 7H9 medium were also active towards M. tuberculosis.  Therefore, the sensitivity 
difference between screening M. smegmatis in LB and 7H9 media conditions is minor, and 
the difference in relevance to activity in M. tuberculosis between the two rich media 
conditions is also minor.  It is recommended that M. smegmatis chemical library screens be 
performed under both rich media conditions to maximise the number of hit compounds with 
potential relevance to M. tuberculosis; although, if researchers are restricted to only one 
media type when screening against M. smegmatis, 7H9 should be utilised for maximum 
relevance to M. tuberculosis.  The concept of differential media conditions and inhibitor 
sensitivity profiles has been touched on in this chapter using the rich media types LB and 
7H9.  This will be further explored in Chapter 4 – Modifying Culture Conditions.
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4.1 Modifying culture conditions introduction 
This chapter expands upon the conventional rich media high throughput screening described 
in Chapter 3, exploring the effects of substantially modifying mycobacterial culture 
conditions by utilising nutrient limited or „starvation‟ media types.  Although the screening 
procedures and methodology remains similar, as in broad spectrum whole cell screening, the 
gene expression and resulting proteome of the mycobacteria are considerably different from 
that expressed in rich media, causing a potentially different susceptibility profile to chemical 
inhibitors. 
4.1.1 Bacterial response to differential culture conditions 
Bacillus licheniformis has been demonstrated to produce and excrete the highest amount of 
proteins when grown in a rich complex medium.
274
  When cultured under carbon and 
nitrogen starvation conditions, protein expression and excretion decreased and many proteins 
not expressed in rich media were secreted under starvation conditions.  These starvation-
specific proteins play essential nutrient scavenging and survival roles and are likely to be 
expressed in starvation conditions by alleviation of catabolite repression.
274
  Therefore; the 
susceptibility profile of B. licheniformis changes based on the culture conditions, expressing 
higher or lower levels of potential drug target proteins.
274
  
 
During persistent tuberculosis infection, such as the scenario of latency and granuloma 
formation, mycobacteria are believed to be subjected to nutrient limited conditions and adjust 
their metabolism accordingly for survival and persistence within the hostile host 
environment.
136
   This includes down-regulating expression of genes involved in non-vital 
processes such as lipid biosynthesis enzymes, translational machinery, aerobic respiration 
apparatus and cell division proteins.
136, 275
 M. tuberculosis present differential expression of 
genes involved in alternative carbon metabolism in the in vivo environment,
276, 277
 this 
response is recreated in vitro as a secondary effect of the Wayne model of progressive 
hypoxia,
130, 131
 the Betts nutrient starvation model
136
 and the Loebel nutrient starvation 
oxygen rich model.
278, 279
  During conditions of nutrient starvation, M. avium are known to 
enter a metabolically dormant state, thought to be similar to latent M. tuberculosis 
infection.
280, 281
  Metabolically inactive phenotypes similar to those isolated from lung 
granulomas have been observed by the culture of M. tuberculosis in nutrient limitation.
282
  
Within macrophages, mycobacteria must survive low levels of free amino acids.
222
  
Alteration of gene expression caused by nutrient starvation conditions results in a differential 
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sensitivity profile to inhibitors, supported by research showing a drastic increase in resistance 
to anti-bacterial agents in starved cultures of M. tuberculosis.
283
  However this effect has been 
demonstrated to work both ways, with starvation media cultures up-regulating the expression 
of genes such as fumarate reductase, alanine dehydrogenase and various transporters all of 
which presumably contribute to survival of M. tuberculosis under conditions of starvation.
136, 
284
  Thus starvation conditions reveal genetic targets that are masked in rich media culture, 
and the genes expressed in starvation conditions may be considered more essential and 
pathogenically relevant targets than their rich media counterparts. 
 
4.1.2 Screening with modified culture conditions in the literature 
Modification of culture conditions towards nutrient limitation and the implications of such 
conditions in drug sensitivity, gene expression and as a pathogenically relevant model for M. 
tuberculosis have been well considered, explored and documented.
129, 130, 136, 285
 
The same research has also been applied to the M. smegmatis model organism finding that it 
too can mimic M. tuberculosis dormancy in vitro when subjected to nutrient limitation 
conditions.
140
  However applying the principle of nutrient starvation to high throughput 
screening of chemical libraries for the discovery of novel mycobacterial inhibitors was first 
published from the present research,
122
 and subsequent related projects originating from 
within our research group.
157, 162
  Although similar screening ideologies involving dormancy 
have been conceptualised,
286
 there is little disclosure of nutrient starvation high-throughput 
drug screening in the literature.   
With the exception of the initial publication of the present research,
122
 the only disclosure 
found by a thorough literature search is a 2010 publication describing chemical library HTS 
against M. tuberculosis in the absence of glycerol, a screening model analogous to carbon 
starvation.
287
  This publication describes the discovery of a novel pyrimidine-imidazole class 
of anti-mycobacterial compounds that unfortunately lacked activity in vivo.  Nonetheless, this 
publication serves as an excellent comparison and cross-reference for the results obtained in 
this research, particularly those obtained through carbon starvation medium screening. 
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4.1.3 Objectives of modified culture condition screening 
Parallel to the objectives laid out in Chapter 3 – High Throughput Screening, three objectives 
were set for the high throughput screening of chemical libraries under conditions of nutrient 
limitation: 
1) Query the suitability of the rich media high throughput screening protocol described 
in Chapter 3 when adapted to nutrient starvation conditions. 
 
2) Compare the hit profile of nutrient starvation condition screens to those performed 
in rich media conditions, and also results of screens performed against M. tuberculosis 
to determine the relevance of M. smegmatis modified culture conditions screening in 
tuberculosis drug discovery. 
 
3) Identify novel antibacterial compounds with potential as inhibitors of M. tuberculosis. 
For achieving these goals the three chemical libraries screened in Chapter 3 were subjected to 
parallel screening against M. smegmatis in HdeB carbon and nitrogen limitation media types, 
this media was used as HdeB is a chemically defined minimal medium, further described in 
section 4.2.3.  Screens were carried out as decribed in section 2.2.3 with a 96-well plate 
format and measuring culture OD 600 nm and M. smegmatis GFP expression as viability 
indicators as discussed in section 3.1.2.  
Hit compounds detected during high throughput screens were then validated against M. 
smegmatis in a quantitative assay to confirm and quantify their inhibitory activity.  Validated 
hits were cross-referenced with data from M. tuberculosis H37Ra and M. bovis BCG 
screening project performed by one of our research group member Mudassar Altaf as part of 
his PhD project.
206, 220
  Hit compounds that were successfully validated were researched in 
the literature and bio-assay databases to ascertain the compounds‟ relevant properties of 
novel bioactivity, known cytotoxicity and biological indications that determine the chemicals 
suitability as a potential candidate for future development as a human tuberculosis treatment. 
 
4.2 Screening conditions 
4.2.1 Chemical libraries and screening conditions 
Chemical libraries utilised in this study, LOPAC, the Spectrum Collection and the NIH 
Diversity and Natural Products Set, are described in Chapter 3.2.  This research utilised four 
different culture conditions in HTS of the fast-growing tuberculosis model organism M. 
smegmatis.   These media conditions are broadly categorised as nutrient rich (LB, 7H9) or 
nutrient limited/starved (HdeB C-, HdeB N-).  Chapter 3 describes the motive for screening 
differential culture conditions in section 3.3.3, details of the M. smegmatis model organism in 
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section 3.3.1 and discloses the results of screening under nutrient rich media conditions in 
3.4.  Whilst the motive and M. smegmatis model organism details remain the same, this 
chapter reports the results of screening under nutrient limitation conditions and discusses 
their implications. 
 
4.2.2 Screening and hit criteria 
HTS were set up and carried out as described in Chapter 2.2.3.  All nutrient limitation screens 
were carried out as independent triplicate experiments.  Hits were defined as compounds that 
exhibited 80% or higher inhibition of growth compared with cell growth (100%) and 
antibiotic (0%) controls in at least two out of three screens.  This hit threshold is lower than 
that used during rich media screening due to the lower maximum growth obtained in nutrient 
limitation media. This provides a larger window for hit detection but quality of hits was still 
validated by dose-response assay to quantify the level of anti-mycobacterial activity and rule 
out false positives.  Nutrient limitation media screens did not contain D-arabinose,
53
 as the 
addition of this carbohydrate may contribute to the nutrient content of the media.  
Tween80
234, 235
 was included in Hartman deBonts starvation medium as directed, although it 
may be considered a utilisable carbon source the concentrations used (0.05%) were 
demonstrated to have negligible impact on growth rate or final culture density.  The assay 
incubation time in nutrient limitation media was 120 h to allow culture growth to reach 
stationary phase.  Plate reader settings of plate dimensions, measurement height and number 
of flashes were optimised using the Perkin Elmer assay optimisation protocol. 
 
4.2.3 Starvation media conditions 
Nutrient limitation or starvation media are chemically defined and provide the minimal 
requirements for bacterial growth.  HdeB nutrient limitation broth was chosen as the synthetic 
defined minimal medium for this research, restricting vital carbon and nitrogen sources, 
although other elements such as phosphorous and sulpur may be limited, they were not 
included in the scope of this research.  As culture in HdeB encourages M. smegmatis cells 
towards a non-culturable, dormant-like metabolic state, although this transition is not 
completed without the omission of oxygen or potassium from the medium 
288
  In HdeB 
medium, individual elements are limited, such as carbon and nitrogen starvation, providing a 
metabolic bottleneck that causes a corresponding metabolic shift in mycobacteria, potentially 
exposing genetic targets essential under these nutrient limitation conditions.
289
  Culture of 
mycobacteria under starvation media conditions induce the expression genes involved in  
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nutrient scavenging and alternative biosynthesis pathways to compensate for the lack of 
readily available sources of nutrition.
290
  For example, mycobacteria are thought to utilise 
lipids as a primary energy source during starvation.
280
  These nutrient limited media types are 
considered to better represent conditions encountered by tuberculosis during infection and 
latency than rich media conditions that present an ideal environment for bacterial growth and 
cause functional redundancy of many genes.
136, 280
 M. smegmatis culture in HdeB medium 
has been demonstrated to exhibit adaptive effects upon protein expression to compensate for 
the nutrient depletion stress, but artificially expressed plasmid GFP remains a viable 
measurement of bacterial growth and survival.
291
  Although nutrient starvation culture 
conditions such as HdeB do not perfectly mimic conditions encountered by tuberculosis 
within a granuloma, they are nonetheless considered a practical in vitro model.
289
    
 
4.2.3.1 HdeB Carbon limitation medium (HdeB C-)  
Hartman deBonts carbon starvation medium is a defined broth that provides adequate 
supplies for mycobacterial requirements of nitrogen, phosphorus, sulphur, metal salts and 
other trace elements but only provides a limited amount of carbon source in the form of 
glycerol.  Glycerol limitation is a known inducing factor of mycobacterial stationary phase.
140
  
For a detailed composition and preparation instructions for HdeB C- consult section 2.2.1.2. 
 
4.2.3.2 HdeB Nitrogen limitation medium (HdeB N-) 
Hartman deBonts nitrogen starvation medium is a defined liquid medium that provides the 
requirements of carbon, phosphorus, sulphur and metal salts but only a limited amount of 
nitrogen source in the form of ammonium sulphate.  Generally the ammonium ion is the 
preferred bacterial nitrogen source.
292
  It has been demonstrated in the close mycobacterial 
relative C. glutamicum that nitrogen limitation causes changes to the composition of the 
intracellular amino acid pool.
293
  The uptake, metabolism and utilisation of nitrogen in 
mycobacteria is tightly regulated, and this adaptive regulation involves many essential 
processes that are proposed to be good drug targets.
294
  For a detailed composition and 
preparation instructions for HdeB N- consult section 2.2.1.2. 
 
4.2.4 Hit Validation  
Hit compounds identified in triplicate HTS were then validated by a dose-response assay 
against M. smegmatis MC
2
155 in the medium type they were detected in as described in 
Chapter 2.2.4.  These data are presented in tabular format beneath the respective compound 
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library scatterplot figures.  Compounds were assessed in triplicate with a starting 
concentration of 25 µM, and MIC was recorded as the minimal concentration of compound 
required to produce no measureable growth in triplicate after 96 h in comparison to media 
and antibiotic controls.  False positive hits were discarded, and only validated hits are 
presented, in order of chemical library.   
For simplicity and comparative purposes, the MIC of validated compounds from HdeB C- 
and HdeB N- media conditions are tabulated together.  Significant differences between media 
conditions (more than one serial dilution MIC difference or lack of detection in either 
medium type is considered significant) are highlighted in red.  Validated results in slow 
growing mycobacterial species M. bovis BCG and M. tuberculosis H37Ra cultured in 7H9 
medium are generously provided by the work of Mudassar Altaf
206, 220
 and provide context to 
hits in these relevant slow growing mycobacterial models.  Compound MIC data for M. bovis 
BCG and M. tuberculosis H37Ra was quantitatively supplied when available.   If a 
quantitative M. bovis BCG or M. tuberculosis H37Ra MIC for a hit compound was not 
available the inhibitory activity in M. bovis BCG or M. tuberculosis H37Ra HTS was used.  
Values of “≤ 20” indicate inhibitory activity ( > 80% growth inhibition) was observed in 
screens estimating the MIC as less than or equal to the chemical screening concentration of 
20 µM.  Values of “-“ indicate that no inhibitory activity ( < 80% growth inhibition) was 
detected in screens for that medium type.  
4.2.5 Statistical analysis of viability 
4.2.5.1 HdeB C- 
Z-factors for screens performed in HdeB C- conditions were Z= 0.84 (OD)and Z=0.86 (GFP) 
for the streptomycin controls and Z=0.05 (OD) and Z=0.67 (GFP) for the rifampicin controls, 
respectively.  Signal to noise ratios were 18.75 (OD) and 21.42 (GFP) for streptomycin 
controls and 3.17 (OD) and 9.31 (GFP) for rifampicin controls, respectively.   The Z factors 
for GFP screens indicate good assay repeatability and validity, and the SNR for GFP values 
on all controls indicate an acceptable signal to noise ratio, meeting the Rose criterion of > 
5.
295
  The OD Z-factor and SNR values for the streptomycin control are considered excellent; 
however, both the Z-factor and SNR for the OD rifampicin control fall into the marginal 
acceptability range bordering on unreliable.  This effect is due to the absorbent (coloured) 
nature of rifampicin and explains why this drug was included as a control antibiotic.  The 
effect is likely more pronounced in HdeB medium compared to rich LB or 7H9 media due to 
lower overall mycobacterial growth in the well and the transparent, minimally absorbing 
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nature of HdeB broth.  The parallel use of GFP and OD signals as measures of viability 
mitigates this shortfall. 
 
4.2.5.2 HdeB N-  
Z-factors for screens performed under HdeB N- conditions were Z=0.58 (OD) and Z=0.59 
(GFP) for the streptomycin control and Z=-0.31 (OD) and Z=0.51 (GFP) for the rifampicin 
controls.  Signal to noise ratios for HdeB N- screens were 7.2 (OD) and 7.4 (GFP) for the 
streptomycin control and 2.3 (OD) and 6.1 (GFP) for the rifampicin controls, respectively.  
These statistical values represent a slight drop from those calculated in HdeB C- media and 
this is caused by further decreased final mycobacterial growth in this medium compared to 
HdeB C-, resulting in a smaller discrepancy between the means of the positive and negative 
controls and also greater standard deviation of the positive control.  Z-factors and SNR for 
streptomycin under both signals and rifampicin under GFP signals are acceptable.  The Z-
factor and SNR for rifampicin when calculated from the OD signal is unacceptable, meaning 
there is too much overlap between the positive and negative controls for the data to be of use 
and a SNR < 5 does not meet the Rose criterion; hence, signal cannot be distinguished from 
noise with 100% certainty.
295
  However, the corresponding GFP signal values for rifampicin 
fall above acceptable levels, making the OD rifampicin controls redundant, and assays under 
these conditions therefore remain viable. 
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4.3 Screen results  
The results of HTS carried out by the methodology described in Chapter 2.2.3 are depicted 
below in graphical format (figures 4.1-4.9), presented by order of chemical library (colour 
coded), medium type and inhibition signal recorded (GFP or OD600).  Compounds are 
numerically categorised on the X axis, and inhibition of growth signal is shown on the Y axis.  
Each graph represents triplicate screens, with the mean inhibition value of a library 
compound over triplicate screens graphed and point size representing the standard deviation 
of a library compound.  The threshold of 80% inhibition that defines a hit in starvation media 
is demonstrated by a blue horizontal line and green highlighting.  Complete information on 
library screen hits by medium type including compound name(s), chemical structure, library 
plate number and well position, validated MIC and known bioactive properties, are provided 
in Appendix 9.5.  Hit compounds identified in screens were then verified by MIC 
determination dose-response assays, these results are tabulated in chemical library order 
(tables 4.1-4.3) and contrasted with 7H9 medium screening results of library compounds 
against slow growing mycobacterial species M. bovis BCG and M. tuberculosis H37Ra.
206, 220
  
Hit compounds were categorised in figures 4.3, 4.6 and 4.9 based on known function 
according to information provided by the chemical library supplier (Sigma-Aldrich, 
Microsource, NIH), published literature and chemical database information.  Sensitivity of 
detection in media types refers to the differential validation MIC or screen hits between LB 
and 7H9 conditions, with greater than 2-fold difference in MIC between LB and 7H9 media 
conditions considered to be significant differential sensitivity.    
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4.3.1 LOPAC Starvation Culture conditions   
4.3.1.1 HdeB C-  
  
   
  
 
 
 
4.3.1.2 HdeB N- 
 
 
    
Figure 4.2: M. smegmatis LOPAC HdeB N- OD & GFP scatterplots. 
Scatterplot depicting the OD 600 nm (left) and GFP fluorescence (right) data derived from a 
HdeB N- medium HTS of the LOPAC for M. smegmatis growth inhibition.  Details as in Fig 
4.1. 
 
Figure 4.1: M. smegmatis LOPAC HdeB C- OD & GFP scatterplots. 
Scatterplot depicting the OD 600 nm (left) and GFP fluorescence (right) data derived 
from HdeB C- medium HTS of the LOPAC for M. smegmatis growth inhibition.  
Percentage growth signal inhibition relative to controls measured on the Y axis, 
compound number is listed on the X axis.  Significant hits exhibiting > 90% inhibition are 
boxed in green.  Points are colour and size coded for mean value and standard deviation 
as depicted in the figure key. 
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4.3.1.3 LOPAC starvation media screening validated hit compounds 
LOPAC Compound M. smegmatis 
MIC (µM) C- 
M. smegmatis 
MIC (µM) N- 
M. bovis BCG 
MIC (µM) 
M. tuberculosis 
H37Ra MIC 
(µM) 
BAY 11-7085 6.25 12.5 ≤ 20 - 
Calcimycin 12.5 12.5 - ≤ 20 
Carboplatin 25 50 - - 
4-
Chloromercuribenzoic 
acid 
6.25 12.5 - ≤ 20 
Cisplatin 12.5 12.5 -  
Calmidazolium 50 12.5 - - 
Clotrimazole 50 50 - - 
Demeclocycline 6.25 6.25 3.125 1.56 
Dequalinium 6.25 12.5 3.125 6.25 
Dequalinium C-14 
linker. (Quinolinium) 
6.25 3.125 - ≤ 20 
Diphenyleneiodonium 3.125 3.125 0.195 0.39 
Doxycycline 3.125 3.125 ≤ 20 - 
Ellipticine   12.5 12.5 
Idarubicin 25 12.5 6.25 6.25 
Lomefloxacin 6.25 6.25 1.56 3.125 
LY-367265 25 50 -  
Methoctramine 12.5 12.5 1.56 6.25 
Minocycline 12.5 12.5 1.56 3.125 
Mitoxantrone 50 50 -  
Niclosamide 6.25 6.25 6.25 6.25 
Ofloxacin 6.25 6.25 1.56 1.56 
Pentamidine 25 50 -  
1,10-Phenanthroline 12.5 12.5 ≤ 20 ≤ 20 
Se-
Methylselenocysteine 
12.5 12.5 12.5 12.5 
Ruthenium red 50 50 - - 
Trifluoperazine 50 50 - - 
U-83836 50 50 - - 
Vancomycin 25 25 ≤ 20 - 
WB 64 50 25 12.5 12.5 
Table 4.1: LOPAC starvation media screening validated hit results.   
Validation MIC values of LOPAC HTS derived hits are presented for M. smegmatis by 
starvation media type.  These values are contrasted with 7H9 medium screening results of 
LOPAC against the slow growing mycobacterial species M. bovis BCG and M. tuberculosis 
H37Ra.
206, 220
  Hit compounds results with significant difference in sensitivity ( > 2-fold 
inhibition) between media types are displayed in red text.  Values of “-“ indicate no 
inhibitory activity was detected in screening (triplicate mean of  > 80% growth inhibition 
compared to positive controls).  Values of “≤ 20” indicate the compound did exhibit 
inhibitory activity in screens (triplicate mean of > 80% growth inhibition compared to 
positive controls) against slow growing mycobacterial species, however confirmatory MIC 
assays were unable to be performed, therefore the MIC is estimated to be less than or equal to 
the screen compound concentration of 20 µM. 
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4.3.1.4 LOPAC starvation media screening results overview 
  
Figure 4.3:  LOPAC starvation media screening hit compound activity. 
Percentage of hits obtained by nutrient starvation media screening of the LOPAC categorised 
by supplier annotated biological activity. 
Screening the LOPAC library under nutrient limitation conditions identified a total of 28 
validated inhibitors, 12 of which were not previously detected in rich media condition 
screening of the LOPAC.  Only two compounds were detected in rich media screening but 
not under starvation conditions.  Twenty-one of these inhibitors were validated in carbon-
limited HdeB medium, and 20 in nitrogen limited HdeB medium.  For comparison 14 of 
these inhibitors were also active in M. bovis BCG and 16 were active in M. tuberculosis 
H37Ra. 
As with rich media screening many chemicals with known anti-bacterial activity were 
identified:  tetracycline family antibiotics demeclocycline, doxycycline, minocycline, 
fluoroquinolone antibiotics lomefloxacin and ofloxacin and glycopeptides vancomycin and 
calcimycin.  The inhibition profile of these antibiotics was similar across both carbon and 
nitrogen limitation conditions and they were also all previously detected in rich media 
screening.  Anti-cancer compounds were detected with greater sensitivity in nutrient 
limitation conditions compared to rich media, detecting not only idarubicin which was also 
identified in rich media screens but also identifying carboplatin, cisplatin and mitoxantrone, 
the anti-neoplastic agent ellipticine was not detected under nutrient limitation conditions; 
26% 
3% 
4% 
15% 
52% 
Categorised Validated Hits from LOPAC Limited Media Screening 
Anti-bacterial
Anti-fungal
Anti-helmintic
Anti-neoplastic
Other
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whereas it was in nutrient rich conditions, but its activity level is at the borderline of 
screening concentration.   
Discarding well known anti-bacterial and cytotoxic anti-cancer compounds, novel 
compounds were identified that were also seen in rich media screens, including 
calmidazolium, clotrimidazole, dequalinium quinolinium, diphenyleneiodonium, 
methoctramine, niclosamide and WB-64.  
The remaining compounds with novel anti-mycobacterial activity not elucidated through rich 
media condition screening were BAY 11-7085, 4-chloromercuribenzoic acid, LY-367265, 
pentamidine, 1,10-phenanthroline, Se-methylselenocysteine, ruthenium red, trifluoperazine 
and U-83836.  Se-methylselenocysteine was not detected in screens under rich media 
conditions; however, it was later validated in rich 7H9 medium.  
All compounds exhibited similar MIC values between carbon and nitrogen limitation 
conditions during validation, with the exception of calmidazolium which demonstrated a 4-
fold reduction in inhibitory concentration in nitrogen limitation. A detailed list of library 
screen hits including chemical structures is included in Appendix 9.5.1.  The biological and 
chemical significance of the LOPAC novel hit compounds with possible application as lead 
molecules in tuberculosis treatment drug discovery (discounting known antibiotics and 
cytotoxic compounds) is discussed in depth in section 4.4.2.1 of this chapter. 
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4.3.2 Spectrum Collection starvation culture conditions   
4.3.2.1 HdeB C- 
 
    
 
 
4.3.2.2 HdeB N- 
 
    
  
Figure 4.4: M. smegmatis Spectrum Collection HdeB C- OD & GFP scatterplots. 
Scatterplot depicting the OD 600 nm (left) and GFP fluorescence (right) data derived 
from a HdeB C- medium HTS of the Spectrum Collection for M. smegmatis growth 
inhibition.  Details as in Fig 4.1. 
Figure 4.5: M. smegmatis Spectrum Collection HdeB N- OD & GFP scatterplots. 
Scatterplot depicting the OD 600 nm (left) and GFP fluorescence (right) data derived from a 
HdeB N- medium HTS of the Spectrum Collection for M. smegmatis growth inhibition.  
Details as in Fig 4.1. 
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4.2.3.3 Spectrum Collection starvation media screening validated hit compounds 
Spectrum Collection 
Compound 
M. smegmatis 
MIC (µM) C- 
M. smegmatis 
MIC (µM) N- 
M. bovis BCG 
MIC (µM) 
M. tuberculosis 
H37Ra MIC 
(µM) 
Khivorin - 12.5 - - 
Merbromin 6.25 6.25 - - 
Chloroacetoxyquinoli
ne (Silital) 
- 0.78 ≤ 20 ≤ 20 
Aklavine - 6.25 ≤ 20 ≤ 20 
Irigenin dibenzyl ether - 12.5 - - 
Celastrol (Tripterine) - 3.125 - - 
Amikacin - 6.25 - - 
Benzethonium - 6.25 - - 
Capreomycin - 6.25 ≤ 20 - 
Cetylpyridinium - 6.25 - - 
Chlorhexidine 6.25 3.125 ≤ 20 ≤ 20 
Chlortetracycline 3.125 0.78 - - 
Colistimethate - 12.5 - - 
Demeclocycline 0.78 0.78 ≤ 20 ≤ 20 
Dihydrostreptomycin 12.5 3.125 - - 
Pyrithione Zinc 1.56 0.39 ≤ 20 ≤ 20 
Clotrimazole 25 12.5 ≤ 20 - 
Doxycycline 0.78 0.78 ≤ 20 ≤ 20 
Ethambutol 3.125 3.125 ≤ 20 ≤ 20 
Gentian / Crystal 
Violet 
3.125 3.125 - - 
Mercaptopurine - 25 ≤ 20 ≤ 20 
Minocycline 1.56 0.78 ≤ 20 ≤ 20 
Nortriptyline - 12.5 - - 
Oxytetracycline  - 1.56 - ≤ 20 
Polymyxin B - 12.5 - - 
Primaquine - 25 - - 
Tetracycline 3.125 1.56 ≤ 20 - 
Streptomycin 3.125 6.25 - - 
Tobramycin 3.125 1.56 - - 
Thimerosal 0.78 3.125 ≤ 20 ≤ 20 
Phenylephrine 3.125 3.125 - - 
Hydrastine - 6.25 - - 
Patulin - 25 ≤ 20 - 
Phenylmercuric 
Acetate 
1.56 0.39 ≤ 20 ≤ 20 
Dichlorodiphenyltrichl
oroethane, DDT 
- 25 - - 
Gemifloxacin 3.125 6.25 ≤ 20 ≤ 20 
Prochlorperazine 
edisylate 
- 6.25 - - 
Thiostrepton - 12.5 ≤ 20 ≤ 20 
2-Aminoethyldiphenyl 
boronate, 2-
aminoethyl 
diphenylborinate. 
- 6.25 - - 
Gatifloxacin 1.56 1.56 ≤ 20 ≤ 20 
Cetrimonium  6.25 - - 
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Spectrum Collection 
Compound 
M. smegmatis 
MIC (µM) C- 
M. smegmatis 
MIC (µM) N- 
M. bovis BCG 
MIC (µM) 
M. tuberculosis 
H37Ra MIC 
(µM) 
Methylbenzethonium 
Chloride 
6.25 6.25 ≤ 20 - 
Roxithromycin - - ≤ 20 - 
Cefdinir  25 ≤ 20 ≤ 20 
Levofloxacin 3.125 3.125 ≤ 20 ≤ 20 
Apramycin 25 6.25 - - 
Erythromycin - 6.25 ≤ 20 - 
Gentisic acid, 
dihydroxybenzoic acid 
- 25 ≤ 20 ≤ 20 
Trifluoperazine HCl - 12.5 ≤ 20 ≤ 20 
Econzole 12.5 12.5 ≤ 20 ≤ 20 
Lomefloxacin 6.25 12.5 ≤ 20 ≤ 20 
Ofloxacin 3.125 3.125 ≤ 20 ≤ 20 
Carboplatin 25 6.25 - - 
Cisplatin 3.125 0.78 - - 
Alexidine 6.25 6.25 ≤ 20 ≤ 20 
Pararosaniline 
pamoate 
- 6.25 ≤ 20 - 
Mitoxantrone 50 50 - - 
Thiram - 12.5 ≤ 20 ≤ 20 
Benzalkonium 
Chloride 
6.25 6.25 - - 
Moxifloxacin 1.56 6.25 ≤ 20 ≤ 20 
Berbamine - 12.5 - - 
Rifampin 6.25 6.25 ≤ 20 ≤ 20 
Acivicin - 25 ≤ 20 ≤ 20 
Chlorothalonil 6.25 3.125 ≤ 20 ≤ 20 
Ciprofloxacin - 12.5 - ≤ 20 
Teniposide - 25 - - 
Rifaximin - 6.25 ≤ 20 ≤ 20 
Sarafloxacin 6.25 6.25 ≤ 20 ≤ 20 
Pefloxacine - 12.5 ≤ 20 ≤ 20 
 
Table 4.2: Spectrum Collection starvation media screening validated hit results.  
Validation MIC values of Spectrum Collection HTS derived hits are presented for M. 
smegmatis by starvation medium type.  Details as for Table 4.1. 
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4.3.2.4 Spectrum Collection starvation media screen hit compound significance 
 
Figure 4.6:  Spectrum Collection starvation screen hit compounds known activity.   
Percentage of hits obtained by nutrient starvation media screening of the Spectrum Collection 
categorised by supplier annotated biological activity. 
Screening the Spectrum Collection under nutrient limitation conditions yielded a total of 68 
validated inhibitors of M. smegmatis.  Of these inhibitors 33 were identified through carbon 
limitation media, and all 68 were validated in nitrogen limitation media.  Of these inhibitors, 
41 were also found to have activity in screens against M. bovis BCG, and 34 exhibited 
activity in screens against M. tuberculosis H37Ra. 
A large proportion of the hits detected in this assay were known antibacterial compounds, 
including tetracycline family antibiotics, fluoroquinolones and tuberculosis treatment drugs 
such as streptomycin, ethambutol and rifampicin.  Similar to nutrient rich screening, many 
chemicals with well known anti-fungal, anti-septic or anti-neoplastic activity were detected.   
Nitrogen starvation conditions in particular rendered M. smegmatis more susceptible to anti-
neoplastics and more sensitive to inhibitors in general, with most compounds exhibiting the 
same or lower MIC values in nitrogen starvation than in carbon starvation conditions.  Only 
two exceptions had significantly lower MIC in carbon starvation relative to nitrogen: 
thimerosal and moxifloxacin. 
43% 
10% 
15% 
13% 
19% 
Categorised Validated Hits from Spectrum Collection Limited Media Screening 
Anti-bacterial
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Anti-septic
Anti-neoplastic
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Nutrient starvation condition screening yielded many more hit compounds relative to nutrient 
rich screening results.  Only 8 compounds were detected in nutrient rich conditions and not 
again in nutrient limitation screens.  These include the macrolide antibiotics roxithromycin, 
telithromycin, dirithromycin and clarithromycin, the quinolones clioquinol and oxyquinoline, 
the anti-psychotic agent thiothixene and the sulphonamide sulfamethoxazole. 
Whereas nutrient rich screening of the Spectrum Collection only identified one compound 
unable to be broadly categorised, nutrient limitation screening revealed many novel inhibitory 
chemicals unable to be assigned to one of the broad activity categories detailed above.   
These “other” class hits included the anti-malarial agent primaquine and the natural products 
khivorin, irigenin, berbamine and hydrastine.  Anti-psychotic drugs nortriptyline, 
prochlorperazine and trifluoperazine, decongestant phenylephrine and pesticidal agent DDT.  
The anti-inflammatory gentisic acid and IP3 modulator 2-aminoethyldiphenyl boronate were 
also identified. 
Several of the chemicals detected to have anti-mycobacterial activity in this nutrient limited 
screening may prove novel leads for implementation as tuberculosis treatment options and 
will be discussed further in section 4.2.2.2 of this chapter.  A complete list of Spectrum 
Collection screen hits including chemical structures is included in Appendix 9.5.2.   
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4.3.3 NIH Diversity Set starvation culture conditions  
4.3.3.1 HdeB C- 
 
 
 
 
4.3.3.2 HdeB N- 
 
 
    
  
Figure 4.5: M. smegmatis NIH Diversity Set HdeB C- OD & GFP scatterplots. 
Scatterplot depicting the OD 600 nm (left) and GFP fluorescence (right) data derived 
from a HdeB C- medium HTS of the NIH Diveristy Set for M. smegmatis growth 
inhibition.  Details as in Fig 4.1. 
 
Figure 4.6: M. smegmatis NIH Diversity Set HdeB N- OD & GFP scatterplots. 
Scatterplot depicting the OD 600 nm (left) and GFP fluorescence (right) data derived from 
a HdeB N- medium HTS of the NIH Diveristy Set for M. smegmatis growth inhibition.  
Details as in Fig 4.1. 
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4.3.3.3 NIH Diversity Set starvation media screening validated hit compounds 
NIH Library 
Compound 
M. smegmatis 
MIC (µM) C- 
M. smegmatis 
MIC (µM) N- 
M. bovis BCG 
MIC (µM) 
M. tuberculosis 
H37Ra MIC 
(µM) 
NSC2347  
(Tricarballylic acid) 
- 25 - - 
NSC27895 - 25 - - 
NSC1684 - 25 - - 
NSC23082 - 6.25 - - 
NSC3907 
(8-Hydroxyquinoline 
salicylate) 
- 6.25 12.5 3.125 
NSC329226 6.25 3.125 ≤ 20 ≤ 20 
NSC359098 - 6.25 - - 
NSC26081 - 6.25 - - 
NSC16865 - 6.25 ≤ 20 - 
NSC130830 - 12.5 - ≤ 20 
NSC17600 - 6.25 - - 
NSC122657 - 12.5 ≤ 20 - 
NSC152686  12.5 - - 
NSC153533 - 25 - - 
NSC289336 
(Rimiterol) 
- 25 - - 
NSC13316 - 6.25 ≤ 20 - 
NSC333003 - 3.125 ≤ 20 ≤ 20 
NSC625324 (Silver 
sulfadiazine) 
6.25 0.39 - - 
NSC24113 - 6.25 ≤ 20 - 
NSC45382 - 3.125 - - 
NSC22907 - 25 - - 
NSC48300 - 6.25 ≤ 20 ≤ 20 
NSC295642 - 6.25 ≤ 20 ≤ 20 
NSC12155 
(Aminoquinuride, 
surfen) 
12.5 6.25 ≤ 20 - 
NSC632536 - 12.5 ≤ 20 - 
NSC3058301 
(Benzenecarboximida
mide) 
- 6.25 - - 
NSC13480 6.25 3.125 12.5 12.5 
NSC17474 
(Trifluoperazine) 
- 6.25 ≤ 20 - 
NSC294526 6.25 3.125 - - 
NSC321206 - 6.25 25 3.125 
NSC311153 - 6.25 6.25 6.25 
NSC311152 
(Datelliptium) 
12.5 6.25 ≤ 20 ≤ 20 
NSC176327 12.5 3.125 ≤ 20 ≤ 20 
NSC92585 25 0.78 ≤ 20 ≤ 20 
NSC354961 25 6.25 ≤ 20 - 
NSC359449  12.5 1.56 ≤ 20 ≤ 20 
NSC97345 3.125 0.19 - - 
NSC268879 3.125 0.19 1.56 3.125 
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NIH Library 
Compound 
M. smegmatis 
MIC (µM) C- 
M. smegmatis 
MIC (µM) N- 
M. bovis BCG 
MIC (µM) 
M. tuberculosis 
H37Ra MIC 
(µM) 
NSC117274 - 12.5 - - 
NSC305787 - 6.25 ≤ 20 ≤ 20 
NSC150289 - 6.25 - - 
NSC114792 - 6.25 - - 
NSC292596 12.5 12.5 - - 
NSC661755 
(Michellamine B) 
12.5 3.125 ≤ 20 ≤ 20 
NSC25485 
(Ouabain) 
- 12.5 - - 
NSC72939 - 12.5 ≤ 20 ≤ 20 
NSC321237 3.125 0.39 - - 
NSC17770 - 6.25 ≤ 20 ≤ 20 
NSC5159 
(Chartreusin) 
-  1.56 1.56 
NSC310551 6.25 3.125 12.5 6.25 
NSC295558 6.25 1.56 - - 
NSC20410 12.5 3.125 - - 
NSC182395 12.5 1.56 - - 
NSC22225  
(Cadmium chlorendic 
acid) 
12.5 12.5 ≤ 20 ≤ 20 
NSC64111 - 6.25 ≤ 20 ≤ 20 
NSC182035 - 6.25 - - 
NSC72938 - 25 - - 
NSC181486  
(Trigilletine) 
- 12.5 ≤ 20 ≤ 20 
NSC52003 - 25 - - 
NSC73101 - 25 - - 
NSC143491 
(Daunorubicin) 
12.5 6.25 ≤ 20 ≤ 20 
NSC321239 3.125 0.39 ≤ 20 - 
NSC23128 - 25 - - 
NSC203328 - 25 - - 
NSC125910 - 25 - - 
NSC402959 - 12.5 - - 
NSC234766 - 12.5 - - 
NSC95609 - 12.5 - - 
NSC77037 
(Tetrandrine) 
- 12.5 - - 
NSC274547 12.5 6.25 - - 
NSC83628 
(DF 8 sensitizer) 
- 25 - - 
NSC13726 - 12.5 ≤ 20 ≤ 20 
NSC130813 - 6.25 - - 
NSC41458 - 25 - - 
NSC169534 
(Quelamycin) 
- 25 - - 
NSC44251 
(Cumertilin) 
 25 - - 
NSC166687 - 25 - - 
NSC59349 
(3-Nortropanol) 
- 12.5 - - 
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NIH Library 
Compound 
M. smegmatis 
MIC (µM) C- 
M. smegmatis 
MIC (µM) N- 
M. bovis BCG 
MIC (µM) 
M. tuberculosis 
H37Ra MIC 
(µM) 
NSC109268 - 12.5 - - 
NSC48171 - 25 - - 
NSC69343 - 6.25 - - 
NSC3283 - 6.25 - - 
NSC71795  
(Ellipticine) 
12.5 3.125 ≤ 20 ≤ 20 
NSC356217 
(HEJ-4) 
- 6.25 - - 
NSC32951 
(Patulin) 
- 3.125 - - 
NSC267461 
(Nanaomycin A) 
- 6.25 ≤ 20 ≤ 20 
NSC312033 
(Straital B) 
- 1.56 - - 
NSC659779 (2- 
Bromoascididemin) 
12.5 1.56 0.781 3.125 
NSC35611 
(Solanine) 
- 6.25 ≤ 20 ≤ 20 
NSC325014 
(Bactobolin) 
25 - - - 
NSC661755 
(Michellamine B) 
6.25 3.125 ≤ 20 ≤ 20 
NSC526417 
(Echinomycin) 
6.25 3.125 ≤ 20 ≤ 20 
NSC45383 
(Streptonigrin) 
12.5 6.25 ≤ 20 ≤ 20 
NSC56346 
(Rottlerin) 
- 6.25 - - 
NSC45737 
(Bacitracin) 
12.5 3.125 ≤ 20 ≤ 20 
NSC51001 
(Carbomycin) 
12.5 3.125 12.5 12.5 
NSC82151 
(Daunorubicin HCl) 
12.5 3.125 ≤ 20 ≤ 20 
NSC62709 
(Imidazoquinoline) 
- - 50 12.5 
NSC18712 
(Streptomycin 
thiosemicarbazone) 
25 1.56 ≤ 20 ≤ 20 
NSC125066 
(Bleomycin) 
1.56 0.39 3.125 1.56 
NSC31048 
(Neohesperidin) 
12.5 3.125 ≤ 20 ≤ 20 
NSC301739 
(Mitoxantrone) 
12.5  ≤ 20  
NSC47151 
(Neomycin, neosule) 
12.5 3.125 ≤ 20 ≤ 20 
NSC52141 
(Nonactin) 
- 3.125 ≤ 20 ≤ 20 
NSC67574 
(Vincristine sulfate) 
- 6.25 ≤ 20 ≤ 20 
NSC368675 
(Azadirachtin) 
12.5 3.125 ≤ 20 ≤ 20 
NSC34936 
(Suramin, Germanin) 
- 6.25 ≤ 20 ≤ 20 
NSC9161 
(Erythromycin  
- 12.5 ≤ 20 ≤ 20 
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NIH Library 
Compound 
M. smegmatis 
MIC (µM) C- 
M. smegmatis 
MIC (µM) N- 
M. bovis BCG 
MIC (µM) 
M. tuberculosis 
H37Ra MIC 
(µM) NSC61586 
(Phleomycin) 
0.19 0.097 25 1.56 
NSC285116 
(Siomycin A) 
1.56 3.125 6.25 6.25 
NSC13252 
(Chlorotetracycline 
HCl) 
- 0.39 - - 
NSC292567 
(Nigericin) 
- 6.25 ≤ 20 ≤ 20 
NSC317629 
(Ketoconazole) 
- 6.25 ≤ 20 ≤ 20 
NSC319518 
(Cotylenin A) 
- 6.25 ≤ 20 ≤ 20 
NSC333856 
(Tetrocarcin A) 
- 6.25 ≤ 20 ≤ 20 
 
 
 
 
 
  
Table 4.3: NIH Diversity Set starvation media screening validated hit results.  Validation MIC 
values of NIH Diversity Set HTS derived hits are presented for M. smegmatis by starvation media 
type.  Compound names are given in addition to NSC number where available.  Details as for Table 
4.1. 
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4.3.3.4 NIH Diversity Set starvation media screen hit compound significance 
 
Figure 4.9:  Pie chart of NIH Diversity set starvation media screening hit compound 
known activity.   
Percentage of hits obtained by nutrient starvation media screening of the NIH Diversity Set 
categorised by supplier annotated biological activity. 
Nutrient limitation condition screening of the NIH Diversity Set identified a total of 113 
validated hits, 40 of which were identified in carbon limitation media and 101 were identified 
in nitrogen limitation.  In contrast, 65 of these compounds were detected as active in M. bovis 
BCG screening and 56 of these compounds were detected as active in M. tuberculosis H37Ra 
screening of the NIH Diversity Set. 
Due to the intended use of the NIH Diversity Set as a cancer drug discovery tool,
296
 it was 
expected that a large number of the compounds detected in this library are generally cytotoxic 
or have anti-neoplastic activity, and this was confirmed, with over half of the total hit 
compounds identified as having anti-neoplastic properties.   
Following the trend observed in the results of screening the other libraries, nitrogen limitation 
conditions were the most sensitive in detecting anti-mycobacterial activity of library 
compounds with 84 compounds exhibiting ≥ 4 fold increase in sensitivity in nitrogen 
starvation compared to carbon starvation conditions, whilst this included many cytotoxic 
chemicals unsuitable for drug leads. 
7% 
4% 
1% 
52% 
36% 
Categorised Validated Hits from NIH Diversity Set Nutrient Limited Media 
Screening 
Anti-bacterial
Anti-viral
Anti-septic
Anti-neoplastic
Other
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There were 16 chemicals identified through rich condition screens that were not detected in 
starvation media screening, included 4 rifamycin derivatives, a prostaglandin receptor 
inhibitor NSC132693, tetracycline NSC69343, chemicals with anti-cancer activity 
NC305787, NSC11241, NSC106408 (anthramycin), NSC134727(mitomycin C), NSC122819 
(teniposide), NSC5159 (chartreusin), NSC3053 (dactinomycin).  Antibiotics NSC363182 
(kijanimicin derivative U-64815), NSC189794 (streptovaricin) and the anti-viral 
immunomodulator NSC62709 (imidazoquinoline). 
Many novel mycobacterial inhibitors were discovered in the NIH Diversity Set through 
nutrient limitation condition screening, the most promising of which based on their validated 
level of activity, confirmation of activity in slow growing mycobacterial species, novelty and 
cytotoxicity will be discussed further in section 4.4.2.3 of this chapter.  A detailed list of 
library screen hits including chemical structures is included in Appendix 9.5.3. 
4.3.4 Overview of nutrient-limited screening goals and outcomes 
There were three reasons for performing anti-mycobacterial screens in nutrient limitation 
media conditions.  First, to explore the viability of the HTS design described in Chapter 3 
when adapted to nutrient starvation media conditions – by using antibiotic compounds 
present in the libraries as internal controls as before in Chapter 3.  Nutrient limitation whole 
cell M. smegmatis HTS was successfully validated through identification of many known 
tuberculosis treatment drugs and other known antibiotic agents included in the chemical 
libraries.   
 
The second objective of nutrient limitation screening was to compare the library hit 
compound profiles between carbon and nitrogen limitation media that emulate conditions of 
in vivo pathogenesis, and also between rich and starvation media types.  This was to provide 
insight and allow evaluation of how media conditions affect sensitivity of M. smegmatis to 
inhibitors, and how these differential culture conditions relate to M. tuberculosis drug 
discovery. 
Library screening in two nutrient limitation media conditions, carbon and nitrogen, yielded 
significantly differing inhibition profiles of hit compounds from the chemical libraries 
screened.   These nutrient limitation conditions screen results in turn were significantly 
different from the inhibition profiles of library screens performed in rich media conditions.  
This demonstrated that minimal culture conditions exert influence in M. smegmatis sensitivity 
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to chemical inhibitors.  This influence generally renders M. smegmatis more sensitive to 
inhibitors; however, it occasionally confers decreased sensitivity to particular compounds.   
 
The third goal was to utilise the nutrient starvation screening in order to identify novel anti-
mycobacterial compounds that may not have been detected under rich media conditions or in 
conventional in vitro M. tuberculosis screens. 
This nutrient limited screening revealed previously unpublished anti-mycobacterial 
compounds.  Many of these identified novel inhibitors are known to be cytotoxic or exhibit 
properties making them undesirable as leads for human tuberculosis treatment.  However, 
several compounds show promising indications as novel tuberculosis drug candidates and 
warrant further study.  The compound Se-methylselenocysteine was chosen for follow up 
study due to its structural novelty, its confirmed level of inhibitory activity towards M. 
tuberculosis and its known administration in humans as a nutritional supplement. 
Hit compounds have been essentially categorised based on known function according to 
information provided by the chemical library supplier (Sigma-Aldrich, Microsource, NIH), 
available chemical database information and the published literature.  Sensitivity of detection 
in media types refers to the differential validation MIC values or screen hits between C- and 
N-conditions, as in Chapter 3, a difference in MIC greater than 2-fold between C- and N- 
media conditions is considered significant differential sensitivity. 
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4.4 Discussion 
4.4.2 Biological significance of starvation media screen hit compounds 
Compounds with known anti-bacterial activity or high levels of cytotoxicity such as anti-
neoplastics are unsuitable as leads for human tuberculosis treatment drugs, for either novelty 
or safety concerns, respectively.  Due to the large quantity of hit compounds identified 
through nutrient limitation screening not all hit compounds are able to be discussed.  
Therefore analysis priority has been given to compounds with novel anti-mycobacterial 
activity, the level of activity exhibited and coinciding activity against the slow growing 
mycobacterial species M. bovis BCG and M. tuberculosis H37Ra, low cytotoxicity and other 
indications of suitability towards human systemic administration.  Compounds considered 
particularly promising as human tuberculosis therapy candidates are highlighted in bold 
underline. 
 
4.4.2.1 Significance of LOPAC starvation media screens hit compounds  
Clotrimidazole, calmidazolium, diphenyleneiodonium, dequalinium, quinolinium, 
methoctramine and WB-64 have been previously detected in rich media screening conditions 
and are discussed in Chapter 3.5.2.1. 
 
BAY 11-7085 or (E)-3-(4-t-Butylphenylsulfonyl)-2-propenenitrile is detailed in the LOPAC 
library as an inhibitor of NFKB phosphorylation.  The PubChem Bioassay online database 
reports a range of differential activity in various assays including inhibition of P. falciparum 
proliferation, inhibition of Lassa and Marburg virus infection and the inhibition of various 
enzyme functions in vitro
237
 in addition to its first reporting as an inhibitor of M. smegmatis 
by this research.
122
  However BAY 11-7085 has not been identified as an inhibitor in any 
screens against slow growing mycobacterial species, indicating its inhibitory activity may be 
drastically reduced against pathogenic mycobacteria.  Furthermore, BAY 11-7085 has 
demonstrated necrotic cell killing in vitro against human Ramos-Burkitt's lymphoma cell 
lines
297
 and it has been shown to reduce the formation of reaction oxygen species by over 
50% in eosinophils activated by M. bovis BCG phagocytosis.
298
  This may be interpreted as 
reduced phagocyte killing of internalised mycobacteria.  These factors detract from the 
viability of BAY-11-7085 as a lead candidate drug for tuberculosis treatment.  
 
4-Chloromercuribenzoic acid is also reported by PubChem Bioassay as an inhibitor of P. 
falciparum proliferation, amongst a large range of other activities in vitro
237
 indicating this 
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molecule is a „frequent flyer‟.  Frequent flyers are chemicals commonly encountered in 
biological activity screens due to a non-specific mechanism of action.  This is most likely 
caused by its reactivity to thiol groups that would disrupt the function of many proteins, 
including documented lysis of human erythrocytes.
299
  This indicates that this compound is 
unsuitably toxic for human systemic administration. 
 
1,10-phenanthroline is a chelating agent that sequesters metal ions, this may explain the wide 
range of activity recorded for this molecule on PubChem Bioassay.
237
  1,10-phenathroline has 
been characterised as a strong inhibitor of M. tuberculosis H37Rv in vitro; however, the 
activity did not extend to a murine in vivo assay for reasons unknown but suspected to 
possibly be insufficient drug penetration or metabolism of the drug rendering it inactive.
300
  
Further research into this molecule particularly into the bio-availability and metabolism is 
required to determine the reason for its lack of in vivo efficacy and how this might be 
mitigated. 
 
LY-367265 is a serotonin reuptake inhibitor and is reported to inhibit the serotonin 
transporter and 5-HT2A receptor.
237
   The mechanism of anti-bacterial action is unclear and 
unconfirmed in slow growing mycobacterial species or in the literature, but it could possibly 
be due to inhibition of bacterial transporters with homology to SERT.  Due to the 
psychological side effects of this molecule in humans, its suitability for tuberculosis therapy 
is low. 
Trifluoperazine is a phenothiazine anti-psychotic agent used in the treatment of conditions 
such as schizophrenia.  Phenothiazines share structural similarity with the thioxanthene anti-
psychotics described in Chapter 3.5.2.1. The inhibitory activity of trifluoperazine towards 
mycobacteria has been confirmed in M. tuberculosis H37Rv in vitro by the Southern 
Research Institute, in addition to identifying it as an inhibitor of P. falciparum.
237
  Despite 
psychological side effects, phenothiazines have been suggested as treatments for XDR-TB.
301
  
These compounds are reported to accumulate within macrophages.
302
  Thioridazine, a 
phenothiazine drug primarily indicated for psychiatric conditions is known to be inhibitory 
toward MDR and XDR strains of tuberculosis in vivo
303
.  Phenothiazines are reported to 
block mycobacterial drug efflux pumps,
304
 indicating that phenothiazine compounds might 
exhibit synergy with other tuberculosis treatment drugs.  Trifluoperazine was detected only 
under nutrient starvation conditions, this could be evidential of phenothiazine interference 
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with mycobacterial transport pumps.  In the last year phenothiazines have received much 
interest as anti-tubercular agents,
305
 and trifluoperazine has been proven effective against 
active and latent MDR-TB.
306
  With further modification to the structure to reduce 
psychological side effects, the phenothiazine chemical class may well produce novel anti-
tuberculosis treatment drugs. 
 
Pentamidine is an anti-microbial agent primarily used in the treatment of pneumocystis 
pneumonia caused by the fungus Pneumocystis jirovcii, particularly in immunocompromised 
HIV positive patients.  It also exhibits inhibitory activity towards protozoan parasites such as 
Trypanosoma brucei, the causative agent of sleeping sickness and Leishmania spp the 
causative agents of leishmaniasis.  Its mechanism of action is thought to be binding to tRNA 
and inhibiting translation.
307
  The activity of pentamidine against M .tuberculosis H37Rv has 
been confirmed by the Southern Research Institute
237
 and has also been reported to have an 
MIC of > 5 µM in an H37Rv intra-macrophage assay.
221
   Due to its primary use as a 
treatment of pneumonia, it is often delivered directly to the lungs in an aerosol form, which is 
relevant to tuberculosis treatment.  Pentamidine exhibits an unfavourable side effect profile 
but its known use in treatment of pneumocystis may indicate it as a viable option in the 
treatment of MDR-TB. 
 
Ruthenium red is a metal based dye used in histological staining and microscopy.
308
  Due to 
its low level of anti-mycobacterial activity and lack of evidence for activity in slow growing 
mycobacterial species, it is regarded as a poor candidate lead for tuberculosis drug 
development. 
 
The vitamin E derivative U-83836 exhibited low levels of activity in M. smegmatis cultured 
in both nitrogen and carbon starvation conditions, and there was no evidence available of 
activity towards slow growing mycobacterial species.  Being a vitamin E derivative and free 
radical scavenger exerting protective effects against external ROS stress,
309
 it presents an 
interesting and unique pharmacophore for TB drug development but is of low priority due to 
lack of compelling evidence of activity in M. tuberculosis. 
 
Se-methylselenocysteine (SMSC) is a natural product found in high concentrations in Allium 
and Brassica edible plant species.  It is a methyl-selenium substituted analogue of the 
sulphurous amino acid cysteine.
310
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SMSC is sold over the counter as a nutritional supplement as a bio-available form of 
selenium to supplement a deficient diet and is anecdotally believed to have positive health 
effects in a range of conditions including cancer, HIV and diabetes.
311
  SMSC has been 
researched as a „chemopreventative‟ agent that reduces the incidence of cancer.312   
The mechanism for SMSC‟s chemopreventative action is through the induction of apoptosis 
in cancerous cells.
313
  The anti-tuberculosis activity of seleno-amino acids has been 
confirmed by the Southern Research Institute
237
 but was first reported in a publication from 
our laboratory.
122
  The novelty, known human consumption and passive cancer prevention 
properties are key factors that make SMSC and its family of seleno-amino acids (Se-AAs) 
excellent leads for tuberculosis drug discovery to explore.  SMSC and Se-AAs are further 
analysed for mechanism of action and structure activity relationship in Chapters 5 and 6 of 
this research. 
 
4.4.2.2 Significance of Spectrum Collection starvation media screen hit compounds 
Pyrithione zinc was detected in 7H9 rich medium screening with similar inhibitory 
concentrations to HdeB media types and is discussed in Chapter 3.5.2.2.  The imidazole anti-
fungals clotrimidazole and econzole were also detected with similar activity in LB rich media 
and were discussed earlier in Chapter 3.5.2.2.   
 
The anti-psychotic drugs prochlorperazine and trifluoperazine have previously been 
discussed in section 4.4.2.1 detailing phenothiazine drugs.  Nortriptyline is a tricyclic anti-
depressant with some structural and mechanistic similarities to phenothiazines.  It has been 
reported to demonstrate inhibitory activity towards M. tuberculosis H37Rv in in vitro 
screens.
237
  Little data exists concerning tricyclic antidepressants as anti-tubercular agents.  
Rifampicin and nortriptyline interact in vivo through common cytochrome P450 metabolism 
pathway,
314
 and there have been earlier reports of nortriptyline and other tricyclics inhibiting 
Campylobacter pylori.
315, 316
  Given the common receptor affinities of tricyclics and 
phenothiazines and both having exclusive activity in nutrient starvation media it is assumed 
they share a common mechanism, possibly interfering with bacterial transport systems that 
exhibit homology to human neurotransmitter receptors such as SERT.  Considering the mild 
psychological effects of tricyclics compared to phenothiazines, tricyclic anti-depressants may 
represent a better scaffold to explore for anti-mycobacterial activity. 
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Chloroacetoxyquinoline (silital) is a quinoline derivative that exhibited strong growth 
inhibition in nitrogen limited medium with a 780 nM MIC.  It was also detected in LB rich 
medium but at a much higher MIC of 25 µM demonstrating a drastic shift in activity based on 
media conditions.  Silital has also been non-quantitatively identified as inhibitory in screens 
against M. bovis BCG and M. tuberculosis H37Ra.  Silital is reported to be protective from 
polyglutamine Huntington toxicity in vitro and also inhibits the bacterial siderophore 
synthesising enzyme BasE.
237
  The pronounced difference in sensitivity of this compound 
between rich and nutrient media types gives credibility to the hypothesis that siderophore 
synthesis may be targeted by this compound, as iron supply is limited in HdeB nutrient 
starvation conditions, placing a considerably higher mycobacterial siderophore demand for 
mycobacterial growth.
317
 
Chloroacetoxyquinoline and other quinoline derivatives have previously been characterised 
as bacteriostatic against Gram positive and Gram negative bacterial and also have anti-fungal 
activity.
318
  Although the anti-mycobacterial activity of silital is promising, there is little 
further information on this compound, particularly in vivo, this makes silital a lower priority 
as an anti-tubercular drug lead until further research is conducted.   
Another quinoline derivative, primaquine, was validated only under nitrogen starvation 
conditions and is flagged on PubChem Bioassay as active against M. tuberculosis H37Rv.  It 
has also been previously disclosed as having an MIC of 5 µM against intra-macrophage M. 
tuberculosis H37Rv.
221
  Orally administered primaquine is routinely used in the treatment 
and prophylaxis of malaria and also in the treatment of Pneumocystis pneumonia.  This route 
of administration and use are favourable indications of primaquines in vivo efficacy and 
tolerance.  The action of primaquine towards not only mycobacteria but also malaria and 
other diseases make it a promising drug, and further development has been encouraged.
319
 
The quaternary ammonium compounds benzethonium, methylbenzethonium, benzalkonium, 
cetrimonium and cetylpyridinium are used as surface disinfectants and topical anti-septic 
agents in products such as medical wipes and mouthwashes.  Compounds such as 
benzethonium have been confirmed to have anti-mycobacterial activity in M. tuberculosis 
H37Rv with an IC50 of 26 µM, however, a subsequent counter screen for human cell 
cytotoxicity had a high IC50 of 40 µM,
237
 this is an unacceptable selectivity.  This is not 
surprising given the non-specific mechanism of action of quaternary ammonium compounds, 
disrupting plasma membranes and enzyme interactions.
320
  Due to toxicity concerns, these 
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compounds best remain as externally applied anti-infectives and therefore are of little use in 
tuberculosis treatment. 
Similar in mechanism to the anti-septics described above, chlorhexidine and alexidine are 
„local anti-infectives‟ with bactericidal action through disruption of membranes.321  
Chlorhexidine is reported to be an inhibitor of M. tuberculosis H37Rv on the PubChem 
Bioassay database,
237
 but the toxicity of these disinfectants at high concentrations or through 
systemic administration makes them undesirable drug development leads. 
The organic mercury compounds thimerosal and phenylmercuric acetate have well 
documented anti-septic and anti-fungal properties and applications, mainly as preservatives 
for example in vaccines.  Thimerosal is recorded on PubChem Bioassay as having an IC50 of 
340 nM against M. tuberculosis H37Rv which corresponds to the MIC of 780 nM found in 
this study in carbon starvation media. The corresponding human VERO cell toxicity IC50 for 
thimerosal was 3559 nM meaning thimerosal demonstrates tenfold selectivity in action 
toward mycobacteria.
237
  These compounds, due to their mercury containing nature are 
intrinsically toxic, being metabolised to form damaging alkylated mercury compounds that 
has caused even their topical use to be questioned for safety concerns.
322
  Due to these safety 
concerns, organomercury compounds are regarded as too toxic to be considered strong 
tuberculosis drug leads. 
Cefdinir is a popularly used 3
rd
 generation cephalosporin antibiotic with a bactericidal 
mechanism of action through disruption of peptidoglycan synthesis.  Although β-lactam 
antibiotics are generally regarded as ineffective against mycobacteria due to their fatty acid-
fast cell wall and highly effective β-lactamase enzymes,323 recent research has suggested that 
certain β-lactam drugs, particularly in combination with β-lactamase inhibitors, can be 
effective against M. tuberculosis in vitro.
324, 325
  Cefdinir exhibited a low level of activity 
against M. smegmatis in nitrogen limited media with an MIC of 25 µM and was also detected 
as inhibitory in screens against M. bovis BCG and M. tuberculosis H37Ra.  Considering that 
cefdinir is already marketed and consumed as an antibiotic its safety profile is considered to 
be extremely good, and that it was actively inhibiting mycobacteria in vitro in the absence of 
a coupled β-lactamase inhibitor indicates that cefdinir in conjunction with a β-lactamase 
inhibitor and other anti-tubercular drugs presents a viable option in the treatment of 
problematic drug resistant TB. 
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Thiram is an anti-fungal agent that targets glutathione reductase and was also identified in 
screens against M. bovis BCG and M. tuberculosis H37Ra.  Thiram is mutagenic and 
therefore is unsuitable for human administration,
326
 however, compounds of the same 
dithiocarbamate scaffold such as disulfiram (which is less toxic than thiram) have been 
explored in the treatment of tuberculosis.
327
 Other substituted dithiocarbamates have been 
demonstrated to inhibit tubercular carbonic anhydrases,
328
 indicating that despite thiram 
being unsuitable for tuberculosis therapy the dithiocarbamate family is a promising novel 
class of anti-mycobacterial agents. 
Khivorin is a natural product isolated from the West African timber Khaya ivorensis that 
exhibited inhibitory activity against M. smegmatis in nitrogen limited medium.  No evidence 
of an inhibitory action towards M. tuberculosis could be found.  Substituted khivorin 
compounds have demonstrated low levels of anti-fungal and anti-bacterial activity.
329
  
Similarly irigenin, a flavonoid isolated from the rhizome of various Iris species showed 
activity in nitrogen limited media but no compounding evidence of inhibition towards M. 
tuberculosis could be found, the closest result being a recent publication describing a broad 
spectrum of anti-microbial activity for a crude methanol extract containing irigenin.
330
  
Berbamine is a Ca
2+
 channel blocker isolated from Berberis species and was identified only 
in nitrogen limited medium.  No evidence of inhibition towards slow growing mycobacterial 
species was presented although a related compound berberine has been reported to have an 
MIC of 31.2 µg/mL against M. tuberculosis
331
 and a 25 µg/mL MIC against M. smegmatis 
cultured in 7H9 broth.
332
  Berbamine is reported to have strong anti-plasmodial activity but is 
also toxic toward human cell lines in vitro.
237
  Hydrastine, derived from the goldenseal plant 
Hydrastis canadensis, again exhibited inhibition against M. smegmatis only in nitrogen 
limitation medium.  No information concerning its inhibitory activity towards M. tuberculosis 
could be found, and β-hydrastine is reported to be inactive against M. smegmatis in 7H9 
medium.
332
 
Due to the lack of confirming anti-tubercular activity and toxicity data the natural products 
khivorin, irigenin, berbamine and hydrastine remain low priorities for anti-tubercular drug 
development. 
A common over the counter decongestant, phenylephrine, was found to inhibit M. smegmatis 
in both carbon and nitrogen limited media to an MIC of 3.125 µM.  However subsequent 
testing of commercially available (R)-(−)-phenylephrine hydrochloride (Sigma-Aldrich) was 
found to have no activity against M. smegmatis in any media type in vitro.  Some literature 
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evidence suggests that phenylephrine may have anti-bacterial properties;
333
 however, this is 
far from compelling.  The positive inhibition result is reported with scepticism, possibly 
arising from contamination of the chemical library well.  Regardless, phenylephrine is a 
potent α-adrenergic receptor agonist, an activity that contraindicates use as an anti-TB agent 
in humans.
334
  
 
Gentisic acid (2-5 dihydroxybenzoic acid) exhibited inhibitory activity against M. smegmatis 
in nitrogen limiting medium, and this activity was also identified in screens against M. bovis 
BCG and M. tuberculosis H37Ra.  Gentisic acid is an anti-inflammatory / analgesic 
compound and a by-product of aspirin metabolism.  Interestingly, PubChem Bioassay reports 
aspirin as active in reducing the spleen concentration of M. tuberculosis in infected mice, and 
the database also notes that gentisic acid and structurally similar compounds such as salicylic 
acid are inhibitors of M. tuberculosis H37Rv  fructose-bisphosphate aldolase in vitro.
237
  
Gentisic acid has also been previously identified as a possible anti-bacterial agent in an in 
silico screen.
335
  Little information directly supporting the anti-mycobacterial properties of 
gentisic acid is available, but considering its favourably low oral toxicity (murine LD50 = 
4500 mg/kg
336
) it deserves further attention to determine its value as a tuberculosis drug lead. 
Chlorothalonil (tetrachloroisophthalonitrile) is a broad-spectrum anti-microbial, particularly 
used as an anti-fungal in agriculture.  It reduces glutathione which disrupts cellular redox 
balance and leads to cell death.
337
  Chlorothalonil presumably acts through a similar 
mechanism in mycobacteria, reducing mycothiones.  Chlorothalonil exhibited strong 
inhibitory activity towards M. smegmatis in both carbon and nitrogen limitation media and 
was also flagged as inhibitory in screens against M. bovis BCG and M. tuberculosis H37Ra.  
Although it is reported to be remarkably non-toxic in murine models particularly when orally 
administered, with LD50 values over 5000 mg/kg,
338
 research has suggested it has  
genotoxicity, carcinogenicity and developmental toxicity
339
 in murine models, but not 
humans.
340
  No information regarding the anti-mycobacterial activity of chlorothalonil could 
be found in the literature; therefore, it is believed that the present research is the first 
disclosure of chlorothalonil as a potential anti-tubercular agent.  Considering the established 
safety profile of chlorothalonil and its inhibitory action towards M. smegmatis, chlorothalonil 
could potentially be developed into an anti-mycobacterial drug with a novel mechanism of 
action.  Further research into the activity against M. tuberculosis H37Rv in vitro and 
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subsequently in vivo are required to determine the effectiveness of this chemical against 
pathogenic mycobacteria before consideration for further development. 
2-aminoethyldiphenyl boronate inhibits eukaryotic IP3 receptors modulating the release of 
intracellular Ca
2+
.  It way also blocks transient receptor potential channels, and is mainly used 
as a research tool.
341
  This chemical has been identified as an inhibitor of Bacillus subtilis Sfp 
phosphopantetheinyl transferase in vitro, the equivilent enzyme in mycobacteria Rv2794c 
PptT serves vital roles such as the synthesis of the siderophore mycobactin and cell wall 
mycolic acids.
342
  Phosphopantetheinyl transferase inhibition is a possible mechanism of its 
anti-mycobacterial action; however, this compound was not detected in screens against slow 
growing mycobacteria, and its effects on cellular Ca
2+ 
release likely indicate severe side 
effects if administered in vivo. 
4.4.2.3 Significance of NIH Diversity Set starvation media screen hit compounds 
Screening of the NIH Diversity Set library under nutrient starvation conditions identified 
several compounds of interest that had previously been identified.  These included the 
phenothiazine compounds NSC17474 trifluoperazine and NSC59349 3-nortropanol.  
Phenothiazines were previously identified in nutrient limited screening of the LOPAC and 
Spectrum Collection and are discussed above in section 4.4.2.1.  NSC12155 aminoquinuride, 
NSC661755 michellamine B, NSC368675 azadirachtin, NSC22225 cadmium chlorendic acid 
and NSC31048 neohesperidin were identified in rich media condition screening of the NIH 
Diversity Set and are discussed in Chapter 3.5.2.3. 
NSC317629 ketoconazole is an azole anti-fungal agent that interferes with ergosterol 
synthesis similar to the previously mentioned econazole and clotrimidazole.  However, 
ketoconazole is highly lipophilic and in addition to topical administration is also able to be 
administered orally for systemic treatment.
343
 This lipophilicity and systemic administration 
makes ketoconazole a much stronger candidate for tuberculosis therapy than other topically 
applied anti-fungals.  Ketoconazole was detected in nitrogen limited screening of M. 
smegmatis and validated to have an MIC of 6.25 µM and is reported to have an MIC of 7.6 
µM against M. tuberculosis H37Rv.
237, 344
  Ketoconazole has demonstrated improved 
treatment of murine tuberculosis in vivo  when combined with front line tuberculosis drugs.
345
  
Our research supports the idea that ketoconazole has strong potential to be a tuberculosis 
treatment adjunct, and further investigation and development is warranted. 
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NSC16865 bismuth-dimercaprol (BisBAL) exhibited activity against M. smegmatis in 
nitrogen limited medium and was also detected as active in screening of the NIH Diversity 
Set against M. bovis BCG.  Bismuth thiols have been previously reported as anti-bacterial.
346
  
Dimercaprol and related thiols have previously been characterised as anti-tubercular in 
vivo
347
 but were abandoned shortly after and deemed clinically unsuitable due to rapid 
development of resistance and poor activity against established murine infections.
348
  BisBAL 
is thought to derive its anti-bacterial action by interfering with capsule and biofilm formation.  
At sub-inhibitory concentrations BisBAL renders bacteria more susceptible to phagocytosis 
due to exposure of subcapsular antigens.
349
  BisBAL may not be an effective tuberculosis 
therapy alone, but its effects in conjunction with conventional tuberculosis treatment drugs 
warrant further investigation, as it may synergistically increase the activity of tuberculosis 
drugs and the immune response. 
  
NSC13316 is a quinoline-based compound with an MIC of 6.25 µM in M. smegmatis 
nitrogen starvation medium and has been confirmed as having an IC50 of 4.5 µM in M. 
tuberculosis H37Rv and also nanomolar level potency in inhibition of P. falciparum growth.  
However, it also has reported activity against cancer cell lines and is therefore deemed too 
cytotoxic to be prioritised for development.
237
   
 
NSC17770 is a quinoline-piperidine compound validated in nitrogen conditions with an M. 
smegmatis MIC of 6.25 µM and was also detected as active in parallel screens of M. bovis 
BCG and M. tuberculosis H37Ra.  No bioactivity is reported on the PubChem database or in 
the literature.  NSC13726 is a diquinoline compound with structural resemblance to 
aminoquinuride.  It was validated as having an MIC of 12.5 µM against M. smegmatis in 
nitrogen starvation medium and was also detected in screens against M. bovis BCG and M. 
tuberculosis H37Ra.  It is noted as an inhibitor of hERG (human Ether-a-go-go Related 
Gene) ion channels, cytochrome P450-2C9 and glucocerebrosidase-p2.
237
   NSC17770 
warrants further investigation to confirm their anti-tuberculosis properties, although 
inhibition of the „anti-target‟ hERG by NSC13726 is considered undesirable in drug 
development as may cause fatal cardiac side effects.
350
 
 
NSC321206 was detected in nitrogen starvation M. smegmatis and also characterised in M. 
tuberculosis H37Ra as having an MIC of 3.125 µM.  NSC321206 is reported to be a potent 
inhibitor of the human proteosome and also has anti-neoplastic properties that make it 
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undesirable for a tuberculosis treatment drug.
351
 
Another proteosome inhibitor NSC109268 was also detected in nitrogen starvation medium 
with an MIC of 12.5 µM in M. smegmatis and, while not neo-plastic itself, has indications as 
an adjunct for improving cancer therapy efficacy.
352
  If well tolerated in vivo and confirmed 
as inhibitory towards pathogenic tuberculosis, NSC109268 may be a candidate anti-
tubercular pharmacophore. 
 
NSC632536 was identified under nitrogen limitation screening in this work and also in 
screening of M. bovis BCG.  Little information is available on this compound, with PubChem 
Bioassay activity results reported to be inhibition of P. falciparum and Tryponasoma cruzi 
and B. subtilis Sfp phosphopantetheinyl transferase.
237
 
NSC292596 was identified under carbon and nitrogen limited conditions in M. smegmatis.  It 
is an inhibitor of H2AX histone phosphorylation,
353
 but lack of confirmation of activity in 
slow growing mycobacterial restrict the priority classification of this as a drug development 
lead. 
 
NSC72939 a manganese complex detected in nitrogen limited M. smegmatis with an MIC of 
12.5 µM and also in screens as having activity against M. bovis BCG and M. tuberculosis 
H37Ra.  NSC72938 is a similar complex to NSC72939 but with manganese substituted for 
copper.  It exhibited an MIC of 25 µM against M. smegmatis and was not detected in screens 
against slow growing mycobacterial species.  The complex comprises of nicotine, salicylic 
acid (which may account for its anti-mycobacterial properties) and manganese/copper.  
NSC72938 is reported as blocking hERG K
+
 channels, the only bioactivity reported for these 
complexes on the PubChem database or in the literature,
237
 therefore, the activity of these 
complexes requires further confirmation before consideration as potential anti-tubercular 
development leads. 
 
NSC181486 trigilletine was validated in nitrogen starvation medium and also indentified in 
screens against M. bovis BCG and M. tuberculosis H37Ra.  It is a natural product isolated 
from West African plant species such as Triclisia and Momordica. It has been found to have 
strong anti-protozoal activity but was also toxic to human cell lines, giving a poor selectivity 
index and making it unsuitable for human therapy.
354
 
 
NSC23128 is a complex organic molecule that was verified to have low activity with an MIC 
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of 25 µM against M. smegmatis cultured in nitrogen starvation conditions, but no other 
indication of anti-mycobacterial activity could be found.  It is reported on PubChem Bioassay 
as inhibitory toward hERG channels, Tau filament binding, Smad transcription factor and the 
EP2 prostaglandin receptor.
237
  NSC125910 shares anthraquinone structural similarity with 
NSC23128.  It was also verified only against M . smegmatis nitrogen limitation at 25 µM and 
is listed as a Smad transcription factor, EP2 prostaglandin receptor and HSD17B4 
hydroxysteroid dehydrogenase inhibitor on PubChem Bioassay.
237
   
 
NSC130813 is a substituted acridine compound identified as having an MIC of 6.25 µM in 
M. smegmatis under nitrogen limiting conditions.  Although there are no further indications 
for activity in slow growing mycobacterial species NSC130813 may be desirable for 
development due to its anti-viral activity.  It blocks viral DNA synthesis
355
 and has a strong 
binding affinity to HIV-1 RNA,  indicating possible dual inhibitory application.
237
  Further 
confirmation of anti-tuberculosis activity and cytotoxicity is required. 
 
NSC356217 HEJ-4 is a harmine derivative that exhibited an MIC of 6.25 µM against M. 
smegmatis cultured under nitrogen starvation.  No other indications of anti-mycobacterial or 
other activity could be found for this molecule.  Based on its parent harmine, it might exhibit 
undesirable side-effects in vivo due to monoamine oxidase inhibiting activity. 
 
NSC35611 solanine is a glycoalkaloid isolated from plants of the Solanaceae family such as 
the potato.  Solanine was detected in nitrogen limitation culture screening of M. smegmatis 
with an MIC of 6.25 µM and was also identified as active in screens against M. bovis BCG 
and M. tuberculosis H37Ra.  Solanine has demonstrated anti-fungal activity
356
 and low levels 
of anti-bacterial activity towards E. coli and S. aureus.
357
  Although generally regarded as a 
toxin, orally administered solanine is tolerated in murine models at concentrations up to 1 
g/kg although gastrointestinal absorption may be limiting.
358
  Solanine and related 
glycoalkaloids warrant further investigation into their anti-mycobacterial properties.  
 
NSC56346 rottlerin is a natural product derived from the plant Mallotus philippensis.  
Identified in nitrogen limited medium screening of M. smegmatis with an MIC of 6.25 µM, 
rottlerin has been identified in silico as an inhibitor of M. tuberculosis 14α-lanosterol 
demethylase
359
 and rottlerin and other isolates from M. philippensis have been characterised 
as anti-tubercular.
360
 Rottlerin has a published murine oral LDLo of 750 mg/kg
361
 and is a 
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known K+ channel opening agent that affects the cardiovascular system.   Further studies into 
the cytotoxicity and in vivo efficacy of rottlerin and its derivatives are required to determine 
its potential as a tuberculosis drug lead. 
 
NSC34936 suramin is a well known anti-protozoal drug implemented in the treatment of 
Trypanosoma spp-induced sleeping sickness.  It was validated in nitrogen starvation culture 
as having an MIC of 6.25 µM against M. smegmatis and also non-quantitatively picked up as 
active in screens against M. bovis BCG and M. tuberculosis H37Ra.  Suramin is also known 
as an RNA reverse transcriptase inhibitor, a property that confers inhibition of HIV.
362
  The 
effects of suramin on M. tuberculosis have been tested, and it has been reported as ineffectual 
in vitro and conversely caused increased mycobacterial growth in vivo. 
363
  This conflict of 
results may be attributed to culture conditions, strain or technique.  Revisitation of the anti-
mycobacterial activity of suramin may be worth pursuing. 
 
NSC319518, the diterpene glycoside cotylenin A, is a regulator of plant growth that can 
cause differentiation of mammalian cells and apoptosis of neoplastic cells.
364
  In the present 
research it was validated to have an MIC of 6.25 µM against M. smegmatis in nitrogen 
limited medium screening, and was also identified as inhibitory in screens against M. bovis 
BCG and M. tuberculosis H37Ra.  No further evidence for anti-microbial action of cotylenin 
A could be found in the literature to confirm this result. 
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4.4.3 The influence of differential starvation culture conditions on screen hits 
Performing screens for anti-mycobacterial chemicals in nutrient starvation conditions using 
HdeB carbon and HdeB nitrogen limitation media revealed a large difference in the 
sensitivity of M. smegmatis to inhibitory library compounds between carbon and nitrogen 
limitation media conditions. 
From the validated hits of screening of all three chemical libraries, 104 were validated in 
carbon limitation medium, 206 hits were validated in nitrogen limitation conditions and 100 
of these hits were validated in both starvation media types.  Comparing the hits derived from 
nutrient limitation screens with the results of M. tuberculosis H37Ra screening in 7H9 
medium
206, 220
 showed that 60 hits were common to carbon starvation medium and M. 
tuberculosis, and 95 hits are common to nitrogen starvation medium and M. tuberculosis.  A 
total of 60 hits were common to both carbon and nitrogen starvation conditions and were also 
active in M. tuberculosis H37Ra. 
 
 
Figure 4.10:  Venn diagram comparing starvation media screening validated hits. 
Results of screens in HdeB C- and N- starvation media types compared with hits detected in 
M. tuberculosis H37Ra screens.
206, 220
  Venn diagram group totals provided are inclusive. 
Performing M. smegmatis chemical library screens in nitrogen starvation media produced 
almost double the number of validated hit compounds compared to screens in carbon 
starvation media.  A greater number of hits derived from M smegmatis screens in nitrogen 
limited conditions were also active against M. tuberculosis H37Ra compared to carbon 
starvation screens of M. smegmatis.  
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All hits active in M. tuberculosis and validated in M. smegmatis carbon starvation conditions 
were also validated in nitrogen starvation conditions.  Therefore for nutrient limitation 
condition screening in M. smegmatis, nitrogen starvation exhibited the greatest sensitivity in 
detecting inhibitors and was most relevant for detected inhibitors active toward M. 
tuberculosis. 
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4.4.3.1 Comparison of validated hits from LOPAC differential media screens  
LOPAC 
Compound 
M. 
smegmatis 
MIC 
(µM) LB 
M. 
smegmatis 
MIC 
(µM) 7H9 
M. 
smegmatis 
MIC 
(µM) C- 
M. 
smegmatis 
MIC 
(µM) N- 
M. bovis 
BCG 
MIC 
(µM) 
M. 
tuberculosis 
H37Ra MIC 
(µM) 
BAY 11-7085 - - 6.25 12.5 ≤ 20 - 
Calcimycin 3.125 - 12.5 12.5 - ≤ 20 
Carboplatin   25 50 - - 
4-Chloromercuribenzoic 
acid 
- - 6.25 12.5 - ≤ 20 
Cisplatin - - 12.5 12.5 - - 
Calmidazolium 12.5 - 50 12.5 - - 
Clotrimazole 12.5 - 50 50 - - 
Demeclocycline 3.125 3.125 6.25 6.25 3.125 1.56 
Dequalinium - 3.125 - - 3.125 6.25 
Dequalinium C-14 linker. 
(Quinolinium) 
6.25 3.125 6.25 3.125 - ≤ 20 
Diphenyleneiodonium 6.25 3.125 3.125 3.125 0.195 0.39 
Doxycycline 1.56 1.56 3.125 3.125 ≤ 20 - 
Ellipticine - 25 - - 12.5 12.5 
Idarubicin 12.5 3.125 25 12.5 6.25 6.25 
Lomefloxacin 12.5 6.25 6.25 6.25 1.56 3.125 
LY-367265 - - 25 50 - - 
Methoctramine 12.5 12.5 12.5 12.5 1.56 6.25 
Minocycline 12.5 12.5 12.5 12.5 1.56 3.125 
Mitoxantrone - - 50 50 - - 
Niclosamide 12.5 25 6.25 6.25 6.25 6.25 
Ofloxacin 3.125 3.125 6.25 6.25 1.56 1.56 
Pentamidine - - 25 50 - - 
1,10-Phenanthroline - - 12.5 12.5 ≤ 20 ≤ 20 
Se-Methylselenocysteine - * 12.5 12.5 12.5 12.5 
Ruthenium red - - 50 50 - - 
Trifluoperazine - - 50 50 - - 
U-83836 - - 50 50 - - 
Vancomycin 12.5 - 25 25 ≤ 20 - 
WB 64 - 12.5 50 25 12.5 12.5 
 
Table 4.4: Comparison of validated hits from LOPAC differential media screening.   
Validated M. smegmatis MIC values of LOPAC HTS hit compounds derived in both rich and 
starvation media types are presented for comparison.  These values are contrasted with 
screening results of LOPAC against slow growing mycobacterial species M. bovis BCG and 
M. tuberculosis H37Ra in 7H9 medium.
206, 220
  *SMSC was later detected and validated in 
7H9 medium.  Values of “-“ indicate no inhibitory activity was detected in screening 
(triplicate mean of  > 80% growth inhibition compared to positive controls).  Values of “≤ 
20” indicate the compound did exhibit inhibitory activity in screens (triplicate mean of > 80% 
growth inhibition compared to positive controls) against slow growing mycobacterial species, 
however confirmatory MIC assays were unable to be performed, therefore the MIC is 
estimated to be less than or equal to the screen compound concentration of 20 µM. 
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4.4.3.2 Comparison of validated hits from Spectrum Collection differential media 
screens 
Spectrum Collection 
Compound 
M. 
smegmatis 
MIC 
(µM) LB 
M. 
smegmatis 
MIC 
(µM) 7H9 
M. 
smegmatis 
MIC 
(µM) C- 
M. 
smegmatis 
MIC 
(µM) N- 
M. 
bovis 
BCG 
MIC 
(µM) 
M. 
tuberculosis 
H37Ra MIC 
(µM) 
Khivorin - - - 12.5 - - 
Merbromin - - 6.25 6.25 - - 
Chloroacetoxyquinoline (Silital) 25 - - 0.78 ≤ 20 ≤ 20 
Aklavine 12.5 - - 6.25 ≤ 20 ≤ 20 
Irigenin dibenzyl ether - - - 12.5 - - 
Celastrol (Tripterine) 25 - - 3.125 - - 
Amikacin - - - 6.25 - - 
Benzethonium - - - 6.25 - - 
Capreomycin - - - 6.25 ≤ 20 - 
Cetylpyridinium - - - 6.25 - - 
Chlorhexidine 12.5 - 6.25 3.125 ≤ 20 ≤ 20 
Chlortetracycline 1.56 1.56 3.125 0.78 - - 
Colistimethate - - - 12.5 - - 
Demeclocycline 1.56 1.56 0.78 0.78 ≤ 20 ≤ 20 
Dihydrostreptomycin 12.5 6.25 12.5 3.125 - - 
Pyrithione Zinc - 1.56 1.56 0.39 ≤ 20 ≤ 20 
Clotrimazole 12.5 - 25 12.5 ≤ 20 - 
Doxycycline 1.56 1.56 0.78 0.78 ≤ 20 ≤ 20 
Ethambutol 3.125 3.125 3.125 3.125 ≤ 20 ≤ 20 
Gentian / Crystal Violet - - 3.125 3.125 - - 
Mercaptopurine - - - 25 ≤ 20 ≤ 20 
Minocycline 1.56 0.78 1.56 0.78 ≤ 20 ≤ 20 
Nortriptyline - - - 12.5 - - 
Oxyquinoline - 12.5 -  ≤ 20 ≤ 20 
Oxytetracycline  6.25 3.125 - 1.56 - ≤ 20 
Polymyxin B - - - 12.5 - - 
Primaquine - - - 25 - - 
Tetracycline 1.56 3.125 3.125 1.56 ≤ 20 - 
Streptomycin 3.125 3.125 3.125 6.25 - - 
Tobramycin 6.25 6.25 3.125 1.56 - - 
Thimerosal 3.125 1.56 0.78 3.125 ≤ 20 ≤ 20 
Phenylephrine - - 3.125 3.125 - - 
Thiothixene (Tiotixene) - 25 - - - - 
Sulfamethoxazole - 25 -  - - 
Hydrastine - - - 6.25 - - 
Patulin - - - 25 ≤ 20 - 
Phenylmercuric Acetate - 3.125 1.56 0.39 ≤ 20 ≤ 20 
Dichlorodiphenyltrichloroethane, 
DDT 
- - - 25 - - 
Gemifloxacin 3.125 3.125 3.125 6.25 ≤ 20 ≤ 20 
Prochlorperazine edisylate - - - 6.25 - - 
Clioquinol 12.5 - -  - - 
Thiostrepton 12.5 12.5 - 12.5 ≤ 20 ≤ 20 
2-Aminoethyldiphenyl boronate, 
2-aminoethyl diphenylborinate. 
- - - 6.25 - - 
Gatifloxacin 1.56 1.56 1.56 1.56 ≤ 20 ≤ 20 
Cetrimonium - - - 6.25 - - 
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Spectrum Collection 
Compound 
M. 
smegmatis 
MIC 
(µM) LB 
M. 
smegmatis 
MIC 
(µM) 7H9 
M. 
smegmatis 
MIC 
(µM) C- 
M. 
smegmatis 
MIC 
(µM) N- 
M. 
bovis 
BCG 
MIC 
(µM) 
M. 
tuberculosis 
H37Ra MIC 
(µM) 
Methylbenzethonium Chloride 1.56 6.25 6.25 6.25 ≤ 20 - 
Roxithromycin 6.25 6.25 -  ≤ 20 - 
Cefdinir - - - 25 ≤ 20 ≤ 20 
Levofloxacin 3.125 3.125 3.125 3.125 ≤ 20 ≤ 20 
Apramycin - - 25 6.25 - - 
Telithromycin 6.25 25 - - ≤ 20 - 
Erythromycin - - - 6.25 ≤ 20 - 
Gentisic acid, dihydroxybenzoic 
acid 
- - - 25 ≤ 20 ≤ 20 
Trifluoperazine HCl - - - 12.5 ≤ 20 ≤ 20 
Econzole - 12.5 12.5 12.5 ≤ 20 ≤ 20 
Lomefloxacin 12.5 12.5 6.25 12.5 ≤ 20 ≤ 20 
Ofloxacin 3.125 3.125 3.125 3.125 ≤ 20 ≤ 20 
Carboplatin - - 25 6.25 - - 
Cisplatin - 12.5 3.125 0.78 - - 
Alexidine - 6.25 6.25 6.25 ≤ 20 ≤ 20 
Pararosaniline pamoate - - - 6.25 ≤ 20 - 
Mitoxantrone - - 50 50 - - 
Thiram - - - 12.5 ≤ 20 ≤ 20 
Benzalkonium Chloride - - 6.25 6.25 - - 
Dirithromycin 12.5 6.25 - - - ≤ 20 
Clarithromycin - 6.25 6.25 - ≤ 20 - 
Moxifloxacin 1.56 1.56 1.56 6.25 ≤ 20 ≤ 20 
Berbamine - - - 12.5 - - 
Rifampin 6.25 6.25 6.25 6.25 ≤ 20 ≤ 20 
Acivicin - - - 25 ≤ 20 ≤ 20 
Tetrachloroisophthalonitrile / 
Chlorothalonil 
- - 6.25 3.125 ≤ 20 ≤ 20 
Ciprofloxacin 12.5 12.5 - 12.5 - ≤ 20 
Teniposide 25 25 - 25 - - 
Rifaximin 6.25 6.25 - 6.25 ≤ 20 ≤ 20 
Sarafloxacin 6.25 6.25 6.25 6.25 ≤ 20 ≤ 20 
Pefloxacine 12.5 12.5 - 12.5 ≤ 20 ≤ 20 
 
Table 4.5: Comparison of hits from Spectrum Collection differential media screening 
Validated M. smegmatis MIC values of Spectrum Collection HTS hit compounds derived in 
both rich and starvation media types are presented for comparison.  These values are 
contrasted with screening results of LOPAC against slow growing mycobacterial species M. 
bovis BCG and M. tuberculosis H37Ra.
206, 220
  Details as for Table 4.4. 
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4.4.3.3 Comparison of validated hits from NIH Diversity Set differential media screens 
NIH Library Compound 
M. 
smegmatis 
MIC 
(µM) LB 
M. 
smegmatis 
MIC (µM) 
7H9 
M. 
smegmatis 
MIC 
(µM) C- 
M. 
smegmatis 
MIC 
(µM) N- 
M. 
bovis 
BCG 
MIC 
(µM) 
M. 
tuberculosis 
H37Ra MIC 
(µM) 
NSC2347 (Tricarballylic acid) - - - 25 - - 
NSC27895 - - - 25 - - 
NSC1684 - - - 25 - - 
NSC23082 - - - 6.25 - - 
NSC3907 (8-Hydroxyquinoline 
salicylate) 
- 25 - 6.25 12.5 3.125 
NSC329226 6.25 6.25 6.25 3.125 ≤ 20 ≤ 20 
NSC359098 - - - 6.25 - - 
NSC26081 - - - 6.25 - - 
NSC16865 - - - 6.25 ≤ 20 - 
NSC130830 - - - 12.5 - ≤ 20 
NSC17600 - - - 6.25 - - 
NSC122657 - - - 12.5 ≤ 20 - 
NSC152686 - - - 12.5 - - 
NSC153533 - - - 25 - - 
NSC289336 (Rimiterol) - - - 25 - - 
NSC13316 - - - 6.25 ≤ 20 - 
NSC333003 - - - 3.125 ≤ 20 ≤ 20 
NSC625324 (Silver 
sulfadiazine) 
- 12.5 6.25 0.39 - - 
NSC24113 - - - 6.25 ≤ 20 - 
NSC45382 - - - 3.125 - - 
NSC22907 - - - 25 - - 
NSC48300 - - - 6.25 ≤ 20 ≤ 20 
NSC295642 - - - 6.25 ≤ 20 ≤ 20 
NSC12155 (Aminoquinuride, 
surfen) 
- 12.5 12.5 6.25 ≤ 20 - 
NSC632536 - - - 12.5 ≤ 20 - 
NSC3058301 
(Benzenecarboximidamide) 
- - - 6.25 - - 
NSC13480 - 12.5 6.25 3.125 12.5 12.5 
NSC17474 (Trifluoperazine) - - - 6.25 ≤ 20 - 
NSC294526 - - 6.25 3.125 - - 
NSC132693 - 25 - - - - 
NSC321206 - 25 - 6.25 25 3.125 
NSC311153 - 25 - 6.25 6.25 6.25 
NSC311152 (Datelliptium) - 12.5 12.5 6.25 ≤ 20 ≤ 20 
NSC176327 - 12.5 12.5 3.125 ≤ 20 ≤ 20 
NSC92585 - - 25 0.78 ≤ 20 ≤ 20 
NSC354961 - - 25 6.25 ≤ 20 - 
NSC359449  - 12.5 12.5 1.56 ≤ 20 ≤ 20 
NSC97345 - - 3.125 0.19 - - 
NSC268879 3.125 3.125 3.125 0.19 1.56 3.125 
NSC117274 - - - 12.5 - - 
NSC305787 - - - 6.25 ≤ 20 ≤ 20 
NSC150289 - - - 6.25 - - 
NSC114792 - - - 6.25 - - 
NSC292596 - - 12.5 12.5 - - 
NSC661755 (Michellamine B) 25 - 12.5 3.125 ≤ 20 ≤ 20 
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NIH Library Compound 
M. 
smegmatis 
MIC (µM) 
LB 
M. 
smegmatis 
MIC (µM) 
7H9 
M. 
smegmatis 
MIC (µM) 
C- 
M. 
smegmatis 
MIC (µM) 
N- 
M. 
bovis 
BCG 
MIC 
(µM) 
M. 
tuberculosis 
H37Ra MIC 
(µM) 
NSC25485(Ouabain) - - - 12.5 - - 
NSC72939 - - - 12.5 ≤ 20 ≤ 20 
NSC133100 (Rifamycin SV) 25 - - -   
NSC305787 - 25 - - 25 6.25 
NSC11241 (C.I. Basic red 6) - 25 - - - - 
NSC321237 - 25 3.125 0.39 - - 
NSC17770 - - - 6.25 ≤ 20 ≤ 20 
NSC5159 (Chartreusin) 3.125 1.56 - - 1.56 1.56 
NSC310551 - 6.25 6.25 3.125 12.5 6.25 
NSC295558 - - 6.25 1.56 - - 
NSC20410 - - 12.5 3.125 - - 
NSC182395 - - 12.5 1.56 - - 
NSC22225 (Cadmium 
chlorendic acid) 
- 1.56 12.5 12.5 ≤ 20 ≤ 20 
NSC145611 (Rifamycin 
derivative) 
25 - - - 50 6.25 
NSC145612 25 - - -  50 
NSC64111 - - - 6.25 ≤ 20 ≤ 20 
NSC182035 - - - 6.25 - - 
NSC72938 - - - 25 - - 
NSC181486 (Trigilletine) - - - 12.5 ≤ 20 ≤ 20 
NSC52003 - - - 25 - - 
NSC73101 - - - 25 - - 
NSC143491 (Daunorubicin) 12.5 12.5 12.5 6.25 ≤ 20 ≤ 20 
NSC321239 6.25 12.5 3.125 0.39 ≤ 20 - 
NSC23128 - - - 25 - - 
NSC203328 - - - 25 - - 
NSC125910 - - - 25 - - 
NSC402959 - - - 12.5 - - 
NSC234766 - - - 12.5 - - 
NSC95609 - - - 12.5 - - 
NSC77037 (Tetrandrine) - - - 12.5 - - 
NSC274547 - - 12.5 6.25 - - 
NSC83628 (DF 8 sensitizer) - - - 25 - - 
NSC13726 - - - 12.5 ≤ 20 ≤ 20 
NSC130813 - - - 6.25 - - 
NSC41458 - - - 25 - - 
NSC169534 (Quelamycin) - - - 25 - - 
NSC44251 (Cumertilin) - - - 25 - - 
NSC166687 - - - 25 - - 
NSC59349 (3-Nortropanol) - - - 12.5 - - 
NSC109268 - - - 12.5 - - 
NSC48171 - - - 25 - - 
NSC69343 12.5 12.5 - 6.25 - - 
NSC3283 - - - 6.25 - - 
NSC71795 (Ellipticine) - - 12.5 3.125 ≤ 20 ≤ 20 
NSC356217 (HEJ-4) - - - 6.25 - - 
NSC32951 (Patulin) - - - 3.125 - - 
NSC267461(Nanaomycin A) - - - 6.25 ≤ 20 ≤ 20 
NSC312033 (Straital B) - - - 1.56 - - 
NSC106408 (Anthramycin) 25 12.5 - - - - 
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NIH Library Compound 
M. 
smegmatis 
MIC (µM) 
LB 
M. 
smegmatis 
MIC (µM) 
7H9 
M. 
smegmatis 
MIC (µM) 
C- 
M. 
smegmatis 
MIC (µM) 
N- 
M. 
bovis 
BCG 
MIC 
(µM) 
M. 
tuberculosis 
H37Ra MIC 
(µM) 
NSC134727 (Mitomycin C) 1.56 - - - - - 
NSC122819 (Teniposide) 12.5 - - - - - 
NSC659779 (2- 
Bromoascididemin) 
12.5 1.56 12.5 1.56 0.781 3.125 
NSC35611 (Solanine) - - - 6.25 ≤ 20 ≤ 20 
NSC325014 (Bactobolin) 12.5 12.5 25    
NSC661755 (Michellamine B) 25  6.25 3.125 ≤ 20 ≤ 20 
NSC526417 (Echinomycin) 1.56 3.125 6.25 3.125 ≤ 20 ≤ 20 
NSC45383 (Streptonigrin) 3.125 25 12.5 6.25 ≤ 20 ≤ 20 
NSC56346 (Rottlerin) - - - 6.25 - - 
NSC45737 (Bacitracin) 12.5 12.5 12.5 3.125 ≤ 20 ≤ 20 
NSC51001 (Carbomycin) 6.25 12.5 12.5 3.125 12.5 12.5 
NSC82151 (Daunorubicin HCl) 6.25 12.5 12.5 3.125 ≤ 20 ≤ 20 
NSC5159 (Chartreusin) 3.125 1.56 - - - - 
NSC62709 (Imidazoquinoline) 25 25 - - 50 12.5 
NSC18712 (Streptomycin 
thiosemicarbazone) 
25 12.5 25 1.56 ≤ 20 ≤ 20 
NSC125066 (Bleomycin) 1.56 1.56 1.56 0.39 3.125 1.56 
NSC31048 (Neohesperidin) 12.5 6.25 12.5 3.125 ≤ 20 ≤ 20 
NSC301739 (Mitoxantrone) - 25 12.5  ≤ 20  
NSC47151 (Neomycin, 
neosule) 
- 12.5 12.5 3.125 ≤ 20 ≤ 20 
NSC52141(Nonactin) - - - 3.125 ≤ 20 ≤ 20 
NSC67574 (Vincristine sulfate) 25 - - 6.25 ≤ 20 ≤ 20 
NSC133100 (Rifamycin SV) 25 - -    
NSC368675 (Azadirachtin) 25 - 12.5 3.125 ≤ 20 ≤ 20 
NSC34936 (Suramin, 
Germanin) 
- - - 6.25 ≤ 20 ≤ 20 
NSC9161 (Erythromycin) - - - 12.5 ≤ 20 ≤ 20 
NSC61586 (Phleomycin) 0.39 0.19 0.19 0.097 25 1.56 
NSC285116 (Siomycin A) 6.25 1.56 1.56 3.125 6.25 6.25 
NSC13252(Chlorotetracycline) 1.56 1.56 - 0.39 - - 
NSC292567 (Nigericin) - - - 6.25 ≤ 20 ≤ 20 
NSC317629 (Ketoconazole) - - - 6.25 ≤ 20 ≤ 20 
NSC319518 (Cotylenin A) - - - 6.25 ≤ 20 ≤ 20 
NSC333856 (Tetrocarcin A) - - - 6.25 ≤ 20 ≤ 20 
NSC189794 (Streptovaricin) 12.5 12.5 - - 25 6.25 
NSC3053 (Dactinomycin) 12.5 - - - - - 
NSC363182 (U-64815) 12.5 - - - 25 3.125 
 
Table 4.6: Comparison of hits from NIH Diversity Set differential media screening 
Validated M. smegmatis MIC values of NIH Diversity Set HTS hit compounds derived in 
both rich and starvation media types are presented for comparison.  These values are 
contrasted with screening results of LOPAC against slow growing mycobacterial species M. 
bovis BCG and M. tuberculosis H37Ra.
206, 220
  Details as for Table 4.4. 
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4.4.4 Implications of nutrient limited culture conditions in tuberculosis drug screening 
Screening of all chemical libraries against M. smegmatis resulted in a total of 112 hits 
detected in LB and 7H9 rich media conditions and 208 hits were detected under carbon and 
nitrogen nutrient limitation media conditions.  Of these hits, 87 were common to both rich 
media and starvation media conditions. 
Comparison with M. tuberculosis H37Ra screen results
206, 220
 showed that 75 rich media hit 
compounds also had activity against M. tuberculosis, and 95 starvation media hit compounds 
were also active against M. tuberculosis.  Of these compounds, 64 were common to both 
nutrient rich and nutrient starvation in addition to being active against M. tuberculosis 
H37Ra.  
 
Figure 4.11:  Venn diagram of validated hits from screening rich and starvation media.    
Validated hits obtained in both starvation media and rich media compared with hits derived 
from in M. tuberculosis H37Ra screens.
206, 220
 Venn diagram group totals provided are 
inclusive. 
This demonstrates the utility of modified culture conditions in anti-bacterial drug screening.  
Hartman de Bonts nutrient limited media, in particular nitrogen limitation, using M. 
smegmatis provide a high level of sensitivity to anti-mycobacterial agents during drug 
screening compared to conventional rich media types.   
Hits obtained through nutrient limitation media screening of M. smegmatis were also more 
relevant towards having activity in M. tuberculosis than hits derived from rich media 
condition screening of M. smegmatis.  Although the sensitivity of nitrogen starvation media 
to detecting inhibiting compounds was highest, over half of the compounds detected under 
nitrogen starvation conditions were not active against M. tuberculosis H37Ra, meaning hit 
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compounds must to be considered anecdotally before verification in a pathogenically relevant 
model species.  Researchers should consider the utilisation of nutrient limited culture 
conditions such as HdeB C- and N- in addition to standard nutrient rich culture conditions to 
maximise inhibitor identification when performing whole cell screens for novel anti-
mycobacterial agents. 
4.5 Summary 
In summary, the three chemical libraries that were screened previously in Chapter 3 against 
M. smegmatis cultured in rich media were also screened against M. smegmatis cultured under 
HdeB starvation media conditions of carbon and nitrogen limitation.  The inhibitory activity 
of the hit compounds identified through these screens was validated and quantified, and the 
validated hit compounds were then cross-referenced with data from library screens of a 
related screening project against M. bovis BCG and M. tuberculosis H37Ra. 
Validated hit compounds were charactered by their MIC towards M. smegmatis in the 
medium conditions in which they were detected.  Validated hit compounds were then 
investigated through database and literature searching and compounds with undesirable 
characteristics for the treatment of human tuberculosis, such as cytotoxicity or anti-cancer 
activity, or previous disclosure as an anti-bacterial activity, which detracted from the novelty 
of the inhibitor, were omitted from further research. 
Compounds that remained were then investigated using literature and database searching to 
determine their suitability as potential leads for further development as a tuberculosis 
treatment drug.   
The majority of hit compounds were discovered to have properties that rendered them 
unfavourable as tuberculosis drug development leads; however, several compounds were 
found to have positive indications and possible applicability as anti-tubercular agents, the 
most prominent of which are revisited below. 
   
The psychoactive phenothiazine compounds such as trifluoperazine have previously been 
documented as harbouring anti-tubercular activity.  The potential use of these compounds 
against TDR-TB and the development of the chemical scaffold has been urged.  The present 
research serves to reinforce those published findings.  Similarly nortriptyline, a tricyclic anti-
depressant with structural likeness to phenothiazines, was also shown to possess anti-
  CHAPTER FOUR:  SCREENING WITH MODIFIED CULTURE CONDITIONS     156 
mycobacterial activity, and our research appears to be the first reporting in the published 
literature of tricyclic anti-depressants exhibiting anti-mycobacterial activities. 
Pentamidine is used in the treatment of pneumocystis pneumonia.  The two quinoline 
compounds chloroacetoxyquinoline (silital) and primaquine are potential inhibitors of 
bacterial siderophore synthesis and an actively used malaria treatment, respectively.   
 
Cephalosporin antibiotics are generally regarded as ineffective against mycobacteria, but 
Cefdinir, a 3
rd
 generation cephalosporin antibiotic, exhibited anti-mycobacterial activity 
including activity against M. tuberculosis.  Cefdinir is a known, well tolerated antibiotic; 
thus, toxicity concerns are low.  Structural modification to enhance the lipophilicity of 
cefdinir and simultaneous administration with a β-lactamase inhibitor may enhance its 
activity to within therapeutic levels.   
Similarly the anti-fungal agent ketoconazole which is able to be orally administered was 
detected as active under nitrogen starvation conditions, contributing evidence of the possible 
novel application for this known drug in the treatment of tuberculosis. 
Chlorothalonil, an agricultural anti-fungal agent was revealed to be a potent novel inhibitor of 
mycobacteria.  Chlorothalonil is known to be well tolerated in mammals and exhibits 
favourable bioavailability in vivo.  It may be a pioneer in a new class of anti-mycobacterial 
drugs that target mycothione. 
 
The bismuth conjugated dimercaprol BisBAL was effective at inhibiting M. smegmatis in 
vitro; however, previous research in M. tuberculosis H37Rv had disregarded dimercaprol due 
to poor in vivo activity and rapid development of resistance.  However, recent evidence 
indicates this compound may be of use as an adjunct to tuberculosis treatment due to its 
interference with bacterial capsule and biofilm formation which result in bacteria being more 
susceptible to chemical and immune attack. 
 
4.5.1 Identification of the novel anti-mycobacterial agent Se-methylselenocysteine 
Se-methylselenocysteine was identified through screening for growth inhibitors of M. 
smegmatis using carbon and nitrogen nutrient limitation media, and later was also 
subsequently validated as active in 7H9 medium.  Se-methylselenocysteine, a selenium 
containing amino acid and natural product, is considered to be the most significant anti-
mycobacterial compound to be discovered though nutrient starvation condition screening.  
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This was due to the novelty of this seleno-amino acid compound class as anti-mycobacterial 
agents, it exhibited level of anti-mycobacterial activity and low indications of toxicity.  It is a 
naturally occurring compound with a number structural analogues readily available, and it is 
regularly used in humans as a dietary supplement. 
Se-methylselenocysteine was selected for further investigation into its potential as a 
tuberculosis treatment drug candidate.  This compound would not have been identified using 
conventional rich media screening.  The chemical class of seleno-amino acids is further 
explored for its anti-bacterial activity spectra, human cell line cytotoxicity in Chapter 5.   
The mechanism of action and structure-activity relationship of the seleno-amino acid class is 
then further researched in Chapter 6.
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5.1 Introduction 
Se-methylselenocysteine (SMSC) was identified to be a novel anti-mycobacterial agent 
during high throughput screening of the LOPAC library under nutrient limitation culture 
conditions of carbon and nitrogen starvation.  
SMSC was verified to have an in vitro MIC of 12.5 µM against M. smegmatis in HdeB 
carbon and nitrogen limitation broth, and produced IC50 values of 2.19 ± 0.18 µM and 0.60 ± 
0.09 µM for carbon and nitrogen limitation broth respectively.  However, SMSC had no 
discernable growth inhibiting effects under LB rich medium conditions.
122
   
The level of growth inhibiting activity produced by SMSC toward M. smegmatis is superior 
to the second-line tuberculosis treatment drug cycloserine, and is comparable to activity of 
the macrolide antibiotics such as clarithromycin. 
Due to the established use of seleno-amino acids such as SMSC in humans as a dietary 
supplementation
365
 and evidence that seleno-amino acids may confer beneficial effects 
towards a range of ailments and diseases beyond fulfilment of a dietary deficiency.
366
  SMSC 
and the chemical class of seleno-amino acids were viewed as a promising novel lead to 
further investigate in the context of their anti-mycobacterial activity and potential 
applicability to tuberculosis treatment. 
The aim of this chapter is to evaluate the potential of Se-AAs as therapeutics for human 
tuberculosis.  This is achieved by: 
 Thoughrough review of scientific literature regarding Se-AAs.  
 Confirmatory testing of Se-AA and related seleno-compound inhibitory activity 
toward mycobacterial species. 
 Testing of Se-AA and related seleno-compound inhibitory activity toward other 
microbial species, to determine Se-AA spectrum of anti-microbial activity. 
 Testing of Se-AA cytotoxicity toward mammalian cell lines. 
In order to characterise and explore the potential of seleno-amino acids as anti-tubercular 
agents, SMSC and other available seleno-amino acid compounds must be verified in terms of 
their inhibitory activity towards slow growing pathogenically relevant mycobacterial species 
such as M. bovis BCG and M. tuberculosis H37Ra.  In addition to anti-mycobacterial activity, 
the inhibitory activity of seleno-amino acid compounds toward other bacterial species must 
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also be characterised.  The toxicity of seleno-amino acids towards human cell lines must also 
be queried in order to gauge the selectivity and safety of the compounds.   
This chapter summarises published literature on seleno-amino acids, their dietary use and 
indications of biological activity.  The experimental activity of the various seleno-amino 
acids towards mycobacteria, other bacterial species, Saccaromyces and human cell lines is 
reported.  In light of the previously mentioned experimental results, the suitability of seleno-
amino acids for human therapy is discussed. 
 
5.1.1 Selenium  
Selenium (Se) is a non-metal element chemically related to sulphur.  Selenium shares many 
of chemical properties of sulphur because they both harbour six valance shell electrons and 
thus belong to the same periodic group, the chalcogens.  Selenium possesses over twice the 
atomic mass of sulphur at 78.96 compared to sulphur‟s 32.065.  This makes selenium‟s 
chemical bonds longer and weaker compared to sulphur.
367
  Selenium compounds are 
generally more nucleophilic and acidic than their sulphur bearing counterparts, at 
physiological pH this means selenol in ionised whereas the equivalent sulfhydryl is 
protonated. 
368
  Selenium is much more easily oxidised relative to sulphur.
367
 
Selenium has had a past reputation for toxicity due to observations that animals grazing 
selenium-accumulator plants such as Astragalus species or „Locoweed‟ provoked toxic 
effects.  However, it is now known the primary toxic effects of consuming such plants are 
caused by alkaloid toxins such as swainsonine present in the plant tissue.
369
 
Selenium is an essential trace nutrient, particularly in mammals.  In humans a strict minimum 
nutritional intake of 17 µg per day of selenium is required to avoid deficiency-based 
disease,
370
 and the consensus minimum intake of selenium is 20 µg per day.
371
  Selenium 
deficiency in humans may manifest as Keshan disease, named after the Keshan area in China 
where it was first observed, a congestive cardiomyopathy that is characterised by an enlarged 
heart , poor heart function and higher coincidence of other diseases such as cancer and 
stroke.
372
  Selenium deficiency is also linked to myxedematous endemic cretinism, a mental 
developmental disdisorder
373
 and Kashin-Beck disease, an osteochondropathy resulting in 
deformation, pain and limited mobility of the joints.
374
  Certain geographical regions are 
more disposed to selenium deficiency-based diseases due to the soils having low selenium 
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content.  Countries with low selenium soil include parts of China, Finland, the East United 
States and New Zealand.
375
 
Although the minimum requirement of selenium to avoid disease is 20 µg per day, the 
recommended intake of selenium is 55 µg per day for adults, with slightly higher values of 60 
µg per day recommended during pregnancy and 70 µg per day recommended during 
lactation.
376
  Regarding the toxicity of selenium in humans, the mean intake with no adverse 
effects observed is 800 µg per day which equates to 15 µg per kg bodyweight. To err on the 
side of safety 400 µg per day is the recommended maximum safe daily intake of selenium.
377
   
 
Although selenium is an essential mineral excessive intake is toxic and manifests in the 
condition selenosis. Selenosis is characterised by symptoms of malodorous breath, irritability, 
fatigue, gastrointestinal upset, discolouration of nails, hair loss and mild nerve damage.
378
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5.1.2 Seleno amino acids 
Seleno-amino acids (Se-AAs) are amino acids containing a selenium atom, the most common 
seleno-amino acids, selenomethionine (Se-met) and selenocysteine (Se-cys), hold selenium in 
place of sulphur in the sulphurous amino acids methionine and cysteine, depicted in Figure 
5.1.  Se-methylselenocysteine (SMSC) is a monomethylated derivative of Se-cys.  Se-AAs 
tend to have lower pKa and higher reduction potentials than their sulphurous equivalents.
379
 
 
Figure 5.1.  Seleno-amino acids and equivalent amino acids.   
Chemical structures of the sulphurous amino acids cysteine and methionine (top) and their 
seleno-amino acid analogues (bottom). 
Selenium serves several essential roles in biology, primarily in the form of Se-AAs.  Se-cys is 
an atypical amino acid referred to as the 21
st
 amino acid, and may be depicted by the three 
letter symbol “Sec” and one letter symbol “U”.380  Se-cys is indirectly but intentionally coded 
for in mRNA by a UGA stop codon in conjunction with a Se-cys insertion sequence which in 
bacteria is directly downstream of the UGA stop codon
381
 or in archaea and eukaryotes 
resides within the 3‟ untranslated region of mRNA.382  Se-cys plays specific roles in many 
“selenoproteins” that are found throughout all domains of life, although they are not 
ubiquitous.  In humans, for example,  25 selenoproteins have been identified.
383
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Selenium in Se-cys is ionised under biological conditions and acts as an efficient catalyst, 
more so than its sulphur counterpart.
379
  The catalytic properties of selenium are utilised by 
selenoproteins in their characteristic role of redox maintenance demonstrated by the various 
glutathione peroxidase enzymes that act as antioxidants to neutralise reactive oxygen species, 
and thioredoxin reductase enzymes that regulate thioredoxin metabolism that again ties in to 
cellular redox regulation.
375
  Another vital role of selenoproteins in humans is deiodination of 
the prohormone thyroxine to the active triiodothyronine thyroid hormone, facilitated by the 
Se-cys of iodothyronine deiodinase enzymes.
384
 
Unlike Se-cys, Se-met is not deliberately incorporated into peptides in vivo but is non-
discriminately incorporated in place of methionine, this substitution has no major discernable 
effects on protein function and is considered to be well tolerated.
385
  This incorporation of Se-
met into proteins is exploited in x-ray crystallography to resolve protein 3D structure using 
techniques of single or multi wavelength anomalous diffraction phasing, since the heavier 
selenium atom produces favourable x-ray scattering properties for structural elucidation.
386
 
Besides selenoproteins, various organic forms of selenium are accumulated in plants, with 
some species accumulating more selenium than others even in low selenium soils such as the 
agriculturally relevant Allium and Brassica species.
310
  Typically these accumulated 
organoselenium compounds are Se-cys and Se-met and their various derivatives such as allyl-
selenocysteine, γ-glutamyl-selenocysteine and methylated derivatives including se-
methylselenocysteine.
387
  The function carried out by these accumulated organoselenium 
compounds in plants is not fully understood but has been postulated to serve protective roles 
by increasing antioxidant defence and plant tolerance to stress,
388
 protecting plants from UV 
radiation,
389
 to defend plants against mammalian 
390
 and insect herbivory
391
 and in the case of 
the aforementioned allyl-, glutamyl- and methyl- derivatives to sequester away excess 
selenium in a form that is unable to cause harm via incorporation into proteins.
392
 
 
5.1.2.1 Dietary sources 
Se-AAs are present in a wide variety of commonly consumed foods,  particularly selenium-
accumulating plant crops, for example Allium species such as onion, garlic and leeks and 
Brassica species including broccoli, cauliflower and cabbage.
393
  The most selenium rich 
food source is Brazil nuts.
394
  Generally the selenium content found in plant crops is 
proportional to the selenium content of the soil in which they were grown.  The same 
principle applies to the accumulation of selenium in animals or fungi.  This has given rise to 
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the production of „selenium enriched‟ foods such as crops, eggs, yeast and meat that are 
marketed for their benefits to health.
395
 
5.1.2.2 Dietary supplementation 
A popular alternative to dietary consumption of selenium through food intake is the use of 
nutritional supplements.  Nutritional supplements are popular amongst all demographics, with 
a Canadian survey revealing that nearly two thirds of the population use some form of 
nutritional supplement.
396
  In New Zealand there are over 6000 health products currently 
being sold by more than 450 companies for an annual turnover of NZ$760 million in 2010.
397
  
Over the counter health products such as vitamins, minerals, dietary supplements, 
nutraceuticals and herbal remedies are a rapidly growing market, estimated to have a global 
value of over US$177 billion by 2013.
398
  Selenium is widely included in most multi-vitamin 
type supplements and specialised selenium supplements are available that typically deliver 
selenium in excess quantities of the recommended 55 µg per day.
399
 
Although selenium supplementation is no-doubt extremely beneficial to human health in 
circumstances of selenium deficiency,
400
 higher doses of selenium are reputed to confer 
beneficial effects to health beyond simply alleviating selenium deficiency.  These beneficial 
effects are discussed further in section 5.1.4.  There is published research-based evidence that 
supports some of the beneficial health effects of extra-dietary selenium, but a general 
scientific consensus regarding beneficial effects of high level selenium supplementation is yet 
to be established.
401
  Extra-dietary selenium supplementation of 200 µg per day is the 
generally considered dose needed to obtain beneficial health effects beyond mitigation of 
dietary insufficiency.
311
  Se-met and SMSC are known to have superior bioavailability to 
inorganic forms of selenium such as selenite and selenate.
400
   These methylated Se-AAs are 
also considered to be principally responsible for the beneficial health effects of selenium.
402
 
 
5.1.3 Bioavailability and metabolism 
In humans, selenium from food or dietary supplements is able to be absorbed both in 
inorganic forms of selenate (SeO4
2-
) and selenite (SeO3
2-
) and in organic forms such as 
seleno-amino acids.
403
  Organic selenium in the form of Se-met is absorbed 26% more 
efficiently than selenite, and Se-met also quickly reached and maintained blood 
concentrations 39% higher than selenite over a prolonged administration of 10 weeks.
404
  
Inorganic forms of selenium are also less well retained in the body compared to organic 
selenium, with inorganic selenium such as selenite having poor retention due to rapid 
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excretion in the urine as selenosugars.
405
  Based on this research, it can be concluded that 
organic forms of selenium such as Se-met exhibit superior bioavailability characteristics 
compared to inorganic forms of selenium. 
The different forms of dietary selenium are metabolised differently in mammals, the 
processes for which are depicted in Figure 5.2.  Se-AAs are subjected to direct enzymatic 
lysis, releasing selenium as volatile methylselenol from the methylated Se-met and Se-cys.
406
  
Se-met may also be indiscriminately incorporated into proteins in place of methionine, 
inadvertently serving as a catabolic reservoir of selenium, or Se-met can be converted to Se-
cys through the intermediate steps of selenocystathionine and selenohomocysteine
402
  The 
non-methylated Se-cys is enzymatically lysed to produce volatile hydrogen selenides under 
reducing conditions.
407
 Inorganic selenate is reduced to selenite, this is sequestered away by 
glutathione mediated reduction to selenodiglutathione.  Selenodiglutathione is in turn 
enzymatically reduced by glutathione reductase to glutathioselenol, this is again reduced by 
thioredoxin reductase in the presence of excess glutathione to yield hydrogen selenide.
408
   
Selenium as hydrogen selenide and methylselenol is interchangeable through the action of 
methyltransferase and demethylase enzymes.
409
  From this central point of selenium 
metabolism selenium may be utilised by selenophosphate synthase to form selenophosphate 
that can be incorporated to seryl-tRNA(sec) by selenotransferases and selenocysteine 
synthases to form Selenocysteinyl-tRNA(sec) which is specifically incorporated into 
selenoproteins.
410
    Hydrogen selenide may also be utilised in the synthesis of selenosugars 
such as methylseleno-N-acetyl-D-glucoseamine which are rapidly excreted in the urine.
411
  
Alternatively, hydrogen selenide may be oxidised to selenium dioxide creating reactive 
oxygen by-products that are potentially damaging to the cell.
412
  Jettison of methylselenol 
occurs through further methylation to dimethylselenide which is excreted through the breath 
and faeces, and the trimethylselenonium ion that is excreted in the urine.
413
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Figure 5.2.  Selenium metabolic pathway in humans.  
Adapted from Rayman et al 2008
414
 and Riaz et al 2012.
401
 
5.1.4 Biological activity indications and research  
The beneficial health effects of selenium and seleno-compounds used in quantities beyond 
nutritional sufficiency has been a controversial subject for the past decade.  Commercial 
selenium supplements have claimed many health improving effects in terms of the prevention 
or improvement of the outcomes of many ailments, including cancer, heart disease, 
Alzheimer‟s disease, arthritis, diabetes and HIV amongst other diseases.366, 415, 416  These 
claims are not always necessarily backed by convincing scientific evidence, although 
generally, claims of dietary supplements are worded in a sufficiently vague manner to avoid 
regulatory infringement.
417
  To distinguish the true health benefits of selenium and seleno-
compounds from unsubstantiated claims and provide a background on seleno-amino acids 
research, a brief synopsis of the literature regarding seleno-compound application in health is 
presented below.  Greater attention is paid to health effects attributed directly to Se-AAs 
rather than to the downstream effects of selenium supplementation.  A comprehensive review 
of the biological effects of seleno-compounds, with particular regard to organic selenium 
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compounds such as the Se-AAs, is described in the 2011 publication of Nogueira and 
Rocha.
418
 
5.1.4.1 Immune system function 
Many of the conventional beneficial health effects attributed to seleno-compounds may be 
consequences of selenium facilitation and enhancement of general immune system function.   
Selenoprotein roles in redox maintenance and mitigation of oxygen radical stress is a 
contributing factor in T-cell proliferation, activation and function.
419
  In humans dietary 
supplementation with selenium enriched yeast increased T-cell counts by 27% relative to 
placebo and enhanced immune function, measured as natural killer cell cytotoxicity.
420
   
Selenium supplementation during cancer therapy increases immune response and functional 
killing of tumour cells in squamous cell carcinoma patients.
421
  In a study of humans infected 
with attenuated polio virus, administration of selenium supplements led to  a faster clearance 
of the virus and an improved immune response, measured by increased interferon-γ and 
cytokine production, faster T-cell proliferation and an increase in helper T-cell populations 
relative to placebo.
422
 
Considering these effects of selenium towards the immune system, it is possible that the 
positive effects of selenium supplementation on inflammation, arthritis, asthma, cancer and 
infection are mediated by the improvement of immune functionality,
401, 416
 although the direct 
and indirect health effects of seleno-compounds make this difficult to distinguish in vivo.  
 
5.1.4.2 Cancer 
One of the most prominent areas of seleno-compound health research is the application of 
selenium in the prevention of cancer.  This has resulted in Se-AAs such as SMSC being 
commonly referred to as chemopreventatives.
423
   
Se-DL-met is selective in vitro in causing apoptotic death of human tumour cell lines, 
including breast cancer, melanoma, colon  cancer, prostate cancer and lung cancer with IC50 
activity ranging from 40-130 µM against neoplastic cell lines and an IC50 of 1 mM against 
normal diploid fibroblasts.
424
   
Co-administration of SMSC potentiates the anti-tumour activity of the platinum anti-
neoplastic agents cisplatin and oxaliplatin in vivo, increasing the cure rate of these 
compounds when treating advanced murine colorectal tumours. SMSC co-administration also 
conferred protection against normally lethal doses of cisplatin and oxaliplatin.
425
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Correlations between organic selenium supplementation in the form of selenium enriched 
yeast and a reduction in skin
426
 and prostate cancer
427
 incidence have been observed in 
double-blind trials.  The incidence of breast cancer has been shown to be decreased in 
individuals with higher selenium status.
428
   
The effects of selenium supplementation as selenium enriched yeast on the incidence of 
prostate cancer was measured in the nutritional prevention of cancer trial (NPC) and results 
indicated that selenium supplementation conferred as much as a 63% reduction in the 
incidence of prostate cancer.
429
  The results of the NPC trial were found to conflict with a 
later publication regarding selenium supplementation and cancer incidence: the selenium and 
vitamin E cancer prevention trial (SELECT), a large double blind clinical trial examining the 
effect of selenium and vitamin E on cancer risk in over 35,000 men with a primary focus on 
prostate cancer.  This study concluded that administration of 200 µg of Se-met per day for a 
period of 5 years did not significantly reduce the risk of localised prostate cancer;
430
 
although, there has been criticism regarding the limitations of the trial design.
431
 
 
The complex relationship between selenium supplementation and carcinogenesis continues to 
be researched.  There is evidence that Se-AAs and their metabolites can potentially reduce 
cancer risk through a variety of avenues such as direct antioxidant activity or facilitation of 
selenoprotein function in neutralising carcinogens.
432
  Se-AAs may also cause inhibition of 
cancerous tumour growth through induction of apoptosis in cancerous cells
433
 and through 
inhibition of tumour angiogenesis.
434
   
Despite this evidence, selenium supplementation has not demonstrated a reduction in cancer 
incidence during large clinical trials; thus, no universally accepted conclusion has been drawn 
regarding selenium effects on cancer incidence in humans. 
 
5.1.4.3 Diabetes 
A large double blind placebo-controlled trial concluded that 200 µg selenium per day in the 
form of selenium-enriched bakers yeast did not reduce the development of type 2 diabetes, 
and high selenium intake may even be a risk factor for disease.
435
  However, a more recent 
study which measured the correlation between selenium status determined through toenail 
selenium content concluded that higher selenium status attributed a lower risk of developing 
type 2 diabetes.
436
  It has been suggested that selenium may play a role in mammalian 
carbohydrate metabolism, and high selenium status may be as much a consequence of 
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diabetes as a causative factor with seleno-compounds and selenoprotein antioxidant activity 
interfering with insulin receptor 2
nd
 messenger H2O2.
437
 
 
5.1.4.4 Cardiovascular disease 
Low levels of plasma selenium have previously been linked to increased risk of 
cardiovascular ischemia
438
 and increased mortality in patients with acute coronary 
syndrome.
439
  As noted before, selenium deficiency can manifest as Keshan disease, a 
cardiomyopathy.  It has been reasoned that the antioxidant properties of seleno-compounds 
and selenoproteins neutralise free radicals that may damage heart tissue or oxidise lipids 
contributing to the formation of coronary plaques.
440
  Meta-analysis of recent publications 
suggest that the evidence for selenium‟s protective effects towards cardiovascular disease is 
insufficient.
441
  
 
5.1.4.5 Anti-viral  
Results of an in vitro study report that 2-8 µM Se-met caused inhibition of porcine parvovirus 
replication in a PK-15 cell culture model.  This inhibition was dose-dependant and also 
selective, not affecting growth of PK-15 cells.
197
 
Selenium deficiency in HIV infected individuals is associated with disease progression and 
decreased survival rate.
416
  Furthermore, the use of selenium supplements such as Se-met in 
HIV infected patients has shown positive effects such as improvement of CD4
+
 cell counts,
442
 
reduction in hospitalisation incidence,
443
 reduced diarrheal morbidity
444
 and synergistic 
reduction of viral load when co-administered with anti-retroviral therapy.
445
  Seleno-
compound supplementation lowers the mortality risk of children born to HIV-positive 
mothers.
446
  Although the anti-viral mechanisms of seleno-compounds are undefined, the 
beneficial effects of selenium administration in humans likely stem from a combination of 
immune function enhancement and direct anti-viral activity.  Further research in this area is 
required.
442
  Considering the co-morbidity of HIV and tuberculosis, any indications towards 
selenium supplementation improving HIV outcome is an advantage that must be exploited. 
 
5.1.4.6 Anti-microbial 
Se-AAs are not documented for their direct anti-microbial activity.  The first publication 
disclosing the direct anti-bacterial effects of seleno-amino acids is derived from the present 
research.
122
  However, the oxidant properties of organic selenium compounds have been 
suggested as having potential use in anti-microbial applications.
447
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Selenium is a promising adjunct to anti-microbial therapy.  Selenium co-administered with 
the aminoglycoside gentamycin confers a protection from gentamycin-induced 
nephrotoxicity, by preventing oxidative damage and subsequent renal tubular epithelial 
necrosis.
448
  Although not a direct anti-microbial effect, this is a positive indication for 
selenium supplementation in antibiotic therapy, considering the use of aminoglycosides as 
tuberculosis treatment is reserved to a second line drugs because of significant oto- and 
nephro-toxic side effects.
449
  Similarly, selenium co-administration with ciprofloxacin 
prevented renal scarring in bacterial pyelonephritis induced by E. coli in a murine in vivo 
model.  This is likely to be due to attenuation of damaging oxygen radicals and inflammatory 
responses.
450
  In chronic bacterial prostatitis induced by E. coli selenium treatment reduced 
inflammatory cell infiltration and inhibited bacterial infection of prostate tissue, producing 
3.866 ± 0.563 log10 CFU/g compared with 3.551 ± 0.229 for ciprofloxacin antibiotic control 
and 6.414 ± 0.885 for the no treatment control.  Administration of both selenium and 
ciprofloxacin was the most effective treatment reducing prostate tissue bacterial counts to 
1.344 ± 0.241 log10 CFU/g.
451
 
Organic selenium-enriched probiotic bacteria and their extracts antagonise E. coli 
pathogenesis and improve outcomes of murine infection in vivo
452
 and complementation with 
selenium and vitamin E for amoxicillin treatment of bovine mastitis improves treatment 
efficacy.
453
   
In regards to mycobacterial disease, decreased serum selenium levels are associated with 
higher tuberculosis incidence in HIV patients, with HIV and TB co-infected patients having 
lower selenium levels than patients with either disease alone.
454
   
In another study, HIV infected individuals undergoing highly-active antiretroviral therapy 
were 13 times more likely to develop mycobacterial disease (75% of which was tuberculosis) 
if serum selenium levels were less than 135 µg/L compared to patients with higher selenium 
levels.  This study suggests a role of selenium in mycobacterial clearance.
455
 
 
Anti-microbial preparations have been fabricated that utilise reactive oxygen radical 
generation catalysed by selenium to produce their anti-microbial activity.  These consisted of 
selenium covalently attached to bacteriophage and peptides that target specific bacterial 
species, delivering the selenium to the target species cell membrane and subsequently 
damaging the bacteria by generation of reactive oxygen species (ROS).  This approach was 
successful in killing E. coli but not P. aeruginosa.
456
  In the same study, similar ideology was 
utilised by covalently attaching selenium to a acetoacetoxyethylmethacrylate (AAEMA) 
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polymer (Figure 5.3) for implementation as a surface coating of cellulose, successfully 
inhibiting biofilm formation of S. aureus and P. aeruginosa.  This method could potentially 
be commercially utilised in manufacture of anti-bacterial wound dressings.
456, 457
  This 
concept was further explored in selenium coating of reverse osmosis membranes to prevent 
fouling by microorganism growth and utilised Se-AAEMA polymer or selenocystamine 
monomers, both of which were successful in reducing S. aureus biofilm formation by at least 
two orders of magnitude.
458
  Selenium nanoparticles were researched by the same group and 
found to be inhibitory toward the in vitro growth of S. aureus and also to have some 
bactericidal activity.
459
 
 
Figure 5.3.  Di-Se-AAEMA.   
Used in the covalent attachment of selenium to cellulose and reverse osmosis membranes.
456
 
In terms of selenium compounds directly used as antibiotics, ebselen was described in a 2007 
review of organoselenium compounds as the most effective anti-bacterial organoselenium 
agent.
460
  Ebselen is an antioxidant that chemically mimics the activity of glutathione 
peroxidise by reducing reactive oxygen/nitrogen species and is itself then reduced by 
glutathione or equivalent free thiols.
461
  Ebslen has an impressive MIC of 1.56 µg/mL (~5.7 
µM) against methicillin resistant strains of S. aureus in vitro and also has strong in vitro 
activity against Enterococcus faecalis and B. subtilis with an MIC of 0.39 µg/mL (~1.4 µM) 
toward these bacterial species.  The selenium is essential for anti-microbial activity, with 
sulphur substituted ebselen losing activity.
462
  Ebselen is considered non-toxic to mammals
463
 
and has a murine LD50 of 6180 mg/kg.
464
   
 
Figure 5.4.  Chemical structure of ebselen. 
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Ebselen (Figure 5.4) has also demonstrated applicability in the treatment of cancers and 
improvement of the outcome of acute ischemic stroke in humans.  This is thought to be due to 
its antioxidant and anti-inflammatory activity.
464, 465
  Ebselen is reported to be an inhibitor of 
M. tuberculosis H37Rv in addition to M. tuberculosis H37Rv dTDP-6-deoxy-L-lyxo-4-
hexulose reductase, membrane-associated serine protease and fructose-bisphosphate aldolase 
enzymes; however, no inhibitory values are listed.
237
  Ebselen is present in both the LOPAC 
and Spectrum Collection chemical libraries but was not detected as an inhibitor of M. 
smegmatis in any rich or starvation media conditions.  This may be due to the mechanism of 
ebselen, proposed to be disruption of proton-translocation at the cell membrane and inhibition 
of protein gradient-dependant ATPase, which renders ebselen more potent towards yeasts and 
Gram positive bacterial species (IC50 = 2-5 µM) than Gram negative species (IC50 = >80 
µM).
466
  This potency reduction may also apply towards mycobacteria due to their resilient 
hydrophobic cell wall structure.
467
  Many derivatives of ebselen have been synthesised and 
have demonstrated anti-viral, anti-bacterial and anti-fungal activity, with some demonstrating 
improved activity towards Gram negative bacteria.
468, 469
 
Ebselen is also an effective in vitro inhibitor of P. falciparum, disrupting the function of 
ferredoxin-NADP+ reductase but is ineffective against the M. tuberculosis FprA ferrodoxin-
reductase, another potential basis for the inactivity of ebselen in the mycobacterial screens of 
the present research. 
  
Selenoxanthene and selenopyrylium compounds have been found to have modest inhibitory 
activity toward E. coli and greater activity toward S. aureus, although it is difficult to gauge 
the activity levels of these compounds since no antibiotic controls were present in the 
assay.
470
  This is an interesting result in light of the thioxanthene and structurally similar 
compounds identified as mycobacterial inhibitors in the screening chapters of this thesis.  A 
variety of further quinolineselenol and pyridineselenol derivatives were then synthesised and 
tested for anti-bacterial and anti-fungal activity.  Two of these organo-selenium compounds 
(hydrazine-dimethyl-pyridoselenolo-pyrimidine and cyanomethyl-phthalimido-
glycylquinoline-phthalimido-glycylquinolineselenol) exhibited growth inhibiting activity 
towards a spectrum of bacterial species including S. aureus, E. coli, P. aeruginosa, S. 
marcescens and Bacillus cereus in addition to having inhibitory activity against a range of 
fungal species.  It was noted that the activity of these organo-selenium compounds is 
dependant on cyano and phthalimido groups in the quinoline ring, or a pyridine nucleus 
hydrazino group, indicating the mechanism of action may not be selenium dependant.  The 
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authors speculate that the mechanism of activity is due to the cyano or quinoline moieties or 
amino-pyrimidine nucleus.  These derivatives were tested by a disc diffusion zone of 
inhibition method; thus, it is difficult to quantify their inhibitory properties; however, the 
authors note the organo-selenium compounds activity is less than the control antibiotics 
chloramphenicol and clotrimazole.
471
 
Selenium substituted morpholines inhibit in vitro growth of S. aureus, possibly by production 
of damaging free radicals.  N,N-methylene-biselenomorpholine was the most effective 
inhibitor tested, and its higher level of activity is postulated to be due to the hydrocarbyl 
group increasing the affinity for the hydrophobic bacterial cell, and the higher selenium 
content giving a greater capacity for radical generation.  It is unfortunate the inhibitory 
profiles of morpholines or thiomorpholines were not juxtaposed with the selenomorpholine 
results for structure activity comparison.
472
  Selenium substituted derivatives of sulfa drugs 
were synthesized for the purpose of exploring their anti-bacterial activity against E. coli, S. 
aureus and Serratia marcescens.  A selenium substituent of sulfacetamide and pyrimidine 
showed bactericidal activity against all aforementioned test species with the lowest MIC of 
all compounds tested being 10 mg/mL.   This is high compared to known anti-bacterial 
compounds.
473
 
 
5.2 Results 
After identifying SMSC as an anti-mycobacterial agent in high throughput screening and 
verification of its anti-mycobacterial activity in downstream validation assays using M. 
smegmatis, SMSC and other commercially available structurally similar Se-AAs, Se-cys and 
Se-met, were purchased to determine the inhibitory activity of these chemicals towards M. 
smegmatis.  Additional non-selenium amino acids, including cysteine s-methylcysteine, s-
ethylcysteine and methionine and non-amino acid selenium compounds were also purchased 
and assessed for their anti-mycobacterial activity to provide a basis for structure-activity 
relationship analysis. 
Quantitative dose-response assays were carried out as described in Chapter 2.2.4, initially 
using M. smegmatis MC
2
155.  SMSC and Se-L-met exhibited appreciable anti-mycobacterial 
activity of < 50 µM; therefore, these and other the selenium compounds methylseleninic acid 
and sodium selenite were used as a seleno-compound panel in the testing of susceptibility 
toward the slow growing mycobacterial species M. bovis BCG and M. tuberculosis H37Ra. 
Gram negative bacterial species E. coli, V. harveyi and P. aeruginosa, Gram positive S. 
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aureus and the eukaryotic yeast S. cerevisiae were also tested for susceptibility to Se-AAs to 
elucidate the activity spectrum of these compounds toward other pathogenically relevant 
microbes.  Susceptibility testing against pathogenic tuberculosis strains H37Rv and 
CDC1551 was kindly performed by Dr. Ronan O‟Toole and the research group of Professor 
William R. Bishai.  The amount of compounds tested was limited, however.  Similarly testing 
against human cell lines was kindly performed by Rekha Veliyayi Murikoli, but the extent of 
compound testing was also limited as above.  Results are presented in a tabulated format for 
major inhibitory activity measured by MIC across different medium conditions for the 
various species tested.  Pertinent inhibition results are subsequently presented in graphical 
format, including differential culture conditions.  The best available viability signal(s) 
applicable (OD600, GFP, resazurin reduction as described in section 2.2.4) to the bacterial 
species and culture condition were used for determination and plotting of inhibition dose-
response figures and the derived MIC values are tabulated for quick reference. 
5.2.1 Bacterial Species 
5.2.1.1 M. smegmatis MC
2
155 
Compound M. smegmatis MC
2
155 pSHIGH_HSP60 MIC (µM) 
 LB 7H9 HdeB C- HdeB N- 
Se-methylseleno-DL-cysteine > 2000 15.6 12.5 7.8 
Seleno-DL-cysteine > 2000 50 25 25 
Seleno-DL-methionine > 2000 31.2 15.6 15.6 
Seleno-L-methionine > 2000 15.6 7.8 7.8 
Seleno-DL-cystine > 2000 250 125 125 
     
DL-cysteine > 2000 > 2000 > 2000 > 2000 
DL-methionine > 2000 > 2000 > 2000 > 2000 
s-methyl-L-cysteine > 2000 > 2000 > 2000 > 2000 
s-ethyl-L-cysteine > 2000 > 2000 > 2000 > 2000 
     
Sodium selenite > 2000 500 500 250 
Diphenyl-selenide 1000 1000  1000 1000 
Benzeneseleninic anhydrous 1000 500 500 500 
Benzeneseleninic acid 2000 500 1000 500 
4-chloro benzeneseleninic acid 1000 2000 1000 125 
Methylseleninic acid > 2000 31.2 125 62.5 
Seleno-urea > 2000 > 2000 > 2000 > 2000 
1,1-dimethyl-2-selenourea > 2000 2000 > 2000 > 2000 
Ebselen 500 62.5 62.5 31.2 
Table 5.1:  Inhibitory activity of seleno-compounds against M. smegmatis.   
Inhibition of Se-AAs and related compounds measured by M. smegmatis MIC from quantitative 
dose-response assays using multiple culture conditions. 
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Figure 5.5a:  Dose-response curves of selenium compound inhibition against M. 
smegmatis.  Triplicate quantitative growth inhibition experiments of M. smegmatis against a 
panel of selenium compounds.  Normalised GFP and OD600 growth signals relative to a 
negative control (no compound, 100% growth) are provided, media conditions are 
distinguished by line colour as denoted in the central key.  
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Figure 5.5b:  Dose-response curves of selenium compound inhibition against M. 
smegmatis (continued).  Details as per figure 5.5a. 
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The use of M. smegmatis as the primary mycobacterial model organism was extended in this 
section, with all compounds being tested for inhibitory activity towards M. smegmatis using 
four differential culture conditions. 
 
Se-L-met exhibited the greatest inhibitory activity with a 7.8 µM MIC in carbon and 
nitrogen-limited medium and 15.6 µM in 7H9 medium.  It is noted that the pure levo isomer 
of Se-met exhibited twice the anti-mycobacterial activity of the racemic dextro-levo mixture.  
This is somewhat expected given the prevalence of L optical isomers of amino acids in 
biology.  It is presumed this optical isomerism linked activity extends to all seleno-amino 
acids such as SMSC; however, the appropriate chemicals could not be sourced to confirm 
this. 
SMSC (DL) exhibited similar activity to Se-L-met, demonstrating an MIC toward M. 
smegmatis of 7.8 µM in nitrogen-limited medium, 12.5 µM in carbon-limited medium and 
15.6 µM in 7H9 medium.  This trend in susceptibility based on media conditions extended to 
all Se-AAs, with LB cultures unsusceptible to inhibition by Se-AA compounds at the highest 
concentrations tested of 2 mM. 
Se-DL-cys demonstrated less activity than its methylated analogue SMSC, and the di-
selenocysteine conjugate, seleno-DL-cystine, exhibited further reduced activity again, 
although this observation could be linked to the lower water solubility of these compounds. 
 
Structurally similar amino acids containing the usual sulphur rather than selenium including 
cysteine, methionine and the methyl- and ethyl- derivatives of cysteine exhibited no 
inhibitory activity towards M. smegmatis as expected, implicating the selenium atom in the 
bioactivity of Se-AAs. 
 
Non amino-acid selenium compounds exhibited poor inhibitory activity against M. smegmatis 
growth regardless of the media conditions used.  Exceptions to this were methylseleninic acid 
that demonstrated reasonable inhibitory activity with an MIC of 31.2 µM in 7H9, and 62.5 
µM in nitrogen-limited media.  Also the organic selenium compound ebselen showed 
reasonable inhibitory activity toward M. smegmatis with an MIC of 62.5 µM in 7H9 and 
carbon-starvation conditions and 31.2 µM in nitrogen-starvation culture conditions.  It should 
be noted that ebselen had poor solubility in all media types at concentrations above 500 µM; 
therefore, the inhibition assay curves in Figure 5.5 using OD600 data are misleading.  The 
curves based on GFP data, however, overcome this problem. 
  CHAPTER FIVE:  SELENO-AMINO ACIDS     178 
 
Based on these activity results in M. smegmatis the methylated seleno-amino acids SMSC 
and Se-L-met along with the non-amino acid selenium compounds methylseleninic acid and 
sodium selenite were selected as a panel of selenium compounds to use in testing other 
bacterial and fungal species for inhibitory activity. 
 
5.2.1.2 M. bovis BCG 
Compound M. bovis BCG pSHIGH_HSP60 MIC (µM) 
 7H9+ Medium 7H9- Medium 
Se-methylseleno-DL-cysteine 62.5 31.25 
Seleno-L-methionine 31.25 31.25 
Methylseleninic acid 125 62.5 
Sodium selenite > 2000 2000 
 
Table 5.2:  Inhibitory activity of seleno-compounds against M. bovis BCG.   
Measured by M. bovis BCG MIC from quantitative dose-response assays in nutrient rich and 
nutrient limited 7H9 culture conditions. 
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Figure 5.6:  Dose-response curves of selenium compound inhibition against M. bovis 
BCG. Triplicate quantitative growth inhibition experiments of M. bovis BCG against a panel 
of selenium compounds.  Normalised resazurin reduction growth signal relative to a negative 
control (no compound, 100% growth) is shown, media conditions are distinguished by line 
colour as denoted in the central key. 
 
Testing of the seleno-compound suite against the vaccine strain M. bovis BCG yielded similar 
results to those encountered in M. tuberculosis H37Ra.  SMSC and Se-L-met were the most 
active compounds tested with an MIC value of 31.25 µM in nutrient limitation 7H9 medium, 
Se-L-met had the same MIC in 7H9 media however SMSC had a higher MIC of 62.5 µM in 
7H9 culture conditions.  Methylseleninic acid exhibited some inhibitory activity towards M. 
bovis BCG but less than that observed in M. tuberculosis H37Ra and sodium selenite did not 
completely inhibit the growth of M. bovis BCG at the highest concentration tested of 2 mM. 
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5.2.1 3 M. tuberculosis H37Ra 
Compound M. tuberculosis H37Ra MIC (µM) 
 7H9+ Medium 7H9- Medium 
Se-methylseleno-DL-cysteine 31.25 15.6 
Seleno-DL-cysteine 125 250 
Seleno-L-methionine 15.6 15.6 
Methylseleninic acid 31.25 31.25 
Sodium selenite > 2000 > 2000 
Ebselen 62.5 N/A 
Table 5.3:  Inhibitory activity of seleno-compounds against M. tuberculosis H37Ra.  
Measured by M. tuberculosis H37Ra MIC by quantitative dose response assay in nutrient rich 
and nutrient limited 7H9 culture conditions. 
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Figure 5.7:  Dose-response curves of selenium compound inhibition vs M. tuberculosis H37Ra. 
Triplicate quantitative growth inhibition experiments of M. tuberculosis H37Ra against a panel of 
selenium compounds.  Normalised resazurin reduction growth signal relative to a negative control 
(no compound, 100% growth) is shown, media conditions are distinguished by line colour as 
denoted in the central key. 
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Based on the range of selenium compounds and non-selenium containing amino-acids that 
were assayed in M. smegmatis, the best inhibitory activity was observed in the methylated 
seleno-amino acids SMSC and Se-met.  Analogous non-selenium containing amino acids that 
were inactive towards M. smegmatis, and are presumed to be inactive against slow-growing 
and pathogenic mycobacterial species, were not further tested in slow growing mycobacterial 
species.  Non-amino acid selenium containing compounds were also largely inactive towards 
M. smegmatis, this inactivity is presumed to extend toward other slow-growing and 
pathogenic mycobacterial species; therefore, they also were not tested in slow growing 
mycobacterial species.  Methylseleninic acid and ebselen were exceptions, exhibiting 
reasonable anti-mycobacterial activity towards M. smegmatis and these were followed up 
with testing against all bacterial species for methylseleninic acid and testing against M. 
tuberculosis H37Ra for ebselen since its activity against other bacterial species has been 
previously investigated.
466
 
 
An extended suite of selenium compounds were tested against M. tuberculosis H37Ra under 
7H9 and nutrient limited 7H9 conditions.  The activity of these compounds in M. tuberculosis 
H37Ra was similar to the activity observed when tested against M. smegmatis in 7H9 media 
conditions.  The use of nutrient limited 7H9 medium evoked mixed responses in the 
inhibitory activity of compounds tested.  For example SMSC had an MIC of 31.25 µM in 
7H9 culture conditions but exhibited stronger inhibitory activity of 15.6 µM MIC in nutrient 
limited 7H9 culture.  Conversely, Se-DL-cys demonstrated poor activity with an MIC of 125 
µM in 7H9, and this activity was further reduced by culturing in nutrient-limited 7H9 
medium resulting in a MIC of 250 µM.  These results indicate that the nutrient-limited 7H9 
conditions used do not substantially increase the sensitivity of M. tuberculosis H37Ra to Se-
AA inhibition. 
 
Se-L-met demonstrated the greatest inhibitory activity of the seleno-compounds tested with 
an MIC of 15.6 µM in both nutrient-limited and regular 7H9 culture conditions.  
Methylseleninic acid was also inhibitory in both culture conditions at 31.25 µM; whereas, 
sodium selenite did not completely inhibit M. tuberculosis H37Ra growth at the highest 
concentration tested of 2 mM.  Ebselen exhibited inhibitory activity with an MIC of 62.5 µM 
in 7H9 but unfortunately was not able to be tested in nutrient limitation 7H9 medium. 
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5.2.1.4 M. tuberculosis H37Rv and CDC1551 
Compound M. tuberculosis H37Rv IC90 (µM) 
 7H9+ Medium 
Se-methylseleno-DL-cysteine 5 µg / mL ( 22.88 µM )* 
Se-methylseleno-DL-cysteine 50 † 
Seleno-DL-methionine 50 † 
Seleno-DL-cystine (NSC172800) 100 † 
Selenocystathionine (NSC90812) > 100 † 
Aminoethylselanylpropanoic acid (NSC261137) > 100 † 
Selenohomolysine (NSC282139) > 100 † 
Aminoethyldiselanylethylazanium (NSC308820) > 100 † 
 
Table 5.4:  Inhibitory activity of seleno-compounds against M. tuberculosis H37Rv.  
Measured by M. tuberculosis H37Rv MIC in nutrient rich 7H9 culture conditions. 
*IC90 result obtained by experiments kindly performed by the research group of Professor William R. Bishai at Johns 
Hopkins School of Medicine, Baltimore, Maryland through the TAACF program. 
†IC90 result obtained by experiments kindly performed by Dr. Ronan O‟Toole at Johns Hopkins School of Medicine, 
Baltimore, Maryland. 
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Figure 5.8:  Dose-response curves of selenium compound inhibition vs M. tuberculosis 
H37Rv.  
Triplicate quantitative growth inhibition experiments of M. tuberculosis H37Rv against 
selenium compounds.  Normalised resazurin reduction growth signal relative to a negative 
control (no compound, 100% growth) is shown. 
Compound M. tuberculosis CDC1551 IC90 (µM) 
 7H9+ Medium 
Se-methylseleno-DL-cysteine 2 µg / mL (9.15 µM)* 
 
Table 5.5:  Inhibitory activity of seleno-compounds against M. tuberculosis CDC1551.  
Measured by M. tuberculosis CDC1551 MIC in nutrient rich 7H9 culture conditions. 
*IC90 result obtained by experiments kindly performed by the research group of Professor William R. Bishai at Johns 
Hopkins School of Medicine, Baltimore, Maryland through the TAACF program. 
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Considering the favourable inhibitory activity of the seleno-amino acids against M. 
tuberculosis H37Ra, the activity of this class of compounds was further queried in the 
virulent tuberculosis strain H37Rv, with experiments kindly performed by Dr. Ronan O'Toole 
at the facilities of John Hopkins School of Medicine.  Due to these experiments being 
outsourced, complete data sets for each compound were not available; therefore, not all dose-
response graphs are presented.   
Using original chemical stocks of SMSC an initial IC90 result of 5 µg / mL (22.88 µM) was 
obtained against H37Rv using a standard MTT assay protocol against M. tuberculosis H37Rv 
cultured under 7H9 medium conditions.  However, subsequent testing using the same 
chemical stocks resulted in an MIC of 50 µM, indicating that there may have been some 
degradation of the compound through storage or freeze/thaw cycling, and this result requires 
further validation. 
 
Several other seleno-amino acids and seleno-compounds were obtained through the NIH 
Developmental Therapeutics Programme repository.  With the exception of Se-DL-met that 
exhibited an IC90 of 50 µM, and Se-DL-cys, with an IC90 of 100 µM, none of these 
compounds exhibited appreciable anti-tubercular activity at the 100 µM concentration tested. 
 
The sensitivity to SMSC of the highly transmissible and reactive oxygen/nitrogen species 
resistant M. tuberculosis CDC1551 strain
474
 was also investigated, with experiments kindly 
performed by the research group of Professor William Bishai at Johns Hopkins School of 
Medicine.  It was found that CDC1551 cultured in 7H9 medium was more sensitive to growth 
inhibition by SMSC with an IC90 of 2 µg / mL (9.15 µM). 
 
These results of inhibitory activity against virulent strains of M. tuberculosis are good 
indications for the potential development of seleno-amino acids as anti-tubercular agents; 
however, further testing in these and other virulent strains including drug resistant isolates is 
required. 
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5.2.1.5 S. aureus  
Compound S. aureus Newman pFDHL::GFP MIC (µM) 
 LB Medium M9 C- Medium 
Se-methylseleno-DL-cysteine > 2000 > 2000 
Seleno-L-methionine > 2000 > 2000 
Sodium selenite 250 1000 
Methylseleninic acid 1000 > 2000 
 
Table 5.6:  Inhibitory activity of seleno-compounds against S. aureus.   
Measured by S. aureus MIC from quantitative dose response assay in nutrient rich LB and 
nutrient limited M9 culture conditions. 
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Figure 5.9:  Dose-response curves of selenium compound inhibition against S. aureus. 
Triplicate quantitative growth inhibition experiments of S. aureus against selenium 
compounds.  Normalised resazurin reduction growth signal (LB) and GFP emission (M9) 
relative to a negative control (no compound, 100% growth) are shown. 
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Selenium compounds had little inhibitory effects towards S. aureus cultured in the rich media 
conditions of LB.  Minor inhibition of growth was observed for SMSC and Se-L-met at high 
concentrations, but both of these compounds failed to completely inhibit S. aureus growth 
even at the highest concentration tested of 2 mM.  The non-amino acid selenium compounds 
methylseleninic acid and sodium selenite caused complete growth inhibition under rich media 
conditions at concentrations of 1000 and 250 µM, respectively, this is considered to be low 
inhibitory activity. 
 
Nutrient limitation conditions made some difference in the sensitivity of S. aureus to the 
seleno-compounds; however, this was insufficient to impact the MIC values.  SMSC, Se-L-
met and methylseleninic acid exhibited dose-dependant inhibition but were unable to fully 
inhibit S. aureus growth at the highest concentration of 2 mM tested.  Sodium selenite 
elicited a similar inhibition response in M9 medium as it did in LB; however, a four-fold rise 
in MIC was observed in M9 minimal medium. 
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5.2.1.6 E. coli 
Compound E. coli DH5α pOT11 MIC (µM) 
 LB Medium M9 C- Medium 
Se-methylseleno-DL-cysteine > 2000 500 
Seleno-L-methionine > 2000 2000 
Sodium selenite > 2000 2000 
Methylseleninic acid 1000 2000 
 
Table 5.7:  Inhibitory activity of seleno-compounds against E. coli.   
Measured by E. coli MIC in nutrient rich LB and nutrient limited M9 culture conditions. 
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Figure 5.10:  Dose-response curves of selenium compound inhibition against E. coli.  
Triplicate quantitative growth inhibition experiments of E. coli against selenium 
compounds.  Normalised resazurin reduction growth signal (LB) and GFP emission (M9) 
relative to a negative control (no compound, 100% growth) are shown. 
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The seleno-amino acids SMSC and Se-L-met exerted no discernable inhibitory effects 
towards E. coli under rich LB culture conditions.  In minimal M9 culture conditions SMSC 
had an MIC of 500 µM and Se-L-met had an MIC of 2 mM which is considered to be a very 
low level of inhibitory activity. 
Methylseleninic acid displayed similar low inhibition with an MIC of 1 mM under LB 
conditions and 2 mM under M9 media conditions.  Sodium selenite also showed low 
inhibitory properties towards E. coli with an MIC 2 mM under M9 media and an LB MIC 
unobtainable; although, some inhibition was observed in LB it was incomplete at the highest 
concentration of 2 mM tested. 
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5.2.1.7 P. aeruginosa  
Compound P. aeruginosa PA01 MIC (µM) 
 LB Medium M9 C- Medium 
Se-methylseleno-DL-cysteine > 2000 > 2000 
Seleno-L-methionine 1000 > 2000 
Sodium selenite > 2000 > 2000 
Methylseleninic acid > 2000 > 2000 
 
Table 5.8:  Inhibitory activity of seleno-compounds against P. aeruginosa.  Measured by 
P. aeruginosa MIC in nutrient rich LB and nutrient limited M9 culture conditions. 
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Figure 5.11:  Dose-response curves of selenium compound inhibition against P. 
aeruginosa.  
Triplicate quantitative growth inhibition experiments of P. aeruginosa against selenium 
compounds.  Normalised resazurin reduction growth signal (LB) and OD600 absorbance (M9) 
relative to a negative control (no compound, 100% growth) are shown. 
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P. aeruginosa was not inhibited by SMSC in LB medium.  In M9 minimal medium some 
inhibition was observed at concentrations of 250 µM and above; however, this inhibition was 
variable and inconsistent with complete inhibition never achieved.  Se-L-met evoked better 
inhibition response against P. aeruginosa with an MIC of 1 mM in LB and strong inhibition 
in minimal M9 medium of approximately 80% at concentrations of 125 µM and above; 
however, despite exhibiting a good dose response curve Se-L-met did not achieve total 
inhibition of P. aeruginosa growth. 
 
Methylseleninic acid had no effect on the growth of P. aeruginosa in LB medium; however, 
under M9 minimal medium, growth was inhibited again to approximately 80% at 
concentrations of 125 µM and above, but complete growth inhibition was never seen.  High 
concentrations of sodium selenite precipitated under LB medium to a brick-red presumably 
elemental selenium (Se
0
).  This interfered with the OD600 readings of the assay; however, 
bacterial growth was observed even at the highest concentration tested of 2 mM.  Under M9 
medium conditions dose-response inhibition was observed, but growth of P. aeruginosa was 
not completely inhibited in triplicate even at the highest concentration tested. 
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5.2.1.8 V. harveyi 
Compound V. harveyi pOT11 MIC (µM) 
 LB Medium M9 C- Medium 
Se-methylseleno-DL-cysteine 250 1000 
Seleno-L-methionine 250 250 
Sodium selenite > 2000 250 
Methylseleninic acid 500 250 
 
Table 5.9:  Inhibitory activity of seleno-compounds against V. harveyi.  Measured by V. 
harveyi MIC in nutrient rich LB and nutrient limited M9 culture conditions. 
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Figure 5.12:  Dose-response curves of selenium compound inhibition against V. harveyi. 
Triplicate quantitative growth inhibition experiments of V. harveyi against selenium 
compounds.  Normalised resazurin reduction growth signal (LB) and GFP emission (M9) 
relative to a negative control (no compound, 100% growth) are shown. 
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SMSC and Se-L-met demonstrated complete inhibition of V. harveyi (also known as V. 
anguillarum or Listonella anguillarum) growth at concentrations of 250 µM and above in 
rich LB medium.  The same level of inhibition was observed for Se-L-met in minimal 
medium; however, SMSC had a four-fold higher MIC of 1000 µM in minimal medium. 
 
Methylseleninic acid produced similar MIC values against V. harveyi in both rich and 
minimal media types with M9 culture conditions being two-fold more susceptible to 
inhibition with an MIC of 250 µM.  Sodium selenite produced a stronger inhibitory response 
against V. harveyi cultured under minimal medium conditions with an MIC of 250 µM where 
as LB medium conditions caused precipitation of red elemental selenium and failed to inhibit 
V. harveyi growth at the highest concentration tested of 2 mM. 
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5.2.2 Eukaryotic Species    
5.2.2.1 S. cerevisiae 
 S. cerevisiae MIC (µM) by media type 
 SC Medium 0.5x SPO Medium 
Compound BY4741 
haploid 
BY4743 
diploid 
BY4741 
haploid 
BY4743 
diploid 
SMSC > 2000 > 2000 > 2000 > 2000 
Se-L-Met 125 125 62.5 125 
Methylseleninic Acid > 2000 2000 > 2000 > 2000 
Sodium Selenite 1000 > 2000 1000 > 2000 
Table 5.10:  Inhibitory activity of seleno-compounds against S. cerevisiae.   
Measured by S. cerevisiae MIC in nutrient rich SC and nutrient limited SPO culture 
conditions. 
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 Figure 5.13a:  Dose-response curves of selenium compound inhibition against S. cerevisiae.  
Triplicate quantitative growth inhibition experiments of S. cerevisiae against selenium 
compounds.  Normalised resazurin reduction growth signal relative to a negative control (no 
compound, 100% growth) is shown. 
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Figure 5.13b:  Dose response curves of selenium compound inhibition against S. 
cerevisiae (cont).   
 
Haploid (BY4741) and diploid (BY4743) strains of S. cerevisiae were tested for sensitivity to 
the panel of selenium compounds to gauge the anti-fungal activity of the compounds and also 
provide an indication of activity towards eukaryotic cells which may provide clues to the 
mammalian toxicity of the selenium compounds.
475
 
 
Under sporulation (0.5x SPO) minimal medium conditions SMSC showed reduction of 
resazurin dye at high concentrations, although this did not occur in the no-cell controls and 
may therefore encourage or be a consequence of yeast metabolism.   Regardless SMSC 
exerted little inhibitory effect upon haploid or diploid yeast strains in 0.5x SPO minimal 
media conditions.  Under rich synthetic complete (SC) medium conditions, SMSC 
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demonstrated a small yet incomplete degree of inhibition towards both haploid and diploid 
yeast strains, with the inhibition more prominent in the haploid strain. 
 
Se-L-met showed complete inhibition of both haploid and diploid S. cerevisiae growth under 
both media conditions, with an MIC of 125 µM in the haploid under rich SC medium and the 
diploid under both media types.  A lower MIC of 62.5 µM was observed for the haploid 
strain under minimal medium conditions.  
 
High concentrations of methylseleninic acid also appeared to reduce resazurin in SPO 
minimal medium conditions, resulting in an erratic dose-response pattern.  Complete 
inhibition was observed only for the haploid/diploid strain in rich SC medium at the highest 
concentration tested of 2 mM.  The haploid strain under both media conditions and the 
haploid/diploid under SPO starvation conditions were not completely inhibited by 
methylseleninic acid. 
 
Sodium selenite exhibited a typical dose-response curve in the haploid strain under both 
media conditions, with an MIC of 1 mM under both media conditions.  The haploid/diploid 
strain showed more resistance to inhibition by sodium selenite, exhibiting a dose-response 
curve with incomplete inhibition at the highest concentration tested of 2 mM. 
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5.2.2.2 Mammalian cell lines  
Compound Human Cell Line IC50 (µM) 
 HL-60 J-774 Vero 
Se-methylseleno-DL-cysteine 73.03 ± 16.73 > 250 > 100 
Seleno-DL-methionine NT NT > 100 
 
Table 5.11:  Inhibitory activity of Se-AAs against HL-60, J-774 and Vero cell lines.  
Measured by MTT assay, HL-60 and J-774 experiments kindly performed by Rekha Veliyayi 
Murikoli.  Vero cell assays were kindly performed by Dr. R. O‟Toole.  NT = not tested. 
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Figure 5.14:  Dose-response curves of selenium compound inhibition against HL-60, J-
774 and Vero cell lines.  
Measured by MTT assay, HL-60 and J-774 experiments kindly performed by Rekha Veliyayi 
Murikoli.  Vero cell assays were kindly performed by Dr. R. O‟Toole. 
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macrophage (J-774) and monkey kidney epithelial (Vero) cell lines.  HL-60 and J-774 
cytotoxicity assays were kindly performed by Rekha Veliyayi Murikoli and Vero cell assays 
were kindly performed by Dr. R. O‟Toole using the MTT assay protocol described in Chapter 
2.5.1.  Unfortunately, other selenium compounds were not able to be assessed for 
cytotoxicity.  In lieu of no further experiments concerning the cytotoxicity of seleno-
compounds in human cell lines, cytotoxicity data was sourced from the literature and is 
discussed in section 5.3.2.3. 
 
SMSC exhibited a low level of cytotoxicity towards the HL-60 cell line with a standard 
sigmoidal inhibition dose-response curve showing an IC50 value of 73.0 ± 16.7 µM.   
Against J-774 macrophages, no inhibition curve could be established for SMSC at the highest 
concentration tested of 250 µM, indicating the need for further testing of SMSC against this 
cell line at higher concentrations to determine the true inhibitory value.  Similarly, SMSC and 
Se-DL-met did not attain an IC50 at the highest concentration tested of 100 µM, although the 
beginning of an inhibition curve is observed for Se-DL-met at 100 µM with 80% growth at 
this concentration. 
 
These human cell line toxicity results indicate favourable selective inhibition of Se-AAs 
towards mycobacteria over human cell lines.  However, these cytotoxicity results require 
further validation and extension to include other anti-mycobacterial Se-AAs such as Se-L-
met before a definitive conclusion can be drawn regarding Se-AA toxicity.   
 
5.3 Discussion 
5.3.1 Biological activity of seleno-compounds 
Based on the range of selenium compounds and non-selenium containing amino-acids which 
were assayed, the best inhibitory activity was observed in the methylated seleno-amino acids 
SMSC and Se-met.  Analogous non-selenium containing amino acids were inactive towards 
M. smegmatis, and are presumed to be inactive against slow-growing and pathogenic 
mycobacterial species.  Similarly non amino acid selenium compounds demonstrated little 
inhibitory activity with the exception of methylseleninic acid and ebselen.  These methylated 
seleno-amino acids demonstrated highest inhibitory activity towards mycobacterial species, 
with activity toward other Gram positive and Gram negative bacteria being above 
therapeutically viable MIC values when contrasted to existing anti-bacterial agents. 
 
  CHAPTER FIVE:  SELENO-AMINO ACIDS     197 
5.3.1.1 Anti-bacterial activity 
5.3.1.1.1 Anti-mycobacterial activity 
5.3.1.1.1.1 M. smegmatis 
Seleno-amino acids exhibited the greatest inhibitory activity towards M. smegmatis under 
HdeB carbon-limitation and HdeB nitrogen-limitation culture conditions.  This was closely 
followed by 7H9 medium conditions that yielded similar but slightly higher inhibitory 
concentration values for M. smegmatis against all tested Se-AAs.  Se-AAs did not achieve a 
measurable MIC value in LB medium conditions at the highest concentration tested. 
 
Methylated Se-AAs, SMSC and Se-L-met, showed the strongest inhibitory activity toward M. 
smegmatis.  The levo optical isomer of Se-met showed double the inhibitory activity with the 
lowest MIC of 7.8 µM compared to 15.6 µM for the racemic dextro/levo mixture.  This 
suggests that the inhibitory activity of Se-AAs is dependant on optical rotation.  Based on 
this, dextro isomers of Se-AAs are likely to have little to anti-mycobacterial activity, 
although this remains to be tested. 
 
Non-methylated Se-AA Se-DL-cys consistently showed two-fold or lower inhibitory activity 
toward M. smegmatis than its methylated counterpart, SMSC.  This suggests that methylation 
of the selenium is an important but not an essential contributing factor to Se-AA inhibitory 
activity.  The dimeric seleno-DL-cystine showed severely reduced inhibitory activity further 
implicating the methylated or free selenium impact on Se-AA activity. 
 
Non-selenium containing Se-AA counterpart amino-acids such as DL-cysteine, DL-
methionine and s-methyl-L-cysteine and s-ethyl-L-cysteine exerted no inhibitory effect on M. 
smegmatis.  This is somewhat unexpected since published results of s-ethyl-L-cysteine claim 
superior anti-mycobacterial activity to pyrazinamide and para-aminosalicyclic acid,
476
 
including activity against isoniazid-resistant TB.
477
  S-Ethyl-L-cysteine was thought to exert 
its anti-tubercular action through formation of ethanthiol,
347
 and the compound underwent 
clinical trials in humans.
477
  Considering these reports of activity, some in vitro inhibition 
towards M. smegmatis and M. tuberculosis H37Ra was expected, but was not detected at the 
highest concentration of 2 mM tested.  It is possible that s-ethyl-L-cysteine only exerts anti-
tubercular activity in vivo since the published results utilised murine TB models.   
From these inactive results, it is deduced that selenium is an essential component of Se-AA 
inhibitory activity, and these compounds were not tested further in other species. 
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Selenium compounds other than Se-AAs generally demonstrated inferior anti-mycobacterial 
activity toward M. smegmatis in any culture conditions tested relative to Se-AAs.  The 
greatest activity was observed for ebselen that had an MIC of 62.5 µM against M. smegmatis 
in 7H9 and HdeB carbon-starvation culture conditions and 31.2 µM in HdeB nitrogen-
starvation conditions.  These MIC values are above the 20 µM concentration used in HTS.  
This explains why ebselen, included in the Spectrum Collection, was not detected in any 
HTS.   
 
Methylseleninic acid exhibited varied inhibitory activity.  As with most selenium compounds 
methylseleninic acid was inactive against M. smegmatis cultured in LB medium conditions 
and showed the strongest activity with an MIC of 31.2 µM in 7H9 medium followed by 
HdeB nitrogen-limitation medium 62.5 µM and HdeB carbon-limitation medium 125 µM.  
This trend in activity across media conditions differs from that observed for other Se-AAs 
and selenium compounds that typically exhibit the greatest activity in HdeB media 
conditions.  4-Chlorobenzeneseleninic acid displayed an MIC of 125 µM against M. 
smegmatis in nitrogen-limited culture but had an MIC of 1 mM or greater under other media 
conditions. 
Sodium selenite showed low inhibitory activity against M. smegmatis in all media types with 
7H9 and HdeB carbon limitation media having an MIC of 500 µM and HdeB nitrogen-
limited medium having an MIC of 250 µM. 
   
5.3.1.1.1.2 M. bovis BCG 
In general, M. bovis BCG demonstrated less sensitivity to the panel of selenium compounds 
tested.  M. bovis BCG had a four-fold decreased level of inhibitory activity for SMSC and 
methylseleninic acid and a two-fold decrease in activity for Se-L-met compared to results 
obtained for M. smegmatis cultured in 7H9 medium.  
This dampened activity was able to be somewhat mitigated by use of 7H9- limited medium in 
the circumstance of SMSC and methylseleninic acid, resulting in a two-fold increase in 
compound inhibitory activity compared to normal 7H9+ medium results; however, the use of 
7H9- limited medium had no effect on the activity of Se-L-met.  M. bovis BCG was also 
more tolerant to sodium selenite compared to M. smegmatis, with the highest concentration of 
2 mM being unable to completely inhibit M. bovis BCG growth, although the usual dose-
response inhibition was observed. 
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Based on the results of M. bovis BCG against the seleno-panel, it is concluded that M. bovis 
BCG is less sensitive than M. smegmatis to growth inhibition by Se-AAs and other selenium 
compounds such as methylseleninic acid, although the use of 7H9- limited medium can 
reduce this discrepancy but not to levels of activity observed in M. smegmatis assays. 
 
5.3.1.1.1.3 M .tuberculosis H37Ra 
The trends of Se-AA inhibitory activity observed in M. smegmatis were also seen in M. 
tuberculosis H37Ra. Methylated Se-AAs SMSC and Se-L-met again exhibited the greatest 
inhibitory activity of 15.6 µM, with Se-L-met demonstrating this level of activity in both 
7H9+ complete and 7H9- minimal media types; however, SMSC activity was reduced two-
fold in 7H9+ medium.  The activity of SMSC and Se-L-met in M. tuberculosis had the same 
MIC values as M. smegmatis cultured in 7H9 medium. 
 
Methylseleninic acid and ebselen also had the same MIC in M. tuberculosis H37Ra as M. 
smegmatis cultured in 7H9 medium, whereas, M. tuberculosis H37Ra was more tolerant to 
sodium selenite compared to M. smegmatis.  It is possible that ebselen is potentially more 
active than the results obtained as it was poorly soluble in water (and thus assay medium) and 
precipitated at concentrations above 500 µM, this may have effected the serial dilution of the 
compound during the assay setup. 
 
The exception to the similarity in Se-AA activity between M. smegmatis cultured in 7H9 and 
M. tuberculosis H37Ra was Se-DL-cys that demonstrated a large increase to 125 µM in MIC 
compared to the M. smegmatis 7H9 MIC result of 50 µM.  This low activity was further 
exacerbated by the use of 7H9- limitation medium culture conditions that increased the MIC 
of Se-DL-cys in H37Ra to 250 µM.  This result was unexpected and opposes other results 
obtained in 7H9- medium, warranting further confirmatory re-testing. 
 
Based on these results it is concluded that M. tuberculosis H37Ra has a comparable 
sensitivity to growth inhibition by Se-AAs as the model organism M. smegmatis cultured 
under 7H9 or HdeB media.  This similarity in sensitivity also extends to the other selenium 
compounds methylseleninic acid and ebselen.  Use of 7H9- starvation medium may render 
H37Ra more sensitive to SMSC but generally has little impact on inhibitory activity values. 
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5.3.1.1.1.4 M. tuberculosis H37Rv and CDC1551 
Initial testing of the first discovered Se-AA compound, SMSC, against virulent M. 
tuberculosis strains H37Rv and CDC1551 resulted in IC90 results of 22.88 µM and 9.15 µM, 
respectively.  This level of inhibition is greater than the MIC of 31.2 µM obtained for M. 
tuberculosis H37Ra in the same assay conditions.  It is noted that for virulent strains, IC90 
values were reported and compared to the MIC values used in this research.  This is thought 
to have minimal impact on the reported different sensitivity between the virulent TB strains 
and H37Ra, since an IC90 of 29.91 µM is extrapolated from the SMSC H37Ra dose-response 
curve, gives a value very similar to the 31.2 µM MIC (Figure 5.6). 
 
Subsequent tests of the same chemical batch of SMSC in M. tuberculosis H37Rv resulted in a 
higher IC90 recording of 50 µM.  It is not known if this higher result is accurate or anomalous 
as a result of chemical degradation or some other change in the stock or assay conditions; 
therefore, confirmatory re-testing is required.  The IC90 result for Se-DL-met of 50 µM is 
higher than expected considering the MIC of Se-DL-met in M. smegmatis 7H9 is 31.2 µM 
and Se-L-met in M. tuberculosis H37Ra is 15.6 µM.  However, this result was also obtained 
from the secondary round of testing as with SMSC above and therefore confirmatory re-
testing is desired for both Se-DL-met and Se-L-met to validate the inhibitory activity and the 
optical selectivity activity of the Se-AAs.  Seleno-DL-cystine exhibited a lower IC90 of 100 
µM against H37Rv than the M. smegmatis MIC result of 250 µM obtained in 7H9 culture 
conditions.  The H37Rv result was more comparable to the MIC of 125 µM for Se-DL-
cystine obtained from M. smegmatis under HdeB nutrient starvation culture assays. 
 
Other selenium compounds with structural similarity to SMSC obtained through the NIH 
Developmental Therapeutics Program Depository exhibited no significant inhibitory activity 
with IC90 values above the highest concentration tested of 100 µM.  These results were also 
obtained through the second round of testing therefore should be regarded with a degree of 
uncertainty.  
 
From the initial results it is concluded that virulent strains of M. tuberculosis H37Rv and 
CDC1551 are more sensitive to the inhibitory action of Se-AAs compared to M. tuberculosis 
H37Ra and 7H9 cultured M. smegmatis.  However only initial results obtained with SMSC 
support this; therefore, further testing with SMSC and Se-L-met is required to confirm the 
activity of these leading Se-AAs against virulent TB strains, in addition to MDR-TB isolates 
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to determine any cross-resistance with existing TB drugs.  Comparative testing of Se-DL-met 
is also desirable to confirm the optical rotation influence on activity of Se-AAs.   
 
5.3.1.1.2 Gram positive 
5.3.1.1.2.1 S. aureus 
The Gram-positive bacterial species S. aureus was tested against the panel of selenium 
compounds to explore the wider anti-bacterial activity spectrum of the seleno-amino acids 
and determine the potential suitability of seleno-amino acids as drugs for the treatment of S. 
aureus.  This strain is increasingly problematic in the clinical environment due to the rise of 
drug resistant strains such as methicillin resistant S. aureus (MRSA).
478
 
 
Experimentally, S. aureus exhibited little sensitivity to Se-AA growth inhibition.  In rich LB 
medium S. aureus displayed gradual dose-response inhibition but the inhibitory response was 
poor and at 2 mM the highest concentrations of SMSC and Se-L-met tested S. aureus growth 
remained at approximately 65% of the cell growth control.  The dose-response inhibition was 
more pronounced in S. aureus cultured under M9 minimal medium conditions; however, an 
MIC was still not achieved at 2 mM for either SMSC or Se-L-met. 
A greater inhibitory response was seen by methylseleninic acid with an MIC of 1 mM in LB 
conditions however an MIC could not be obtained under M9 minimal medium conditions.  
The strongest inhibitory activity was derived from sodium selenite with an MIC of 250 µM 
under LB conditions and 1 mM in M9 conditions.   
 
Therefore it appears S. aureus is not susceptible to any significant degree of growth inhibition 
by Se-AAs under rich or starvation culture conditions.  Furthermore, S. aureus is more 
resilient to selenium compound inhibition under starvation culture conditions, since although 
the dose-response curves were similar, low levels of S. aureus growth at high compound 
concentrations prevented determination of MIC values at the concentrations tested. 
 
5.3.1.1.3 Gram negative 
5.3.1.1.3.1 E. coli 
Gram negative E. coli was tested against the selenium compounds panel to further explore the 
anti-bacterial activity spectrum of the seleno-amino acids, and determine the potential 
suitability of Se-AAs as drugs for treatment of E. coli infection which outbreaks of virulent 
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strains can occur, such as the 2011 outbreak of E. coli O104:H4 in Germany
479
 and as a 
bacterial pathogen increasing drug resistance is an ongoing issue.
480
 
 
E. coli showed little sensitivity towards growth inhibition by selenium compounds.  In LB 
medium no inhibitory dose-response curve was observed for Se-AAs SMSC and Se-L-met 
across the concentrations tested.  A dose-response relationship was observed in LB medium 
for methylseleninic acid with an MIC of 1 mM, and a dose-dependent inhibitory response 
was also observed for sodium selenite in LB media; however, this did not cause complete 
inhibition at the highest concentration tested of 2 mM. 
Using M9 minimal medium assay conditions, an inhibitory response was observed for Se-
AAs.  SMSC caused complete inhibition of E. coli growth at 500 µM.  Se-L-met was less 
potent, only completely inhibiting E. coli growth at 2 mM, the highest concentration tested.  
Methylseleninic acid showed a similar inhibitory dose-response in M9 minimal medium as 
was observed in LB; however, the MIC was slightly higher in M9 at 2 mM.  E. coli was more 
sensitive to inhibition by sodium selenite in M9 medium compared to LB, although the MIC 
in M9 medium was only at the highest concentration tested of 2 mM, the dose-response was 
more gradual, as observed in Figure 5.10 for sodium selenite. 
 
These results suggest that Se-AAs have only minor inhibitory effects towards E. coli.   E. coli 
demonstrated a typical inhibitory response to non-amino acid selenium compounds 
methylseleninic acid and sodium selenite.  SMSC under M9 nutrient-limited conditions was 
the only Se-AA to exert inhibitory activity towards E. coli, and this was at a concentration too 
high to be practical as a drug development lead.   
 
5.3.1.1.3.2 P. aeruginosa 
P. aeruginosa is a Gram negative bacterial pathogen of clinical importance in opportunistic 
infections such as cystic fibrosis patients and nosocomial infection of burn injuries.
481
  
Pseudomonas species such as P. aeruginosa are notoriously difficult to treat with antibiotic 
therapy,
482
 primarily due to innate resistance by drug efflux pump expression
483
 and 
aggressive expression of antibiotic negating enzymes.
484
   
 
 P. aeruginosa displayed some sensitivity to growth inhibition by Se-L-met under both rich 
LB and nutrient-limited M9 media types.  Although an inhibitory dose-response relationship 
was observed for Se-L-met, particularly under nutrient-limitation conditions (Figure 5.11), 
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this was insufficient to completely inhibit P. aeruginosa growth; thus, high MIC values were 
recorded.  P. aeruginosa showed little sensitivity toward SMSC under both rich and 
starvation media conditions with the highest concentration tested of 2 mM unable to inhibit 
growth beyond 75% of the cell growth control. 
 
Methylseleninic acid and sodium selenite did not cause any significant dose-response 
inhibition of P. aeruginosa in LB media at the concentrations tested.  High concentrations of 
sodium selenite precipitated to red elemental selenium in P. aeruginosa LB assay conditions, 
likely contributing to the lack of inhibitory activity.  This precipitation was not observed in 
M9 nutrient limited conditions and a dose dependant growth curve was produced but as with 
methylseleninic acid in M9 medium this dose-dependant growth inhibition did not inhibit P 
.aeruginosa completely at the highest concentration tested.  These experiments indicate that 
Se-AAs do not exert significant inhibitory action towards P. aeruginosa. 
 
5.3.1.1.3.3 V. harveyi 
Vibro harveyi (also known as Listonella anguillarum) is a Gram negative motile marine 
bacterium.  This species is a pathogen in fish causing vibriosis, a disease that is financially 
damaging to the aquaculture industry.
485
   V. harveyi also shares several characteristics with 
the human pathogen and causative agent of cholera, Vibrio cholerae, for which recent 
emergence of drug resistance has been published.
486
  V. harveyi may be a relevant model in 
drug discovery for V. cholerae. 
 
Of the three Gram negative bacterial species tested for sensitivity to Se-AA inhibition, V. 
harveyi demonstrated the greatest inhibitory response.  This is reflected in the dose-response 
curves of growth inhibition for SMSC and Se-L-met (Figure 5.12) in which both compounds 
completely inhibited V. harveyi growth in LB medium at concentrations of 250 µM.  Se-L-
met demonstrated this same level of inhibition in M9 minimal medium; however, V. harveyi 
showed reduced sensitivity to SMSC in M9 minimal medium since the MIC increased to 1 
mM. 
 
Methylseleninic acid and sodium selenite produced the expected inhibitory effects against V. 
harveyi with MIC values in LB of 500 µM and > 2 mM, respectively (again precipitation of 
sodium selenite was observed at high concentrations).  As observed in other bacterial species 
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a stronger inhibitory response was caused by these compounds in M9 minimal medium with a 
recorded MIC of 250 µM for both these compounds. 
 
In line with trends observed in other non-mycobacterial species of bacteria Se-AAs did not 
demonstrate strong inhibitory activity against the growth of V. harveyi, although V. harveyi 
was more susceptible to Se-AAs in LB medium than any other non-mycobacterial species 
tested.  An MIC value of 250 µM is beyond the range considered conducive to anti-bacterial 
drug discovery. 
 
5.3.1.2 Anti-fungal activity  
5.3.1.2.1 S. cerevisiae 
Two strains of the yeast S. cerevisiae were tested against the selenium compound panel for 
growth inhibition, the haploid strain BY4741 and the diploid strain BY4743.  Both haploid 
and diploid strains were tested as anti-fungal drug resistance levels may be dependant on the 
ploidy of yeast.
487
  
 
Neither haploid nor diploid S. cerevisiae growth was not significantly inhibited by SMSC 
under rich SC medium or starvation medium conditions, with no measurable MIC being 
obtained for either strain under either media condition.  Although a slight inhibitory dose-
response was observed for both strains in SC medium, in nutrient limited SPO medium 
conditions, SMSC had a positive growth effect on both strains of S. cerevisiae.  This effect 
was not observed in SPO medium only controls of SMSC testing; therefore, is either caused 
by increased growth of S. cerevisiae by utilisation of SMSC as a nutrient, or metabolism of 
SMSC into a derivative able to provoke reduction of resazurin. 
The result of negligible toxicity of SMSC agrees with published reports of SMSC exhibiting 
no toxic effects upon S. cerevisiae at concentrations of up to 10 mM.
488
 
 
In the present research, Se-L-met caused inhibition of S. cerevisiae growth under both strains 
and media conditions.  Under rich SC medium conditions, both haploid and diploid yeast 
growth was completely inhibited at 125 µM, a greater sensitivity than observed in other 
species tested with the exception of mycobacteria.  Under SPO starvation medium conditions, 
diploid S. cerevisiae maintained the same sensitivity to Se-L-met as observed in SC medium; 
however, haploid S. cerevisiae was more sensitive since its MIC dropped two-fold to 62.5 
µM.   
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This result is at odds with two publications regarding the toxicity of Se-met towards S. 
cerevisiae.
488, 489
  In one publication Se-met is reported to be non-toxic at concentrations of 
10 mM and below during both exponential and stationary phase growth.
488
  This may be due 
to a different strain of S. cerevisiae (SJR751) being used.  Also the optical rotation of the Se-
met used in this study is not defined, and a different media type (YPD medium) and assay 
method were utilised in this study.
488
  Conversely, a 2012 publication declares Se-met to have 
an MIC of 1 µM towards S. cerevisiae.  Again, this article does not mention the optical 
rotation of the Se-met used and utilised the different strain W303-1A and SC medium lacking 
methionine, this likely accounts for the high toxicity value reported.
489
  A published study 
using S. cerevisiae strain BY4741 report an IC50 of 28 µM for Se-met in YPD medium,
490
 
very similar to the IC50 of ~32 µM observed in the dose-response of S. cerevisiae to Se-L-met 
in the present work. 
 
Methylseleninic acid produced minor inhibition of growth in both strains of yeast under SC 
conditions, with an MIC only being achieved at the highest concentration tested for the 
diploid strain.  Under nutrient-limited SPO conditions a resazurin reducing effect was 
observed at high methylseleninic acid concentrations, similar to that observed for SMSC in 
SPO medium conditions. 
Sodium selenite caused a gradual dose-dependant inhibition of growth in haploid S. 
cerevisiae under rich SC medium conditions, and greater resistance to inhibition by sodium 
selenite was observed for the haploid strain cultured under SPO nutrient-limited medium.  
Diploid S. cerevisiae exhibited a steeper inhibitory dose- response in SC medium, and again 
were less inhibited under nutrient-limited conditions.  These findings are in agreement with 
literature reports regarding the toxicity of sodium selenite toward S. cerevisiae.
488, 490
 
 
The results obtained in this work for selenium compound inhibition towards the growth of S. 
cerevisiae agree with the published literature results that SMSC is non-toxic and sodium 
selenite exhibits some toxicity toward S. cerevisiae growth.  The results for Se-met in the 
literature are varied, either being the similar, higher or lower than toxicity than those found in 
the present work.  However these discrepancies are likely attributed to differences in assay 
set up such as the S. cerevisiae strain, media and assay methodology used. 
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5.3.1.3 Mammalian cell line cytotoxicity 
Se-AA cytotoxicity testing was kindly carried out by Rekha Veliyayi Murikoli and Dr. R. 
O‟Toole.  Three different mammalian cell lines were tested, promyelocytic human leukaemia 
(HL-60), murine macrophage (J-774) and green monkey kidney epithelial (Vero) cell lines. 
 
The IC50 result of 73.03 ± 16.73 µM for the HL-60 cell line is in the range of published 
literature reports for HL-60 cell line toxicity of SMSC.  For example SMSC has a published 
IC50 of 85 µM produced by WST-1 cell proliferation assay and 165 µM by a Lac-DH release 
type assay.
491
  The authors who obtained these results, conclude that SMSC demonstrates loss 
of metabolic activity through an apoptosis mechanism opposed to causing necrotic cell 
lysis.
491
  The same study also found selenite to be approximately 10-fold more toxic toward 
HL-60 cells with an IC50 of 15 µM by WST-1 and 18 µM by Lac-DH release, indicating a 
more necrotic mechanism of cell death.
491
  It is noted that HL-60 cells, being a cancer line, 
may be more sensitive to the apoptotic action of SMSC, compared to other cell lines or whole 
organism in vivo toxicity. 
Unfortunately inhibitory concentrations for SMSC towards J-774 macrophages could not be 
found by  literature searching; however, published research has tested the toxicity of SMSC 
towards RAW 264.7 macrophages in MTT and Lac-DH release assays, and found it to have 
no effects on viability at the highest concentration tested of 50 µM.
492
  This agrees with the 
non-cytotoxic results obtained for SMSC toward J-774 macrophages in the present study. 
The IC50 value of SMSC and Se-DL-met toward Vero cells could not be determined from the 
maximum concentration tested of 100 µM.  This shows that Se-AAs have minimal toxicity 
toward this non-cancerous cell line.  This result is similar to a published result of Se-met 
having only 34% inhibitory activity at 50 µM
493
 however the Se-met used was a sodium salt 
that may account for the slight discrepancy between the results of this work and the 
publication of Carmelli et al.
493
  No prior published results of SMSC cytotoxicity toward 
Vero cells was found in the literature. 
 
Se-L-met is reported to exhibit toxicity toward human leukaemia and murine lymphoma cell 
lines with an IC50 of 90 µM.  Se-L-met toxicity was increased to IC50 40 µM by reduction of 
cell culture medium methionine content to 10µM.
494
  This study also reported that Se-DL-met 
is approximately half as toxic as Se-L-met, and Se-L-met at sub-inhibitory concentrations 
below 40 µM stimulated cell line growth and plating efficiency by 50%.
494
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5.3.2 Suitability of Seleno Amino Acids for Human Therapy 
From the growth inhibition test results in this thesis of selenium compounds against a range 
of mycobacterial species, the Se-AAs, SMSC and Se-L-met, have been demonstrated to cause 
complete growth inhibition against most mycobacterial species in vitro (including M. 
smegmatis, M. tuberculosis H37Ra, M. tuberculosis H37Rv and M. tuberculosis CDC1551) 
at concentrations of 8 µM – 31 µM.  The exception to this is M. smegmatis cultured in LB 
medium, this medium causes Se-AAs to lose their inhibitory potency.   We can compare this 
with the SMSC IC50 value of 73.03 ± 16.73 µM obtained for the HL-60 cell line and that 
shows that SMSC demonstrates favourable selective inhibition towards mycobacteria over 
mammalian cell lines. 
Other selenium compounds tested, sodium selenite and methylseleninic acid, did not produce 
such a consistently strong inhibitory response against mycobacteria and are therefore 
disregarded. 
 
To predict the suitability of Se-AAs as anti-tubercular therapeutics, the following sections 
will evaluate results obtained from growth inhibition assays against microbial species, and 
compare these values to published toxicity results of Se-AAs towards human cell lines and in 
vivo animal models to determine the potential suitability of Se-AAs as anti-infective agents 
for human administration. 
 
5.3.2.1 Activity towards mycobacteria 
Se-AAs, with the exception of Seleno-DL-cystine, demonstrated good inhibition toward M. 
smegmatis in all media types except LB rich medium.  The greatest inhibitory activity 
towards mycobacteria was observed for SMSC and Se-L-met, both demonstrating an MIC of 
15.6 µM or lower against M. smegmatis cultured in 7H9 and HdeB carbon and nitrogen-
limited media.  These two compounds were then further evaluated in other bacterial species. 
 
Activity of both SMSC and Se-L-met was lower against the vaccine strain M. bovis BCG 
than in M. smegmatis.  However, activity was retained in the more relevant model M. 
tuberculosis H37Ra at 15.6 - 31.25 µM levels.  Furthermore SMSC exhibited this activity 
level in M. tuberculosis H37Rv testing, although variation of MIC results for H37Rv was 
observed.  Due to the consistency of MIC values for SMSC against other mycobacterial 
species, the initial IC90 of 22.88 µM obtained for M. tuberculosis H37Rv is assumed to be 
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correct.  However; this requires validation by further re-testing, due to variation in the IC90 
values of SMSC as discussed is section 5.2.1.4.   
 
The IC90 value of 22.88 µM (5 µg/mL) towards M. tuberculosis H37Rv places the activity of 
SMSC at a similar level to other TB treatment drugs clarithromycin (MIC 8 µg/mL),
199
 
cycloserine (MIC 25 µg/mL),
199
 pyrazinamide (MIC 6-50 µg/mL at pH 5.5)
495
 and 
thioridazine (MIC 10 µg/mL against M. tuberculosis ATCC 27294).
496
  All MIC values are 
against M. tuberculosis H37Rv unless otherwise stated.  SMSC continued to demonstrate a 
high level of inhibitory activity when tested in the virulent and highly pathogenic strain M. 
tuberculosis CDC1551 with an IC90 of 9.15 µM.  This inhibitory activity is on par with not 
only the aforementioned TB treatment drugs but also capreomycin
497
 and kanamycin
199
 that 
also have in vitro MIC values of 2 µg/mL against M. tuberculosis H37Rv. 
Therefore, SMSC shows anti-mycobacterial activity levels potentially equivalent to several 
TB treatment drugs.  This inhibitory activity likely extends to other Se-AAs such as Se-L-
met, and other Se-AA derivatives may demonstrate greater anti-mycobacterial activity.  
SMSC and other Se-AAs require further re-testing to confirm their activity level toward 
pathogenic M. tuberculosis strains. 
 
5.3.2.2 Activity towards other bacterial and fungal species 
In contrast to the mycobacterial inhibition results, Se-AAs demonstrated little inhibitory 
activity towards other bacterial species tested, with high or unachievable MIC values.  S. 
aureus was unable to be completely inhibited in nutrient rich or starvation media by both 
SMSC or Se-L-met at 2 mM, the highest concentration tested.  Similar lack of inhibition was 
observed for E. coli that demonstrated no obtainable MIC in rich media at 2 mM, although 
complete inhibition was achieved in minimal media, it was at very high concentrations of 500 
µM for SMSC and 2000 µM for Se-L-met.  Likewise with P. aeruginosa, MIC values could 
not be obtained, with the exception of Se-L-met in rich media which had an MIC of 1000 
µM.  Se-AAs demonstrated better activity against V. harveyi, with the lowest MIC achieved 
being 250 µM.  This is still considered; however, well outside the viable therapeutic range.  
Inhibition of the yeast S. cerevisiae was reasonable for Se-L-met in the range of 62.5-125 
µM; however, SMSC was unable to cause complete inhibition at 2 mM.  
 
These results indicate Se-AAs do not exhibit enough inhibitory activity towards S. aureus, E. 
coli, P. aeruginosa, V. harveyi or S. cerevisiae to be considered worth pursuing as antibiotic 
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drugs for the treatment of human infection caused by these or related microorganisms.  Se-
AAs evidently have a narrow spectrum of anti-bacterial activity, effectively inhibiting 
mycobacteria but no other Gram positive or Gram negative species tested.  This is of interest 
as the inhibitory activity of Se-AAs may be specific to a mechanism unique to mycobacteria. 
 
5.3.2.3 Mammalian cell line toxicity 
SMSC was found to have an IC50 of 73.03 µM against the human leukaemia HL-60 cell line.  
This agrees with published results of SMSC against the same cell line with IC50 results of 85 
µM by WST-1 cell metabolism assay.
491
   These values are relatively low for a compound 
being considered for human therapy; however, it should be noted that Se-AAs such as SMSC 
have known anti-proliferative and apoptosis-inducing activities towards tumour cell lines, 
and are purported to be 1000-fold more inhibitory toward tumour cell lines than normal 
human fibroblasts.
424
 
No inhibition was able to be recorded for SMSC against the J-774 murine macrophage cell 
line at the highest concentration tested of 250 µM.  Furthermore, it is stated in the literature 
that no adverse effects of SMSC towards viability of RAW 264.7 macrophages were 
observed at the highest concentration tested of 50 µM.
492
  SMSC (L) has a reported IC50 of 
472 µM and Se-L-met has a reported IC50 of 267 µM against the V79 cell line (Chinese 
hamster lung fibroblasts).
498
 
Se-met has been described as “essentially non-toxic” toward HepG2 human liver carcinoma 
and Hepa1-6 cell lines with an IC50 in excess of 10 mM; however, against primary murine 
hepatocytes, Se-met demonstrated an more sensitive IC50 of 30 µM.
499
  Se-met was also 
found non-toxic at concentrations up to 1 mM against HCT-116 cells.
500
  Therefore the 
toxicity of Se-met and other Se-AAs is dependant on the cell line and culture conditions used, 
although it is generally thought that Se-AAs and other organic selenium compounds exhibit 
low levels of toxicity towards most cell lines,
500
 particularly those of non cancerous nature.  
For example, human fibroblasts with an IC50 of 1 mM
424
 and human keratinocytes displayed 
no cytotoxicity at 316.6 µM Se-Met.
501
  These low cell line toxicity values are encouraging 
for Se-AAs as anti-mycobacterial agents, but due to variation of cytotoxicity based on cell-
type, the toxicity toward whole animal models must be taken into account to better determine 
the potential of Se-AAs as anti-microbials. 
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5.3.2.4 Animal model toxicity 
A single oral administration of SMSC in mice had an LD50 value of 14.6 mg/kg (95% 
confidence limits of 13.1-16.2).
502
  It has been shown in mice that an orally administered 
single dose of 200 µg SMSC raises plasma Se to a peak concentration of 8.9 ± 0.2 µM after 1 
h.  At the highest plasma concentration achieved of 11.5 ± 0.2 µM after 28 days of daily oral 
administration of 200 µg SMSC, no adverse effects were observed.
503
  This plasma 
concentration is within the inhibitory concentration range of SMSC towards pathogenic 
strains of M. tuberculosis.  For Se-met, the murine oral LD50 has been determined to be 25.6 
mg/kg (95% confidence limits of 22.6-28.6).
504
  For non-oral administration, Se-met toxicity 
in rats gave a LD50 of 4.25 mg/kg for intraperitoneal injection,
505
 in mice, racemic Se-DL-met 
had an intravenous LD50 of 8.8 ± 1.37 mg/kg.
505
 
A study of female macaques administered Se-L-met in doses of 0-600 µg/kg/day for 30 days 
reports a maximum tolerated dose of 150 µg/kg/day, with the 300 µg/kg/day dose group 
exhibiting adverse side effects and premature death of two of the twenty animals in the 
highest 600 µg/kg/day dose group.
506
  Another study of pregnant macaques treated for 30 
days with daily doses of 0-300 µg Se-L-met per kg bodyweight found at the highest doses of 
150 and 300 µg/kg/day that plasma Se levels peaked at day 21 of treatment and significant 
adverse effects of selenium toxicity (anorexia and vomiting) were observed in the 300 
µg/kg/day group.
507
  Nasogastric administration of Se-L-met in pregnant macaques caused 
limited developmental defects at low doses and embryonic and fetal death at higher doses of 
300 µg/kg/day. In addition, teratogenesis of selenium has been demonstrated in non-
mammalian species such as birds and fish.
508
  In pigs, ingestion of Se-DL-met caused the 
greatest uptake and retention of Se in blood/tissue compared to ingestion of sodium selenate 
feed or Se-accumulator plant material, but Se-DL-met ingestion also caused less toxicity in 
pigs than ingestion of sodium selenate or Se-accumulating plants.
509
 
 
Therefore, in animal models, Se-AAs such as Se-Met can exhibit toxic effects at high 
concentrations such as 300 µg/kg/day; however, the incidence and extent of these toxic 
effects is dependant on the route of administration and the animal model used, with oral 
administration provoking less toxicity. 
 
As covered in section 5.1.1, selenium has an established toxicity in humans (using inorganic 
selenium) in which the mean oral intake with no adverse effects observed is 800 µg per day 
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(≈ 15 µg/kg), and a maximum safe daily intake 400 µg per day is recommended.377   
A more recent human supplementation study used oral doses of selenium in the form of 
selenized yeast that contains organic forms of Se such as Se-AAs (predominately Se-met).  
Doses of 3200 µg/day of selenized yeast for 24 months provoked symptoms of Se toxicity; 
however, the incidence of these symptoms did not correlate to plasma Se concentration.  No 
serious Se toxicity was observed at this dosage, and the authors suggest that the maximum 
safe daily intake of 400 µg/day may be exceeded for extended periods of time without serious 
toxicity concerns.
510
  However, the European Food Safety Authority cautions the use of 
SMSC as a nutritional supplement at levels of 400 µg/day, citing that there is insufficient 
research data to support that 400 µg/day SMSC is conclusively safe.
511
  In mammals excess 
selenium such as from Se-met supplementation is excreted through the breath, exposing lung 
tissue to volatile selenides compounds.
512
  Additionally, organ distribution studies following 
oral SMSC administration show accumulation preference for the lung, with SMSC 
accumulating in the lung tissue at higher concentrations than methylseleninic acid or sodium 
selenite,
513
 and this lung accumulation is favourable in the context of treating pulmonary TB.  
Se-AAs demonstrate anti-mycobacterial activity that is on par with several current TB 
treatment drugs.  However the toxicology of Se-AAs have not yet been fully determined in 
humans, although experimental observations have set an initial maximum safe daily limit of 
400 µg/day that is likely to be similar inhibitory plasma concentrations that are anti-
mycobacterially effective.  Further studies on Se-AA anti-mycobacterial activity using in vivo 
models are required to better determine how suitable Se-AA are for development as a human 
TB treatment. 
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5.4 Summary 
Screening of chemical libraries under nutrient starvation conditions identified a novel class of 
anti-mycobacterial chemicals, the seleno-amino acids.  These exhibit inhibitory activity 
against pathogenic M. tuberculosis strains at levels similar to several current TB treatment 
drugs.  Se-AAs did not have any significant inhibitory activity towards other bacterial species 
tested and exhibited less inhibitory effect toward human cell lines relative to mycobacteria. 
Se-AAs are widely marketed and consumed as nutritional supplements and have research 
implications for treatment of various pathologies such as cancer.  They are generally 
considered to have low toxicity in humans; however, this requires further investigation.  
Considering that Se-AA human toxicity and anti-bacterial activity may both be further 
improved by combination with other drugs or modification of the Se-AA chemical structure 
and delivery method, Se-AAs represent a promising novel class of tuberculosis treatment that 
warrants further investigation and development.
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6.1 Introduction 
6.1.1 Seleno-amino acid biological activity  
Seleno-amino acids demonstrate inhibitory activity towards mycobacteria typically in the 8-
30 µM MIC range.  This inhibitory activity seems to be exclusive to mycobacterial species, 
with other bacteria such as E. coli, S. aureus, P. aeruginosa and V. harveyi displaying little or 
no sensitivity to growth inhibition by Se-AAs.  Eukaryotic species such as S. cerevisiae and 
mammalian cell lines are less inhibited by Se-AAs than mycobacterial species.   
 The aim of this chapter is to investigate Se-AA structure-activity relationship 
and anti-mycobacterial mechanism, in order to better understand Se-AAs for 
development as human tuberculosis treatment candidates.   
 
6.1.2 Differential activity and media conditions overview 
Based on the results of dose-response growth inhibition testing detailed in Chapter 5.2 it is 
observed that Se-AAs show differential inhibitory activity based on the bacterial species 
being tested and also the media conditions in which they are cultured. 
 
6.1.2.1 Se-AA activity toward bacterial species overview 
Mycobacterial model species M. smegmatis displayed great variation in its sensitivity to 
growth inhibition by Se-AAs based on the media type used in the dose-response assay.  Using 
rich LB medium, M. smegmatis was resistant to complete growth inhibition by Se-AAs, 
methylseleninic acid and sodium selenite at concentrations up to 2 mM.  However in culture 
in rich 7H9 medium, HdeB carbon- or HdeB nitrogen-starvation media caused complete 
inhibition of M. smegmatis growth at concentrations of 7.8-15.6 µM for SMSC and Se-DL-
met.  Methylseleninic acid and sodium selenite also showed complete inhibitory activity in 
these media types but not to the same extent as Se-AAs (see Table 5.1). 
Therefore, there is a clear trend in M.  smegmatis culture conditions and the inhibitory 
activity of the Se-AAs, culturing mycobacteria in the complex LB rich medium negates the 
inhibitory activity of these organoselenium compounds. 
Slow growing mycobacterial species and vaccine strain M. bovis BCG cultured in 7H9 
medium were less sensitive to inhibition by Se-AAs with MICs in the range of 31.25 - 62.5 
µM.  This strain was also less sensitive to inhibition by methylseleninic acid 125 - 62.5 µM.  
The attenuated, slow growing M. tuberculosis H37Ra strain cultured in 7H9 medium 
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displayed similar sensitivity to inhibition by Se-AAs and methylseleninic acid as M. 
smegmatis cultured in 7H9, with MIC values of 15.6-31.25 µM.  The use of a nutrient limited 
7H9 medium produced inconsistent results, but generally M. tuberculosis H37Ra cultured in 
the nutrient-limited 7H9 medium were more sensitive to inhibition by Se-AAs. 
With regards to non-mycobacterial species, the use of nutrient starvation media had little 
impact on the activity of Se-AAs.  S. aureus showed no sensitivity to Se-AAs at the 2 mM 
concentration tested in either nutrient-rich LB or nutrient-limited M9 medium.  E. coli 
demonstrated some differential sensitivity to SMSC, with the MIC being unobtainable in LB 
medium but dropped to 500 µM in nutrient limitation M9.  Conversely, P. aeruginosa was 
more sensitive to Se-L-met in rich LB medium, with an MIC of 1 mM, and no MIC could be 
obtained in M9 medium.  Of all the non-mycobacterial species of bacteria tested, V. harveyi 
showed the most sensitivity to Se-AA inhibition with MIC values of 250 µM for both SMSC 
and Se-L-met in LB medium; however, in nutrient-limited M9 medium the MIC for SMSC 
increased to 1 mM.  It is unclear why P. aeruginosa and V. harveyi are more sensitive to Se-
AA inhibition in rich LB media conditions; however, as the inhibitory activity of Se-AAs 
towards these and other non-mycobacterial species is low this was not considered to be a 
priority of the present research.    
6.1.2.2 Media conditions 
The major influential factor on M. smegmatis sensitivity to seleno-compound inhibition is the 
type of culture medium used, specifically, LB medium culture confers resistance to inhibition 
of M. smegmatis growth by Se-AAs.  Use of an improvised 7H9 nutrient starvation media 
with reduced carbon source (glycerol) and OADC enrichment (section 2.2.1.2.4) had a slight 
effect on the sensitivity of slow growing mycobacterial species to Se-AA inhibition; 
however, this effect was marginal (one serial dilution) and inconsistent.  
 
An obvious key difference between LB medium, in which Se-AAs are practically inactive, 
and the 7H9 or HdeB media, in which the Se-AAs have inhibitory activity, is the tryptone and 
yeast extract content of LB.  Tryptone is an enzymatic digest of casein and is rich in amino 
acids and oligopeptides.  Yeast extract is also rich is free amino acids.  Both 7H9 and HdeB 
media do not contain any free amino acids or oligopeptides; the closest constituent of 7H9 to 
amino acids is albumin, present in the OADC enrichment.   
 
It is known that cysteine and methionine are both capable of negating Se-AA inhibition in 
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human cell lines,
494
 this was confirmed in mycobacteria in this research (section 6.4.1). 
Therefore, it is hypothesised that the cysteine and/or methionine content of LB is responsible 
for blunting Se-AA inhibitory activity in LB medium.  This may take place at the transporter 
itself, where these amino acids compete with the Se-AAs for import into the cell.  
Alternatively, cysteine and/or methionine may compete with Se-AAs somewhere later in their 
metabolism or during incorporation into proteins.  This hypothesis is investigated in section 
6.4.1. 
 
6.2 Seleno amino acid pharmacophore 
For this study, Se-cys is used as the basic theoretical scaffold of the Se-AAs.  SMSC is 
derived by methylation of the selenium of Se-cys.  An additional side chain carbon to SMSC 
at the γ position results in Se-met.  Dimeric Se-cys joined by a diselenide bond results in 
seleno-cystine.  These modifications of the Se-cys structure encompass the commonly 
available Se-AAs used in this work. 
 
The non-selenated amino acids DL-cysteine and DL-methionine are identical to their Se-AA 
counterparts with the exception of a sulphur atom in place of the selenium.  S-methylcysteine 
is the non-selenated equivalent of SMSC, having a methyl group attached to the sulphur; 
similarly, S-ethylcysteine has an ethyl group attached to the sulphur of cysteine.  
Unfortunately ethyl-selenocysteine could not be obtained for testing in this research. 
Some non-amino acid selenium compounds bear some structural similarity to the Se-AAs, the 
closest of which is methylseleninic acid that shares a common methylated selenium with 
SMSC and Se-met.  However, methylseleninic acid does not have amine or carboxylic acid 
groups, instead sporting a seleninic acid functional group, the selenium equivalent of sulfinic 
acid.  Sodium selenite is similar again to methylseleninic acid but has substituted the methyl 
group for a hydroxyl group (in solution). 
Other non-amino acid selenium compounds bear little structural resemblance to Se-AAs.  
Seleno-urea, for example, has a primary amine group but also a primary ketimine.  
Benzeneselenic acid-containing seleno-compounds have the seleninic acid moiety of 
methylseleninic acid but also have the steric bulk of benzene substituted in place of the 
methyl group.  Compounds such as diphenylselenide and ebselen have almost no structural 
resemblance to Se-AAs in their native form, except for the common selenium atom. 
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6.2.1 Seleno-compound structure and activity in M. smegmatis  
Seleno-compounds used in this research had a wide range of inhibitory activity toward 
mycobacteria.  The relationship between seleno-compound structure and inhibitory activity is 
assessed in Table 6.1, using M. smegmatis MIC in 7H9 medium, as all compounds were 
assayed in this model organism and inhibitory activity of M. smegmatis in 7H9 medium is 
well correlated with inhibition observed in M. tuberculosis. 
Table 6.1:  Seleno-compound structure and anti-mycobacterial activity 
Compound M. smegmatis MIC 
7H9 (µM) 
Chemical structure* 
Seleno-Amino Acids   
Se-methylseleno-DL-
cysteine (SMSC) 
15.6 
 
Seleno-DL-cysteine (Se-cys) 50 
 
Seleno-DL-methionine (Se-
met) 
31.2 
 
Seleno-L-methionine (Se-L-
met) 
15.6 
 
Seleno-DL-cystine 250 
 
Sulphur-Amino Acids   
DL-cysteine  > 2000 
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Compound M. smegmatis MIC 
7H9 (µM) 
Chemical structure* 
DL-methionine > 2000 
 
s-methyl-L-cysteine > 2000 
 
s-ethyl-L-cysteine > 2000 
 
Other selenium compounds   
Sodium selenite 500 
 
Diphenyl-selenide 1000 
 
Benzeneseleninic anhydrous 500 
 
Benzeneseleninic acid 500 
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Compound M. smegmatis MIC 
7H9 (µM) 
Chemical structure* 
4-chloro benzeneseleninic 
acid 
2000 
 
   
Methylseleninic acid 31.2 
 
Seleno-urea > 2000 
 
1,1-dimethyl-2-selenourea 2000 
 
Ebselen 62.5 
 
Table 6.1:  Seleno-compound structure and anti-mycobacterial activity.   
Organic and inorganic selenium compounds are presented, including Se-AAs and their 
equivalent sulphurous amino acids with corresponding inhibitory activity toward M. 
smegmatis under 7H9 media conditions. 
*Images obtained and modified from NIH PubChem database. 
For Se-AAs, the greatest anti-mycobacterial activity was observed for the methylated SMSC 
and Se-met.  The addition of a methyl group to the selenium of Se-DL-Cys, to form SMSC, 
results in a greater than 2-fold increase in the inhibitory activity towards M. smegmatis in 
7H9 conditions. 
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From the anti-mycobacterial testing carried out in Chapter 5.2, several key structural 
characteristics that influence the inhibitory activity of seleno-compounds were observed, 
these are illustrated in Figure 6.1.  The most vital of these was the selenium atom itself, as 
non-seleniferous amino acids DL-cysteine and DL-methionine do not demonstrate any anti-
mycobacterial activity at the concentrations tested.  Furthermore, methylated and ethylated 
derivatives of DL-cysteine also fail to show inhibitory activity towards M. smegmatis.  This is 
contradictory to earlier publications describing the inhibitory action of compounds such as S-
methylcysteine toward mycobacterial species including M. smegmatis; however, these 
publications are based on in vivo experimental models and this may account for the 
discrepancy.
476, 477, 514
  Considering the lack of activity of the sulphurous equivalents of 
SMSC and Se-met, it is concluded that the selenium is an essential component for Se-AA 
anti-mycobacterial activity. 
The methyl group directly bonded to the selenium is not vital for Se-AA activity.  This is 
evidenced by Se-DL-cys showing 50 µM MIC toward M. smegmatis in 7H9 medium.  
However, the presence of methyl-selenium increases the activity of Se-AAs towards 
mycobacteria, as SMSC has an MIC of 15.6 µM in M. smegmatis 7H9 culture, representing a 
Figure 6.1:  Seleno-compound key functional groups.   
Seleno-compound panel chemicals and key structural characteristics for activity.  Selenium is 
highlighted in yellow, the methyl group in red, side chain carbons in green, primary amines in 
teal and carboxylic acid in blue. 
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greater than 3-fold increase in anti-mycobacterial activity attributed solely to methylation of 
the selenium.  Additionally, Se-met also sports methyl-selenium and demonstrates a high 
level of anti-mycobacterial activity with an MIC of 15.6 µM.  Methylation of selenium is 
confirmed in the literature as a contributor to selenium toxicity.
515
  However, in the case of 
the non-amino acid selenium compound methylseleninic acid, the methyl group appears to be 
vital for anti-mycobacterial activity, as sodium selenite shares common hydroxyl and 
selenoxide groups with methylseleninic acid but lacks methylation of the selenium, 
consequently resulting in sodium selenite having 15-fold less inhibitory activity than 
methylseleninic acid. 
A two-fold increase in anti-mycobacterial activity is observed for the pure levo stereoisomer 
of Se-met over the racemic DL mixture.  Stereospecific activity has also been observed in 
other studies where L-enantiomers are more readily assimilated in humans,
516
 and also 
exhibit greater glutathione peroxidase activity and inhibition of V79 cell lines.
498
 It is 
hypothesised that levo rotation of Se-AAs is responsible for anti-mycobacterial activity, with 
the dextro form having little or no anti-mycobacterial activity.  This is evidenced by a halving 
of anti-mycobacterial activity for Se-DL-met relative to Se-L-met; however, further 
validation using Se-D-met and other Se-AAs is required to confirm the hypothesis.  This may 
be caused by preferential uptake of levo enantiomers, exclusive incorporation into proteins or 
stereospecificity-dependant enzymatic or metabolic interactions. 
 
Increasing the number of side chain carbons from two (SMSC) to three (Se-met) appeared to 
have a minor negative impact on anti-mycobacterial activity, as the (DL)-SMSC has an MIC 
of 15.6 µM toward M. smegmatis cultured in 7H9 media and Se-DL-met has an MIC of 31.2 
µM.  Thus, addition of a carbon at the γ position of the amino acid side chain slightly reduces 
anti-mycobacterial activity. 
 
Carboxylic acid and primary amine moieties are defining characteristics of amino acids.  It is 
thought that Se-AA anti-mycobacterial activity could be dependant on either or both of these 
constituent groups.  This hypothesis remains to be tested, but it is observed that 
methylseleninic acid retains anti-mycobacterial activity, and it does not contain either 
carboxylic acid or amine groups.  Although methylseleninic acid has no amine, hydroxyl and 
selenoxide groups attached to the selenium are similar substituents to carboxylic acid, and 
perhaps either or both structurally compensate for the lack of a carboxylic acid moiety.  
Seleno-urea on the other hand has a primary amine but no carboxylic acid group, and lacks 
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anti-mycobacterial activity towards M. smegmatis in 7H9 medium.  Although seleno-urea has 
a ketimine functional group and also lacks methylation of the selenium, this may contribute 
to its lack of activity. 
Se-DL-cys does not exhibit a high level of anti-mycobacterial activity, with an MIC in M. 
smegmatis of 50 µM in 7H9 medium.  However, seleno-cystine, the dimeric form of Se-DL-
cys has a 5-fold reduction in activity compared to Se-DL-cys.  This indicates the diselenide 
bond that links the two Se-DL-cys to form seleno-cystine impedes anti-mycobacterial activity 
or is not efficiently metabolised by mycobacteria in vitro.  Furthermore, dimerisation of Se-
DL-cys causes a reduction in activity either through reducing chemical solubility,
517
 and the 
resulting lowered mycobacterial uptake. 
In summary from the limited anti-mycobacterial activity testing that has been performed 
several structural influences upon seleno-compound activity have been observed.  Most 
important is the presence of the selenium, which is indispensible for anti-mycobacterial 
activity.  Levo stereochemistry increases inhibitory activity toward mycobacteria two-fold 
over racemic dextro/levo mixture.  Levo stereochemistry may be essential for activity of Se-
AAs.  It is uncertain if the carboxylic acid and primary amine functional groups are essential 
for activity, although the carboxylic acid or similar moiety appears more influential on anti-
mycobacterial activity.  Methylation of the selenium is not a vital component of the anti-
mycobacterial activity of Se-AAs, but methylation significantly enhances activity.  
Conversely, dimerisation by a diselenide bond severely reduces Se-AA activity.  Increasing 
the number of carbons in the amino acid side chain evidently results in a minor reduction in 
activity. 
6.2.2 Seleno-amino acid derivatives 
Several chemical derivatives of Se-AAs were kindly synthesised by Zaid Amso and Dr. Viji 
Sarojini.
518
  These were alanine dipeptide conjugates of Se-L-met, as alanyl- conjugates are 
thought to have increased uptake into the mycobacterial cell,
519
 and also alanyl-methionine 
dipeptides were shown to have 2.5-fold increased methanethiol production by Brevibacterium 
linens compared to L-methionine.
520
  Also included were arginine dipeptide conjugates, with 
positively charged arginine
521
 believed to have greater affinity and penetration of the 
negatively charged mycobacterial cell wall.
522, 523
  Mycobacteria also have a predilection for 
arginine uptake with several arginine importing transporters, believed to functionally contest 
host macrophage arginine uptake to diminish macrophage nitric oxide mediated attack.
524
  
Arginine, when included as an adjuvant in TB therapy, has also shown to improve clinical 
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outcomes.
525
  Finally, amide derivatives of Se-L-met and the aforementioned dipeptides, as 
the amide derivative of methionine, L-methioninamide, was shown to have a 4.7-fold 
increase in methanethiol production compared to L-methionine in B. linens.
520
  It is possible 
this phenomenon may extend to increased methylselenol production, and anti-mycobacterial 
activity, from the selenium equivalents of these derivatives in mycobacteria.  Derivatives 
were tested for their inhibitory activity towards M. tuberculosis H37Ra in a 7H9+ medium 
dose-response assay, with Se-L-met, SMSC and frontline TB drug controls. 
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Derivative Chemical Name M. tuberculosis 
H37Ra MIC (µM) 
Structure 
Sem001 Ala-SeMet 250 
 
Sem003 Ala-SeMet-NH2 250 
 
Sem005 SeMet-Ala 1000 
 
Sem006 SeMet-Arg 125 
 
Sem007 SeMet-NH2 125 
 
Table 6.2:  Seleno-amino acid derivatives.   
Derivatives of Se-L-met synthesised by Zaid Amso and Dr. Viji Soarojini.
518
  The derivatives 
internal name, its chemical name, the MIC in µM against M. tuberculosis H37Ra in 7H9 
medium and the chemical structure diagram are presented.  Note Sem002 and 004 were 
unpurified extracts of Sem001 and 003, respectively; thus, are not included in this table. 
None of these derivatives showed increased inhibitory activity over the parent Se-L-met; but 
nonetheless, they provide additional valuable insight into the structure-activity relationship of 
the Se-AAs, discussed below.   
 
6.2.2.1 Seleno-amino acid derivatisation influence on anti-mycobacterial activity 
Alanine dipeptides both decrease MIC activity to 250 µM (Ala-SeMet) and 1000 µM 
(SeMet-Ala). This is a large contrast in activity that is dependant on the conjugation terminus. 
  CHAPTER SIX:  SE-AA STRUCTURE-ACTIVITY RELATIONSHIP AND MECHANISM OF ACTION     225 
Substitution of the c-terminal amide seemed to have no impact here, possibly indicating 
uptake rate limitation before lyase cleavage, as the SeMet-NH2 itself also exhibited 
diminished activity.  The SeMet-Arg dipeptide showed less reduction of activity, with an 
MIC of 125 µM.  This is much improved over the SeMet-Ala and is a favourable indication 
for the positively charged arginine derivative.  Perhaps the opposite Arg-SeMet could be 
worth pursuing considering the trend in activity exhibited by the alanyl c- and n- terminal 
conjugations.  The amide SeMet-NH2 also showed a reduction in activity, although a lesser 
reduction to 125 µM.  The results encountered by Ferchichi et al
520
 unfortunately did not 
cross over to our to our anti-mycobacterial assay as hoped.  Either SeMet-NH2 is not as 
efficiently recognised for uptake, or is not as efficiently subjected to lysis of methylselenol, 
either because of recognition and degradation by other enzymes or lowered affinity to the 
lyase. This indicates that the carboxylic acid group could be vital for mycobacterial prodrug 
recognition and cleavage.  Further considerations for Se-AA derivatives for increased anti-
mycobacterial activity are discussed in Chapter 7.4.7. 
 
6.3 Seleno-amino acid mechanism of action 
Seleno-amino acids are known in the literature for various properties, detailed in Chapter 
5.1.4.  The main current research interest for Se-AAs is in their use in the reduction of cancer 
incidence, termed „chemoprevention‟.  A mechanism for Se-AA chemoprevention involving 
methylselenol has been proposed.  Potentially, the anti-mycobacterial activity of Se-AAs may 
take place through a similar mechanism. 
 
6.3.1 Seleno-amino acid anti-neoplastic mechanism 
Supra-nutritional selenium supplementation, in the form of Se-AAs such as Se-met, is 
associated with reduced incidence of colon, lung and prostate cancer,
426
 including a 63% 
reduction in prostate cancer incidence.
427
  Selenium demonstrated protective effects against 
liver cancer
526
 and improved breast cancer outcomes.
527
  Results of the SELECT selenium 
and vitamin E cancer prevention trial showed that neither selenium nor vitamin E 
significantly prevented prostate cancer; however, this has been attributed to limitations in the 
study population.
528
  Recent meta-analysis of 12 distinct studies observed that an increasing 
plasma selenium concentration correlates with a decreased incidence of prostate cancer.
529
  
Another meta-analysis of 49 observational studies and six randomised controlled trials also 
observed an inverse correlation between selenium supplementation and prostate cancer 
incidence; however, this was not conclusive and further trials are required.
530
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The chemopreventative mechanism of seleno-compounds has been proposed to involve 
apoptosis caused by reactive oxygen species (ROS) generated from selenium radicals.
531
  
Free radicals are independent chemical species with an unpaired electron.
532
  ROS is a 
general term referring to oxygen radicals including superoxide (O2
●-
), hydroxyl (
●
OH)  and 
non-radical oxygen compounds such as hydrogen peroxide (H2O2).
532
 
 
Figure 5.2 shows that the generation of selenol and selenide compounds such as 
methylselenol and hydrogen selenide are central to selenium compound metabolism.  These 
volatile seleno-compounds are derived from both inorganic selenium metabolism and also 
metabolic lysis of organo-selenium compounds, such as Se-AAs, by β and γ-lyase 
enzymes.
414, 533
  Methylselenol and hydrogen selenide are convertible via methyl transferase 
and demethylase enzyme activity.
409
  These volatile selenium species are pivotal steps in 
excretion of selenium in mammals.
401, 534
    
The oxidising action of selenol and selenide species on cellular glutathione and other reduced 
thiols causes the continuous cyclical generation of ROS such as superoxide O2
●-
, and 
subsequent formation of hydrogen peroxide (H2O2) and hydroxyl radicals (
●
OH) as shown in 
Figure 6.2.  These ROS in turn cause cellular stress through damage to DNA, proteins and 
membranes, resulting in a cellular apoptotic response.
531, 534
  Methylselenol displays stronger 
inhibitory properties towards cancer cells than to non-cancer cell lines, thought possibly due 
to differential expression of cancer associated genes such as mitogen-activated protein 
kinases and c-Myc.
433, 533
  Various selenium compounds are known to induce superoxide 
generation in vitro through the glutathione mechanism, including selenite, selenocystine and 
methylseleninic acid.  In contrast, seleno-amino acids such as Se-met and SMSC do not 
generate superoxide in vitro through glutathione.
535
  However, addition of methioninase, a γ-
lyase enzyme, to the in vitro superoxide generation assay results in superoxide generation 
from Se-met.  Superoxide generation is not observed for sulphurous methionine or SMSC.
535
  
This indicates that selenium is vital for the catalytic mechanism of superoxide generation, 
since normal sulphur methionine does not generate appreciable superoxide.  Although 
superoxide is not produced by γ-lyase activation on SMSC, this is expected as there is no γ –
position carbon in SMSC.  Thus, SMSC is not a feasible substrate for γ –lyase.  However, it 
is thought that in vivo, similar methylselenol generation occurs from SMSC by action of a β-
lyase enzyme.
533, 535, 536
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Figure 6.2:  Redox cycling of methylselenium species.   
Methylselenol (CH3SeOH) forms an adduct with glutathione or other free reactive thiols 
(GSH) and methylselenide anion (CH3Se
-
) is formed by oxidation of this adduct to form 
glutathione disulphide (GSHGSH).  Methylselenide (CH3Se
-
) reacts with molecular oxygen 
to form superoxide anion (O2
●-
) that reacts with water to form other ROS such as hydrogen 
peroxide (H2O2) and hydroxyl radicals (
●
OH) that cause cellular damage and may also react 
with methylselenide (CH3Se
-
) to form methylselenol (CH3SeOH) and begin the cycle anew.  
The methylselenide radical (CH3Se
●
) is recycled to methylselenide (CH3Se
-
) either by 
reduction by cellular glutathione or thiols (GSH) or by dimerisation to dimethyldiselenide 
(CH3SeSeCH3). Dimethyldiselenide is also reduced by glutathione forming a glutathione-
methylselenol adduct.  Adapted from Spallholz et al (2004)
535
 and Chaudiere et al (1992)
537
. 
 
In summary, selenium compounds are generally thought to exert anti-cancer effects through 
generation of reactive oxygen species, causing apoptosis.  Se-AAs act as pro-drugs that are 
cleaved by lyase enzymes into their active methylselenol form that reacts with cellular 
glutathione and other free reactive thiols to cyclically generate reactive oxygen species. 
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6.3.2 Seleno-amino acids as anti-mycobacterial agents 
The 2009 publication of this research is the first and currently only public disclosure of the 
anti-mycobacterial properties of Se-AAs.
122
  Additional to this publication and the further 
analysis of Se-AAs as anti-mycobacterials in this thesis, there is some isolated evidence 
supporting selenium supplementation reducing incidence or improving outcomes of 
pulmonary TB.  For example, a controlled study of HIV-infected drug users associated 
patient selenium status with a significantly lower incidence of mycobacterial disease, with 
plasma selenium levels < 135 µg/L having 13x higher probability of developing 
mycobacterial disease compared to matched controls.
455
   
Supplementation of vitamin A, B complex, C, E and selenium in patients undergoing 
treatment for pulmonary TB (with and without HIV) reduces the overall risk of TB 
recurrence by 45%.
538
  Low plasma selenium is associated with physical wasting and health 
decline in TB, pulmonary TB risk and TB disease progression.
539-542
   
 
Selenium supplementation is known to contribute to TB patient anti-oxidant status and reduce 
oxidative stress, a by-product of the immune response to TB infection that provokes 
inflammation, leading to tissue damage such as pulmonary fibrosis.
543
   
It remains unclear if patient selenium depletion is a cause or consequence of TB infection, but 
in any case, high patient selenium status appears to be associated with improved disease 
outcomes, reduced disease incidence and reduced disease-associated symptoms.  Further 
trials are required to specifically investigate this association.  In light of Se-AAs being shown 
in this research to have direct anti-mycobacterial activity in vitro, it is possible that patient 
selenium supplementation actively contributes to inhibiting M. tuberculosis infection in vivo, 
in addition to having positive effects such as improving immune function and reducing the 
inflammatory response. 
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6.3.2.1 Proposed mechanism of Se-AA anti-mycobacterial activity  
Considering the known chemopreventative / anti-neoplastic mechanism of action known to 
occur with seleno-compounds such as Se-AAs (detailed above in section 6.3.1), it is likely 
that the anti-mycobacterial action of Se-AAs occurs through a similar mechanism.  The 2009 
publication of this work proposed that SMSC exerted its anti-mycobacterial effects by 
enzymatic cleavage into pyruvate, ammonia and the toxic metabolite methylselenol.
122
  While 
this putative mechanism is not considered incorrect, it is considered incomplete in light of 
further literature research, particularly concerning the toxic properties of methylselenol as 
detailed in Figure 6.2. 
The anti-mycobacterial activity of Se-AAs is absent in rich LB medium, containing complex 
nutrients such as amino acids.  It is likely that Se-AAs are recognised as amino acid nutrients 
and are indiscriminately transported into the cell.  The Se-AA pro-drug is then cleaved into 
its active methylselenol form by the action of mycobacterial lyase enzymes.  Methylselenium 
species are then redox cycled in a similar fashion as displayed in Figure 6.2, generating 
damaging oxygen radical by-products that cause damage to mycobacterial cell components 
including DNA, proteins and lipids.
544
  This three-step hypothesis is described below, and 
illustrated in Figure 6.3. 
1) Se-AA pro-drug is recognised as a nutrient and transported into mycobacterial 
cells. 
2) Se-AA pro-drug is cleaved into active methylselenium species and other  
metabolites by mycobacterial lyase enzymes. 
3) Methylselenium species are redox cycled by mycobacteria cellular processes that 
generate damaging reactive oxygen species. 
It is not known why Se-AAs do not exhibit inhibitory activity toward other bacterial species, 
even in nutrient limited conditions.  However, this lack of broad spectrum activity indicates 
Se-AAs may act via a specific mycobacterial enzyme or process. 
  CHAPTER SIX:  SE-AA STRUCTURE-ACTIVITY RELATIONSHIP AND MECHANISM OF ACTION     230 
Figure 6.3:  Hypothetical three-step mechanism of Se-AA anti-mycobacterial activity.   
1. Se-AAs such as Se-met (pictured) are recognised as nutrients by mycobacterial amino acid 
transporters and imported into the cell.  2. Se-AA is cleaved by mycobacterial lyase enzyme.  
Pictured is Se-met lysed by methionine γ-lyase, producing α-ketobutyric acid, ammonia and 
methylselenol.  Other Se-AAs are lysed by alternative lyase enzymes such as β-lyase and 
produce different metabolites although methylselenol is conserved.  3.  Methylselenol 
undergoes redox cycling that produces ROS that cause damage to mycobacterial cell 
components such as DNA, proteins and lipids. 
 
6.3.2.1.1 Missing link in methylselenium species-induced toxicity 
Mycobacteria do not synthesise or utilise glutathiol; thus, the redox cycling of 
methylselenium compounds and subsequent generation of ROS and anti-mycobacterial 
activity may be attributed to a similar functional chemical or enzyme.   One candidate for this 
mycobacterial glutathione stand-in is mycothiol, the major low molecular weight thiol of 
Actinobacteria that serves a homologous redox maintenance function to glutathione in 
eukaryotes and other bacteria.
545
  Alternatively, a redox-homeostasis protein such as a 
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thioredoxin, oxidoreductase or peroxidase type enzyme may be responsible for the redox 
cycling of methylselenium. 
Mycothiol is known to have a protective effect against reactive oxygen and nitrogen species, 
in addition to detoxifying alkylating agents and antibiotics.
546
  Therefore, it is of no surprise 
that mycothiol is essential for M. tuberculosis growth,
547
 considering the intracellular nature 
of the M. tuberculosis pathogen and its frequent exposure to oxygen and nitrogen radical 
attack by the immune system.
548
  However, in addition to these protective functions, evidence 
suggests mycothiol plays a role in the activity of ethionamide and isoniazid, as mycothiol-
deficient mutants exhibit resistance to these nicotinamide pro-drugs.
549
  Considering the 
typical protective role of mycothiol against free radical stress, the redox cycling of 
methylselenol by mycothiol and subsequent production of ROS toxicity appears contrary to 
the typical function of mycothiol.  This indicates that additional factors may possibly be 
involved in the anti-mycobacterial mechanism of Se-AAs.  These may include as mycothiol-
dependant peroxidase or thiol transferase enzymes,
550
 or an alternative redox maintenance 
system to mycothiol such as thioredoxin, peridoxin or a combination of any of the above. 
 
6.3.2.1.2 Testing the proposed Se-AA mode of action 
In order to test the three components of the Se-AA mechanism of action hypothesis (detailed 
in Figure 6.3), a variety of experiments were carried out.   
To determine if Se-AAs were recognised by mycobacteria as their sulphur analogue amino 
acids and imported into the cell as nutrients, a competition assay was performed.  
 
To query the enzymatic lysis and pro-drug activation of Se-AAs by mycobacterial β- and γ-
lyase enzymes, differential sensitivity assays using anti-sense RNA down-regulation of 
suspect lyase gene (identified through bioinformatic analysis detailed in section 6.5.2.1) 
expression was carried out.  Additionally, S. cerevisiae strains with deleted genes 
homologous to mycobacterial lyases were also tested for differential susceptibility to Se-AAs.  
M. tuberculosis homologues of aforementioned suspected lyase enzymes were also purified 
and assayed in vitro for utilisation of Se-AA substrates.   
 
Finally to question the final step in the proposed modem of action of Se-AAs, random 
transposon mutants resistant to Se-AAs were generated in the hope of elucidating key 
enzymes and associated metabolic pathways involved in the redox cycling of methylselenium 
compounds. 
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6.4 Results   
6.4.1 Seleno-amino acid uptake - competition assays 
Rescue assays were performed as in Chapter 2.2.4 using M. tuberculosis H37Ra in 7H9 and 
M. smegmatis in HdeB media. DL-cys and DL-met were supplemented in equimolar amounts 
to Se-AAs. 
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These dose-response curves show that either cysteine or methionine supplementation is able 
to alleviate toxic effects of SMSC or Se-L-Met against M. tuberculosis H37Ra.  Similar 
results were observed for M. smegmatis cultured in HdeB C- and N- media conditions (results 
not shown).  This non-specific sulphurous amino acid rescue effect indicates that Se-AAs 
compete with sulphurous amino acids at the amino acid transporter level, and may also 
Figure 6.4a:  SMSC toxicity is 
alleviated by equimolar amounts 
of DL-cys or DL-met.   
M. tuberculosis inhibition by SMSC 
is negated by supplementation with 
DL-cys or DL-met.  Lines are 
colour-coded as depicted below, with 
circles representing SMSC and DL-
cys and triangles representing 
combinations of SMSC and sulphur 
amino acids. 
Figure 6.4b:  Se-L-met toxicity is 
alleviated by equimolar amounts 
of DL-cys or DL-met.   
M. tuberculosis inhibition by Se-L-
met is negated by supplementation 
with DL-cys or DL-met.  Lines are 
colour-coded as depicted below, with 
circles representing Se-L-met and 
DL-met and triangles representing 
combinations of Se-L-met and 
sulphur amino acids. 
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compete specifically at the lyase level. 
 
6.4.2 Seleno-amino acid lyase pro-drug activation 
6.4.2.1 Anti-sense RNA gene down-regulation using pMIND_2357 
M. smegmatis pMIND_2357 was generously supplied by Dr. S. Nisa.  pMIND_2357 is a 
tetracycline inducible vector that contains the MSMEG_2357 cysteine desulphurase gene in 
the anti-sense orientation.  Tetracycline induction of this vector causes down-regulation of 
MSMEG_2357 expression.
162
  M. smegmatis pMIND_2357 exhibits similar growth and 
fitness characteristics to wildtype M. smegmatis and was used as an anti-sense control strain 
in screening for inhibitors of ParA mycobacterial chromosomal partitioning protein.
157
  
Initially the M. smegmatis pMIND_2357 strain was queried with a dose-response assay to 
SMSC compared to the screening strain M. smegmatis pSHIGH+HSP60 as per methodology 
described in Chapter 2.2.5. 
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Figure 6.5: Anti-sense knockdown of MSMEG_2357 increases SMSC resistance.   
Anti-sense down-regulation of the cysteine desulphurase MSMEG_2357 using the pMIND 
vector increases the MIC of SMSC towards M. smegmatis 8-fold in HdeB C- medium and 32-
fold in HdeB N- medium over the control vector strain pSHIGH+HSP60. 
 
Clear differential sensitivity was observed between M. smegmatis pMIND_2357 and the 
control strain M. smegmatis pSHIGH+HSP60.  Down-regulation of MSMEG_2357 cysteine 
desulphurase resulted in increased resistance to SMSC, with an 8-fold MIC increase in HdeB 
C- medium and a 32-fold increase in HdeB N- medium. 
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6.4.2.2 Anti-sense RNA gene down-regulation using pKW08 vector 
pKW08 is a mycobacterial tetracycline inducible expression vector, similar to pMIND with a 
different vector backbone and improved tetRO promoter.
188
  pKW08 was generously 
provided by Dr. K. Williams.  pKW08_GFP vectors were created in this work and used to 
down-regulate expression of M. smegmatis genes.  In this work, GFP was cloned into pKW08 
downstream of the tetRO promoter as a reporter of tetRO induction.  A 10x10 scan of 
pKW08_GFP tetracycline induction of GFP expression is shown in Figure 6.6.  
Figure 6.6:  Tetracycline inducible expression using M. smegmatis pKW08_GFP vector. 
10x10 plate scan of GFP expression (excitation 488 nm emission 509 nm) of M. smegmatis 
pKW08_GFP in triplicate with increasing concentrations of tetracycline inducer.   
 
MSMEG_2357 cysteine desulphurase and MSMEG_5265 cystathionine gamma-
synthase/lyase were cloned downstream of tetRO in pKW08_GFP, both in the sense (with 
RBS) and anti-sense orientation, for up and down-regulation of these genes, respectively.  
Gene expression was measured by the GFP reporter and the highest level of expression was 
induced by 100 ng/mL tetracycline with higher concentrations dropping in expression most 
likely due to tetracycline induced toxicity, as shown for pKW08_GFP_2357S and for 
pKW08_GFP _5265S in Figure 6.7. 
  
Figure 6.7:  Induction of 
tetRO expression as 
measured by GFP.   
24 hour induction of 
MSMEG_2357 (blue) and 
MSMEG_5265 (red) 
expression as measured by 
a downstream co-translated 
GFP reporter.  Induction is 
highest at 100 ng/mL 
tetracycline. 
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pKW08 tetracycline induced gene expression strains were queried with a dose-response assay 
to SMSC and Se-L-met as described in Chapter 2.2.5. 
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Figure 6.8a:  Dose-response curves for pKW08 mediated up- and down-regulation of 
MSMEG_2357 and MSMEG_5265.   
M. smegmatis cultured in HdeB C- and HdeB N- media, induced by tetracycline.  Growth is 
measured in triplicate wells by OD600 relative to a no-drug control (100% growth). 
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Figure 6.8b:  Dose-response curves for pKW08 mediated up- and down-regulation of 
MSMEG_2357 and MSMEG_5265 M. smegmatis against Se-AAs.   
For M. smegmatis cultured in 7H9 and LB media, only cultures induced tetracycline are 
shown.  Details as per Figure 6.8a. 
 
No significant differential sensitivity was observed using the pKW08 tetracycline inducible 
up- and down-regulation of MSMEG_2357 and MSMEG_5265 in M. smegmatis cultured in 
any of the media types tested.  This result is in contrast to the initial observations seen with 
pMIND_2357.  Possible reasons for the lack of activity are discussed in section 6.5.2.2. 
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Figure 6.8c:  Dose-response curves for pKW08 mediated up- and down-regulation of 
MSMEG_2357 and MSMEG_5265 M. smegmatis against Se-AAs.  For M. smegmatis 
pKW08_GFP controls cultured in HdeB C-, HdeB N-, 7H9 and LB media.  Both tetracycline 
induced and un-induced cultures are shown as detailed in the central figure legend.  Details as 
per Figure 6.8a. 
  
  CHAPTER SIX:  SE-AA STRUCTURE-ACTIVITY RELATIONSHIP AND MECHANISM OF ACTION     238 
6.4.2.3 S. cerevisiae lyase gene deletion strains 
S. cerevisiae gene deletion mutant strains YCL017C (cysteine desulphurase), YAL012W 
(cystathionine γ-lyase) and YLR303W (O-acetyl homoserine-O-acetyl serine sulfhydrylase) 
were kindly provided by Bede Busby of the VUW Chemical Genetics laboratory.  These 
knockout straoms of non-essential S. cerevisiae genes
551
 were selected for their homology to 
mycobacterial  β- and γ-lyases MSMEG_2357 and MSMEG _5265 and were tested in seleno-
compound dose-response assays wih both nutrient-rich SC and nutrient-limited SPO media. 
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Figure 6.9:  Dose-response curves for Se-AAs against S. cerevisiae lyase gene deletion strains 
in SC and 0.5x SPO media.   
For wild type reference strain graphs: see Figures 5.13a, 5.13b and 6.10. 
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As seen in Chapter 5.2.2.1, high concentrations of SMSC in conjunction with S. cerevisiae 
cultured in SPO media caused resazurin reduction.  S. cerevisiae YAL012W was unable to be 
cultured in SPO media, suggesting the CYS3 γ-lyase gene is essential under SPO media 
conditions.  The significant finding of this experiment was that the CYS3 γ-lyase knockout 
strain YAL012W is resistant to Se-L-met, with an 8-fold increase in MIC compared to the S. 
cerevisiae 4743 diploid control strain.  This resistance is better seen in Figure 6.10 that 
includes control strains 4741 (haploid) and 4743 (diploid).  Interestingly, YAL012W was also 
more sensitive to sodium selenite with a MIC of 125 µM compared to the 2000 µM MIC 
exhibited by the 4743 diploid control strain (results not shown). 
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6.4.2.4 Pro-drug activation in vitro enzyme activity assays 
Mycobacterial β and γ-lyase genes used in anti-sense constructs and additional genes of 
interest were identified bioinformatically using the published literature, the KEGG database 
and NCBI BLAST.  These genes were cloned into the pET28a+ expression vector, as 
described in Chapter 2.3.2, and overexpressed in E. coli BL-21.  Enzymes were purified by 
Ni
2+
 affinity chromatography as described in Chapter 2.3.3.1.  Purified enzymes were utilised 
in enzymatic assays in vitro to determine mycobacterial lyase activity toward Se-AA 
substrates and query the prodrug mechanism hypothesis described in Figure 6.3.  
Figure 6.10:  Comparison 
of S. cerevisiae lyase 
knockout strain and wild 
type strain dose-response 
to Se-L-met. Growth 
measured in triplicate by 
OD600 compared to 100% 
growth (no drug) controls. 
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6.4.2.4.1 Enzyme purification 
Cysteine desulphurase enzyme MSMEG_2357 and its M. tuberculosis H37Rv homologue 
Rv3025c, cysteine desulphurase / selenocysteine lyase Rv1464 and O-acetylhomoserine 
aminocarboxypropyltransferase Rv3340 were successfully purified from recombinant E. coli 
BL-21 as shown in Figure 6.11, proteins were identified by their size and intensity relative to 
the standard ladder, but MALDI mass spectroscopy would be a more desirable method to 
confirm protein identity.  O-acetylhomoserine sulfhydralyase Rv0391 and cystathionine γ-
synthase Rv1079 were successfully expressed in E. coli BL-21 but were unable to be 
purified, suggesting these proteins may have misfolded during the protein expression and 
purification procedure, or alternatively Rv0391 may be membrane bound. 
 
 
 
  
Figure 6.11:  Protein purification SDS-PAGE.   
Left panel shows eluted protein fractions prior to size-based purification and desalting.   
Lanes 1 and 2 are MSMEG_2357.  Lanes 3, 4 and 5 are Rv3025c.  Lane 7 is Rv0391, lane 8 
Rv1079, Lane 9 Rv1464 and lane 10 Rv3340.  The right panel shows lysed recombinant E. 
coli BL-21 induced overnight to express proteins.  Lanes A: Rv0391, B: Rv1079, C: 
Rv1464, D: Rv3340.  Lane E shows Rv0391 elution by column chromatography, and lane F 
shows Rv1079 eluted by column chromatography.  Protein molecular weight ladders are 
included in the centre of the gels with molecular weight of relevant bands labelled. 
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6.4.2.4.2 Metabolite Detection 
To determine the mycobacterial enzymes involved in the lysis of Se-AAs and to confirm the 
viability of prepared mycobacterial enzymes, a variety of metabolite detection assays were 
used as described in below.  
 
6.4.2.4.2.1 Gas chromatography-mass spectrometry 
GC-MS analysis of Rv3025c reaction products was carried out with the kind instruction of 
Dr. R. Keyzers, the methodology for which is described in Chapter 2.4.4.   
 
A volatile selenium species was detected with 96% spectral similarity to NIST 11 database 
methyldiselenide specrum, at 7.15 sec into the run, as shown in Figure 6.12.  Values of over 
95% spectral similarity are considered to be highly indicative of compound identity.  This 
methyldiselenide was produced as a product of the Rv3025c enzyme reaction with 1 mM 
SMSC in ISCS buffer, the dimeric methyldiselenide is a known indicator of 
methylselenide.
552
  Methyldiselenide was not detected in a no-enzyme control reaction using 
BSA in place of Rv3025c, or using Se-DL-cys as the substrate.  Implications of this finding 
are discussed in section 6.5.2.4.1. 
 
 
 
Figure 6.12:  GC-MS result for methyldiselenide.   
The top panel shows the peak spectrum for the sample at 7.15 seconds into the run.  The 
bottom panel shows the peak spectrum for methyldiselenide, the most similar match to the 
sample result with 96% spectral identity.   
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Borane-methyl sulphide with 97% similarity or dimethylsulphide with 96% similarity was 
detected at 1.93 seconds into the run following incubation of DL-cysteine as above with 
either Rv3025c or BSA enzyme control, shown in figure 6.13. 
 
Figure 6.13:  GC-MS result for dimethylsulphide.   
The top panel shows the peak spectrum for the sample at 1.93 seconds into the run.  The 
middle panel shows the peak spectra of the best match, borane-methyl sulphide, with 97% 
identity to the sample, and the bottom panel shows the next best match, dimethylsulphide, 
with 96% identity to the sample.  
 
6.4.2.4.2.2 Methylene blue sulphide/selenide detection 
Production and quantification of sulphide and selenide species by purified mycobacterial 
enzyme lyase activity towards DL-cys, DL-met and Se-AAs in vitro was carried out as 
described in Chapter 2.4.2.2.  No sulphides or selenides were detected using this method 
using either DL-cys, DL-met or SMSC, Se-DL-cys or Se-L-met in conjunction with Rv1464, 
Rv3025c or Rv3340.  This may be due to the volatile nature of the sulphide/selenides species 
leading to loss from the solution. 
 
6.4.2.4.2.3 Lead acetate sulphide/selenide detection 
To identify volatile sulphide / selenide species produced by mycobacterial lyase enzyme 
reactions, PbAc paper was prepared as described in Chapter 2.4.2.1 and placed over 96-well 
plates containing lyase enzyme cocktail prior to sealing the plates and assay incubation. 
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Figure 6.14:  PbAc paper detection of volatile sulphide / selenide. 
Top left panel shows an Rv3025c enzyme assay plate, with rows of 10 µg Rv3025 
(+Rv3025c) or 10 µg BSA (-Rv3025c) against various substrates (2mM).  Note the orange-
red precipitate for Se-DL-cys and Se-L-cys only in conjunction with Rv3025c.  Bottom left 
panel shows the same image but with the PbAc paper digitally overlayed on the image.  Note 
the dark precipitate of PbS for DL-cys in combination with Rv3025c.  The right panel shows 
a follow-up dose-response assay for Rv3025c with increasing concentrations of DL-cys.  The 
no-enzyme control column (marked –Rv3025c) contains 10 µg BSA and duplicate 
experimental columns (marked + Rv3025) contain 10 µg of purified Rv3025c enzyme.  A 
clear trend of the PbAc paper reaction is observed with increasing DL-cys concentration.  
Some sulphide release in the no-enzyme control is seen, predominantly at 0.5-1.0 mM DL-
cys. 
 
Reaction of PbAc paper forming a dark precipitate of PbS was observed only for Rv3025c 
enzyme and DL-cys substrate.  As seen in Figure 6.14, an orange-red precipitate (presumed 
to be elemental selenium Se
0
) was observed in the well for Rv3025c with Se-DL-cys and Se-
L-cys, Se-L-cys produced more precipitation than Se-DL-cys.  No reaction of PbAc paper 
was observed for other mycobacterial enzymes or substrates.  An increasing PbAc paper 
response was seen for increasing DL-cys concentrations in the presence of Rv3025c, and a 
slight PbAc reaction was seen for low concentrations (0.5-1.0 mM) DL-cys in the absence of 
Rv3025c. 
 
6.4.2.4.2.4 Alanine dehydrogenase-coupled assay 
Mycobacterial enzyme reactions as described in Chapter 2.4.1 were coupled with an alanine 
dehydrogenase (Ala-DH) reaction, both simultaneously and as a two-step reactions as 
described in Chapter 2.4.2.2.  The rationale for these tests was if alanine is produced as a by-
product by mycobacterial lyase action on sulphur-AA / Se-AA substrates, this enzymatic 
activity may be able to be quantifiably detected by measuring corresponding β-NAD 
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reduction by Ala-DH.   
No Ala-DH activity was detected from 10 µg mycobacterial lyase enzymes Rv1464, 
Rv3025c, Rv3340 and MSMEG_2357 using the substrates DL-cys, DL-met, Se-DL-cys, 
SMSC and Se-L-met.  Positive controls using L-alanine yielded the expected β-NAD 
reduction curve (increase in OD340 over time at a concentration-dependant rate; results not 
shown).  The implications of the Ala-DH coupled assay are discussed in section 6.5.2.4.4. 
 
6.4.2.4.2.5 Lactate Dehydrogenase coupled assay 
Similar to the Ala-DH coupled assay described above, mycobacterial enzyme reactions 
described in Chapter 2.4.1  were coupled with lactate dehydrogenase (Lac-DH), both 
simultaneously and as two-step reactions as described in Chapter 2.4.2.3.  The reasoning 
again being if pyruvate is product of mycobacterial lyase action on sulphur-AA / Se-AA 
substrates this activity may be able to be detected and quantified by measuring corresponding 
NADH oxidation by Lac-DH.  As above for Ala-DH, no Lac-DH activity was detected from 
10 µg mycobacterial lyase enzymes Rv1464, Rv3025c, Rv3340 and MSMEG_2357 using the 
substrates DL-cys, DL-met, Se-DL-cys, SMSC and Se-L-met.  Positive controls using 
sodium pyruvate yielded the expected NADH oxidation curve (decrease in OD340 over time at 
a concentration-dependant rate; results not shown).  The implications of the Lac-DH coupled 
assay are discussed in section 6.5.2.4.4.    
 
6.4.2.4.2.6 Methylbenzothiazolinone hydrazone alpha-keto acid detection 
Detection of the possible Se-AA metabolite α-ketobutyrate or similar α-keto acids was 
carried out on mycobacterial lyase reactions using the 3-methyl-2-benzothiazolinone 
hydrazone hydrochloride method of Tokoro et al
553
  as described in methods Chapter 2.4.2.4.  
No α-keto acids were able to be detected from mycobacterial lyase reactions with sulphur-
AAs or Se-AAs substrates; whereas, the α-ketobutyrate control produced the expected dose-
dependant increase in OD320; results not shown.   
 
6.4.3 Mycobacterial redox cycling of methylselenol  
6.4.3.1 Seleno-amino acid resistant transposon mutants 
To identify the metabolic pathways and genetic components involved in Se-AA resistance, 
and provide insight into the Se-AA mechanism of action, transposon gene-disruption mutant 
strains of M. smegmatis with resistance to SMSC and Se-L-met were generated and selected 
for as described previously in section 2.3.2.8.  Four generations of Se-AA resistant 
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transposon mutants were generated, two generations each for SMSC and Se-L-met.  For each 
generation 10 of the largest colonies were picked, cultured and verified for Se-AA resistance 
by dose-response assays, before undergoing DNA purification and sequencing to determine 
the transposon insert site and resulting gene disruption responsible for Se-AA resistance.  Out 
of 40 mutants selected, 14 were unable to be genetically identified and were discarded, 
leaving 26 unique Se-AA resistant mutants with defined gene disruptions (listed in Table 
6.3). 
Mutant # 
Origin 
(µM) 
Tn611 gene 
insertion 
Gene annotation 
MIC (µM) 
SMSC SeMet 
TN-G1-M3 SMSC 10 MSMEG_3638 
CBS domain protein (membrane 
bound Fe2+ transporters) 
62.5 62.5 
TN-G1-M4 SMSC 10 MSMEG_4695/6 
Alpha amylase family protein and 
haemoglobin like protein 
125 125 
TN-G1-M6 SMSC 20 MSMEG_4270 Adenosine kinase 125 125 
TN-G1-M7 SMSC 30 MSMEG_6756/7 Glycerol kinase glpK 250 250 
TN-G1-M9 SMSC 30 MSMEG_2729 
miaB adenosine tRNA 
methylthiotransferase 
250 125 
TN-G1-M11 SMSC 40 MSMEG_6759 Glycerol kinase glpK 500 125 
TN-G1-M12 SMSC 40 MSMEG_3200 L-aspartate oxidase nad A/B/C 250 125 
TN-G2-M3 SMSC 60 MSMEG_1098 Acyl CoA Synthase 250 125 
TN-G2-M4 SMSC 60 MSMEG_4162 Conserved hypothetical 125 62.5 
TN-G2-M6 SMSC 80 MSMEG_6075/6 
Methyl erythritol 
cyclodiphosphate synthase 
62.5 62.5 
TN-G2-M7 SMSC 80 MSMEG_1701 Purine nucleoside phosphorylase 125 62.5 
TN-G2-M8 SMSC 80 MSMEG_6756 Glycerol kinase glpK 125 62.5 
TN-G2-M9 SMSC 80 MSMEG_1019 
Ribonucleotide diphosphate 
reductase α-subunit 
250 62.5 
TN-G2-M14 SMSC 100 MSMEG_0376 araC transcriptional regulator 250 62.5 
TN-G2-M15 SMSC 100 MSMEG_6024 Acetoacetyl CoA reductase 62.5 62.5 
TN-G3-M1 SeMet 50 MSMEG_0848 
NADH ubiquinone 
oxidoreductase subunit 5 
32 62.5 
TN-G3-M2 SeMet 50 MSMEG_0211 
ABC transporter, ATP-binding 
protein 
32 62.5 
TN-G3-M3 SeMet 100 MSMEG_1221 rifampin ADP-ribosyl transferase 62.5 100 
TN-G3-M4 SeMet 100 MSMEG_4606 hypothetical protein 6.25 100 
TN-G3-M5 SeMet 100 MSMEG_5842 Conserved Hypothetical Protein 32 100 
TN-G3-M10 SeMet 100 MSMEG_4890/1 
Alkylhydroperoxidase, ahpC/D 
family protein 
250 500 
TN-G4-M1 SeMet 50 MSMEG_3756 23s Ribosomal Subunit (rrlA) 32 80 
TN-G4-M3 SeMet 50 
MSMEG_2199 
MSMEG_2200 
Flanked by formyltetrahydrofolate 
deformylase[purU] and 
Conserved hypothetical protein. 
32 50 
TN-G4-M4 SeMet 50 MSMEG_4842 Amidohydrolase 32 50 
TN-G4-M5 SeMet 50 MSMEG_4431 Putative regulatory protein 32 50 
TN-G4-M8 SeMet 80 MSMEG_5925 Rieske [2Fe-2S] domain protein 250 62.5 
 
Table 6.3: Se-AA resistant transposon mutants of M. smegmatis.   
Detailed from the left are the internal mutant designations, Se-AA concentrations used to 
generate the mutants (origin), genetic location of the transposon insertions (and likely genes 
disrupted), annotation for the genes disrupted and the MIC of the mutant strains against 
SMSC and Se-L-met in 7H9 medium. 
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Unfortunately several mutants that demonstrated high levels of Se-AA resistance were unable 
to be genetically identified, due to difficulty isolating re-ligated mutant gDNA or restriction 
enzyme sites being situated too close to the Tn611 insert, resulting in insufficient DNA 
sequence length to identify the insert site.  The significance of these mutations with regard to 
the Se-AA mechanism of action is discussed in section 6.5.3.  The relationship between the 
mutations and the Se-AA mechanism is not readily apparent for many of the mutants; 
however, for TN-G3-M10, a mutant in MSMEG_4890 ahpD alkylhydroperoxidase that 
confers protection against oxidative damage, fits directly into the hypothesised Se-AA 
mechanism of anti-mycobacterial action.  Dose-response curves of the TN-G3-M10 AhpD 
mutant alongside control strains of M. smegmatis pSHIGH+HSP60 and pMV261, shown in 
Figure 6.15.  These illustrate the clear shift in Se-AA resistance of the TN-G3-M10 mutant, a 
16-fold increase in the SMSC MIC and an 8-fold increase in the Se-L-met MIC compared to 
the control strains.  
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6.4.3.2 Inducible gene regulation of M. smegmatis alkylhydroperoxidase 
 M. smegmatis alkylhydroperoxidase genes were up- and down-regulated using the pKW08 
vector sense and anti-sense tetracycline inducible expression of these genes.  These strains 
were tested for differential susceptibility in a dose-response assay against SMSC and Se-L-
met.  As the TN-G3-M10 Tn611 insert occurs between the MSMEG_4890 (ahpD) and 
MSMEG_4891 (ahpC) genes, both of these genes have been knocked up/down by inducible 
expression in the pKW08.  Se-AAs dose-response curves of these constructs to are shown in 
Figure 6.16a for MSMEG_4890 (ahpD) and Figure 6.16b for MSMEG_4891 (ahpC). 
Figure 6.15:  Differential susceptibility of M. smegmatis 
TN-G3-M10 ΔahpD mutant strain.  Measured by triplicate 
resazurin fluorescence relative to 100% growth (no drug) 
controls, compared to screening strain pSHIGH+HSP60 and 
empty transposon vector strain pMV261. 
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The differential sensitivity of MSMEG_4890 (ahpD) sense over-expression and anti-sense 
under-expression strains is presented in Figure 6.16a.  Induction of both up- and down-
regulation of MSMEG_4890 using sense / antisense, respectively, results in a 2-fold increase 
in SMSC MIC for ahpD over-expression and a 4-fold increase in for ahpD under-expression.  
For Se-L-met, ahpD over-expression caused an increase in sensitivity (2-fold decrease in 
MIC); whilst ahpD under-expression produced a 4-fold rise in the Se-L-met MIC from 16 to 
64 µM. 
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Figure 6.16a:  Differential susceptibility of M. 
smegmatis to Se-AAs using tetracycline inducible 
over and under-expression of MSMEG_4890 
alkyhydroperoxidase ahpD.   
Measured by triplicate OD600 compared to 100% 
growth (no drug) control. 
 
Figure 6.16b:  Differential susceptibility of M. 
smegmatis to Se-AAs using tetracycline inducible 
over and under-expression of MSMEG_4891 
alkyhydroperoxidase ahpC.   
Measured by triplicate OD600 compared to 100% 
growth (no drug) control. 
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The differential sensitivity of MSMEG_4891 (ahpC) sense over-expression and anti-sense 
under-expression strains is shown in Figure 6.16b.  Both up- and down-regulation of 
MSMEG_4891 caused a 2-fold increase in the MIC of SMSC from 32 µM to 64 µM.  There 
was no change in MIC for Se-L-met with either up- or down- regulation of ahpC. 
 
6.4.3.3 Seleno-amino acid synergy with isoniazid 
Subsequent to the identification of alkylhydroperoxidases ahpC and ahpD in the mechanism 
of action of Se-AAs, investigation was made into the link between mycobacterial 
alkylhydroperoxidase and other peridoxins such as the catalase-peroxidase katG.  katG is 
implicated in isoniazid pro-drug activation,
554
 and consequently mutation in this gene can 
cause isoniazid resistance.
555, 556
 
 
It is known that in katG mediated isoniazid resistant M. tuberculosis ahpC may be hyper-
expressed to compensate for loss of katG function in protecting the mycobacterial cell from 
oxidative stress.
557, 558
 Therefore, it was predicted that if transposon mediated inactivation of 
mycobacterial ahpC/D leads to Se-AA resistance, the opposite effect of increased 
susceptibility to Se-AAs may be seen with ahpC/D up-regulation, such as in the case of katG 
mediated isoniazid resistant TB.    
In addition, a synergistic inhibitory effect may be observed between Se-AAs and the front 
line tuberculosis treatment drug, isoniazid, as these two drugs have interrelated genetic 
targets.  This synergy effect was tested using the checkerboard dilution method
208
 described 
in Chapter 2.2.6 using Se-L-met, isoniazid against M. tuberculosis H37Ra. 
 
Using the MIC values illustrated in Figure 6.17, and the fractional inhibitory concentration 
index (FIC index) equation described in Chapter 2.2.6, a FIC index of 0.5 was calculated for 
Se-L-met and isoniazid.  This value indicates synergistic effect between Se-L-met and 
isoniazid. 
  CHAPTER SIX:  SE-AA STRUCTURE-ACTIVITY RELATIONSHIP AND MECHANISM OF ACTION     249 
Figure 6.17:  Checkerboard assay for synergy between Se-L-met and isoniazid (INH).  
Cell values are the mean OD of triplicate assays, and are colour coded with dark red 
indicating < 10% growth, light red < 25% growth, yellow < 50% growth and green > 50% 
growth (compared to controls).  Concentration (µM) is shown in purple, and MIC is indicated 
in tan.  Top panel shows Se-L-met only, serially diluted in rows with MIC at 8 µM.  Middle 
panel shows INH only, serially diluted in columns with MIC at 2 µM.  Bottom panel shows 
the Se-L-met and INH checkerboard, with MIC values of 4 and 0.5 µM respectively. 
 
6.5 Discussion 
The hypothesised anti-mycobacterial mechanism of Se-AAs is as follows: Se-AAs are taken 
up by mycobacteria under the guise of a nutrient.  The Se-AA pro-drug is then cleaved into 
its active methylselenol form that undergoes redox cycling, producing ROS and causing 
damage within the mycobacterial cell (illustrated in Figure 6.3).  This hypothesis is based on 
the known anti-carcinoma activity of Se-AAs and the proposed mechanism for this 
activity.
447, 535
  The nutrient recognition hypothesis was then tested by competition assays of 
Se-AAs with the sulphur amino acids cysteine and methionine.  Mycobacterial lyase 
activation of Se-AAs was explored by anti-sense down-regulation of key mycobacterial lyase 
genes, and also purification of these lyases and in vitro enzyme activity assays.  Finally the 
mechanism behind Se-AA induced toxicity was queried via transposon mutant profiling of 
Se-AA resistant M. smegmatis. 
 
   
  CHAPTER SIX:  SE-AA STRUCTURE-ACTIVITY RELATIONSHIP AND MECHANISM OF ACTION     250 
6.5.1 Competition assays 
Competition assays investigating the nutritional recognition and uptake of Se-AA matched 
both SMSC and Se-L-met with equimolar concentrations of sulphur amino acids DL-cys and 
DL-met.  Supplementing either SMSC or Se-L-met with DL-cys or DL-met completely 
reversed Se-AA inhibition to the highest level tested of 2 mM (evidenced in Figures 6.4a and 
6.4b). 
This competition effect may be take place at the cellular uptake level, in which sulphur amino 
acids saturate transporters, resulting in reduced Se-AA import into the cell and consequential 
loss of toxicity.  It is known that Se-met and methionine both share a common Na
+
 driven 
active transport process in mammals,
559
 and that Se-DL-met causes a reduction
560
 or 
inhibition
561
 of the transport rate of DL-met; therefore, it is plausible that this reduction in 
transport could work both ways.  Another possibility is the nutrient content of the medium 
modulates Se-AA activity, rather than specifically cysteine or methionine.  This could be 
tested by using other non-sulphurous amino acids in competition assays. 
In addition to substrate competition at the transporter level, the presence of sulphur amino 
acids at higher concentrations may also induce changes in mycobacterial gene expression, 
both for amino acid transport and metabolism such as by mycobacterial lyase enzymes.  
Supplementary sulphur amino acids such as DL-cys also bolster the pool of mycobacterial 
cellular thiols, such as mycothiol, that are known to confer protective effects against 
oxidative attack.
549
    Further experimentation such as measurement of radio-labelled Se-AA 
uptake by mycobacteria may help to elucidate this mechanism.    
                                                                                                                           
6.5.2 Mycobacterial lyase enzymes 
6.5.2.1 Bioinformatic gene selection 
Eukaryotic metabolism of Se-AAs has been well researched, with SMSC and Se-cys being 
cleaved by β-lyase enzymes,562 and metabolism of Se-met being carried out by γ-lyase 
enzymes.
563
  Orthologous lyase proteins are conserved in bacterial species;
564
 therefore, it can 
be assumed that mycobacterial lyase enzymes would play similar roles to their eukaryotic 
counterparts in the anti-mycobacterial mechanism of Se-AA activity.  Protein BLAST 
searching for mycobacterial equivalents of lyase genes that are reported in the literature to 
cleave Se-AAs such as Trichomonas vaginalis methioninase
535
 (γ-lyase, NCBI accession 
number EAX91132) and E. coli IscS
565
 (β-lyase, NCBI accession number ZP_03034145.1) 
produced five homologous mycobacterial enzymes: 2 β-lyases and 3 γ-lyases (listed in Table 
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6.4) with a BLAST total score > 100.  BLAST total score is of a measure of protein sequence 
alignment.  Cutoff of 100 was arbitrarily selected based on drop off in total score results after 
100. 
 
Gene Annotation Information 
Rv1464 csd  
Cysteine desulphurase (β-lyase), 1254 bp / 44.6 kDa.  
Catalyses removal of elemental sulphur/selenium atoms 
from substrates such as L-cysteine, L-cystine and their 
selenium analogues, producing alanine. 
Rv3025c iscS  
Cysteine desulphurase (β-lyase), 1182 bp / 40.9 kDa.  
Catalyses removal of elemental sulphur from cysteine 
producing alanine.  100% homology to MSMEG_2357. 
Rv0391 metZ  
Probable O-succinylhomoserine sulfhydrylase or 
cystathionine γ-synthase, 1221 bp / 43.3 kDa.  Catalyses 
formation of homocysteine from O-succinylhomoserine 
and hydrogen sulphide.  Facilitates de-novo methionine 
biosynthesis. 
Rv1079 metB  
Probable O-succinylhomoserine thiol lyase or 
cystathionine γ-synthase, 1167 bp 41.0 kDa.  Catalyses 
formation of cystathionine and succinate from o-
succinylhomoserine and cysteine, can also utilise 
hydrogen sulphide or methanthiol as substrates.  100% 
homology to MSMEG_5265. 
Rv3340 metC 
Probable O-acetylhomoserine sulfhydrylase or 
homocysteine synthase, 1350 bp / 47.4 kDa.  Catalyses 
formation of methionine and acetate from O-
acetylhomoserine and methanethiol. 
Table 6.4: M. tuberculosis H37Rv enzymes putatively involved in Se-AA lysis.   
Gene annotation derived from Tuberculist.
566 
 
These lyase enzymes all share a common traits of being pyridoxal-5‟-phosphate (PLP, also 
known as the active form of vitamin B6) dependant and are putatively involved in cysteine or 
methionine biosynthesis and metabolism.  Pyridoxal 5‟-phosphase is derived from vitamin B6 
and is an essential cofactor of many enzymes predominantly involved in amino acid 
metabolism.  Approximately 1.5% of all prokaryotic genes encode PLP-dependent enzymes, 
a value much higher than the proportion encoded in eukaryotes.  The PLP-dependant 
enzymes hydroxymethyltransferase
567
 and alanine racemase are the target of anti-malarial and 
anti-tubercular agents, respectively.
568
 
Mycobacterial lyase genes were selected for scrutinisation in Se-AA mechanism of action 
studies, due to their homology to lyases involved in methylselenol production from Se-AAs, 
and their annotated function in sulphur amino acid metabolism.
535, 565
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Cysteine desulphurase Rv1464 has been identified in the cytosolic and membrane fractions of 
M. tuberculosis whilst Rv3025c has been identified only in membrane fractions.
569
  Both 
have been determined to be essential for H37Ra growth in vitro by transposon 
mutagenesis.
570, 571
  Furthermore, the M. smegmatis equivalents of these genes are 
transcriptionally up-regulated in response to hypoxia and starvation.
223, 572
  
 
O-succinylhomoserine thiol lyase or cystathionine γ-synthase Rv1079 (metB) is bi-functional 
and is able to synthesise cystathionine from L-homocysteine and L-serine, and also lyse 
cystathionine through a γ-elimination reaction to form cysteine, α-ketobutyrate and 
ammonia.
573, 574
  Due to the close homology of these synthase enzymes to known γ-lyases, it 
is possible they have dual synthase-lyase function.
553
  Methionine is also the preferred source 
of sulphur in pathogenic mycobacteria.
573
  Thus, the γ-lyase activity and methionine 
scavenging apparatus are indispensible to mycobacteria and are likely to have stronger 
expression levels compared to their cysteine equivalents.  Methionine γ-lyase enzymes such 
as MetB are present in plants and bacteria, but are absent in mammals, this makes them 
excellent drug targets.
575, 576
 
 
6.5.2.2 Transcriptional modulation of M. smegmatis putative lyase enzymes 
An M. smegmatis anti-sense RNA inducible gene knock-down strain of the cysteine 
desulphurase MSMEG_2357 (M. smegmatis homologue of Rv3025c) using the vector 
pMIND_2357 was serendipitously present in our laboratory, created as an anti-sense negative 
control strain for an unrelated lab project.
162
  Initial Se-AA sensitivity testing using this 
induced vector showed a significant 8-32 fold increase in resistance to SMSC compared to 
the control strain (Figure 6.5).  This resistance effect was thought to be caused by down-
regulation of the key β-lysis step in the Se-AA mechanism of anti-mycobacterial action, 
resulting in the majority of SMSC remaining sequestered in a relatively inert form, rather 
than being cleaved into the radical-generating methylselenol.  Subsequent experiments using 
this vector were unable to replicate these results; however, it has been suggested that the 
pMIND vector tetRO promoter had leaky background expression.
188
  In the case of an 
essential gene such as MSMEG_2357, this may result in selection for mutations that rendered 
the anti-sense gene regulation ineffective. 
The top BLAST derived lyase hits cysteine desulphurase MSMEG_2357 and methionine 
lyase MSMEG_5265 were then cloned into an improved tetracycline-inducible vector 
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pKW08
188
 in both the sense orientation with RBS for overexpression and anti-sense 
orientation for gene-knockdown to better investigate their effect upon Se-AA sensitivity.  
These results are summarised in Table 6.5. 
Strain SMSC MIC (µM) 
 HdeB C- HdeB N- 7H9+ LB 
MSMEG_2357S 250 125 125 > 1000 
MSMEG_2357AS 125 62.5 62.5 > 1000 
MSMEG_5265S 125 31.25 62.5 > 1000 
MSMEG_5265AS 250 125 250 > 1000 
 Se-L-Met MIC (µM) 
MSMEG_2357S 31.25 15.6 15.6 125 
MSMEG_2357AS 31.25 31.25 31.25 500 
MSMEG_5265S 31.25 31.25 15.6 125 
MSMEG_5265AS 31.25 31.25 31.25 125 
Table 6.5:  Summarised results of MSMEG_2357 / MSMEG_5265.   
Summary of MIC values derived from triplicate dose-response assays shown in Figure 6.8.  
Gene expression of MSMEG_2357 (putative β-lyase) and MSMEG_5265 (putative γ-lyase) 
was up- and down-regulated using the tetracycline inducible pKW08 vector. 
 
In HdeB C- media the induction of MSMEG_5265 anti-sense increased the MIC of SMSC to 
125 µM compared to 62.5 µM of the sense-expression of MSMEG_5265; whereas, 
expression of MSMEG_2357 in either orientation had no discernable effect upon SMSC 
sensitivity.  A similar effect was observed in HdeB N- media where the MIC of SMSC was 
raised to 125 µM for MSMEG_5265 antisense expression over the 31.25 µM MIC the sense 
expression construct, but no significant change in MIC was observed for MSMEG_2357 
against SMSC.  This also occurred to a lesser extent in 7H9 media with an MIC shift from 
125 µM to 250 µM between the sense and anti-sense expression of MSMEG_5265.  Neither 
MSMEG_2357 and MSMEG_5265 sense nor anti-sense expression had any effect upon 
sensitivity to Se-L-met in HdeB C-, HdeB N- or 7H9 media.  LB media produced no 
significant changes in SMSC resistance for any strain tested however for Se-L-met, 
MSMEG_2357 anti-sense showed increased sensitivity with an MIC of 125 µM; whereas, the 
MIC was 500 µM in the sense expression of this gene.  Modulation of MSMEG_5265 
expression showed a 2-fold increase in MIC for antisense expression to 250 µM compared to 
125 µM for the sense.   
The differential sensitivity in these results is far less than expectations based on the 
pMIND_2357 results.  Vector sequences were confirmed to be error-free and promoter 
induction was confirmed by GFP expression.  It is possible that there was degradation of the 
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MSMEG_2357 plasmid under selection pressure as this is an essential gene.
570
  Alternatively 
the expressional strength of the tetRO promoter was insufficient to significantly up-regulate 
protein levels or down-regulate protein levels by anti-sense RNA counter-expression.  Finally 
these genes may not be responsible for Se-AA lysis, or these genes may be functionally 
redundant in this regard in M. smegmatis.
577
 
 
6.5.2.3 S. cerevisiae lyase gene deletion strains 
S. cerevisiae yeast gene deletion set strains YAL01C (NFS1), YAL012W (CYS3) and 
YLR303W (MET17) are the respective homologues of M. tuberculosis H37Rv genes 
Rv3205c, Rv1079 and Rv3340.  CYS3 and MET17 both share close homology to Rv0391, 
Rv1079 and Rv3340. 
Testing of these strains under nutrient-rich SC and nutrient-limited SPO media demonstrated 
again that SMSC in conjunction with S. cerevisiae in SPO medium causes resazurin reduction 
proportional to SMSC concentration, also noted in Chapter 5.2.2.1.  As this effect was not 
observed in no-cell controls, it is possibly a downstream effect from S. cerevisiae metabolism 
or gene expression response to SMSC.  
 
It is also noted that the YAL012W (CYS3) strain could not grow in SPO media conditions.  
This agrees with published results that CYS3 knockout in S. cerevisiae is a cysteine 
auxotrophy phenotype,
578
 and has decreased resistance to starvation.
579
  The CYS3 knockout 
exhibited an MIC of 1000 µM for Se-L-met in SC medium, an 8-fold increase in resistance 
elative to the 4743 control strain.  This is supported in the literature which reports that 
YAL012W is 7-fold more resistant to Se-met compared to wild type.
580
  Conversely, 
knockout of CYS3 also resulted in increased resistance to sodium selenite in SC media, with 
an MIC of 125 µM compared to the > 2000 µM MIC of the 4743 strain control, and this also 
concurs with published results.
581
  It has been proposed that CYS3, a cystathionine γ-lyase, 
may also be responsible for metabolism of Se-met, producing methylselenol.
580
  The 
experimental evidence discovered in the present research supports that proposal.  No 
significant changes where observed in the Se-AA sensitivity of NFS1 or MET17 knockout 
strains. 
  
6.5.2.4 Lyase enzyme metabolite detection assays 
Mycobacterial enzymes suspected to be responsible for the lysis of Se-AAs were cloned into 
the pET28a+ expression vector, and overexpressed in E. coli BL-21, for purification and in 
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vitro activity assays. Rv1464 (cysteine desulphurase / selenocysteine lyase ), Rv3025c and 
MSMEG_2357 (cysteine desulphurase) and Rv3340 (and O-acetylhomoserine 
aminocarboxypropyltransferase) were successfully purified.  Rv0391 (O-acetylhomoserine 
sulfhydralyase) and Rv1079 (cystathionine γ-synthase) were expressed in BL-21, as 
evidenced by correctly sized bands in whole cell lysate; but there proteins were unable to be 
successfully purified, possibly due to excessive imidazole concentrations used in the 
purification procedure (detailed in Chapter 2.3.3.1).  A NaCl gradient elution procedure may 
be more successful in purifying these proteins.
574
  Rv1464, Rv3025c (and MSMEG_2357), 
and Rv3340 were utilised in a number of enzymatic assays to determine if they were able to 
lyse Se-AA substrates.  
6.5.2.4.1 Gas chromatography-mass spectrometry 
The M. tuberculosis H37Rv enzymes that were successfully purified (Rv1464, Rv3025c and 
Rv3340) were used in the in vitro enzyme assay detailed in Chapter 2.4.1, and the headspace 
was sampled by SPME fibre and analysed by GC-MS.   
Assays containing Rv3025c + SMSC identified methyldiselenide and Rv3025c + DL-cys 
produced dimethylsulphide, but this was also seen in the no enzyme control of BSA + DL-
cys.  Methyldiselenide is known to be a marker of methylselenol, as methylselenol undergoes 
spontaneous oxidation.
552
  This indicates that the M. tuberculosis cysteine desulphurase 
Rv3025c is able to utilise SMSC as a substrate for β-lysis, producing volatile methylselenol 
and other products, most likely alanine.
582
  Methyldiselenide detection by GC-MS using is in 
agreement with the initial anti-sense knockdown experiments of the M. smegmatis 
homologue MSMEG_2357 using the pMIND vector.   
The detection of dimethylsulphide produced by DL-cys in the presence or absence of 
Rv3025c is difficult to account for; however, dimethylsulphide may not be the correct 
identification as borane-methylsulphide showed a higher identity in the MS results.  
Dimethylsulphide may have arisen through microbial contamination of the assay, as it is a 
known that a variety of volatile sulphur compounds are produced by microbial cysteine 
metabolism.
583
  Alternatively, dimethylsulphide may be a product of cysteine degradation 
under assay conditions.   
Hydrogen sulphide was the expected product of Rv3025c and DL-cys assay; however, this 
compound is notoriously volatile, with a boiling point of -60 °C and thus has a very small 
window of detection in the GC-MS method used. 
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6.5.2.4.2 Methylene blue sulphide/selenide detection 
Methylselenol production was indicated by the GC-MS detection of methyldiselenide
552
 
produced from SMSC and the cysteine desulphurase Rv3025c, as explained in section 
6.5.2.4.1.  Confirmatory detection and quantification of methylselenide production was 
carried out using the commonly employed methylene blue formation test.
584
  No results were 
obtained using this assay, with the exception of the Na2S control that was used as a standard 
curve.  This deviates from the expected result of H2S production from Rv3025c lysis of DL-
cys.
585
  This may be caused by the produced H2S concentration being below the assay 
detection threshold of 0.01 ppm,
586
 or possibly interference of enzyme reaction buffer 
components such as salts and DTT.  Alternatively, atmospheric oxidation may sequester any 
volatile H2S produced.
587
  It is unknown if this assay method can detect volatile selenides, 
such as H2Se and methylselenol; however, the assay has been adapted for the detection of 
other selenium species such as SeO2.
588
  Since no volatile selenium species were detected in 
this assay, and the negative result for the DL-cys positive control means that no conclusion 
can be made on the production of selenides from Rv1464, Rv3025c and Rv3340 in 
conjunction with Se-DL-cys, SMSC and Se-L-met. 
6.5.2.4.3 Lead acetate sulphide/selenide detection 
A different attempt to identify volatile selenium and sulphur species generated from Rv1464, 
Rv3025c and Rv3340 actions on selenium and sulphur amino acid substrates was made using 
the PbAc paper method.  This assay is based on the reaction of H2S with PbAc, with 
production of black PbS precipitate.
589
  This reaction is known to also work with H2Se to 
produce a yellow-brown PbSe precipitate,
590
 but it is not known if the reaction proceeds with 
methylselenol.  A reaction seems likely due to the reactive nature of the selenol;
591
 however, 
it is unknown if the reaction products would be visibly detectable. 
The PbAc paper assay had a positive reaction for Rv3025c with a DL-cys substrate, this was 
also found to be DL-cys concentration dependant, this agrees with published results of 
cysteine desulphurase activity for Rv3025c,
585
 as expected no reaction was observed for DL-
met and Rv3025c.  No reaction of PbAc paper was noted for Rv3025c using any Se-AA 
substrates however orange precipitate in the enzyme reaction solution was observed for 
Rv3025c using Se-DL-cys and Se-L-cys, presumably elemental selenium or SeO2 not PbSe 
since the PbAc paper had no observable colour change.  This result, whilst not actually taken 
place on PbAc paper, concurs with published results of a Rv3025c homologue E. coli 
cysteine desulphurase IscS able to mobilise Se from selenocysteine.
565
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No positive results for Rv3340 using DL-cys is expected considering the annotation of this 
gene as a homocysteine synthase that does not utilise DL-cys as a substrate.
592
  The Csd 
homologue, Rv1464, is annotated as a NifS like cysteine desulphurase;
585, 593
 however, these 
results indicate that Rv1464 was unable to metabolise DL-cys to H2S under the assay 
conditions.  This may be a gene ontology misnomer, as Rv1464 has only been functionally 
annotated through bioinformatics, and no publications can be found regarding in vitro 
biochemical analysis of this enzyme‟s lyase function.  Lack of positive results for any of the 
enzymes tested using DL-met, SMSC and Se-L-met may be due to the terminal methyl group 
of these substrates, resulting in methanethiol or methylselenol instead of H2S or H2Se.  These 
methylated chalogenide-lead complexes such as lead methylthiolate, may not react with PbAc 
paper to form a visible precipitate.  It is also possible they might form homodimers,
552
 that act 
as protective groups,
591
 sequestering the reactivity and masking the detection by PbAc or 
other methods.  Reducing assay conditions from the DTT in the buffer may have not been at 
high enough concentration to avoid this dimerisation. 
 
6.5.2.4.4 Alanine dehydrogenase / Lactate dehydrogenase coupled assays 
Due to the volatile nature of chalcogenides and the difficulty in detection and quantification 
using the methods discussed above, lyase enzyme reactions were coupled to the NAD/NADH 
dependant enzymes alanine dehydrogenase (Ala-DH) and lactate dehydrogenase (Lac-DH).  
In theory, this would allow kinetic measurements of lyase enzyme activity towards the 
various substrates, and additionally to provide information on the non-chalcogenide 
metabolic products of lyase enzymes based on the coupled enzymes substrate specificities. 
The use of Ala-DH
590
 and Lac-DH
594
 coupled assays are well known for detecting cysteine 
and seleno-cysteine lyase activity.  However in this work, no Ala-DH or Lac-DH activity 
could be detected by measuring the NAD/NADH concentration at 340 nm when Ala-
DH/Lac-DH were coupled with Rv1464, Rv3025c or Rv3340 in vitro reactions with Se-AA 
or sulphur amino acid substrates.  Coupled assay conditions were verified through the 
positive controls of DL-alanine and sodium pyruvate, these yielded the expected dose-
dependant responses with Ala-DH and Lac-DH, respectively.  Possible inhibitory interactions 
between lyase substrates and Ala-DH or Lac-DH were ruled out experimentally, with Ala-
DH and Lac-DH retaining activity with their respective controls in the presence of all lyase 
substrates.   
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It is unclear why Ala-DH or Lac-DH activity was not detected in coupled assays, particularly 
for Rv3025c with substrates DL-cys and Se-DL-cys, as GC-MS, PbAc and elemental 
selenium precipitation indicated that Rv3025c was utilising these substrates.  Rv3025c has 
been experimentally confirmed as a cysteine desulphurase that produces alanine from 
cysteine; however, the methodology used was a radio-labelled sulphur transfer assay under 
inert argon gas that liberates sulphur this is then incorporated into a terminal [Fe-S] cluster 
acceptor.
585
  It is possible that the assay conditions used in this research were insufficiently 
reducing, since although DTT was included in the assay, buffer reactions were carried out 
under oxidising atmospheric conditions and without a terminal sulphur acceptor.  This may 
have disrupted cysteine desulphurase function. 
Purified Rv3025c is reported to have a yellow colour
585
 that is characteristic of pyridoxal 
phosphate binding enzymes.  This yellow colouration was observed in the Rv3025c enzyme 
fractions isolated in this research, but was not seen for Rv1464, Rv3340 or MSMEG_2357 
enzyme isolates that are also pyridoxal phosphate binding.
592, 595
  This may be an indication 
that these enzymes, despite being identified by SDS-PAGE on the basis of their size, may not 
be correctly folded or are lacking the pyridoxal phosphate co-factor. Additionally, lyase 
enzymes may not be producing alanine or pyruvate, alternatively producing to a 
chalcogenide, ammonia and an α-keto acid,533 another possible lyase product that may not be 
able to be utilised by that Ala-DH or Lac-DH, although later keto-acid detection assays did 
not detect this metabolite. 
6.5.2.4.5. Methylbenzothiazolinone hydrazone alpha-keto acid detection 
Hydrogen sulphide production was detected as a product of Rv3025c metabolising DL-cys by 
PbAc paper and Rv3025c lyase activity towards Se-DL-cys was indicated by the precipitation 
of orange-red selenium species in the lyase assay.  Mobilisation of sulphur or selenium by a 
β-lyase such as Rv3025c is expected to yield alanine,585 in addition to the respective 
chalcogenide species.  However, depending on the particular lyase enzyme and substrate, 
other co-metabolites may include pyruvate or α-ketobutyrate and ammonia533  As neither 
alanine or pyruvate were able to be detected in the couped enzyme assays, to determine if α-
ketobutyrate was the corresponding co-metabolite of lyase enzyme activity the methyl-
benzothiazolone hydrazone method was utilised.
216, 553
  No positive results for α-keto acid 
production from any mycobacterial lyase enzymes acting on any substrates were obtained.  
Since the expected results were obtained for α-ketobutyrate positive control, it is concluded 
that the mycobacterial lyase assay is not producing detectable amounts of stable α-keto acids, 
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possibly due to non-functional lyase enzyme. 
 
6.5.3 Seleno-amino acid resistant transposon mutant M. smegmatis 
A number of Se-AA resistant transposon mutant M. smegmatis were isolated and sequenced 
to identify gene disruptions that conferred Se-AA resistance.  Transposon mutagenesis has 
been previously applied to mycobacteria and has contributed to the understanding the modes 
of action of isoniazid
212
 and various other antibiotics and chemicals.
546
  It was expected that 
essential mycobacterial enzymes such as cysteine desulphurase would not be detected via 
transposon mutagenesis as mutations affecting the function of these genes would not be 
viable.
570
  However, due to the hypothesised pro-drug nature of Se-AAs, with multiple steps 
toward the final anti-mycobacterial mechanism, transposon mutagenesis may provide insight 
into the first and last steps of the hypothesised Se-AA activity mechanism, transport and 
redox cycling.  Transposon mutants with defined genetic disruptions identified were searched 
for in Mycobrowser Smegmalist/Tuberculist
566
 (http://mycobrowser.epfl.ch/smegmalist.html) 
and literature searched using the M. smegmatis gene name, the M. tuberculosis H37Rv gene 
equivalent and if necessary the enzyme common name and family.  The findings of this 
analysis have been grouped into broad functional categories. 
 
6.5.3.1 Redox gene function Se-AA resistant transposon mutants 
Both MSMEG_4695 and _4696 (Rv2470 and Rv2471) may have been affected in TN-G1-M4 
as the transposon insert site was between both ORFs.  Rv2471 is a glucosidase involved in 
sugar metabolism.  Rv2470 gene product GlbO is a haemoglobin-like oxygen carrier.
596
  The 
M. leprae glbO is involved in both aerobic respiration and the protective scavenging of 
reactive nitrogen species,
597, 598
 and this function fits well with the proposed final step of free 
radical damage in the Se-AA anti-mycobacterial mechanism. 
 
The L-aspartate oxidase nadB MSMEG_3200 (TN-G1-M12 or Rv1595 nadB) is situated in 
an operon between functionally related genes of the NAD biosynthetic pathway, nadA and 
nadC, that may also be affected by this transposon insertion.  nadB is predicted in silico as 
the target of the anti-mycobacterial drug clofazimine
599
 and is down regulated  in M. 
tuberculosis under nutrient starvation.
136
  nadB mutants are known to be dependant on niacin 
for in vitro growth.
600
  NadB functions to convert L-aspartate to iminoaspartate that is then 
condensed with dihydroxyacetone phosphate forming quinolinic acid in a downstream 
reaction catalysed by NadA.  NadA is known to be a [Fe-S] cluster binding protein,
601
 and 
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inhibition of the NAD synthetic pathway leads to mycobacterial cell death.
602
  Therefore as 
with the miaB mutant TN-G1-M9, Se-AAs may interfere with the formation of the [Fe-S] 
cluster essential for NAD biosynthesis, or interact with the enzymes utilising this [Fe-S] 
cluster, impeding their function and generating oxygen radicals. 
 
MSMEG_1019 is a ribonucleotide-diphosphate reductase (TN-G2-M9, Rv3051c nrdE) 
catalyses reduction of ribonucleotides to deoxyribonucleotides for DNA synthesis and 
repair.
603
  Ribonucleotide-diphosphate reductases use an iron dependant free radical tyrosine 
residue in their mechanism.
604
  nrdE is up-regulated by diamide mediated thiol-disulphide 
stress, and being a radical containing enzyme is sensitive to reactive nitrogen/oxygen 
damage.
605
  Upstream of nrdE is the glutaredoxin MSMEG_1017 (Rv3053c) that serves as 
the hydrogen donor (alongside glutaredoxin) for nrdE, although likely undisrupted by in the 
TN-G2-M9 mutant, demonstrates the redox-centric nature of this gene cluster.  This provides 
evidence of Se-AAs toxicity being mediated through these redox function genes in 
mycobacteria in a similar but distinct manner to eukaryotes.
606
 
MSMEG_0848 encodes the NADH ubiquinone oxidoreductase subunit 5 (TN-G3-M1, 
closest H37Rv homologue Rv3156 nuoL).  nuoL encodes a type I NADH dehydrogenase, and 
this enzyme complex is part of the primary respiratory chain producing ATP through the 
oxidation of NADH.
136
 
nuoL expression in M. tuberculosis is repressed by reactive nitrogen species,
607
 and M. 
tuberculosis deficient in nuoL are unable to prevent acidification of the macrophage 
phagosome.
608
  Type I NADH dehydrogenase is also able to function, not only in ATP energy 
generation, but can neutralise the defensive ROS produced by macrophage NOX-2 enzyme 
activity, reducing phagosomal ROS accumulation and thus toxicity to resident 
mycobacteria.
609
  Disruption of this oxidoreductase conferring resistance to Se-AAs indicates 
that it may play a role in ROS generation from Se-AA metabolites. 
 
Alkylhydroperoxidase enzymes ahpD/ahpC MSMEG_4890 and MSMEG_4891 (TN-G3-
M10, Rv2428 and Rv2429 respectively) are unrelated in sequence but are genetically situated 
together in both M. tuberculosis and M. smegmatis. Both function similarly as components of 
the mycobacterial anti-oxidant defence system by reducing hydroperoxides, having broad 
substrate specificity but demonstrate a preference for organic hydroperoxides.
610
   
Thiol-dependant peridoxin proteins such as these use cysteine residues to react with oxidising 
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agents to produce a sulfenic acid group that is converted to a disulphide bond by interaction 
with a free thiol, either intra-molecularly on the same enzyme or inter-molecularly in the case 
of multimeric or interacting proteins.  Unlike in other bacteria that have a flavin containing 
disulphide reductase, AhpF,
611
 in mycobacteria the disulphide is regenerated to cysteine by a 
substitute reducing agent, proposed to be mycothiol,
558, 612
 but alternatively, may be a bound 
lipoamide of succinate dehydrogenase.
611
 
Both ahpC and ahpD are up-regulated in response to acidic phagosomal conditions
613
 and 
ahpC is vital for survival of mycobacteria within macrophages indicating ahpC plays a role in 
virulence,
614
 particularly in early stages of infection.
615
 
Strikingly, ahpC expression is up-regulated in the case of katG-mediated isoniazid 
resistance
557
 and etaA-mediated ethionamide resistance.  This up-regulation may compensate 
for the loss of catalase/peroxidise function of these pro-drug activating genes.
558, 612
  This 
could indicate that Se-AAs would act in a complimentary or even synergistic fashion with the 
1
st
 line tuberculosis drugs isoniazid and ethionamide.  Up-regulation of ahpC in response to 
isoniazid resistance can be dependant on promoter mutations that result in ahpC hyper-
expression.  While this up-regulation does not effect resistance to isoniazid, it serves to 
compensate for the loss of katG anti-oxidant protection.
616
 
ahpC/D is an ideal candidate component for the “missing link” redox cycling mechanism of 
the methylselenol component of the proposed mechanism in Figure 6.2, although further 
evidence is required to confirm that alkylhydroperoxidases are able to act on the 
methylselenol substrate producing reactive oxygen species. 
Rieske [2Fe-2S] domain protein MSMEG_5925 (TN-G4-M8, Rv3526 kshA) is part of the 
two component ketosteroid hydroxylase complex kshAB in the mycobacterial cholesterol 
catabolism pathway.  KshA is the oxygenase component, containing a [2Fe-2S] cluster 
binding a ferrous iron atom.
617
  It is known that sub-optimal substrates (e.g. non-steroid) for 
this class of enzyme may uncouple its reaction causing heedless NADH consumption and 
production of damaging ROS.
618, 619
   It has been published that this enzyme complex, 
particularly kshA, is a good candidate target for tuberculosis drug discovery as there is no 
human homologue of this enzyme
620
.  Additionally, inhibitors that cause the uncoupling of 
the reaction kshA catalyses would not only impede mycobacterial cholesterol catabolism, a 
process critical for tuberculosis pathogenesis,
621
 but also accumulate damaging intracellular 
ROS and deplete cellular NADH reserves.
617
  This mechanism matches evidence obtained 
from Se-AA resistant transposon mutant profiling in this thesis. 
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6.5.3.2 Kinase gene function Se-AA resistant transposon mutants 
MSMEG_4270 (TN-G1-M6, Rv2202c) is an adenosine kinase that is essential in H37Rv
571
 
although evidently it is not essential for M. smegmatis or M. tuberculosis
622
 under in vitro 
conditions.  Rv2202c has been described as an atypical adenosine kinase with little specificity 
for adenosine, and it has been suggested that its primary function may be the phosphorylation 
of other substrates.
623
  It is possible that it is involved in the phosphorylation of xenobiotics, 
such as Se-AAs. 
6.5.3.2.1 Glycerol kinase function Se-AA resistant mutants 
Genes involved in glycerol metabolism were identified as transposon insert sites for three 
unique Se-AA resistant mutants.  These are MSMEG_6756/7 (TN-G1-M7, glpK that has no 
direct H37Rv homologue and Rv1773c) MSMEG_6759 (TN-G1-M11, glpK that has no 
direct H37Rv homologue) and MSMEG_6756 (T N-G2-M8, glpK that has no direct H37Rv 
homologue).  Sequence analysis confirms that all three mutants are unique insertions, not 
clonal duplicates.   
Considering that three unique Se-AA resistant glpK transposon mutants were encountered, it 
is possible that glpK is a hotspot for Tn611 insertion, a similar trend of transposon directed 
mutation has been observed for IS5 insertion upstream of E. coli glpFK promoter in the 
presence of glycerol.
624, 625
  However, this does not explain the high levels of Se-AA 
resistance this transposon insertion confers.  The H37Rv gene with the closest homology to 
the M. smegmatis glpK is Rv3696c, and this enzyme is also annotated as a glycerol kinase 
that is essential for H37Rv growth in vitro.
571
  The glycerol kinase GlpK phosphorylates 
glycerol to glycerol-3-phosphate, trapping it in the cytoplasm; thus, glycerol can be used in 
central carbon metabolism.
626
   Rv1773c is a regulator of the glpK.  Hyper-activity of glpK 
leads to accumulation of poisonous levels of glycerol-3-phosphate and ATP depletion.  
Glycerol is a preferred mycobacterial carbon source.
287
  M. tuberculosis ΔglpK mutants are 
able to colonise mouse lung effectively showing this gene is not essential in vivo.
287
  It is 
known that different carbon sources can modulate GlpK activity.  For example, the presence 
of pyruvate will repress glpK activity.
627
 Mutations affecting glycerol kinase activity may 
induce alternative carbon metabolism by catabolite repression, this may render mycobacteria 
more resistant to Se-AAs.  MSMEG_6758 is a glycerol facilitator within the gplK operon that 
assists import of glycerol into the cell.
628
  This facilitator may play a role in Se-AA import 
and its function may have been disrupted by the transposition event.  It is also possible (albeit 
improbable) that GlpK has a direct interaction with Se-AAs, including phosphorylation of the 
Se-AAs, or Se-AA binding to free GlpK thiol residues,  effecting the enzyme‟s function as 
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selenium compounds are known to inhibit kinase function in prostate cancer cells.
629
  The 
most likely cause of Se-AA resistance in GlpK deficient mutant M. smegmatis is a 
downstream reduction in metabolic flux, mitigating ROS production by methylselenium 
species. 
 
6.5.3.3 Other Se-AA resistant transposon mutants 
miaB (TN-G1-M9, MSMEG_2729 or Rv2733c) is a tRNA methylthiotransferase that forms 
2-methylthio-N
6
-isopentenyl-adenosine from tRNA isopentenyl-adenosine in two steps of 
sulphur insertion, likely to occur by iron-sulphur [Fe-S] cluster formation and methylation 
using S-adenosylmethionine as a donor with a radical adenosine intermediate.
630
  The 
cysteine desulphurase, IscS, sulphur mobilisation activity is implicated in the 
formation/reconstitution MiaB [Fe-S] clusters which act as a thiol donor reservoir.
631, 632
  It is 
unknown how MiaB interacts with Se-AAs.  It may act through the disruption of [Fe-S] 
clusters, leading to insufficient methylthio-N
6
-isopentenyl-adenosine tRNA, or it may be 
substituted into adenosine itself resulting, in a non-functional tRNA analogue. 
 
Acyl-CoA synthase MSMEG_1098 (TN-G2-M3, Rv0551c fadD8) is not well researched.  
The fadD gene cluster is involved in lipid metabolism converting fatty acids into acyl 
adenylates,
633
 these have a wide range of cellular applications, including acetyl-CoA, 
mycobacterial cell wall and possibly mycobactin synthesis.
634
  The expression of many fatty 
acid synthesis genes, including fadD8 is induced within two hours of macrophage 
infection.
635
  Free fatty acids, along with reactive oxygen and nitrogen species, are 
components of the immune response to mycobacterial infection,
636
 acyl-CoA synthase and β-
oxidation of these free fatty acids may mitigate their anti-microbial activity.
637, 638
  The 
relationship between Se-AA toxicity and fatty acid ligase remains vague, but a potential route 
of Se-AA-mediated toxicity via acyl-CoA synthase, and the resistance of this transposon 
mutant, may be linked to mycothiol biosynthesis, since acetyl-CoA is required for the final 
acetylation step of mycothiol biosynthesis.
639
 
 
An acetoacetyl-CoA reductase MSMEG_6024 (TN-G2-M15, Rv3667 acs) catalyses 
transformation of acetate into acetyl-CoA.
640
  Similar to TN-G2-M3 the contribution of this 
gene to Se-AA toxicity is suspected to be linked to mycothiol production that facilitates free 
radical generation from methylselenol. 
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The erythritol cyclodiphosphate synthase genes involved in isoprenoid and terpenoid 
synthesis MSMEG_6075 and MSMEG_6076 (TN-G2-M6, ispF Rv3581c and ispD Rv3582c) 
were found to be marginally resistant to Se-AAs.  ispF has no human homologue but is 
essential in M. tuberculosis
641
 thus this enzyme and its pathway are considered good drug 
targets.
642
  It is not clear how Se-AAs interact, directly or indirectly, with these enzymes.   
Interestingly, immediately downstream of the ispD/ispF genes where the transposon insertion 
occurred, is MSMEG_6074 (cysS, Rv3085c) a cysteinyl-tRNA synthetase that charges tRNA 
with a cysteine residue.  This gene may have potentially been disrupted by a frameshift 
mutation caused by the TN-G2-M6 transposon insert.  CysS is very similar in function to the 
mycothiol synthesis enzyme MshC (incorporates L-cysteine into 1-O-(2-amino-1-deoxy-α-D-
glucopyranosyl)-D-myo-inositol forming pre-acetylated mycothiol).
545
  The mshC gene is 
believed to have evolved from a gene duplication of cysS.
643, 644
  Therefore if this 
transposition has adversely effected CysS function, this serves as more evidence to implicate 
mycothiol in the Se-AA mechanism of action, not directly but likely in the recharging of 
redox cycling enzymes such as alkylhydroperoxidases.  Alternatively, Se-cys utilisation by 
cysteinyl-tRNA synthase has been suggested as the mechanism for selenium toxicity;
645
 
however, this suggestion is dated and has little supporting evidence. 
The purine nucleoside phosphorylase MSMEG_1701 (TN-G2-M7, Rv3307 deoD) facilitates 
the cleavage of adenosine, inosine and guanosine in the mycobacterial nucleoside salvage 
pathway.
646, 647
  This salvage pathway is critical for mycobacterial persistence and starvation 
response.
648
  It is unclear how Se-AAs may interact with this gene product. 
 
MSMEG_0211 (TN-G3-M2) is annotated as an ABC transporter however the closest H37Rv 
protein BLAST match is an ABC excinuclease (Rv1638, uvrA) involved in nucleotide 
excision DNA repair, a process important in the recovery of DNA damage caused by host 
reactive nitrogen/oxygen attack.
649
  Although it is established that uvrA is important in DNA 
repair particularly of physiologically relevant DNA damage such as those caused by reactive 
oxygen and nitrogen,
650
 the reasons for disruption of this gene conferring resistance to Se-
AAs are not established. 
 
The mono-ADP-ribosyl transferase (arr) MSMEG_1221 (TN-G3-M3,  no similar H37Rv 
homologue) is known to ribosylate rifampicin, lending M. smegmatis some resistance to the 
drug.
651
  Rifampin is ribosylated within the mycobacterial cytoplasm, and is the only known 
target substrate of ADP-ribosyl transferase, although this gene is up-regulated in response to 
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stress such as DNA damage and reactive oxygen.
652
  In addition to its ribosylating activity, 
arr has a role in the stringent stress response of mycobacteria, suppressing translation and 
transcription particularly of rRNA.
652
  The wider stress response functions of the gene are 
likely to be responsible for arr inactivation conferring Se-AA resistance. 
 
The araC transcriptional regulator MSMEG_0376 (TN-G2-M14, closest H37Rv homologue 
Rv1931c) is known to contribute to M. tuberculosis virulence and fitness in murine 
models.
653
  The araC family regulate functions such as carbon metabolism/catabolism, stress 
response and virulence response.
654
  It is noted that in M. tuberculosis H37Rv, the thiol-
peroxidase tpx Rv1932 is situated immediately upstream of Rv1931c, and may be under 
control of this regulator in mycobacteria, as araC regulators are known to confer resistance to 
oxidative killing in Salmonella enterica.
655
  Tpx confers protection from oxidative/nitrosative 
attack and is a key component of mycobacterial anti-oxidant defence and is easily linked back 
to Se-AA mode of action.
656
 
Transposition occurred between MSMEG_2199 and MSMEG_2200 (TN-G4-M3, Rv1356c 
and Rv2964 (purU), respectively) and may have disrupted either or both of these genes.  
Rv1356c is annotated as a hypothetical protein of unknown function.
566
  Rv2964 purU is a 
formyltetrahydrofolate deformylase, the in silico predicted target of mefloquine.
599
  This 
enzyme generates formate and tetrahydrofolate by hydrolysis of 10-
formyltetrahydrofolate.
657, 658
  Se-L-met may inadvertently over/under activate this enzyme 
and unbalance the tetrahydrofolate – formyltetrahydrofolate pool, as this enzyme is activated 
by methionine.
657
  It is noted that downstream of purU lies MSMEG_2201 (Rv0130 htdZ 
thioester dehydratase)
659
 that may act to lyse methylselenol from Se-L-met.  Also 
downstream is MSMEG_2202 a dimethylaniline monooxygenase, both of these enzymes 
involved in cellular redox processing, and fit the proposed Se-AA mechanism. 
 
 6.5.3.4 Poorly defined Se-AA resistant transposon mutants 
Transposon insertion in the following genes was implicated in Se-AA resistance, but lack of 
annotation for these genes rendered their possible link to the Se-AA mechanism inconclusive.  
Nonetheless, they are included below since the information may be of use to future 
researchers. 
 
MSMEG_3638 (TN-G1-M3, Rv1841c) is a membrane bound cystathionine β-synthase (CBS) 
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domain protein, although the CBS nomenclature is misleading as it does not necessarily 
implicate cystathionine-related activity of this gene
660
 despite how convenient that would be 
is to this study.  MSMEG_3638 expression is up-regulated in immune competent murine 
models.
661
 
MSMEG_4162 (TN-G2-M4) is annotated as a conserved hypothetical protein.
566
  Protein 
BLAST analysis against the M. tuberculosis H37Rv proteome shows Rv3719 to be the 
highest match but with only 13% query coverage.  MSMEG_4606 (TN-G3-M4) is a 
conserved hypothetical protein with no known or predicted function.
566
  Protein BLAST 
against M. tuberculosis H37Rv produces the closest match of Rv3216 acetyltransferase; 
however, query coverage is non-significant at 6%.  MSMEG_5842 (TN-G3-M5, Rv0779c) is 
a conserved membrane protein of unknown function.  The 23S ribosomal RNA subunit 
MSMEG_3756 (TN-G4-M1, rrlA) conferred low level Se-AA resistance when subjected to 
transposon insertion, although the mechanism behind this resistance is unclear.  The putative 
regulatory protein MSMEG_4431 (TN-G4-M5, closest H37Rv homologue Rv0386 LuxR 
transcriptional regulator however with poor query coverage of 6%).  LuxR is involved in the 
mycobacterial response to reactive nitrogen attack.
607
 
MSMEG_4842 is an amidohydrolase (TN-G4-M4, Rv0074) that hydrolyses carbon-nitrogen 
amide bonds.  There are a wide variety of amidohydrolases acting on a range of substrates, 
from long chain fatty acids to small molecules such as amino acids.
662
  Due to the lack of 
further annotation for this gene it is difficult to place its interaction with Se-AAs.  Noted 
downstream of this gene are two acyl-CoA dehydrogenase enzymes MSMEG_4844 and 
MSMEG_4845, these may have been affected by frameshift mutation caused by the 
transposon insert. 
 
6.5.3.5 Inducible regulation of alkylhydroperoxidase expression 
After Se-AA transposon mutant genetic profiling revealed that M. smegmatis knockouts of 
MSMEG_4890 (ahpC) and MSMEG_4891 (ahpD) cause a drastic increase in Se-AA 
resistance.  These genes were cloned into the pKW08 vector in the sense (with RBS) and 
anti-sense orientation to confirm their participation in the Se-AA resistance mechanism of 
action.  These inducible gene knock-up / knock-down strains did not mimic the large 8-16 
fold increase in Se-AA resistance seen in the transposon mutant TN-G3-M10, giving mixed 
results with a 2-fold increase in the MIC of SMSC when over-expressed and 4-fold when 
ahpC was under-expressed by inducible antisense knockdown.  Similarly induction of either 
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up- or down-regulation of ahpD only yielded a 2-fold increase in SMSC resistance, and had 
no effect on the MIC of Se-L-met. 
The consequences of ahpC expression on Se-L-met activity were somewhat indicated by a 2-
fold decrease in MIC upon ahpC overexpression and a 4-fold increase in MIC on under-
expression. 
This, in addition to other tetracycline inducible anti-sense gene expression modulation 
previously carried out in this research, indicates that these vectors are not performing as 
required.  The tetRO promoter may be insufficiently strong to cause significant up- or down-
regulation of these genes, or a compensatory response is carried out by the mycobacteria that 
mitigates the modulation of gene expression. 
 
6.5.3.6 Seleno-amino acid synergy with isoniazid 
Alkylhydroperoxidase enzymes are known to be up-regulated in katG loss of function 
mediated isoniazid resistant M. tuberculosis.
557, 558
  This is a compensatory response to loss of 
KatG antioxidant defence function.
663
  Expression of ahpC and sensitivity to isoniazid have 
an inverse correlation.
664
  Therefore it was proposed that if the ahpC/D knockout mutant TN-
G3-M10 exhibited increased resistance to Se-AAs, up-regulated ahpC/D expression, such as 
in response to isoniazid exposure, may increase mycobacterial sensitivity to Se-AAs.  This 
drug-target relationship may also cause a synergistic inhibitory effect between Se-AAs and 
isoniazid.  This was tested by the checkerboard assay for drug synergy,
208
 where the MIC of 
Se-L-met decreased from 8 to 2 µM when in combination with INH, and the MIC of INH 
decreased from 2 to 0.5 µM in combination with Se-L-met.  This yielded fractional inhibitory 
concentrations of 0.25 for both Se-L-met and INH, and resulted in a fractional inhibitory 
concentration index of 0.5 between Se-L-met and INH.  This value implies a 2-fold increase 
in inhibitory activity when Se-L-met and INH are in combination, although this is the lowest 
level of synergy detectable by this checkerboard assay.
208
   
This synergy is a promising indication for Se-AAs in tuberculosis combination drug therapy,  
necessary for thorough tuberculosis treatment.  In MDR-TB strains with resistance to INH 
mediated through katG loss of function mutation where ahpC is hyper-expressed,
557, 558
 this 
synergy may be even more pronounced.  This requires further investigation using MDR-TB 
strains, as combination therapy including INH and Se-AAs would deliver a synergistic “two 
hit combo” against tuberculosis katG and ahpC genetic targets, where loss of function 
mutations conferring resistance to INH may also provoke increased sensitivity to Se-AAs. 
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6.5.4 General conclusions of mechanism of action studies 
Several results disclosed and discussed above are in agreement with the three-part hypothesis 
for the mode of Se-AA anti-mycobacterial action depicted in Figure 6.3.  Competition assays 
with Se-AAs and their regular sulphur amino acid counterparts show that methionine and 
cysteine are able to alleviate Se-AA toxicity, indicating these are competing with Se-AAs at 
either the transport or substrate level, or both.  Anti-sense RNA regulation of 
bioinformatically identified putative lyase enzymes proved largely inconclusive, with the 
exception of MSMEG_2357 β-lyase downregulation using pMIND vector conferring 
resistance to SMSC.  However, experiments using the S. cerevisiae orthologue of 
cystathionine- γ-lyase which conferred resistance to Se-L-met demonstrated that lyase genes 
are involved in Se-AA toxicity, activating Se-AA pro-drugs to their active form within the 
cell.  Enzyme based assays were able to determine that Rv3025c can cleave SMSC in vitro 
producing methyldiselenide, an indicator of methylselenol; however, further kinetic and 
substrate preference analysis through a variety of enzymatic assay routes were unsuccessful.  
Follow-up studies to define the specific mycobacterial enzymes involved in Se-AA lysis and 
their reaction products are required.  Finally, profiling of transposon insert generated Se-AA 
resistant mutant M. smegmatis directly implicates several redox function genes such as 
alkylhydroperoxidases and ketosteroid hydroxylase in the Se-AA mechanism, likely through 
redox cycling of methylselenol and generation of the reactive oxygen that causes cellular 
damage.  Other genes such as those contributing to mycothiol synthesis, for example acetyl-
CoA synthase, are also indirectly implicated in Se-AA resistance in M. smegmatis.  The 
potential genetic targets of methylselenol in mycobacteria are illustrated in Figure 6.18. 
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6.6 Summary  
Seleno-amino acids were discovered to be anti-mycobacterial agents through modified 
culture-condition chemical library screening against M. smegmatis.  Structure-activity 
relationship analysis showed that methylated selenium, primary amine, carboxylic acid and 
levo stereoisomerism are key structural features for Se-AA anti-mycobacterial potency.  
Several Se-AA derivatives were synthesised and tested based on literature indications of 
increased activity; however, these derivatives all exhibited various reductions in potency, 
providing additional insight into the Se-AA structure-activity relationship. 
Figure 6.18:  Proposed methylselenium anti-mycobacterial effects.   
Based on resistant transposon mutants, Se-AAs are hypothesised to exert anti-mycobacterial effects 
through methylselenium species such as methylselenide.  Methylselenium causes toxicity through ROS 
generation via mycobacterial redox function enzymes, Fe-S cluster disruption, halting cholesterol 
catabolism and paired NADH depletion, decreasing cellular mycothiol and other unelucidated mechanisms. 
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Seleno-amino acids are predominantly researched for their anti-cancer properties, the 
mechanism of action for which is understood to involve radical oxygen production causing 
apoptosis of cancer cells.  However; mycobacteria lack glutathiol, a key component for the 
activation of Se-AAs toxicity in eukaryotes.  In this work mechanism is proposed for Se-AA 
anti-mycobacterial activity.  First, the Se-AA pro-drug is recognised by mycobacteria as a 
nutrient and imported into the cell.  Second the Se-AA pro-drug is cleaved by mycobacterial 
β or γ-lyase enzymes (dependant on the Se-AA species) producing amongst other metabolites 
reactive methylselenol/selenide.  Finally reactive methylselenium species generate damaging 
reactive oxygen species through continued redox cycling within the mycobacterial cell. 
 
Evidence for this mechanism presented included a competition effect with Se-AAs and their 
sulphur amino acid counterparts, cysteine and methionine, that can alleviate Se-AA anti-
mycobacterial activity.  Down-regulation of the β-lyase MSMEG_2357 conferred resistance 
to SMSC; however, further experiments failed to define what mycobacterial lyase enzymes 
are involved in Se-AA activation.  Supplementary research using S. cerevisiae identified the 
CYS3 cystathionine γ-lyase gene deletion strain as resistant to Se-L-met.  This evidence 
indicates the second step of the hypothesis is correct but could not be confirmed in 
mycobacteria due to experimental difficulty.  Furthermore, enzymatic evidence that M. 
tuberculosis cysteine desulphurase Rv3025c acted upon SMSC to create methylselenol was 
found by GC-MS analysis and in vitro enzyme assays, although these could not be kinetically 
defined or reproduced for other M. tuberculosis lyase enzymes.  Transposon mutants of M. 
smegmatis resistant to Se-AAs were genetically profiled, revealing a clear trend in redox-
function gene disruptions conferring a Se-AA resistant phenotype.  Such as 
alkylhydroperoxidase genes ahpC and ahpD that usually function to protect mycobacteria 
from reactive oxygen, but are hijacked by reactive methylated selenium into producing and 
cycling damaging reactive oxygen species.  Ketosteroid hydroxylase kshA also appears to be 
uncoupled by methylselenium causing mycobacterial energy depletion by NADH 
consumption and reactive oxygen generation via the enzymes [2Fe-2S] cluster oxygenase in 
addition to obstructing the enzymes pathogenically critical function in cholesterol catabolism.  
The implication of mycobacterial redox processes in Se-AA mechanism, particularly the 
alkylhydroperoxidase ahpC, may be a unique opportunity for synergistic drug combination 
therapy with isoniazid, as Se-AAs and isoniazid exhibit a 2-fold increase in activity in 
combination with one another.  In MDR-TB with a loss of katG function, ahpC may be over-
expressed, further increasing the redox cycling and inhibitory activity of Se-AAs.
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7.1 Overall synopsis 
Tuberculosis is an ancient disease caused by the bacterium M. tuberculosis, a pathogen that 
has evolutionarily adapted to endure and thrive within the immune response intended to 
destroy it.  Despite the discovery and development of antibiotic drugs effective in treating 
tuberculosis, it remains a major infectious disease causing 1.4 million deaths in 2010.
9, 10
  
Due to the pathogen‟s resilient nature and inadequate treatment regimens, development of 
drug resistant M. tuberculosis strains has rendered many conventional antibiotic therapies 
ineffective and some clinical manifestations of the disease practically untreatable.
11, 77, 82, 83
  
Therefore development of new antibiotics to treat TB infections is integral for the plan to stop 
TB, in addition to new diagnostics, treatment procedures and vaccines.  This plan is in effect 
and has the ambition of eradicating TB by the year 2050.
9, 10, 14
 
 
This thesis contributes to global TB eradication efforts, presenting a novel high-throughput 
drug screen for anti-mycobacterial compounds using modified culture conditions and nutrient 
limitation culture media with the fast growing tuberculosis model species M. smegmatis.  
Three chemical libraries were screened against four different culture conditions, two nutrient 
rich conditions and two nutrient limited conditions.  These screens demonstrated that 
mycobacterial sensitivity to chemical inhibitors was dependent upon the culture conditions 
utilised.   These screens also identified a number of previously unknown mycobacterial 
inhibitors some of which exhibit desirable characteristics warranting further research into 
their development as anti-tubercular drugs. 
 
Se-methylselenocysteine (SMSC), a novel compound identified during nutrient limitation 
screening,
122
 was selected for further research as an anti-mycobacterial agent due to its anti-
mycobacterial novelty,  inhibitory activity specific towards mycobacterial species and known 
consumption as a health supplement.
401
  SMSC would not have been detected if the HTS of 
this work had been restricted to standard nutrient conditions.  SMSC represents a new class of 
anti-mycobacterial compounds, the seleno-amino acids.  Seleno-amino acids are naturally 
occurring selenium analogues of the sulphurous amino acids cysteine and methionine and 
their structural derivatives.
387
  These compounds are implicated as beneficial in a variety of 
medical conditions, including diabetes,
436 cardiovascualar disease{Navas-Acien, 2008 #531
 cardiovascular 
disease
441
 and most predominantly cancer. 
428, 429, 433, 434
  Little attention has been afforded to 
the anti-microbial properties of Se-AAs as they have little inhibitory activity towards other 
bacterial species such as E. coli, S. aureus and P. aeruginosa. This work is the first to 
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disclose the anti-mycobacterial activity of these compounds, with MIC values in the 10-30 
µM range towards M. tuberculosis.  Se-AAs have varying toxicity toward human cell lines 
but are generally considered to be in the non-toxic range against non-cancerous cell lines.
500
  
The maximum recommended human doses of Se-AAs as nutritional supplements can raise 
plasma selenium levels into the M. tuberculosis MIC range.
505
  Se-AAs show a preference for 
accumulation in lung tissues compared with other selenium compounds,
513
 a favourable 
indication for treatment of pulmonary infection. 
 
The relationship between Se-AA structure and the inhibitory activity towards mycobacteria 
was queried, and key structural aspects contributing to anti-mycobacterial potency included 
methylated selenium, primary amine and carboxylic acid functional groups and levo 
stereochemistry.  The basic mechanism of Se-AAs inhibitory action towards cancer is 
understood to involve enzymatic lysis of Se-AAs producing reactive selenide species
535, 665
 
that in turn are redox cycled by glutathione, generating reactive oxygen species that cause 
cellular damage and an ensuing apoptotic response.
666
  A similar mechanism of action was 
suspected for mycobacteria; however, mycobacteria do not utilise glutathione;
545
 therefore, 
the redox cycling of selenide species must be carried out by an unknown mycobacterial 
equivalent.   
 
This thesis proposes a three-part mechanism for the anti-mycobacterial action of Se-AAs:  
First, Se-AAs are recognised as nutrients and are actively transported into the mycobacterial 
cell by ABC transporters and super-facilitator type transporters
667
 possibly assisted by 
chaperones such as Rv0411c glutamine binding lipoprotein.  This transport is pronounced 
under nutrient limited conditions such as those encountered during pathogenesis.
668
 Second, 
the Se-AA acts as a pro-drug and is enzymatically cleaved by mycobacterial lyases, 
producing the active metabolite methylselenol or an equivalent selenide species.  Third, these 
selenide species are redox cycled in mycobacteria producing reactive oxygen that damages 
cellular components such as DNA, proteins and lipids. 
 
Support for this three-step mechanism included competition effects between Se-AAs and 
cysteine and methionine in which these amino acids are able to alleviate Se-AA inhibition in 
mycobacteria, indicating mycobacterial recognition of Se-AAs as their sulphur amino-acid 
equivalents at the transport and or substrate level. Furthermore, down-regulation of the β-
lyase MSMEG_2357 in M. smegmatis confers resistance to SMSC, with methyldiselenide 
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production detected with the M. tuberculosis homologue of this enzyme Rv3025c using an in 
vitro enzyme reaction. A red selenium precipitate is observed upon incubation of Rv3025c 
with Se-cys.  This suggests that mycobacterial β-lyase enzymes are involved in metabolising 
seleno-cysteine pro-drugs such as SMSC and Se-cys into an active methylselenol and other 
forms of selenides.  No experimental link between mycobacterial γ-lyase enzymes and Se-
met could be made; however, the S. cerevisiae CYS3 cystathionine γ-lyase gene deletion 
strain was found to confer resistance to Se-L-met, indicating this gene‟s significance in Se-
met activation that likely coincides with a mycobacterial equivalent enzyme.
573
  Conclusive 
evidence demonstrating the kinetic parameters and substrate specificity of M. tuberculosis 
lyase enzymes toward Se-AAs was not available, and further research is required to 
determine what lyase enzymes metabolise Se-AAs in mycobacteria. 
 
Using transposon mutagenesis, mycobacterial genes contributing to Se-AA toxicity were 
identified that included genes for alkylhydroperoxidase enzymes that typically function to 
protect mycobacteria from oxidative damage but produce reactive oxygen species by redox 
cycling of methylselenium species.  Several other mycobacterial genetic targets of Se-AAs 
such as the ketosteroid hydroxylase were identified as playing a role in generation of reactive 
oxygen from methylselenium. 
 
This thesis describes a novel approach to anti-mycobacterial drug discovery, from initial 
chemical screening through to lead development studies of seleno-amino acids, a novel class 
of anti-tuberculosis compounds, detailing the structure activity relationship of these 
compounds and providing a foundation for their mechanism of anti-mycobacterial activity. 
 
7.2 Summary of experiments 
7.2.1 Conventional media high-throughput screening 
The model tuberculosis organism M. smegmatis was used in a high-throughput screen against 
three chemical libraries to identify compounds with anti-mycobacterial activity.  Use of dual 
viability indicators in screening, absorbance and GFP, minimised false positives and both 
provided good indications of bacterial growth.  Use of an unstable GFP variant
669
 may 
improve the assay for kinetic purposes by removing interference of lingering GFP 
accumulated from dead or lysed cells, but this was not required for this end-point growth 
assay.   Hit compounds exhibiting ≥ 90% inhibition of M. smegmatis growth were validated 
in quantitative dose-response experiments, and the resulting confirmed inhibitors were cross-
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referenced with screening project results from M. bovis BCG and M. tuberculosis H37Ra. 
These screening experiments showed that screening under 7H9 media conditions produced 
slightly more hit compounds compared with LB media but more importantly, hits derived 
from 7H9 media screening were more likely to have common inhibitory activity towards M. 
tuberculosis H37Ra. 
 
Several compounds were identified through rich media screening that exhibited strong 
inhibition towards mycobacteria and also had favourable indications with regard to novelty 
and low toxicity that warranted further investigation of these hit compounds.  Compounds 
considered to be of high priority for further investigation into their anti-tubercular potential 
included the anti-helminthic chemical, niclosamide, used in the treatment of parasitic worm 
infection in humans and therefore likely to be safe and well tolerated in human 
administration.
670
  Niclosamide showed a good activity towards M. tuberculosis with an MIC 
of 6.25 µM against the H37Ra strain in vitro. 
 
Pyrithione zinc a coordinated zinc complex, commonly used in topical applications such as 
shampoos and anti-microbial ointments
248
 completely inhibited virulent tuberculosis strains 
in vitro at a low concentration of 2.5 µM.
221
 It is believed to cause iron starvation in yeast.
671
  
Pyrithione zinc is also reported to be have low oral toxicity in canines with a LD50 of 600 
mg/kg.
249
 
 
A limonoid natural product of the neem tree, azadirachtin, is typically used as an insect 
repellent and anti-feedant.
260
 Neem oil is used in Indian folk medicine against mycobacterial 
disease such as tuberculosis and leprosy.
262
  Azadirachtin showed only modest anti-
mycobacterial activity in the present study, having an MIC of 25 µM toward M. smegmatis. 
The selectivity, however, of this compound is very favourable due to its non-toxic nature in 
mammals with daily doses up to 1500 mg/kg having no observable effect in murine 
models.
259
  Azadirachtin is a high priority for further analysis, first to determine its activity 
toward virulent M. tuberculosis strains and later to define its mechanism of action to provide 
insight into potential chemical derivatisation for improving activity.  
 
Neohesperidin is also a natural product of citrus plants and is used as a sweetener/flavour 
enhancer in many foods. It is therefore considered very safe for human consumption
271
 with 
daily oral doses of up to 3300 mg/kg having no adverse effects.
273
   In the present study, 
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neohesperidin had an in vitro MIC of 6.25-12.5 µM towards M. smegmatis in rich media 
types.  Citrus plant extracts have shown inhibition against MDR strains of M. tuberculosis 
and methicillin resistant S. aureus,
272
  and neohesperidin may be the culprit responsible for 
the activity of these extracts.  This compound is a high priority for further investigation into 
its antibiotic potential. 
 
7.2.2 Modified culture conditions for high-throughput screening 
Continuing on the high-throughput screening using conventional rich media conditions, 
chemical libraries were used to screen M. smegmatis again using nutrient limited culture 
conditions of HdeB media.  These screens were carried out to investigate the influence of 
culture conditions on mycobacterial susceptibility to chemical inhibitors, as mycobacteria are 
known to alter their gene expression and metabolism under conditions of nutrient 
starvation.
276, 277
  This work sought to use nutrient limited culture media to emulate 
conditions encountered by M. tuberculosis during pathogenesis, including low available 
nutrients such as amino acids,
222
 leading to utilisation of activation of catabolic nutrient 
scavenging pathways that lie dormant in rich media conditions.
274
  This would provide an 
ideal screen for anti-tubercular drugs in order to identify pathogenically relevant hit 
compounds with the ease and speed of using the M. smegmatis model organism. 
 
Compounds demonstrating ≥ 80% inhibition were validated in a dose-response quantitative 
assay as was done in conventional media screens, and the resulting validated inhibitors were 
cross-referenced with results of M. tuberculosis H37Ra and M. bovis BCG screening projects. 
HdeB nitrogen starvation medium was found to be the most sensitive culture condition for 
detecting anti-mycobacterial compounds, revealing more than twice the number of 
compounds than HdeB carbon starvation medium.  The hits from HdeB nitrogen limited 
medium also had 37% more hit compounds coinciding with hit compounds from M. 
tuberculosis H37Ra screens.  Both of these nutrient limited media types identified more 
mycobacterial inhibitors than the conventional rich media 7H9 and LB.  Overall, nutrient 
limited conditions identified almost double the amount of anti-mycobacterial compounds that 
were detected in nutrient rich media, and 33% more compounds identified by nutrient 
starvation screens were also identified as inhibitory towards M. tuberculosis H37Ra. The 
overall percentage of coinciding hits with H37Ra, however, was lower for nutrient starvation 
conditions. 
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Further promising anti-mycobacterial drug development leads were elucidated by screening 
chemical libraries using nutrient starvation conditions, including finding novel anti-
mycobacterial activity for already known drugs.  For example, one such known compound 
was the anti-fungal agent pentamidine, delivered as an aerosol for the treatment of 
pneumocystis
307
  and identified as eradicating virulent tuberculosis at doses as low as 5 µM in 
an intra-macrophage assay.
221
       
 
Phenothiazine and tricyclic psychiatric drugs such as trifluoperazine used in the treatment of 
schizophrenia and depression were also identified as having anti-mycobacterial activity.  
These classes of chemical have a good pharmacological profile and are routinely 
administered to humans; however, these drugs also have psychological side effects.  
Phenothiazines are known to inhibit XDR strains of tuberculosis
303
 accumulate within 
macrophages
302
 and block drug efflux pumps,
304
 making them ideal for combination therapy, 
provided the psychiatric effects of these drugs can be structurally mitigated. 
 
The agricultural fungicide chlorothalonil (tetrachloroisophthalonitrile) is non-toxic in murine 
models with a good safety profile and an oral LD50 > 5000 mg/kg.
338
  Chlorothalonil is active 
only under nutrient limitation culture conditions, and the MIC is 3.125-6.25 µM against M. 
smegmatis. It has an excellent selective activity against mycobacteria and has confirmed 
activity in the slow growing mycobacterial species M. bovis BCG and M. tuberculosis 
H37Ra. 
 
Cefdinir, a cephalosporin that disrupts peptidoglycan synthesis, is an interesting hit because 
mycobacteria are generally resistant to β-lactams due to their complex cell wall and 
expression of β-lactamase enzymes.323  Not demonstrating potent anti-mycobacterial activity, 
with a high MIC of 25 µM against M. smegmatis in HdeB nitrogen starvation, cefdinir is a 
worthwhile development lead as it is extremely well tolerated.   
 
A similar new use for an old drug is the anti-fungal agent ketoconazole, a highly lipophilic 
ergosterol synthesis inhibitor suitable for oral systemic administration.
343
 Studies have shown 
that ketoconazole improves treatment outcomes in conjunction with first line tuberculosis 
drug treatment.  
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Se-methylselenocysteine and its chemical class of seleno-amino acids were first identified in 
the nutrient limited anti-mycobacterial screening of this work.
122
  A natural product found in 
many commonly consumed plant species,
310, 393
  Se-AAs such as SMSC and Se-met are also 
sold over the counter as nutritional supplements.
311
  Most scientific  research on Se-AAs 
concerns their cancer preventing properties,
312
 although Se-AAs are thought to have a wide 
array of beneficial health effects.
311
  These compounds were chosen for more detailed follow 
up study as they are novel anti-mycobacterial agents with good anti-mycobacterial potency. 
Human consumption of Se-AAs is known to be well tolerated.  Se-AAs represent a promising 
class of anti-mycobacterial agents as they mimic sulphur amino acids, and mycobacteria such 
as M. tuberculosis have an unusually high consumption and utilisation of sulphated 
metabolites,
672
 this may cause differential sensitivity toward mycobacteria over other 
bacterial and eukaryotic species.  
 
7.2.3 Seleno-amino acids  
Seleno-amino acids are known in the literature for their health effects towards various 
conditions such as cancer; however, little is published regarding the anti-microbial activity of 
these compounds.  Therefore in the present study the inhibitory activity of a range of organic 
and inorganic selenium compounds was assessed in the primary mycobacterial model 
organism M. smegmatis.  Strong inhibition of M. smegmatis growth within the 7.8-31.2 µM 
range was observed for the Se-AAs SMSC, Se-DL-met and Se-L-met.  Moderate activity in 
the 25-50 µM range was observed for Se-DL-cys, and poor inhibitory activity of 125-250 µM 
was seen for the dimerised seleno-DL-cystine.  The inhibitory activity for all the 
aforementioned Se-AAs was seen in all media types with the exception of LB nutrient rich 
media, where no inhibitory activity was observed at 2 mM, the highest concentration tested. 
Non-selenium amino acids such as DL-cys, DL-met and s-methyl-L-cys were found to have 
no inhibitory activity towards M. smegmatis regardless of media type.  Non-amino acid 
selenium compounds were found to have poor inhibitory activity toward M. smegmatis in all 
media types, apart from methylseleninic acid and ebselen that had MIC activity in the 31.2 – 
125 µM range in all media types except LB. 
 
Based on these results in M. smegmatis, a panel of selenium compounds was tested against a 
range of bacterial species. This panel of compounds included the most potent inhibitory Se-
AAs SMSC and Se-L-met, the non-amino acid selenium inhibitory compound 
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methylseleninic acid and the low-inhibitory activity inorganic selenium compound sodium 
selenite. 
 
M. tuberculosis H37Ra exhibited a similar inhibition profile to M. smegmatis with MIC 
concentrations of 15.6 for the top Se-AA compounds SMSC and Se-L-met.  Methylseleninic 
acid and ebselen also demonstrated good inhibition at 31.2 and 62.5 µM MIC, respectively, 
and sodium selenite as expected did not cause any significant inhibition.  The virulent strains 
of M. tuberculosis H37Rv and CDC1551 were sensitive to inhibition by Se-AAs with the 
lowest MIC values of 22.88 and 9.15 µM for each of those strains, respectively.  These 
inhibitory concentrations towards M. tuberculosis are comparable to tuberculosis treatment 
drugs such as clarithromycin, cycloserine and pyrazinamide. The slow growing 
mycobacterial species M. bovis BCG demonstrated similar but slightly lower sensitivity 
compared to M. smegmatis for inhibition by Se-AAs, with SMSC and Se-L-met causing 
complete growth inhibition at 31.2-62.5 µM.  This indicates that dietary Se-AA 
supplementation may be a useful and inexpensive adjunct to controlling bovine TB in cattle, 
particularly in regions with low soil selenium content.  
 
Selenium compounds, including Se-AAs, showed little inhibitory activity toward other 
bacterial species cultured in rich or nutrient limited media.  S. aureus was unable to be 
completely inhibited by either SMSC or Se-L-met even at the highest concentration tested of 
2 mM.  E. coli was somewhat susceptible to Se-AA inhibition at high concentrations under 
M9 minimal media conditions with MIC values of 500 µM for SMSC and 2000 µM for Se-L-
met.  E. coli was uninhibited by Se-AAs in rich LB media.  P. aeruginosa was also not 
inhibited by the selenium panel of compounds with the exception of Se-L-met that had an 
MIC of 1000 µM in LB media.  V. harveyi was more sensitive to inhibition by Se-AAs with 
MIC values in the 250 - 1000 µM range; however, these MICs are still considered to be too 
high for a viable antibiotic development lead toward Vibrio species. 
 
The panel of selenium compounds was also tested against haploid and diploid strains of the 
eukaryotic yeast S. cerevisiae.  Se-L-met evoked complete inhibition of yeast growth at 62.5 
– 125 µM; while, SMSC could not completely inhibit growth even at the highest 
concentration of 2 mM. 
 
SMSC was tested against the human cell lines HL-60 and J-774 macrophages, and SMSC 
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inhibited the HL-60 leukaemia cell line with an IC50 (not an MIC) value of 73.03 µM.  No 
inhibition was seen for the J-774 murine macrophage cell line at the highest concentration 
tested of 250 µM.  Both SMSC and Se-DL-met were found to exhibit little inhibitory activity 
at 100 µM toward Vero cells. 
 
Therefore, it was concluded that Se-AAs demonstrated a high level of specificity towards 
mycobacteria but with little or no inhibitory activity towards other bacterial species, even at 
high concentrations.  The inhibitory activity of Se-AAs toward mycobacteria was dependant 
on nutrient limited culture conditions.  Se-AAs are known to have inhibitory properties 
towards cancer cell lines
491
  but are generally considered to be non-toxic against non-
cancerous cells.
499
   
 
Considering the tolerance of selenium compounds in mammals, with toxic levels above 800 
µg / day in humans,
377
 Se-AAs are a viable developmental lead for a novel tuberculosis 
treatment drug.  Further studies into the Se-AA mechanism of action and structure-activity 
relationship may improve both the anti-mycobacterial activity and decrease the human cell 
toxicity of these compounds.  The groundwork for future mechanism of action and structure-
activity studies was carried out in this research.  Key structural features influencing the anti-
mycobacterial activity of Se-AAs were determined to be substitution of a selenium atom for 
the sulphur of methionine or cysteine, methylation of the selenium, primary amine and 
carboxylic acid moieties and levo stereochemistry.  A number of Se-AA derivatives, such as 
di-peptides and amides, were synthesised for increased selective anti-mycobacterial activity; 
however, these all exhibited lower inhibitory activity than the parent molecule.
518
  Although, 
these derivatives did, provide insight into the Se-AA structure activity relationship such as 
the diminishing effect of c-terminal conjugations on activity. 
 
A mechanism of Se-AA anti-mycobacterial action was hypothesised based on a published 
hypothesis of the mechanism of Se-AA anti-neoplastic activity.
447, 534, 535
  This mechanism 
consisted of three parts; first, Se-AA were imported into the mycobacterial cell under the 
guise of a nutrient; second, the Se-AA acted as a pro-drug and was cleaved by mycobacterial 
lyase enzymes into its active methylselenide constituent; and last, the methylselenide was 
then redox cycled by mycobacterial antioxidant processes to produce damaging oxygen free 
radicals.  This hypothesis was explored and supporting evidence included a competition 
effect between Se-AAs and sulphurous amino acids, where supplementing culture media with 
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DL-cys or DL-met rescued the mycobacteria from Se-AA toxicity.  Down-regulation of the 
β-lyase MSMEG_2357 by anti-sense RNA induced resistance to SMSC in M. smegmatis with 
an 8-32 fold increase in its MIC, and gene deletion of CYS3, a γ-lyase in S. cerevisiae, 
conferred resistance to Se-L-met with an 8-fold increase in MIC.  Methyldiselenide and an 
orange selenium precipitate
673
 was detected as a product of the in vitro enzyme reaction of 
purified M. tuberculosis H37Rv β-lyase Rv3025c and Se-DL-cys, indicating utilisation of Se-
DL-cys as a substrate by this enzyme.   
Transposon mutants resistant to Se-AAs were generated and the mutation caused by 
transposon insertion was genetically defined, revealing several genes involved in 
mycobacterial redox homeostasis such as alkylhydroperoxidase and ketosteroid hydroxylase 
in addition to more cryptic gene disruptions for which the role in Se-AA resistance is unclear. 
Finally, Se-AAs demonstrated synergistic potential in combination with the front line 
tuberculosis treatment drug isoniazid.  This is thought to be due to the see-saw gene 
expression relationship between ahpC, responsible for Se-AA activity, and katG, responsible 
for isoniazid activity, where loss of function of katG is compensated by ahpC 
hyperexpression.
557
 This over-expression of AhpC may cause increased sensitivity to Se-AAs 
and is believed to have no effect on isoniazid sensitivity but rather compensates by 
maintaining mycobacterial redox status.
674
  This is a favourable indication for treatment of 
MDR-TB that is isoniazid resistant through KatG loss of function mutations, as these strains 
may exhibit higher sensitivity to Se-AA inhibition. 
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7.3 Critical evaluation 
After completion and contemplation of this work, several improvements and critiques of this 
research are indicated, as suggested below. 
 
7.3.1 High-throughput screening 
The screening aspect of this project could have been improved in several ways.  For example, 
adaptation of the assay from 96-well plate format to 384-well plate format would decrease 
screening costs and increase the throughput of the assay. This would allow quadruplicate 
replicates to be carried out on a single plate, minimising plate to plate variation that arises 
from using three separate 96-well plates for triplicate repeats. 
Rich culture conditions used in the screening could have been more defined. For example, a 
complete synthetic media such as the 7H9 with amino acid supplementation described by 
Parish
222
 in which amino acid concentrations can be titrated, as opposed to LB in which 
undefined amino acids are supplied via peptone and yeast extract.  Similarly, expansion of the 
nutrient limited medium types to include HdeB oxygen starvation would provide a more 
pathogenically relevant culture environment. For example, forming non-culturable cells
675
 
compared to HdeB carbon and nitrogen starvation media; however, this would require 
specialised air-tight plate seals or a similar arrangement to exclude atmospheric oxygen from 
the assay.  In retrospect, HdeB sulphur limitation media would also provide interesting 
culture conditions for the detection of chemical inhibitors of essential mycobacterial sulphur 
metabolism processes.
643
 
 
Hit compounds derived from high-throughput screening would be more pathogenically 
relevant if the screen were a high content whole cell type, for example, an intra-macrophage 
assay using phagocytosed bacteria.
676
  This was considered to be beyond the scope of the 
project but was explored by another research team member.
676
  Validation of hit compounds 
derived from high-throughput screening proved to be a laborious process and could have 
been better streamlined by literature searching hit compounds to rule out cytotoxic agents 
with little therapeutic potential, thus, saving compound, time and consumables.  Ideally anti-
mycobacterial activity screening of chemical libraries could be run in parallel with a 
cytotoxicity counter screen to integrate a toxicity validation step for compounds in the initial 
screening.  Although this project was intended as proof of concept for modified culture 
condition screening, increasing the number of chemicals screened would provide further 
developmental leads for novel anti-mycobacterial agents. 
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7.3.2 Seleno-amino acid activity 
For the testing of mycobacterial susceptibility to Se-AAs, a wider range of media types such 
as HdeB oxygen and sulphur starvation may have provided earlier insight into the mechanism 
of action of Se-AAs.  Similarly, using a defined rich medium in which amino acids could be 
excluded or titrated could have been of similar use in elucidating the Se-AA mechanism. 
 
A major omission of this work was the selenium compound testing against virulent strains of 
tuberculosis such as M. tuberculosis H37Rv and CDC1551, since assays were performed 
using these strains failed to give consistent results regarding the inhibitory activity of Se-AAs 
towards these pathogenically relevant strains; therefore, it is difficult to draw conclusions 
regarding the inhibitory activity of Se-AAs toward these pathogenic strains and confirmatory 
retesting is required.  This was problematic to address as the facilities where this research was 
carried out were restricted to a PC-2 level laboratory, with no PC-3 facility available at 
VUW; thus, testing using these virulent PC-3 strains had to be out-sourced to NIH and JHU.  
Inhibitory activity levels of Se-AAs are consistent between mycobacterial species; therefore, 
the activity of SMSC is presumed to follow this trend against H37Rv.  Nontheless, the 
variation in results for SMSC against H37Rv casts some doubt on the specific level of 
activity of this compound toward virulent tuberculosis. In addition, testing was carried out for 
racemic Se-DL-met against H37Rv, but not Se-L-met, the most promising member of the Se-
AA family.  This research could definitely benefit from more thorough susceptibility testing 
of a full panel of selenium compounds against both M. tuberculosis H37Rv and CDC1551. 
In testing the susceptibility of the non-mycobacterial species S. aureus, E. coli, P. aeruginosa 
and V. harveyi, altering the sulphur concentration by titrating the amount of MgSO4 may have 
resulted in increased susceptibility of these species to Se-AAs.  At present it is unknown if 
these bacterial species are inherently resistant to Se-AA inhibition or if these species are able 
to synthesise sulphur amino acids de novo from the constituents of M9 minimal media, 
rescuing the bacterium from Se-AA inhibition. 
 
The auto-reduction of resazurin in 0.5x SPO media during S. cerevisiae susceptibility testing 
against SMSC proved problematic. This could be avoided by omitting resazurin from this 
assay and measuring the absorbance at 600 nm; however, this would remove the comparison 
to other selenium compounds for which resazurin was used, and the assays would lack the 
sensitivity of resazurin.  Visual inspection of wells confirmed that SMSC was unable to 
inhibit S. cerevisiae growth under SC or SPO media conditions, with the exception of the 
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YAL012W CYS3 strain that was not culturable due to auxotrophy under SC conditions.  
 
The limited cytotoxicity testing of Se-AA compounds against mammalian cell lines was 
another weakness of this project, since SMSC and Se-DL-met were the only Se-AA tested.  
This testing was carried out against three cell lines, human leukaemia HL-60, murine 
macrophage J-774 and green monkey kidney epithelial Vero cells; however, this testing was 
carried out in an incomplete manner, not all Se-AAs were tested against all cell lines.  This 
aspect of the project could be improved by testing the complete panel of selenium compounds 
against the mammalian cell lines, and including additional cell lines such as human 
fibroblasts
677
 and murine alveolar macrophages MH-S. The latter could even be adapted for 
an intra-macrophage assay with phagocytosed mycobacteria to provide an excellent 
pathogenically relevant cytotoxicity and anti-mycobacterial activity validation.
678
  Ideally, in 
vivo bio-availability, toxicity and infection clearance assays would also be performed for Se-
AAs in a murine model; however, this was considered beyond the scope of this project. As a 
consequence, this research relied on the literature to provide in vitro cytotoxicity and in vivo 
animal toxicity data on the seleno-compounds. 
 
7.3.3 Seleno-amino acid structure-activity analysis 
Examination of the relationship between Se-AA chemical structure and biological activity 
was restricted to selenium compounds that were available commercially or through the 
Developmental Therapeutics Program Repository of NIH, resulting in a somewhat haphazard 
SAR analysis.  SAR of Se-AAs could be better explored using a wider range Se-AAs and 
other selenium compounds. For example, inclusion of both dextro and levo optical isomers 
and racemic mixtures of the most active Se-AAs SMSC and Se-L-met for determining that 
Se-AAs have levo optical rotation dependant activity.   
 
A wider range of substituted selenium compounds would also further SAR understanding. 
Therefore, it would have helped to continue the trend of Se-cys, Se-methylselenocysteine 
with the addition of Se-ethylselenocysteine and Se-propylselenocysteine, likewise for Se-met 
selenohomocysteine and seleno-ethionine. These would provide valuable information on the 
influence of selenium substitution on Se-AA activity and may have even demonstrated 
increased anti-mycobacterial activity.  It was demonstrated that the sulphur amino acids 
equivalents cysteine, s-methyl-cysteine and methionine did not exhibit anti-mycobacterial 
activity.  It would interesting to further explore this effect with tellurium amino acids, as 
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these have been reported to also have redox modulating properties more potent than seleno-
amino acids
679
 and be of interest in antibiotic drug design.
680
 
 
To properly investigate the impact amine and carboxylic acid groups have upon Se-AA anti-
mycobacterial activity, these groups could have been substituted with protecting groups, for 
example t-BOC protection of the amine,
681
 and this protection could have been applied to all 
Se-AA functional groups to determine their importance in Se-AA activity. 
Finally, inclusion of other methylated Se-AAs with variation in the number of side chain 
carbons, such as methylselenol-glycine, methylselenol-norvaline and methylselenol-
norleucine would provide insight into the substrate specificity of mycobacterial β-eliminating 
lyases and may have provided direction for structural configurations that might increase the 
specific activity towards mycobactetria. 
 
7.3.3.1 Seleno-amino acid derivatisation 
Seleno-L-methionine di-peptide and amide derivatives that were synthesised and provided by 
Zaid Amso and Dr. Viji Sarojini provided useful SAR information showing that conjugation 
of Se-AAs and amide substitution of the hydroxyl group diminished the anti-mycobacterial 
activity of these compounds.
518
   
 
This derivatisation work would have been more complete if dipeptide and amide derivatives 
of Se-cys or SMSC were included as well as additional to Se-L-met derivatives; however, 
these were omitted due to financial constraints.  Both carboxyl- and amine-conjugates of 
alanine to Se-L-met were synthesised and a 4-fold difference in anti-mycobacterial activity 
was observed between these, with the c-terminal conjugate having reduced activity.  Only the 
c-terminal conjugate of arginine to Se-L-met was synthesised, and this di-peptide exhibited 
only marginally reduced activity compared to Se-L-met.  An n-terminal conjugate of Se-L-
met and arginine may have anti-mycobacterial activity on par with Se-L-met, if the trend 
observed in Ala-SeMet conjugations also extended to the arginine dipeptide.  This dipeptide 
has been synthesized by Zaid Amso and will undergo bioactivity testing against M. 
tuberculosis H37Ra.   
Furthermore, testing the mammalian cell cytotoxicity of these derivatives and calculating the 
corresponding selection index towards M. tuberculosis would provide more insight into 
derivatisation selective for anti-mycobacterial activity. 
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7.3.4 Seleno-amino acid mechanism of action 
7.3.4.1 Competition assays 
The competition assays used to determine the rescue effect of sulphur amino acid 
supplementation on Se-AA toxicity could have been improved in several ways.  For example, 
commercially available radio-labelled Se-cys
682
 and Se-met
683
 containing the γ-radiation 
emitting 
75
Se could have been used.  This would allow quantitative measurement of 
mycobacterial Se-AA uptake to determine how this is affected by supplementation with cys 
and met, ascertaining whether this competition effect is occurring at the transport level as 
opposed to the lyase substrate level. 
 
7.3.4.2 Anti-sense inducible modulation of gene expression 
Experiments involving the modulation of M. smegmatis lyase enzymes MSMEG_2357 and 
MSMEG_5265 and alkylhydroperoxidase enzymes MSMEG_4890 and MSMEG_4891 using 
the improved tetracycline inducible vector pKW08
188
 did not evoke as strong a response in 
Se-AA sensitivity as expected for alkylhydroperoxidases based on the Se-AA resistant  
phenotype of the alkylhydroperoxidase transposon mutant TN-G3-M10.  No significant 
changes in Se-AA sensitivity were observed for MSMEG_2357 and MSMEG_5265 sense 
overexpression and anti-sense under-expression strains. This was unexpected since anti-sense 
RNA technology has been used in several instances in bacteria to knock down gene 
expression, for example, in the identification of the FabF inhibitor platensimycin
165
 and in the 
discovery of inhibitors of mycobacterial chromosome partitioning apparatus.
157
 
 
The lack of effect from these experiments may be due to an insufficient quantity of anti-sense 
RNA being generated to significantly reduce protein expression to have an effect on Se-AA 
sensitivity, as anti-sense RNA does not completely silence gene expression.
684
  Similarly, 
insufficient expression of sense RNA may result in a reduced impact on cellular protein 
levels if the cell is already sufficiently saturated with the protein of interest.  Pursuing a 
stronger constitutive promoter such as HSP60
685
 may allow sufficient RNA expression at the 
expense of inducibility.  Using homologous recombination to knockout genes completely 
may provide a better response if the anti-sense RNA expression was insufficient to have an 
impact on gene function.
686
  
Alternatively, these genes may not be essential in M. smegmatis as they are in M. 
tuberculosis, resulting in a phenotype that is not conditionally lethal.
163
  This could be due to 
functionally redundant or duplicated genes, as M. smegmatis is known to have a large 
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genomic duplication and resulting genetic redundancy.
577
  The alkylhydroperoxidase ahpC 
was down-regulated in M. bovis, producing a distinctly less virulent phenotype, and up-
regulation of ahpC expression caused increased resistance to cumene hydroperoxide.
614
 The 
lack of effect in M. smegmatis constructs may be due to functional redundancy and 
acquisition, and testing Se-AA sensitivity of the ΔahpC strains of Wilson et al (1998) may 
have proved more fruitful. 
 
7.3.4.3 Enzymatic assays 
Mycobacterial lyase enzymes from M. tuberculosis H37Rv suspected of performing β and γ-
elimination reactions which activate Se-AAs were successfully cloned into the pET28a+ 
expression vector, expressed in E. coli BL-21 and purified by nickel affinity chromatography.  
Of five proteins expressed, only three were successfully purified and only one of these 
exhibited the characteristic bright yellow colour of pyridoxal phosphate binding enzymes.
585
  
This could indicate that the mycobacterial enzymes were not expressed correctly in the E. 
coli system.  It is known that E. coli does not perform the correct post-translational 
modifications when expressing foreign mycobacterial proteins,
687
 and only half of the M. 
tuberculosis proteins expressed in E. coli are soluble.
688
  More successful protein expression 
may have been achieved using a specialised mycobacterial protein expression strain such as 
M. smegmatis GroEL1ΔC689 and vector such as pDESTsmg.688  For assay conditions, DTT 
was used as the reducing agent, and use of glutathione, or ideally, reduced mycothiol would 
better facilitate mycobacterial lyase enzyme function. 
 
7.3.4.4 Mass spectrometry 
GC-MS analysis identified in vitro methyldiselenide production from M. tuberculosis 
cysteine desulphurase Rv3025c using SMSC as a substrate but was unable to identify 
evolution of selenium species from other Se-AA substrates or mycobacterial lyase enzymes.  
Use of commercial β and γ lyase enzymes as positive controls552 would have better validated 
the results of these experiments.  This experiment requires further testing utilising additional 
mycobacterial lyase enzymes and Se-AA substrates.  Coupling GC-MS detection of volatile 
selenium and sulphur species with LC-MS may have facilitated the determination of other 
metabolites of lyase cleavage of Se-AAs, the major suspects being alanine,
594
 pyruvate
690
 or 
α-ketobutyrate.535  Knowing the identity of other products of the lyase reaction may have 
allowed development of a specific assay for the detection and quantification of lyase assay 
function. 
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7.3.5 Mycobacterial lyase metabolite detection assays 
7.3.5.1 Methylene blue sulphide/selenides detection 
The methylene blue method of sulphide detection may have been better utilised if carried out 
at lower temperatures to avoid loss of volatile sulphide/selenide compounds
691
 although this 
may have yielded inaccurate results for enzyme activity as this would likely fall below the 
lyase optimal temperature range.  Methylated sulphur/selenium species such as those 
produced by lyase activity on SMSC, Se-met, S-methyl-cysteine may also interfere with the 
methylene blue assay.
692
  An assay based on fluorescent probes for hydrogen sulphide or 
selenides may prove more reliable.
693
 
 
7.3.5.2 Coupled enzyme assays 
Alanine dehydrogenase and Lactate dehydrogenase commercial enzymes were coupled with 
the in vitro mycobacterial lyase reaction in the hope of quantifying lyase enzyme activity by 
measuring the production of the theoretical lyase metabolites alanine
594
 and pyruvate.
690
  
Alanine has been reported as the product of Rv3025c lysis of cysteine,
585
 but this could not 
be detected in the coupled enzyme assays of this research, with the exception of positive 
controls using these compounds.   
It is possible that alanine and pyruvate are not the metabolites produced by mycobacterial 
lyase activity on Se-AA substrates; however, alanine not being detected from Rv3025c using 
DL-cys substrate and having positive H2S production in the PbAc paper method makes this 
unlikely.  Substituting the reducing agent DTT in this assay for glutathione or reduced 
mycothiol, and incorporation of an anaerobic environment with a sulphur acceptor may have 
increased lyase enzyme function to detectable levels. 
 
7.3.6 Seleno-amino acid-resistant transposon mutants 
Transposon mutants with identified insertion regions such as TN-G3-M10 ahpC/D 
alkylhydroperoxidase would have been better validated by complementation experiments, 
supplementing the suspected mycobacterial transposon disrupted gene with a plasmid borne 
copy.  This complementation method is more commonly used
546
 and in retrospect is 
considered a better standard than anti-sense RNA gene modulation.  Testing of Se-AA 
resistant strains for differential sensitivity to redox cycling agents such as paraquat and 
menadione
694
 may provide additional insight into the hypothesised mechanism of Se-AA 
ROS generation, as such chemicals produce superoxide.
695
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7.3.7 Seleno-amino acid synergy with isoniazid 
Se-L-met was demonstrated to exhibit a low level of synergy with the front line tuberculosis 
treatment drug isoniazid in the strain M. tuberculosis H37Ra.  This was an expected result as 
the genetic targets of Se-AAs and isoniazid are co-dependently expressed, with ahpC being 
up-regulated upon loss of katG function.
557
  This synergy experiment would be worth 
carrying out using MDR-TB strains as well, particularly those with known katG loss of 
function as these may exhibit even greater sensitivity to Se-AA inhibition, as ahpC 
transcription will likely be up-regulated, resulting in increased sensitivity to Se-AAs that may 
outweigh the level of INH resistance.  Further synergy experiments using other TB treatment 
drugs such as ethionamide may also reveal synergy of Se-AAs with such drugs. 
 
7.4 Future directions 
The following experiments are recommended for the continuation of this research, 
predominantly concerning the development of Se-AAs as antibiotics but also regarding 
differential culture condition screening and dealing with other hits derived from screens. 
 
7.4.1 Modified culture condition screening of additional chemical libraries 
The chemical libraries used in the screening components of this project were small in terms 
of the number of compounds, and they had little novel compound content.  Although new use 
for known drugs can be favourable because of their known pharmacology and toxicology 
profiles,
696
 this should be coupled with exploring novel chemical structures as well.  
Modified culture condition screening such as the nutrient limited conditions described in this 
thesis should be carried out on large, structurally diverse chemical collections such as the 
ChemBridge™ MicroFormat, Specs™ World Diversity Set and the ChemDiv™ Drug-Like 
libraries, particularly structure diversity orientated libraries to allow hit compound follow up 
with a range of structural variants on a lead scaffold.
697
 
7.4.2 Follow up of key library hit compounds 
Other library compounds identified as having anti-mycobacterial activity and through 
literature searching found to have favourable indications for development as human 
tuberculosis treatment drugs, such as low toxicity could be screened.  Follow-up research 
scrutinising these compounds as potential anti-tubercular agents is encouraged, including 
testing of activity toward virulent M. tuberculosis strains and human cell line toxicity.  
Compounds considered to be excellent leads and require immediate follow-up investigation 
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include niclosamide, pyrithione zinc, azadirachtin, neohesperidin, pentamidine and 
chlorothalonil (tetrachloroisophthalonitrile).  Other leads worthy of follow up study include 
phenothiazines, cefdinir, gentisic acid, michellamine B, bismuth-dimercaprol, solanine and 
ketoconazole. 
 
7.4.3 Further testing of Se-AAs against virulent / drug resistant M. tuberculosis strains 
To verify the anti-mycobacterial results of SMSC against virulent M. tuberculosis strains 
H37Rv and CDC1551 reported in this thesis, repeated dose-response experiments using a full 
suite of Se-AA compounds should be carried out using these strains. Additionally, testing of 
Se-AAs against MDR and XDR-TB strains, particularly ΔkatG mediated isoniazid resistant 
strains, would be of much interest due to the synergy between Se-AAs and isoniazid and 
potentially elevated sensitivity of isoniazid resistant tuberculosis to Se-AAs as described in 
Chapter 6.5.3.6. 
 
7.4.4 Further testing of Se-AAs against mammalian cell lines 
Similar to above, verification of Se-AA cytotoxicity towards mammalian cell lines should 
take place using the full range of Se-AA compounds against a variety of cell lines, 
particularly human cell lines.  Furthermore, testing of Se-AA activity toward phagocytosed 
mycobacteria would provide an interesting combination anti-bacterial and cytotoxicity assay.  
Assuming that validation studies using virulent M. tuberculosis and cytotoxicity results are 
favourable, the next step is testing of Se-AA compounds in vivo using murine models of 
tuberculosis to measure bio-availability, toxicity, infection clearance and compatibility with 
standard tuberculosis treatment drugs. 
 
7.4.5 Target gene knockout and complementation sensitivity 
For absolute validation of the Se-AA anti-mycobacterial mechanism, putative non-essential 
M. smegmatis lyase genes MSMEG_0769 (Rv0391), MSMEG_5265 (Rv1079) and 
MSMEG_1652 (Rv3340) and alkylhydroperoxidase genes MSMEG_4890 (Rv2429) and 
MSMEG_4891 (Rv2428) should be reliably knocked out using homologous 
recombination.
698, 699
  Putative essential genes, like MSMEG_3125 (Rv1464), and 
MSMEG_2357 (Rv3025c), may be possibly knocked out by homologous recombination if a 
rich culture media is used, supplemented with sulphur and alanine if necessary to substitute 
for the lost function of these genes.  The resulting knockout strains should be tested for Se-
AA sensitivity, and any changes to the Se-AA sensitivity phenotype should be validated by 
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complementation experiments using a plasmid borne copy of the gene to restore the Se-AA 
sensitivity to original levels.  Construction of M. smegmatis knockouts may be bypassed 
using M. tuberculosis H37Rv transposon mutants available from Johns Hopkins University 
School of Medicine where a Rv0391 transposon knockout strain is available and knockouts 
for other non-essential lyase genes Rv1079 and Rv3340 and peroxidise genes Rv2428 and 
Rv2429 are likely to be available in future. Based on the sensitivity of these knockouts to Se-
AA inhibition, these enzymes may then be purified and an in vitro enzyme assay developed. 
 
7.4.6 In silico docking analysis of Se-AAs with mycobacterial lyase enzymes 
For clarification regarding mycobacterial lyase utilisation of Se-AAs substrates, and to help 
guide structural modifications to increase anti-mycobacterial activity, in silico docking of Se-
AAs with mycobacterial lyase enzymes should be carried out.  This has the advantage of 
allowing many virtual chemicals to be inexpensively screened against a known target.
2, 700
 
The crystal structures of the mycobacterial lyase enzymes Rv1079
574
 and Rv3340
592
 have 
been solved.
701
  Cystathionine γ-synthase/lyase enzymes such as Rv1079 are of particular 
interest as these enzymes and their de novo methionine synthesis function occur only in 
microorganisms and plants
702
 but not mammals, and are therefore good drug targets. 
 
7.4.7 Derivatisations improving biological activity 
The following derivatisations were conceptualised based on known trends in Se-AA 
structure-activity, and information sourced in the literature and anti-mycobacterial testing of 
these derivatives would provide comprehensive structure-activity analysis and may produce 
novel Se-AAs with improved drug-like qualities such as increased bioavailability, increased 
anti-mycobacterial activity and decreased human cytotoxicity.  
 
7.4.7.1 Se substitution 
Described briefly in section 7.3.3.1, exploring substitution at the selenium position of Se-cys 
and Se-met with ethyl, propyl and phenyl groups would provide valuable insight into changes 
in activity with modulation of this functional group.
703
  For Se-cys, exploring Se-
ethylselenocysteine, Se-propylselenocysteine and Se-phenylselenocysteine and for Se-met, 
exploring selenohomocysteine, seleno-ethionine, seleno-propionine and Se-phenyl-
selenohomocysteine would provide a good foundation for Se substitution, particularly since 
the Se-phenyl derivatives, being electron rich, should form a more reductive Se anion that 
may lead to a more reactive phenylselenide radical.  Se-phenyl-L-selenocysteine is reported 
  CHAPTER SEVEN:  GENERAL DISCUSSION     292 
to be non-toxic toward rat hepatocytes.
679
  Many Se-substituted derivatives have been 
previously synthesised,
704
 and Se-methyl, ethyl, n-propyl and n-butyl L-selenocysteine 
derivatives are also reported to be non-toxic toward rat renal proximal tubular cells.
703
   
Trifluoromethionine is a pro-drug similar to Se-AAs that is cleaved by methionine γ-lyase to 
produce α-ketobutyrate, ammonia and the amine cross-linking agent trifluoromethanthiol.705  
Trifluoromethionine has anti-bacterial and anti-protozoal activity in vitro and in vivo.
705-708
  
Combining fluorinated methionine derivatives with Se-AAs, i.e. trifluoroselenomethionine 
may represent a pro-drug with dual mode of action cross-linking amines that generates 
reactive oxygen and would also provide insight to the SAR of Se-AAs, as this Se-substitution 
would be highly electronegative. 
 
7.4.7.2 Side chain carbon length 
Also described in section 7.3.3.1, modifying the Se-AA side chain carbons would provide 
valuable insight into the SAR of Se-AAs.  Decreased side chain carbons in methylseleno-
glycine and increased side chain carbons in methylseleno-norvaline and methylseleno-
norleucine would elucidate the effect of side chain length on anti-mycobacterial activity. The 
suitability of these chemicals or their sulphur analogues as lyase substrates has not previously 
been determined. 
 
7.4.7.3 Amide conjugates 
Various amide conjugated derivatives of trifluoromethionine were found to have up to 7-fold 
increased activity toward Entamoeba histolytica, in addition to having over 100-fold 
selectivity for this pathogen over mammalian CHO cells.
707
  Although amide derivatives of 
Se-L-met were tested in this work revealing lowered anti-mycobacterial activity, 
condensation of such amides with aniline or benzylamine may increase activity toward 
mycobacteria, as was observed in E. histolytica.
707
 
 
7.4.7.4 Dipeptide conjugates 
Alanine and arginine dipeptide derivatives of Se-AAs were synthesised and found to have 
reduced in vitro anti-mycobacterial activity, described in section 6.2.2.  Following this trend, 
proline – Se-AA dipeptides and seleno-proline itself may be worth exploring since 
mycobacteria actively import proline into the cell
709
 but also express specialised proline 
dipeptide hydrolysing enzymes such as PepE that release N-terminal amino acids linked to 
proline.
710
  These modifications could provide increased delivery of Se-AA dipeptide to 
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bacteria and provide selective activity through mycobacterial proline dipeptidase cleavage.  
An N-terminal Se-L-met-arginine conjugate dipeptide has been synthesized by Zaid Amso 
and will soon undergo bioactivity testing.  Pathogenic mycobacteria demonstrate specifically 
preferential arginine uptake, with several dedicated transporters.
524
  Further exploration into 
Se-AA - arginine dipeptides such as the N-terminal conjugation of Se-L-met – arginine that 
has been synthesized by Zaid Amso, and even selenoarginine itself
711
 may increase 
specificity and potency toward mycobacteria.  Selenocystathionine (dipeptide of 
selenocysteine and serine) and related serine dipeptides could prove beneficially selective 
toward mycobacteria over mammalian cells, as cystathionine γ-lyase enzymes are present 
only in microorganisms and plants, not mammals.
702
  Additionally di-, tri- and tetra- peptides 
of Se-L-met have been synthesized by Zaid Amso and will soon undergo bioactivity testing. 
 
7.4.7.5 Allyl / glutamyl substitution 
Allyl and glutamyl derivatives of Se-cys are naturally occurring Se-AAs found in various 
plant species such as the Allium genus.
712
  It is thought that Se-AA derivatives such as SMSC, 
γ-glutamylmethylselenocysteine and allylselenocystine are synthesised to mitigate selenium 
toxicity as these amino acids are non-protogenic.
713
  γ-glutamyl Se-AAs act as carriers for Se-
AAs with increased solubility and bioavailability, and require an addition γ-glutamyl 
transpeptidase cleavage step
714
 that may increase the selectivity of Se-AA action toward 
mycobacteria.  Se-allylselenocysteine was found to exhibit more cancer protective effects in 
murine models compared to SMSC and Se-propylselenocysteine,
715
 and this may be due to 
increased reactivity of the allylselenol, the active metabolite of lyase cleavage of Se-
allylselenocysteine.
716
 
 
7.4.7.6 Increased uptake and specificity  
Conjugation of anti-mycobacterial drugs to the mycobacterial iron sequestering siderophore 
mycobactin has been shown to be a useful delivery mechanism to increase the specific 
activity of drug molecules towards mycobacteria
717
 even if the drug did not exhibit anti-
mycobacterial activity to begin with, as seen for the anti-malarial agent artemisinin.
243
  C-
terminal conjugation of Se-AAs to a siderophore such as mycobactin may increase the uptake 
and therefore inhibitory potency of the conjugated Se-AAs toward mycobacteria, in addition 
to presumably having favourable selective activity for mycobacteria.  An alternative method 
for increasing mycobacterial uptake is the conjugation of long carbon chain fatty acid tails to 
increase Se-AAs lipophilicity, allowing them to better permeate the waxy mycobacterial cell 
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wall. Increased lipophilicity would tend to increase anti-bacterial activity
718, 719
 and overcome 
bacterial resistance.
720
 
 
7.5 Concluding remarks 
Infectious diseases such as tuberculosis continue to be a heavy burden on global health.  
Pathogen resistance to anti-microbial agents is ever increasing; therefore, new drugs with 
novel mechanisms of action are required to provide the clinicians with the varied arsenal of 
treatments necessary to tackle these resistant strains. 
This thesis describes the development and implementation of high-throughput screens for 
anti-mycobacterial compounds with a unique aspect of using modified culture conditions to 
reveal alternative inhibitors of mycobacteria.  Several novel inhibitors of mycobacteria were 
discovered, the most prominent being the seleno-amino acids, a new family of anti-
mycobacterial compounds.  The basic structure-activity relationship for Se-AA was 
described, detailing several key structural  
characteristics for which anti-mycobacterial activity of these compounds is dependant. 
  
 Modified culture condition screening identifies alternative inhibitors of 
mycobacteria. 
 Using modified culture condition screening lead to the discovery of seleno-amino 
acids, a novel class of anti-mycobacterial compounds. 
 
Utilising a variety of techniques, a hypothesis for the mechanism of anti-mycobacterial action 
of Se-AAs is proposed, in which Se-AAs are recognised by mycobacteria as nutrients but 
upon metabolism act as a Trojan horse within the mycobacterial cell, producing reactive 
selenium species that interact with mycobacterial oxidoreductase and antioxidant defence 
enzymes to continuously generate oxygen radicals that cause irreparable damage within the 
mycobacterial cell. 
 
 Seleno-amino acids compete with sulphur amino acids as nutrients to 
mycobacteria. 
 
 Seleno-amino acids exert their activity through a novel mechanism. 
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 Seleno amino acids are pro-drugs that are cleaved by mycobacterial lyases into 
their active methylselenium metabolites. 
 
 Methylselenium metabolites cause the production of damaging reaction oxygen 
species from mycobacterial redox regulation and anti-oxidant defence enzymes. 
 
 Methylselenium metabolites also disrupt mycobacterial processes such as Fe-S 
cluster enzyme function, cholesterol catabolism and also deplete the 
mycobacterial NADH reserves. 
 
In summary, this work presents an alternative approach to anti-mycobacterial drug discovery 
using modified culture condition screening.  As a result of implementing this approach, a new 
class of anti-mycobacterial agents was discovered that act via a novel mechanism.  This new 
class, Se-AAs, have good potential for development as a human tuberculosis treatment 
therapy or a nutritional supplement that serves as an adjunct to improve outcomes of 
conventional tuberculosis treatment. 
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